{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "9411c7fc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Home path : /opt/bioasq/col-un-bioasq11\n",
      "Eval path : /opt/bioasq/Evaluation-Measures\n"
     ]
    }
   ],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import os\n",
    "import re\n",
    "import json\n",
    "import copy\n",
    "import sys\n",
    "from tqdm import tqdm\n",
    "from pprint import pprint\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "import pytrec_eval\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "from elasticsearch import Elasticsearch\n",
    "from haystack.pipelines import Pipeline\n",
    "from haystack.nodes import BM25Retriever, ElasticsearchRetriever\n",
    "from haystack.document_stores import ElasticsearchDocumentStore\n",
    "from haystack.nodes import BM25Retriever, SentenceTransformersRanker\n",
    "from haystack.nodes.reader import FARMReader\n",
    "from haystack.utils import print_answers\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "\n",
    "sys.path.append('../../')\n",
    "import globals\n",
    "from elastic_search_utils import elastic_utils\n",
    "from haystack_utils.retrievers import BioASQ_Retriever\n",
    "import bioasq_eval\n",
    "import haystack_util\n",
    "\n",
    "working_folder = globals.PATH.home + '/data/working_folder'\n",
    "eval_home = globals.PATH.eval_home + '/'\n",
    "gs_google_docs = eval_home + '/examples/aueb_google_docs/aueb_nlp-bioasq6b-submissions/'\n",
    "index_name = globals.BIOASQ.index + 'working_folder'\n",
    "model_id = 'doc_retrieval_test'\n",
    "\n",
    "es = Elasticsearch(globals.ES.server)\n",
    "\n",
    "# set document store\n",
    "document_store = ElasticsearchDocumentStore()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "32444db8",
   "metadata": {},
   "outputs": [],
   "source": [
    "test_batch_doc = f'{globals.PATH.home}/data/11b_testset/BioASQ-task11bPhaseA-testset3.json'\n",
    "test_batch_json = json.load(open(test_batch_doc))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "e38dd2b8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3233328c24584220b945fd52d3d63319",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set document store\n",
    "document_store = ElasticsearchDocumentStore()\n",
    "# create the retriever\n",
    "retriever = BioASQ_Retriever(document_store = document_store)\n",
    "\n",
    "# create the Sentence Transformer Ranker\n",
    "ranker = SentenceTransformersRanker(model_name_or_path=\"cross-encoder/ms-marco-MiniLM-L-12-v2\")\n",
    "\n",
    "# create the Query Pipeline\n",
    "pipeline = Pipeline()\n",
    "\n",
    "# add bm25 retriever\n",
    "pipeline.add_node(component=retriever, name=\"BM25Retriever\", inputs=[\"Query\"])\n",
    "pipeline.add_node(component=ranker, name=\"Ranker\", inputs=[\"BM25Retriever\"])\n",
    "#my_model = \"deepset/roberta-base-squad2\"\n",
    "my_model = \"deepset/roberta-base-squad2-covid\"\n",
    "#my_model = \"twielema/biobert_v1.1_pubmed_squad_v2_entericdisease\"\n",
    "reader = FARMReader(model_name_or_path=my_model, use_gpu=True)\n",
    "pipeline.add_node(component=reader, name=\"Reader\", inputs=[\"Ranker\"])\n",
    "\n",
    "# run the pipeline\n",
    "prediction = pipeline.run(query=\"Which gene is most frequently mutated in hereditary angioedema ?\", params={\"BM25Retriever\": {\"top_k\": 100}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "51f54ac4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'query': 'Which gene is most frequently mutated in hereditary angioedema ?',\n",
       " 'no_ans_gap': 17.294288128614426,\n",
       " 'answers': [<Answer {'answer': 'type 2', 'type': 'extractive', 'score': 0.8722091317176819, 'context': 'used by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation,', 'offsets_in_document': [{'start': 152, 'end': 158}], 'offsets_in_context': [{'start': 72, 'end': 78}], 'document_ids': ['33780405'], 'meta': {'title': 'Recognition, Evaluation, and Management of Pediatric Hereditary Angioedema.', 'issue': '37(4)', 'pages': '218-223', 'abstract': \"Hereditary angioedema (HAE) is a rare, often underrecognized genetic disorder caused by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation, vascular leakage, and transient nonpitting angioedema occurring most frequently in the face, neck, upper airway, abdomen, and/or extremities. Involvement of the tongue and laryngopharynx has been associated with asphyxiation and death. Hereditary angioedema is an autosomal-dominant condition; therefore, there is a 50% chance an offspring will inherit this disorder. Any patient presenting with isolated angioedema should be screened with a C4 measurement, as 25% of cases have no family history of HAE. All patients with HAE will have a functional deficiency of C1 esterase inhibitor. Contributors that delay the diagnosis of HAE include recognition delay by clinicians who confuse this condition with histaminergic angioedema, the disease's varied presentations, and limitations to timely testing. Pediatric emergency clinicians should be knowledgeable about how to distinguish between bradykinin- and histamine-mediated angioedema, as there are significant differences in the diagnostic testing, treatment, and clinical response between these 2 different conditions. Evidence indicates that early diagnosis and treatment of HAE reduces morbidity and mortality. Clinician recognition of the mechanistically different problems will ensure patients are appropriately referred to an expert for outpatient management.\", 'journal': 'Pediatric emergency care', 'authors': 'Krack|Andrew T|AT|;Bernstein|Jonathan A|JA|;Ruddy|Richard M|RM|', 'pubdate': '2021', 'pmid': '33780405', 'mesh_terms': 'D000799:Angioedema; D054179:Angioedemas, Hereditary; D001176:Arthrogryposis; D002648:Child; D050718:Complement C1 Inhibitor Protein; D006801:Humans; D009154:Mutation', 'publication_types': 'D016428:Journal Article', 'chemical_list': 'D050718:Complement C1 Inhibitor Protein', 'keywords': '', 'doi': '10.1097/PEC.0000000000002402', 'references': '', 'delete': False, 'affiliations': \"From the Clinical Fellow, Department of Pediatrics, Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, and University of Cincinnati Department of Pediatrics.;Professor of Medicine, Department of Internal Medicine, Division of Immunology/Allergy, University of Cincinnati Medical Center.;Professor of Pediatrics, Department of Pediatrics, Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, and University of Cincinnati Department of Pediatrics, Cincinnati, OH.\", 'pmc': '', 'other_id': '', 'medline_ta': 'Pediatr Emerg Care', 'nlm_unique_id': '8507560', 'issn_linking': '0749-5161', 'country': 'United States'}}>,\n",
       "  <Answer {'answer': 'NF2 tumor suppressor gene', 'type': 'extractive', 'score': 0.8325167894363403, 'context': 'd protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and ', 'offsets_in_document': [{'start': 1311, 'end': 1336}], 'offsets_in_context': [{'start': 63, 'end': 88}], 'document_ids': ['8586465'], 'meta': {'title': 'Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.', 'issue': '15(3)', 'pages': '297-307', 'abstract': 'Most of the genes for hereditary tumor syndromes cloned thus far have subsequently been shown to be mutated not only in the germlines and tumors from patients with the relatively rare inherited disease, but also in the much more common sporadic tumor counterparts in the general population. Thus, the isolation and functional characterization of genes associated with hereditary tumor syndromes have emerged as a major strategy to gain insights into some of the most fundamental mechanisms of tumorigenesis. The search for the genes causing two hereditary tumor syndromes of the nervous system, neurofibromatosis type 2 (NF2) and von Hippel-Lindau disease (VHL), has recently culminated in the cloning of both disease genes. This represents another successful application of the so-called positional cloning approach, i.e., the isolation of a hereditary disease gene with unknown function, based on the determination of its chromosomal location in the human genome. The gene for NF2, a syndrome typically associated with vestibular schwannomas and meningiomas, is homologous with a family of genes whose members appear to play an important role in bridging the cell membrane with the intracellular cytoskeleton, including moesin, ezrin, radixin, and protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and meningiomas from NF2 patients, but also in their sporadic counterparts, which represent approximately one-third of all human brain tumors. Furthermore, malignant human tumors seemingly unrelated to the NF2 syndrome, such as neural crest-derived malignant melanomas, as well as malignant mesotheliomas (a pleural mesoderm-derived tumor), have also been found to be frequently mutated or deleted in the NF2 locus, suggesting a broader role for the NF2 gene in the initiation and progression of human neoplasms. VHL is a rare tumor syndrome characterized by certain types of nervous system tumors (cerebellar and spinal hemangioblastomas as well as retinal angiomas), in conjunction with bilateral renal cell carcinomas and pheochromocytomas. Similar to NF2, recent genetic mutation studies have revealed that the VHL tumor suppressor gene is not only mutated in the hereditary tumors from VHL patients, but also in their sporadic counterparts. Importantly, the VHL gene represents the most frequently mutated cancer-related gene thus far identified in sporadic renal cell carcinoma. In contrast to most other hereditary cancer syndromes, however, VHL mutations are surprisingly specific for tumors typically associated with the VHL syndrome, and have not been detected in any other tumor type unrelated to VHL. The cloning and initial genetic characterization of the NF2 and VHL genes have now provided a rational basis for subsequent functional studies on the elucidation of the normal and tumor-associated cellular signaling pathways of these tumor suppressor genes.', 'journal': 'Glia', 'authors': 'Kley|N|N|;Whaley|J|J|;Seizinger|B R|BR|', 'pubdate': '1995', 'pmid': '8586465', 'mesh_terms': 'D000818:Animals; D001932:Brain Neoplasms; D003001:Cloning, Molecular; D016515:Genes, Neurofibromatosis 2; D018095:Germ-Line Mutation; D006801:Humans; D009154:Mutation; D016518:Neurofibromatosis 2; D006623:von Hippel-Lindau Disease', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': '', 'keywords': '', 'doi': '10.1002/glia.440150310', 'references': '', 'delete': False, 'affiliations': 'Department of Molecular Genetics, Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.', 'pmc': '', 'other_id': '', 'medline_ta': 'Glia', 'nlm_unique_id': '8806785', 'issn_linking': '0894-1491', 'country': 'United States'}}>,\n",
       "  <Answer {'answer': 'SERPING1', 'type': 'extractive', 'score': 0.7754096388816833, 'context': 'mally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prop', 'offsets_in_document': [{'start': 1135, 'end': 1143}], 'offsets_in_context': [{'start': 71, 'end': 79}], 'document_ids': ['27826968'], 'meta': {'title': 'A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation.', 'issue': '9(1)', 'pages': '96-98', 'abstract': 'Hereditary angioedema is a disease of congenital deficiency or functional defect in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-pitting, non-pruritic subcutaneous, or submucosal edema as well as an erythematous rash in some cases. These symptoms result from the uncontrolled localized production of bradykinin. The most commonly affected sites are the extremities, face, gastrointestinal tract, and respiratory system. When the respiratory system is affected by hereditary angioedema, swelling of the airway can restrict breathing and lead to life-threatening obstruction. Herein, we report a case of a 24-year-old woman with type 2 hereditary angioedema who presented with recurrent episodic abdominal pain and swelling of the extremities. She had no family history of angioedema. Although her C4 level was markedly decreased (3.40 mg/dL; normal range: 10-40 mg/dL), she presented with a very high C1-INH level (81.0 mg/dL; normal range: 21.0-39.0 mg/dL) and abnormally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prophylactic tranexamic acid, as needed, and subsequently reported fewer and less severe episodes. To our knowledge, this is the first reported case of type 2 hereditary angioedema in Korea that was consequent to SERPING1 mutation and involved a significantly elevated level of C1-INH as well as a low level of C1-INH activity.', 'journal': 'Allergy, asthma & immunology research', 'authors': 'Sim|Da Woon|DW|;Park|Kyung Hee|KH|;Lee|Jae Hyun|JH|;Park|Jung Won|JW|', 'pubdate': '2017', 'pmid': '27826968', 'mesh_terms': '', 'publication_types': 'D002363:Case Reports', 'chemical_list': '', 'keywords': 'Hereditary angioedema; SERPING1 gene mutation; Type 2', 'doi': '10.4168/aair.2017.9.1.96', 'references': '15514703;15356569;17620062;8628358;22126399;18220147;23437219;27334777;11855162;17186468;18768946;24957111;23277880;23283143;15356535', 'delete': False, 'affiliations': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. parkjw@yuhs.ac.', 'pmc': '', 'other_id': '', 'medline_ta': 'Allergy Asthma Immunol Res', 'nlm_unique_id': '101518382', 'issn_linking': '2092-7355', 'country': 'Korea (South)'}}>,\n",
       "  <Answer {'answer': 'SERPING1', 'type': 'extractive', 'score': 0.7303817272186279, 'context': 'ct in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-p', 'offsets_in_document': [{'start': 149, 'end': 157}], 'offsets_in_context': [{'start': 71, 'end': 79}], 'document_ids': ['27826968'], 'meta': {'title': 'A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation.', 'issue': '9(1)', 'pages': '96-98', 'abstract': 'Hereditary angioedema is a disease of congenital deficiency or functional defect in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-pitting, non-pruritic subcutaneous, or submucosal edema as well as an erythematous rash in some cases. These symptoms result from the uncontrolled localized production of bradykinin. The most commonly affected sites are the extremities, face, gastrointestinal tract, and respiratory system. When the respiratory system is affected by hereditary angioedema, swelling of the airway can restrict breathing and lead to life-threatening obstruction. Herein, we report a case of a 24-year-old woman with type 2 hereditary angioedema who presented with recurrent episodic abdominal pain and swelling of the extremities. She had no family history of angioedema. Although her C4 level was markedly decreased (3.40 mg/dL; normal range: 10-40 mg/dL), she presented with a very high C1-INH level (81.0 mg/dL; normal range: 21.0-39.0 mg/dL) and abnormally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prophylactic tranexamic acid, as needed, and subsequently reported fewer and less severe episodes. To our knowledge, this is the first reported case of type 2 hereditary angioedema in Korea that was consequent to SERPING1 mutation and involved a significantly elevated level of C1-INH as well as a low level of C1-INH activity.', 'journal': 'Allergy, asthma & immunology research', 'authors': 'Sim|Da Woon|DW|;Park|Kyung Hee|KH|;Lee|Jae Hyun|JH|;Park|Jung Won|JW|', 'pubdate': '2017', 'pmid': '27826968', 'mesh_terms': '', 'publication_types': 'D002363:Case Reports', 'chemical_list': '', 'keywords': 'Hereditary angioedema; SERPING1 gene mutation; Type 2', 'doi': '10.4168/aair.2017.9.1.96', 'references': '15514703;15356569;17620062;8628358;22126399;18220147;23437219;27334777;11855162;17186468;18768946;24957111;23277880;23283143;15356535', 'delete': False, 'affiliations': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. parkjw@yuhs.ac.', 'pmc': '', 'other_id': '', 'medline_ta': 'Allergy Asthma Immunol Res', 'nlm_unique_id': '101518382', 'issn_linking': '2092-7355', 'country': 'Korea (South)'}}>,\n",
       "  <Answer {'answer': 'SERPING1', 'type': 'extractive', 'score': 0.7205500602722168, 'context': 'he hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible', 'offsets_in_document': [{'start': 256, 'end': 264}], 'offsets_in_context': [{'start': 71, 'end': 79}], 'document_ids': ['34065094'], 'meta': {'title': 'The Genetics of Hereditary Angioedema: A Review.', 'issue': '10(9)', 'pages': '', 'abstract': 'Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible for the majority of cases of hereditary angioedema. C1 esterase inhibitor (C1-INH) is a major regulator of critical enzymes that are implicated in the cascades of bradykinin generation, which increases the vascular permeability and allows the flow of fluids into the extracellular space and results in angioedema. Moreover, a dominantly inherited disease has been described that has a similar clinical picture to C1-INH-HAE (Hereditary angioedema due to C1 inhibitor deficiency), but with normal C1-INH level and activity. This new type of HAE has no mutation in the SERPING1 gene and it is classified as nC1-INH-HAE (HAE with normal C1-INH). Currently mutations in six different genes have been identified as causing nC1-INH-HAE: factor XII (F12), plasminogen (PLG), angiopoietin 1 (ANGPT1), Kininogen 1 (KNG1), Myoferlin (MYOF), and heparan sulfate (HS)-glucosamine 3-O-sulfotransferase 6 (HS3ST6). In this review we aim to summarize the recent advances in genetic characterization of angioedema and possible future prospects in the identification of new genetic defects in HAE. We also provide an overview of diagnostic applications of genetic biomarkers using NGS technologies (Next Generation Sequencing).', 'journal': 'Journal of clinical medicine', 'authors': \"Santacroce|Rosa|R|0000-0003-4632-5727;D'Andrea|Giovanna|G|;Maffione|Angela Bruna|AB|;Margaglione|Maurizio|M|0000-0001-5627-9221;d'Apolito|Maria|M|\", 'pubdate': '2021', 'pmid': '34065094', 'mesh_terms': '', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': '', 'keywords': 'ANGPT1; C1-INH-HAE; F12; HAE; HS3ST6; KNG1; MYOF; PLG; SERPING1; nC1-INH-HAE', 'doi': '10.3390/jcm10092023', 'references': '29548426;29130992;23994767;29513108;32940350;29753808;33133137;31669336;16271103;24388213;31087670;31517426;31982983;24141983;10963200;11700154;17976427;21849258;24673465;29410040;27130860;30809376;28601681;15580551;23282406;25113305;16638441;23662043;32181278;28795768;30847342;23265861;26248961;33114181;22791189;30689269;14046003;24698534;10984376;31959500;29343682;33508266;24077912;18768946;32542751;27742086;21859431', 'delete': False, 'affiliations': 'Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Human Anatomy, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.', 'pmc': '', 'other_id': '', 'medline_ta': 'J Clin Med', 'nlm_unique_id': '101606588', 'issn_linking': '2077-0383', 'country': 'Switzerland'}}>,\n",
       "  <Answer {'answer': 'FXII gene', 'type': 'extractive', 'score': 0.6601048707962036, 'context': 'erapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. In ', 'offsets_in_document': [{'start': 642, 'end': 651}], 'offsets_in_context': [{'start': 71, 'end': 80}], 'document_ids': ['27271546'], 'meta': {'title': 'Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema.', 'issue': '185(3)', 'pages': '332-7', 'abstract': 'Hereditary angioedema (HAE) is a rare disease associated with either a quantitative or qualitative deficiency in C1-inhibitor (C1-INH) or normal C1-INH. HAE with normal C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE. A recent review described 41 families, including 14 German and 15 Spanish families. We have constructed a register of French patients and their characteristics. A national survey was launched through the French National Center of Reference for Angioedema (CREAK) to study the clinical, biological and therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. In most cases they were young women (mean age at diagnosis: 31 years, mean age at first symptom: 21 years, female/male ratio: 76%). Twenty-one per cent of the patients experienced angioedema attacks only during pregnancy or when on oestrogen contraception. Sixty-three per cent had attacks at all times, but they were more severe during these same periods. Male carriers of the mutation were more frequently asymptomatic than females (P\\u2009=\\u20090·003). C1-INH concentrate and icatibant were both effective for treating attacks. The prophylactic use of tranexamic acid led to a 64% decrease in the number of attacks. This is one of the largest series reported of HAE patients with FXII mutation. The therapeutic management appeared to be identical to that of HAE with C1-INH deficiency.', 'journal': 'Clinical and experimental immunology', 'authors': 'Deroux|A|A|;Boccon-Gibod|I|I|;Fain|O|O|;Pralong|P|P|;Ollivier|Y|Y|;Pagnier|A|A|;Djenouhat|K|K|;Du-Thanh|A|A|;Gompel|A|A|;Faisant|C|C|;Launay|D|D|;Bouillet|L|L|', 'pubdate': '2016', 'pmid': '27271546', 'mesh_terms': 'D000293:Adolescent; D000328:Adult; D054179:Angioedemas, Hereditary; D001920:Bradykinin; D002648:Child; D050718:Complement C1 Inhibitor Protein; D003278:Contraceptives, Oral, Hormonal; D005174:Factor XII; D005190:Family; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D009154:Mutation; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular; D014148:Tranexamic Acid; D055815:Young Adult', 'publication_types': 'D016428:Journal Article', 'chemical_list': 'D050718:Complement C1 Inhibitor Protein; D003278:Contraceptives, Oral, Hormonal; D014148:Tranexamic Acid; D005174:Factor XII; D001920:Bradykinin', 'keywords': 'C1 inhibitor; bradykinin; factor XII; hereditary angioedema', 'doi': '10.1111/cei.12820', 'references': '23517043;17976427;19178407;17381464;22126399;17825897;25744496;23517035;20490261;10963200;17186468;16638441;24673465;19647418;26395818;24054366;23994767;12639808;20384613;10984376;19477491', 'delete': False, 'affiliations': 'Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Internal Medicine Department, Hôpital Saint Antoine, Université Paris, France.;Dermatology Department, Allergology and Photobiology, CHU De Grenoble, Grenoble, France.;Internal Medicine Department, Caen, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Service De Biologie Médicale, EPH De Rouïba, Alger, Algéria.;Dermatology Department, Hôpital Saint-Eloi, Centre Hospitalier Universitaire De Montpellier, Montpellier, France.;Gynecology Department, CHU Paris-Centre, Hopital, Cochin, Paris, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Université Lille, Lille Inflammation Research International Center, Lille, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.', 'pmc': '', 'other_id': '', 'medline_ta': 'Clin Exp Immunol', 'nlm_unique_id': '0057202', 'issn_linking': '0009-9104', 'country': 'England'}}>,\n",
       "  <Answer {'answer': 'SERPING1', 'type': 'extractive', 'score': 0.6024283170700073, 'context': 'utosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin ', 'offsets_in_document': [{'start': 147, 'end': 155}], 'offsets_in_context': [{'start': 71, 'end': 79}], 'document_ids': ['24760113'], 'meta': {'title': 'A novel splice site mutation in the SERPING1 gene leads to haploinsufficiency by complete degradation of the mutant allele mRNA in a case of familial hereditary angioedema.', 'issue': '34(5)', 'pages': '521-3', 'abstract': \"Hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH) is a rare autosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin and/or the mucosa of the upper airways, as well as the intestinal mucosa. Here we report the case of a patient with HAE-C1INH without family history of angioedema. By sequencing the SERPING1 gene we detected a novel mutation (c.1249\\u2009+\\u20095G\\u2009>\\u2009A) affecting the 5' donor splice site in intron 7. We analyzed the SERPING1 cDNA expecting a defect in splicing process but only the wild type allele was detected. SNP analysis of the cDNA sequence demonstrated that only one of the two alleles was present, indicating that the mRNA from the mutated allele was completely degraded. This study reinforces the concept of incomplete penetrance of this disorder since the patients' mother never presented any sign of angioedema despite carrying the same mutation.\", 'journal': 'Journal of clinical immunology', 'authors': 'Colobran|Roger|R|;Pujol-Borrell|Ricardo|R|;Hernández-González|Manuel|M|;Guilarte|Mar|M|', 'pubdate': '2014', 'pmid': '24760113', 'mesh_terms': 'D000328:Adult; D000483:Alleles; D054179:Angioedemas, Hereditary; D001483:Base Sequence; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D005260:Female; D057895:Haploinsufficiency; D006801:Humans; D007438:Introns; D008969:Molecular Sequence Data; D009154:Mutation; D019683:Penetrance; D022821:RNA Splice Sites; D020871:RNA Stability; D012333:RNA, Messenger', 'publication_types': 'D016428:Journal Article', 'chemical_list': 'D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D022821:RNA Splice Sites; D012333:RNA, Messenger; C469952:SERPING1 protein, human', 'keywords': '', 'doi': '10.1007/s10875-014-0042-3', 'references': '23348838;19178938;22452843;16199547;24412907;19162547;21905496;22305226', 'delete': False, 'affiliations': \"Immunology Division, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron (HUVH), Barcelon, Spain.\", 'pmc': '', 'other_id': '', 'medline_ta': 'J Clin Immunol', 'nlm_unique_id': '8102137', 'issn_linking': '0271-9142', 'country': 'Netherlands'}}>,\n",
       "  <Answer {'answer': 'SERPING1', 'type': 'extractive', 'score': 0.5593665838241577, 'context': ' (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency', 'offsets_in_document': [{'start': 92, 'end': 100}], 'offsets_in_context': [{'start': 71, 'end': 79}], 'document_ids': ['30530986'], 'meta': {'title': 'The hereditary angioedema syndromes.', 'issue': '129(1)', 'pages': '66-68', 'abstract': 'Hereditary angioedema (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency, resulting in recurrent attacks of severe swelling. In the current issue of the JCI, Haslund et al. show that in a subset of patients with type I HAE, mutated C1INH encoded by HAE-causing SERPING1 acts upon wildtype (WT) C1INH in a dominant-negative manner and forms intracellular C1INH aggregates. These aggregates lead to a reduction in the levels of secreted functional C1INH, thereby manifesting in the condition that allows the disease state. Interestingly, administration of WT SERPING1 gene is able to restore the levels of secreted C1INH, thereby opening up a novel mechanism justifying gene therapy for HAE.', 'journal': 'The Journal of clinical investigation', 'authors': 'Schmaier|Alvin H|AH|', 'pubdate': '2019', 'pmid': '30530986', 'mesh_terms': 'D054179:Angioedemas, Hereditary; D050718:Complement C1 Inhibitor Protein; D006801:Humans; D009154:Mutation; D013577:Syndrome', 'publication_types': \"D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013486:Research Support, U.S. Gov't, Non-P.H.S.; D016420:Comment\", 'chemical_list': 'D050718:Complement C1 Inhibitor Protein; C469952:SERPING1 protein, human', 'keywords': '', 'doi': '', 'references': '1324834;11956243;25775543;16638441;28795768;3918266;26193639;14046003;6601240;30398465;12464660;10963200;26153520;28601681;11830581;14461960;28069606', 'delete': False, 'affiliations': '', 'pmc': '', 'other_id': '', 'medline_ta': 'J Clin Invest', 'nlm_unique_id': '7802877', 'issn_linking': '0021-9738', 'country': 'United States'}}>,\n",
       "  <Answer {'answer': 'SERPING1', 'type': 'extractive', 'score': 0.554612398147583, 'context': ' may influence HAE disease severity. HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor. Attacks of angioe', 'offsets_in_document': [{'start': 1214, 'end': 1222}], 'offsets_in_context': [{'start': 71, 'end': 79}], 'document_ids': ['23282866'], 'meta': {'title': 'The pathophysiology of hereditary angioedema.', 'issue': '3(9 Suppl)', 'pages': 'S25-8', 'abstract': 'Hereditary angioedema (HAE) causes recurrent episodes of angioedema that may be very severe and are frequently associated with significant morbidity and even mortality. Understanding the pathophysiology of this disease is crucial for proper diagnosis and management of these patients. HAE is caused by mutations in the SERPING1 gene that result in decreased plasma levels of functional C1 inhibitor. A large number of different mutations have been described that result in HAE. About 15% of patients have a mutation at or near the active site of the reactive mobile loop, resulting in a protein that lacks functional activity (type II HAE). Type I HAE is caused by a diverse range of mutations, some of which cause the nascent protein to misfold and thus to be unable to enter the secretory pathway. The primary mediator of swelling in HAE is bradykinin, a product of the plasma contact system. Bradykinin induces increased vascular permeability by activating the bradykinin B2 receptor, which results in phosphorylation of vascular endothelial cadherin. The regulation of both the bradykinin B2 receptor and peptidases that degrade bradykinin may influence HAE disease severity. HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor. Attacks of angioedema result from generation of bradykinin, which acts on bradykinin B2 receptors to enhance vascular permeability.', 'journal': 'The World Allergy Organization journal', 'authors': 'Zuraw|Bruce L|BL|', 'pubdate': '2010', 'pmid': '23282866', 'mesh_terms': '', 'publication_types': 'D016428:Journal Article', 'chemical_list': '', 'keywords': '', 'doi': '10.1097/WOX.0b013e3181f3f21c', 'references': '18180402;1275365;8989315;872360;17724112;2026152;7814636;14046003;6601240;14461960;17418383;3734104;5813121;11956243;18758157;8755917;148134;6587741;3756141;11389203;9003221;15787598;14277836;18447596;12086766;9069585;3289579;17488724;17085287;17085281;8287604;15734727;6833491;6222104;19581505;6902743;3388291;4107267;18158172;10719305;19796797;11112899;3730610;11597672;1518394;9734886;18768946;12039525;12612637', 'delete': False, 'affiliations': \"From the Department of Medicine, University of California San Diego and San Diego Veteran's Affairs Medical Center, La Jolla, Cal.\", 'pmc': '', 'other_id': '', 'medline_ta': 'World Allergy Organ J', 'nlm_unique_id': '101481283', 'issn_linking': '1939-4551', 'country': 'United States'}}>,\n",
       "  <Answer {'answer': '. Gene mutations are the most common genetic cause of HAE and observed in more than 90% of patients. More than 700 mutation variants have been described so far. Patients with angioedema who have no mutations in the gene for C1-INH and normal levels and activity of this inhibitor are labelled: normal C1 inhibitor HAE. These include genetic mutations in factor 12 gene, plasminogen gene, angiopoietin gene, kininogen 1, and myoferlin genes', 'type': 'extractive', 'score': 0.5314473509788513, 'context': 'a. Gene mutations are the most common genetic cause of HAE and observed in more than 90% of patients. More than 700 mutation variants have been described so far. Patients with angioedema who have no mutations in the gene for C1-INH and normal levels and activity of this inhibitor are labelled: normal C1 inhibitor HAE. These include genetic mutations in factor 12 gene, plasminogen gene, angiopoietin gene, kininogen 1, and myoferlin genes', 'offsets_in_document': [{'start': 200, 'end': 639}], 'offsets_in_context': [{'start': 1, 'end': 440}], 'document_ids': ['33442779'], 'meta': {'title': 'Pathophysiology of Hereditary Angioedema (HAE) Beyond the SERPING1 Gene.', 'issue': '60(3)', 'pages': '305-315', 'abstract': 'Hereditary Angioedema (HAE) is an autosomal dominant disorder characterized clinically by recurrent episodes of swelling involving subcutaneous tissues, gastrointestinal tract, and oro-pharyngeal area. Gene mutations are the most common genetic cause of HAE and observed in more than 90% of patients. More than 700 mutation variants have been described so far. Patients with angioedema who have no mutations in the gene for C1-INH and normal levels and activity of this inhibitor are labelled: normal C1 inhibitor HAE. These include genetic mutations in factor 12 gene, plasminogen gene, angiopoietin gene, kininogen 1, and myoferlin genes. The clinical manifestations of patients with these mutations are similar to with patients with C1-INH gene mutations. However, a later age of onset, oro-pharyngeal involvement, and higher female preponderance have been reported in these rare subtypes of hereditary angioedema. With the advent and increased accessibility of whole-exome sequencing, it is expected that new genetic defects and novel pathophysiological pathways will be identified in families with HAE of unknown cause or normal C1-INH angioedema. This review covers some of the recent advances in the field of HAE. The review focuses on pathophysiology of HAE beyond the well-known C1-INH deficiency phenotypes, including various biomarkers that can serve the diagnosis and management of these rare disorders.', 'journal': 'Clinical reviews in allergy & immunology', 'authors': 'Sharma|Jyoti|J|;Jindal|Ankur Kumar|AK|http://orcid.org/0000-0002-7954-0661;Banday|Aaqib Zaffar|AZ|;Kaur|Anit|A|;Rawat|Amit|A|;Singh|Surjit|S|;Longhurst|Hilary|H|', 'pubdate': '2021', 'pmid': '33442779', 'mesh_terms': 'D054179:Angioedemas, Hereditary; D050718:Complement C1 Inhibitor Protein; D005174:Factor XII; D005260:Female; D006801:Humans; D010641:Phenotype', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': 'D050718:Complement C1 Inhibitor Protein; C469952:SERPING1 protein, human; D005174:Factor XII', 'keywords': 'Angioedema; Angiopoietin; Factor XII; Hereditary; Kininogen; Myoferlin; Plasminogen', 'doi': '10.1007/s12016-021-08835-8', 'references': '16112343;32187470;29410040;27116602;28601681;28795768;16638441;31087670;32542751;14367514;3877053;25113305;25952149;25790805;17976427;27788882;10984376;8495195;31507620;17186468;21849258;30463937;27878882;1518394;27271546;20384613;27905115;25744496;22519593;23517043;20617841;29548426;30809376;29952006;29987869;30009523;30689269;30421787;17702744;21586340;15121728;31005824;21339899;32073435;25640891;21030179;24552232;27685806;31955064;28318558;25186184;29957871', 'delete': False, 'affiliations': \"Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India. ankurjindal11@gmail.com.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Department of Clinical Immunology, University College Hospitals, London and Addenbrooke's Hospital, Cambridge, UK.\", 'pmc': '', 'other_id': '', 'medline_ta': 'Clin Rev Allergy Immunol', 'nlm_unique_id': '9504368', 'issn_linking': '1080-0549', 'country': 'United States'}}>],\n",
       " 'documents': [<Document: {'content': \"Hereditary angioedema (HAE) is a rare, often underrecognized genetic disorder caused by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation, vascular leakage, and transient nonpitting angioedema occurring most frequently in the face, neck, upper airway, abdomen, and/or extremities. Involvement of the tongue and laryngopharynx has been associated with asphyxiation and death. Hereditary angioedema is an autosomal-dominant condition; therefore, there is a 50% chance an offspring will inherit this disorder. Any patient presenting with isolated angioedema should be screened with a C4 measurement, as 25% of cases have no family history of HAE. All patients with HAE will have a functional deficiency of C1 esterase inhibitor. Contributors that delay the diagnosis of HAE include recognition delay by clinicians who confuse this condition with histaminergic angioedema, the disease's varied presentations, and limitations to timely testing. Pediatric emergency clinicians should be knowledgeable about how to distinguish between bradykinin- and histamine-mediated angioedema, as there are significant differences in the diagnostic testing, treatment, and clinical response between these 2 different conditions. Evidence indicates that early diagnosis and treatment of HAE reduces morbidity and mortality. Clinician recognition of the mechanistically different problems will ensure patients are appropriately referred to an expert for outpatient management.\", 'content_type': 'text', 'score': 0.9986832737922668, 'meta': {'title': 'Recognition, Evaluation, and Management of Pediatric Hereditary Angioedema.', 'issue': '37(4)', 'pages': '218-223', 'abstract': \"Hereditary angioedema (HAE) is a rare, often underrecognized genetic disorder caused by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation, vascular leakage, and transient nonpitting angioedema occurring most frequently in the face, neck, upper airway, abdomen, and/or extremities. Involvement of the tongue and laryngopharynx has been associated with asphyxiation and death. Hereditary angioedema is an autosomal-dominant condition; therefore, there is a 50% chance an offspring will inherit this disorder. Any patient presenting with isolated angioedema should be screened with a C4 measurement, as 25% of cases have no family history of HAE. All patients with HAE will have a functional deficiency of C1 esterase inhibitor. Contributors that delay the diagnosis of HAE include recognition delay by clinicians who confuse this condition with histaminergic angioedema, the disease's varied presentations, and limitations to timely testing. Pediatric emergency clinicians should be knowledgeable about how to distinguish between bradykinin- and histamine-mediated angioedema, as there are significant differences in the diagnostic testing, treatment, and clinical response between these 2 different conditions. Evidence indicates that early diagnosis and treatment of HAE reduces morbidity and mortality. Clinician recognition of the mechanistically different problems will ensure patients are appropriately referred to an expert for outpatient management.\", 'journal': 'Pediatric emergency care', 'authors': 'Krack|Andrew T|AT|;Bernstein|Jonathan A|JA|;Ruddy|Richard M|RM|', 'pubdate': '2021', 'pmid': '33780405', 'mesh_terms': 'D000799:Angioedema; D054179:Angioedemas, Hereditary; D001176:Arthrogryposis; D002648:Child; D050718:Complement C1 Inhibitor Protein; D006801:Humans; D009154:Mutation', 'publication_types': 'D016428:Journal Article', 'chemical_list': 'D050718:Complement C1 Inhibitor Protein', 'keywords': '', 'doi': '10.1097/PEC.0000000000002402', 'references': '', 'delete': False, 'affiliations': \"From the Clinical Fellow, Department of Pediatrics, Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, and University of Cincinnati Department of Pediatrics.;Professor of Medicine, Department of Internal Medicine, Division of Immunology/Allergy, University of Cincinnati Medical Center.;Professor of Pediatrics, Department of Pediatrics, Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, and University of Cincinnati Department of Pediatrics, Cincinnati, OH.\", 'pmc': '', 'other_id': '', 'medline_ta': 'Pediatr Emerg Care', 'nlm_unique_id': '8507560', 'issn_linking': '0749-5161', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '33780405'}>,\n",
       "  <Document: {'content': 'Hereditary angioedema is a disease of congenital deficiency or functional defect in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-pitting, non-pruritic subcutaneous, or submucosal edema as well as an erythematous rash in some cases. These symptoms result from the uncontrolled localized production of bradykinin. The most commonly affected sites are the extremities, face, gastrointestinal tract, and respiratory system. When the respiratory system is affected by hereditary angioedema, swelling of the airway can restrict breathing and lead to life-threatening obstruction. Herein, we report a case of a 24-year-old woman with type 2 hereditary angioedema who presented with recurrent episodic abdominal pain and swelling of the extremities. She had no family history of angioedema. Although her C4 level was markedly decreased (3.40 mg/dL; normal range: 10-40 mg/dL), she presented with a very high C1-INH level (81.0 mg/dL; normal range: 21.0-39.0 mg/dL) and abnormally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prophylactic tranexamic acid, as needed, and subsequently reported fewer and less severe episodes. To our knowledge, this is the first reported case of type 2 hereditary angioedema in Korea that was consequent to SERPING1 mutation and involved a significantly elevated level of C1-INH as well as a low level of C1-INH activity.', 'content_type': 'text', 'score': 0.99857497215271, 'meta': {'title': 'A Case of Type 2 Hereditary Angioedema With SERPING1 Mutation.', 'issue': '9(1)', 'pages': '96-98', 'abstract': 'Hereditary angioedema is a disease of congenital deficiency or functional defect in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-pitting, non-pruritic subcutaneous, or submucosal edema as well as an erythematous rash in some cases. These symptoms result from the uncontrolled localized production of bradykinin. The most commonly affected sites are the extremities, face, gastrointestinal tract, and respiratory system. When the respiratory system is affected by hereditary angioedema, swelling of the airway can restrict breathing and lead to life-threatening obstruction. Herein, we report a case of a 24-year-old woman with type 2 hereditary angioedema who presented with recurrent episodic abdominal pain and swelling of the extremities. She had no family history of angioedema. Although her C4 level was markedly decreased (3.40 mg/dL; normal range: 10-40 mg/dL), she presented with a very high C1-INH level (81.0 mg/dL; normal range: 21.0-39.0 mg/dL) and abnormally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prophylactic tranexamic acid, as needed, and subsequently reported fewer and less severe episodes. To our knowledge, this is the first reported case of type 2 hereditary angioedema in Korea that was consequent to SERPING1 mutation and involved a significantly elevated level of C1-INH as well as a low level of C1-INH activity.', 'journal': 'Allergy, asthma & immunology research', 'authors': 'Sim|Da Woon|DW|;Park|Kyung Hee|KH|;Lee|Jae Hyun|JH|;Park|Jung Won|JW|', 'pubdate': '2017', 'pmid': '27826968', 'mesh_terms': '', 'publication_types': 'D002363:Case Reports', 'chemical_list': '', 'keywords': 'Hereditary angioedema; SERPING1 gene mutation; Type 2', 'doi': '10.4168/aair.2017.9.1.96', 'references': '15514703;15356569;17620062;8628358;22126399;18220147;23437219;27334777;11855162;17186468;18768946;24957111;23277880;23283143;15356535', 'delete': False, 'affiliations': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. parkjw@yuhs.ac.', 'pmc': '', 'other_id': '', 'medline_ta': 'Allergy Asthma Immunol Res', 'nlm_unique_id': '101518382', 'issn_linking': '2092-7355', 'country': 'Korea (South)'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '27826968'}>,\n",
       "  <Document: {'content': 'Hereditary angioedema (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency, resulting in recurrent attacks of severe swelling. In the current issue of the JCI, Haslund et al. show that in a subset of patients with type I HAE, mutated C1INH encoded by HAE-causing SERPING1 acts upon wildtype (WT) C1INH in a dominant-negative manner and forms intracellular C1INH aggregates. These aggregates lead to a reduction in the levels of secreted functional C1INH, thereby manifesting in the condition that allows the disease state. Interestingly, administration of WT SERPING1 gene is able to restore the levels of secreted C1INH, thereby opening up a novel mechanism justifying gene therapy for HAE.', 'content_type': 'text', 'score': 0.998160183429718, 'meta': {'title': 'The hereditary angioedema syndromes.', 'issue': '129(1)', 'pages': '66-68', 'abstract': 'Hereditary angioedema (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency, resulting in recurrent attacks of severe swelling. In the current issue of the JCI, Haslund et al. show that in a subset of patients with type I HAE, mutated C1INH encoded by HAE-causing SERPING1 acts upon wildtype (WT) C1INH in a dominant-negative manner and forms intracellular C1INH aggregates. These aggregates lead to a reduction in the levels of secreted functional C1INH, thereby manifesting in the condition that allows the disease state. Interestingly, administration of WT SERPING1 gene is able to restore the levels of secreted C1INH, thereby opening up a novel mechanism justifying gene therapy for HAE.', 'journal': 'The Journal of clinical investigation', 'authors': 'Schmaier|Alvin H|AH|', 'pubdate': '2019', 'pmid': '30530986', 'mesh_terms': 'D054179:Angioedemas, Hereditary; D050718:Complement C1 Inhibitor Protein; D006801:Humans; D009154:Mutation; D013577:Syndrome', 'publication_types': \"D016428:Journal Article; D052061:Research Support, N.I.H., Extramural; D013486:Research Support, U.S. Gov't, Non-P.H.S.; D016420:Comment\", 'chemical_list': 'D050718:Complement C1 Inhibitor Protein; C469952:SERPING1 protein, human', 'keywords': '', 'doi': '', 'references': '1324834;11956243;25775543;16638441;28795768;3918266;26193639;14046003;6601240;30398465;12464660;10963200;26153520;28601681;11830581;14461960;28069606', 'delete': False, 'affiliations': '', 'pmc': '', 'other_id': '', 'medline_ta': 'J Clin Invest', 'nlm_unique_id': '7802877', 'issn_linking': '0021-9738', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '30530986'}>,\n",
       "  <Document: {'content': 'Hereditary Angioedema (HAE) is an autosomal dominant disorder characterized clinically by recurrent episodes of swelling involving subcutaneous tissues, gastrointestinal tract, and oro-pharyngeal area. Gene mutations are the most common genetic cause of HAE and observed in more than 90% of patients. More than 700 mutation variants have been described so far. Patients with angioedema who have no mutations in the gene for C1-INH and normal levels and activity of this inhibitor are labelled: normal C1 inhibitor HAE. These include genetic mutations in factor 12 gene, plasminogen gene, angiopoietin gene, kininogen 1, and myoferlin genes. The clinical manifestations of patients with these mutations are similar to with patients with C1-INH gene mutations. However, a later age of onset, oro-pharyngeal involvement, and higher female preponderance have been reported in these rare subtypes of hereditary angioedema. With the advent and increased accessibility of whole-exome sequencing, it is expected that new genetic defects and novel pathophysiological pathways will be identified in families with HAE of unknown cause or normal C1-INH angioedema. This review covers some of the recent advances in the field of HAE. The review focuses on pathophysiology of HAE beyond the well-known C1-INH deficiency phenotypes, including various biomarkers that can serve the diagnosis and management of these rare disorders.', 'content_type': 'text', 'score': 0.9979376792907715, 'meta': {'title': 'Pathophysiology of Hereditary Angioedema (HAE) Beyond the SERPING1 Gene.', 'issue': '60(3)', 'pages': '305-315', 'abstract': 'Hereditary Angioedema (HAE) is an autosomal dominant disorder characterized clinically by recurrent episodes of swelling involving subcutaneous tissues, gastrointestinal tract, and oro-pharyngeal area. Gene mutations are the most common genetic cause of HAE and observed in more than 90% of patients. More than 700 mutation variants have been described so far. Patients with angioedema who have no mutations in the gene for C1-INH and normal levels and activity of this inhibitor are labelled: normal C1 inhibitor HAE. These include genetic mutations in factor 12 gene, plasminogen gene, angiopoietin gene, kininogen 1, and myoferlin genes. The clinical manifestations of patients with these mutations are similar to with patients with C1-INH gene mutations. However, a later age of onset, oro-pharyngeal involvement, and higher female preponderance have been reported in these rare subtypes of hereditary angioedema. With the advent and increased accessibility of whole-exome sequencing, it is expected that new genetic defects and novel pathophysiological pathways will be identified in families with HAE of unknown cause or normal C1-INH angioedema. This review covers some of the recent advances in the field of HAE. The review focuses on pathophysiology of HAE beyond the well-known C1-INH deficiency phenotypes, including various biomarkers that can serve the diagnosis and management of these rare disorders.', 'journal': 'Clinical reviews in allergy & immunology', 'authors': 'Sharma|Jyoti|J|;Jindal|Ankur Kumar|AK|http://orcid.org/0000-0002-7954-0661;Banday|Aaqib Zaffar|AZ|;Kaur|Anit|A|;Rawat|Amit|A|;Singh|Surjit|S|;Longhurst|Hilary|H|', 'pubdate': '2021', 'pmid': '33442779', 'mesh_terms': 'D054179:Angioedemas, Hereditary; D050718:Complement C1 Inhibitor Protein; D005174:Factor XII; D005260:Female; D006801:Humans; D010641:Phenotype', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': 'D050718:Complement C1 Inhibitor Protein; C469952:SERPING1 protein, human; D005174:Factor XII', 'keywords': 'Angioedema; Angiopoietin; Factor XII; Hereditary; Kininogen; Myoferlin; Plasminogen', 'doi': '10.1007/s12016-021-08835-8', 'references': '16112343;32187470;29410040;27116602;28601681;28795768;16638441;31087670;32542751;14367514;3877053;25113305;25952149;25790805;17976427;27788882;10984376;8495195;31507620;17186468;21849258;30463937;27878882;1518394;27271546;20384613;27905115;25744496;22519593;23517043;20617841;29548426;30809376;29952006;29987869;30009523;30689269;30421787;17702744;21586340;15121728;31005824;21339899;32073435;25640891;21030179;24552232;27685806;31955064;28318558;25186184;29957871', 'delete': False, 'affiliations': \"Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India. ankurjindal11@gmail.com.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Department of Clinical Immunology, University College Hospitals, London and Addenbrooke's Hospital, Cambridge, UK.\", 'pmc': '', 'other_id': '', 'medline_ta': 'Clin Rev Allergy Immunol', 'nlm_unique_id': '9504368', 'issn_linking': '1080-0549', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '33442779'}>,\n",
       "  <Document: {'content': 'Most of the genes for hereditary tumor syndromes cloned thus far have subsequently been shown to be mutated not only in the germlines and tumors from patients with the relatively rare inherited disease, but also in the much more common sporadic tumor counterparts in the general population. Thus, the isolation and functional characterization of genes associated with hereditary tumor syndromes have emerged as a major strategy to gain insights into some of the most fundamental mechanisms of tumorigenesis. The search for the genes causing two hereditary tumor syndromes of the nervous system, neurofibromatosis type 2 (NF2) and von Hippel-Lindau disease (VHL), has recently culminated in the cloning of both disease genes. This represents another successful application of the so-called positional cloning approach, i.e., the isolation of a hereditary disease gene with unknown function, based on the determination of its chromosomal location in the human genome. The gene for NF2, a syndrome typically associated with vestibular schwannomas and meningiomas, is homologous with a family of genes whose members appear to play an important role in bridging the cell membrane with the intracellular cytoskeleton, including moesin, ezrin, radixin, and protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and meningiomas from NF2 patients, but also in their sporadic counterparts, which represent approximately one-third of all human brain tumors. Furthermore, malignant human tumors seemingly unrelated to the NF2 syndrome, such as neural crest-derived malignant melanomas, as well as malignant mesotheliomas (a pleural mesoderm-derived tumor), have also been found to be frequently mutated or deleted in the NF2 locus, suggesting a broader role for the NF2 gene in the initiation and progression of human neoplasms. VHL is a rare tumor syndrome characterized by certain types of nervous system tumors (cerebellar and spinal hemangioblastomas as well as retinal angiomas), in conjunction with bilateral renal cell carcinomas and pheochromocytomas. Similar to NF2, recent genetic mutation studies have revealed that the VHL tumor suppressor gene is not only mutated in the hereditary tumors from VHL patients, but also in their sporadic counterparts. Importantly, the VHL gene represents the most frequently mutated cancer-related gene thus far identified in sporadic renal cell carcinoma. In contrast to most other hereditary cancer syndromes, however, VHL mutations are surprisingly specific for tumors typically associated with the VHL syndrome, and have not been detected in any other tumor type unrelated to VHL. The cloning and initial genetic characterization of the NF2 and VHL genes have now provided a rational basis for subsequent functional studies on the elucidation of the normal and tumor-associated cellular signaling pathways of these tumor suppressor genes.', 'content_type': 'text', 'score': 0.9972681999206543, 'meta': {'title': 'Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.', 'issue': '15(3)', 'pages': '297-307', 'abstract': 'Most of the genes for hereditary tumor syndromes cloned thus far have subsequently been shown to be mutated not only in the germlines and tumors from patients with the relatively rare inherited disease, but also in the much more common sporadic tumor counterparts in the general population. Thus, the isolation and functional characterization of genes associated with hereditary tumor syndromes have emerged as a major strategy to gain insights into some of the most fundamental mechanisms of tumorigenesis. The search for the genes causing two hereditary tumor syndromes of the nervous system, neurofibromatosis type 2 (NF2) and von Hippel-Lindau disease (VHL), has recently culminated in the cloning of both disease genes. This represents another successful application of the so-called positional cloning approach, i.e., the isolation of a hereditary disease gene with unknown function, based on the determination of its chromosomal location in the human genome. The gene for NF2, a syndrome typically associated with vestibular schwannomas and meningiomas, is homologous with a family of genes whose members appear to play an important role in bridging the cell membrane with the intracellular cytoskeleton, including moesin, ezrin, radixin, and protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and meningiomas from NF2 patients, but also in their sporadic counterparts, which represent approximately one-third of all human brain tumors. Furthermore, malignant human tumors seemingly unrelated to the NF2 syndrome, such as neural crest-derived malignant melanomas, as well as malignant mesotheliomas (a pleural mesoderm-derived tumor), have also been found to be frequently mutated or deleted in the NF2 locus, suggesting a broader role for the NF2 gene in the initiation and progression of human neoplasms. VHL is a rare tumor syndrome characterized by certain types of nervous system tumors (cerebellar and spinal hemangioblastomas as well as retinal angiomas), in conjunction with bilateral renal cell carcinomas and pheochromocytomas. Similar to NF2, recent genetic mutation studies have revealed that the VHL tumor suppressor gene is not only mutated in the hereditary tumors from VHL patients, but also in their sporadic counterparts. Importantly, the VHL gene represents the most frequently mutated cancer-related gene thus far identified in sporadic renal cell carcinoma. In contrast to most other hereditary cancer syndromes, however, VHL mutations are surprisingly specific for tumors typically associated with the VHL syndrome, and have not been detected in any other tumor type unrelated to VHL. The cloning and initial genetic characterization of the NF2 and VHL genes have now provided a rational basis for subsequent functional studies on the elucidation of the normal and tumor-associated cellular signaling pathways of these tumor suppressor genes.', 'journal': 'Glia', 'authors': 'Kley|N|N|;Whaley|J|J|;Seizinger|B R|BR|', 'pubdate': '1995', 'pmid': '8586465', 'mesh_terms': 'D000818:Animals; D001932:Brain Neoplasms; D003001:Cloning, Molecular; D016515:Genes, Neurofibromatosis 2; D018095:Germ-Line Mutation; D006801:Humans; D009154:Mutation; D016518:Neurofibromatosis 2; D006623:von Hippel-Lindau Disease', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': '', 'keywords': '', 'doi': '10.1002/glia.440150310', 'references': '', 'delete': False, 'affiliations': 'Department of Molecular Genetics, Oncology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.', 'pmc': '', 'other_id': '', 'medline_ta': 'Glia', 'nlm_unique_id': '8806785', 'issn_linking': '0894-1491', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '8586465'}>,\n",
       "  <Document: {'content': 'Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible for the majority of cases of hereditary angioedema. C1 esterase inhibitor (C1-INH) is a major regulator of critical enzymes that are implicated in the cascades of bradykinin generation, which increases the vascular permeability and allows the flow of fluids into the extracellular space and results in angioedema. Moreover, a dominantly inherited disease has been described that has a similar clinical picture to C1-INH-HAE (Hereditary angioedema due to C1 inhibitor deficiency), but with normal C1-INH level and activity. This new type of HAE has no mutation in the SERPING1 gene and it is classified as nC1-INH-HAE (HAE with normal C1-INH). Currently mutations in six different genes have been identified as causing nC1-INH-HAE: factor XII (F12), plasminogen (PLG), angiopoietin 1 (ANGPT1), Kininogen 1 (KNG1), Myoferlin (MYOF), and heparan sulfate (HS)-glucosamine 3-O-sulfotransferase 6 (HS3ST6). In this review we aim to summarize the recent advances in genetic characterization of angioedema and possible future prospects in the identification of new genetic defects in HAE. We also provide an overview of diagnostic applications of genetic biomarkers using NGS technologies (Next Generation Sequencing).', 'content_type': 'text', 'score': 0.9969114661216736, 'meta': {'title': 'The Genetics of Hereditary Angioedema: A Review.', 'issue': '10(9)', 'pages': '', 'abstract': 'Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible for the majority of cases of hereditary angioedema. C1 esterase inhibitor (C1-INH) is a major regulator of critical enzymes that are implicated in the cascades of bradykinin generation, which increases the vascular permeability and allows the flow of fluids into the extracellular space and results in angioedema. Moreover, a dominantly inherited disease has been described that has a similar clinical picture to C1-INH-HAE (Hereditary angioedema due to C1 inhibitor deficiency), but with normal C1-INH level and activity. This new type of HAE has no mutation in the SERPING1 gene and it is classified as nC1-INH-HAE (HAE with normal C1-INH). Currently mutations in six different genes have been identified as causing nC1-INH-HAE: factor XII (F12), plasminogen (PLG), angiopoietin 1 (ANGPT1), Kininogen 1 (KNG1), Myoferlin (MYOF), and heparan sulfate (HS)-glucosamine 3-O-sulfotransferase 6 (HS3ST6). In this review we aim to summarize the recent advances in genetic characterization of angioedema and possible future prospects in the identification of new genetic defects in HAE. We also provide an overview of diagnostic applications of genetic biomarkers using NGS technologies (Next Generation Sequencing).', 'journal': 'Journal of clinical medicine', 'authors': \"Santacroce|Rosa|R|0000-0003-4632-5727;D'Andrea|Giovanna|G|;Maffione|Angela Bruna|AB|;Margaglione|Maurizio|M|0000-0001-5627-9221;d'Apolito|Maria|M|\", 'pubdate': '2021', 'pmid': '34065094', 'mesh_terms': '', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': '', 'keywords': 'ANGPT1; C1-INH-HAE; F12; HAE; HS3ST6; KNG1; MYOF; PLG; SERPING1; nC1-INH-HAE', 'doi': '10.3390/jcm10092023', 'references': '29548426;29130992;23994767;29513108;32940350;29753808;33133137;31669336;16271103;24388213;31087670;31517426;31982983;24141983;10963200;11700154;17976427;21849258;24673465;29410040;27130860;30809376;28601681;15580551;23282406;25113305;16638441;23662043;32181278;28795768;30847342;23265861;26248961;33114181;22791189;30689269;14046003;24698534;10984376;31959500;29343682;33508266;24077912;18768946;32542751;27742086;21859431', 'delete': False, 'affiliations': 'Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Human Anatomy, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.;Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.', 'pmc': '', 'other_id': '', 'medline_ta': 'J Clin Med', 'nlm_unique_id': '101606588', 'issn_linking': '2077-0383', 'country': 'Switzerland'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '34065094'}>,\n",
       "  <Document: {'content': 'Hereditary angioedema (HAE) is a rare disease associated with either a quantitative or qualitative deficiency in C1-inhibitor (C1-INH) or normal C1-INH. HAE with normal C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE. A recent review described 41 families, including 14 German and 15 Spanish families. We have constructed a register of French patients and their characteristics. A national survey was launched through the French National Center of Reference for Angioedema (CREAK) to study the clinical, biological and therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. In most cases they were young women (mean age at diagnosis: 31 years, mean age at first symptom: 21 years, female/male ratio: 76%). Twenty-one per cent of the patients experienced angioedema attacks only during pregnancy or when on oestrogen contraception. Sixty-three per cent had attacks at all times, but they were more severe during these same periods. Male carriers of the mutation were more frequently asymptomatic than females (P\\u2009=\\u20090·003). C1-INH concentrate and icatibant were both effective for treating attacks. The prophylactic use of tranexamic acid led to a 64% decrease in the number of attacks. This is one of the largest series reported of HAE patients with FXII mutation. The therapeutic management appeared to be identical to that of HAE with C1-INH deficiency.', 'content_type': 'text', 'score': 0.9966562986373901, 'meta': {'title': 'Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema.', 'issue': '185(3)', 'pages': '332-7', 'abstract': 'Hereditary angioedema (HAE) is a rare disease associated with either a quantitative or qualitative deficiency in C1-inhibitor (C1-INH) or normal C1-INH. HAE with normal C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE. A recent review described 41 families, including 14 German and 15 Spanish families. We have constructed a register of French patients and their characteristics. A national survey was launched through the French National Center of Reference for Angioedema (CREAK) to study the clinical, biological and therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. In most cases they were young women (mean age at diagnosis: 31 years, mean age at first symptom: 21 years, female/male ratio: 76%). Twenty-one per cent of the patients experienced angioedema attacks only during pregnancy or when on oestrogen contraception. Sixty-three per cent had attacks at all times, but they were more severe during these same periods. Male carriers of the mutation were more frequently asymptomatic than females (P\\u2009=\\u20090·003). C1-INH concentrate and icatibant were both effective for treating attacks. The prophylactic use of tranexamic acid led to a 64% decrease in the number of attacks. This is one of the largest series reported of HAE patients with FXII mutation. The therapeutic management appeared to be identical to that of HAE with C1-INH deficiency.', 'journal': 'Clinical and experimental immunology', 'authors': 'Deroux|A|A|;Boccon-Gibod|I|I|;Fain|O|O|;Pralong|P|P|;Ollivier|Y|Y|;Pagnier|A|A|;Djenouhat|K|K|;Du-Thanh|A|A|;Gompel|A|A|;Faisant|C|C|;Launay|D|D|;Bouillet|L|L|', 'pubdate': '2016', 'pmid': '27271546', 'mesh_terms': 'D000293:Adolescent; D000328:Adult; D054179:Angioedemas, Hereditary; D001920:Bradykinin; D002648:Child; D050718:Complement C1 Inhibitor Protein; D003278:Contraceptives, Oral, Hormonal; D005174:Factor XII; D005190:Family; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D009154:Mutation; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular; D014148:Tranexamic Acid; D055815:Young Adult', 'publication_types': 'D016428:Journal Article', 'chemical_list': 'D050718:Complement C1 Inhibitor Protein; D003278:Contraceptives, Oral, Hormonal; D014148:Tranexamic Acid; D005174:Factor XII; D001920:Bradykinin', 'keywords': 'C1 inhibitor; bradykinin; factor XII; hereditary angioedema', 'doi': '10.1111/cei.12820', 'references': '23517043;17976427;19178407;17381464;22126399;17825897;25744496;23517035;20490261;10963200;17186468;16638441;24673465;19647418;26395818;24054366;23994767;12639808;20384613;10984376;19477491', 'delete': False, 'affiliations': 'Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Internal Medicine Department, Hôpital Saint Antoine, Université Paris, France.;Dermatology Department, Allergology and Photobiology, CHU De Grenoble, Grenoble, France.;Internal Medicine Department, Caen, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Service De Biologie Médicale, EPH De Rouïba, Alger, Algéria.;Dermatology Department, Hôpital Saint-Eloi, Centre Hospitalier Universitaire De Montpellier, Montpellier, France.;Gynecology Department, CHU Paris-Centre, Hopital, Cochin, Paris, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.;Université Lille, Lille Inflammation Research International Center, Lille, France.;Internal Medicine Department, Centre Hospitalier Des Alpes, Grenoble, France.', 'pmc': '', 'other_id': '', 'medline_ta': 'Clin Exp Immunol', 'nlm_unique_id': '0057202', 'issn_linking': '0009-9104', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '27271546'}>,\n",
       "  <Document: {'content': 'Hereditary angioedema (HAE) causes recurrent episodes of angioedema that may be very severe and are frequently associated with significant morbidity and even mortality. Understanding the pathophysiology of this disease is crucial for proper diagnosis and management of these patients. HAE is caused by mutations in the SERPING1 gene that result in decreased plasma levels of functional C1 inhibitor. A large number of different mutations have been described that result in HAE. About 15% of patients have a mutation at or near the active site of the reactive mobile loop, resulting in a protein that lacks functional activity (type II HAE). Type I HAE is caused by a diverse range of mutations, some of which cause the nascent protein to misfold and thus to be unable to enter the secretory pathway. The primary mediator of swelling in HAE is bradykinin, a product of the plasma contact system. Bradykinin induces increased vascular permeability by activating the bradykinin B2 receptor, which results in phosphorylation of vascular endothelial cadherin. The regulation of both the bradykinin B2 receptor and peptidases that degrade bradykinin may influence HAE disease severity. HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor. Attacks of angioedema result from generation of bradykinin, which acts on bradykinin B2 receptors to enhance vascular permeability.', 'content_type': 'text', 'score': 0.9963576197624207, 'meta': {'title': 'The pathophysiology of hereditary angioedema.', 'issue': '3(9 Suppl)', 'pages': 'S25-8', 'abstract': 'Hereditary angioedema (HAE) causes recurrent episodes of angioedema that may be very severe and are frequently associated with significant morbidity and even mortality. Understanding the pathophysiology of this disease is crucial for proper diagnosis and management of these patients. HAE is caused by mutations in the SERPING1 gene that result in decreased plasma levels of functional C1 inhibitor. A large number of different mutations have been described that result in HAE. About 15% of patients have a mutation at or near the active site of the reactive mobile loop, resulting in a protein that lacks functional activity (type II HAE). Type I HAE is caused by a diverse range of mutations, some of which cause the nascent protein to misfold and thus to be unable to enter the secretory pathway. The primary mediator of swelling in HAE is bradykinin, a product of the plasma contact system. Bradykinin induces increased vascular permeability by activating the bradykinin B2 receptor, which results in phosphorylation of vascular endothelial cadherin. The regulation of both the bradykinin B2 receptor and peptidases that degrade bradykinin may influence HAE disease severity. HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor. Attacks of angioedema result from generation of bradykinin, which acts on bradykinin B2 receptors to enhance vascular permeability.', 'journal': 'The World Allergy Organization journal', 'authors': 'Zuraw|Bruce L|BL|', 'pubdate': '2010', 'pmid': '23282866', 'mesh_terms': '', 'publication_types': 'D016428:Journal Article', 'chemical_list': '', 'keywords': '', 'doi': '10.1097/WOX.0b013e3181f3f21c', 'references': '18180402;1275365;8989315;872360;17724112;2026152;7814636;14046003;6601240;14461960;17418383;3734104;5813121;11956243;18758157;8755917;148134;6587741;3756141;11389203;9003221;15787598;14277836;18447596;12086766;9069585;3289579;17488724;17085287;17085281;8287604;15734727;6833491;6222104;19581505;6902743;3388291;4107267;18158172;10719305;19796797;11112899;3730610;11597672;1518394;9734886;18768946;12039525;12612637', 'delete': False, 'affiliations': \"From the Department of Medicine, University of California San Diego and San Diego Veteran's Affairs Medical Center, La Jolla, Cal.\", 'pmc': '', 'other_id': '', 'medline_ta': 'World Allergy Organ J', 'nlm_unique_id': '101481283', 'issn_linking': '1939-4551', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '23282866'}>,\n",
       "  <Document: {'content': 'Hereditary angioedema is a relatively rare genetic disorder affecting between one in 10,000 and one in 50,000 individuals worldwide. The most common clinical symptoms observed are relapsing swelling of the skin and abdominal pain attacks. However, more serious and potentially fatal laryngeal attacks can also occur. Hereditary angioedema is most frequently caused by a deficiency of C1-inhibitor. Replacement therapy with Berinert, an intravenous pasteurized C1-inhibitor concentrate derived from human plasma, is a recommended treatment for rapid resolution of acute attacks of hereditary angioedema due to C1-inhibitor deficiency. Prophylactic therapy with C1-inhibitor is also available. Future advances may improve morbidity and mortality associated with hereditary angioedema.', 'content_type': 'text', 'score': 0.9963317513465881, 'meta': {'title': 'Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency.', 'issue': '7(6)', 'pages': '723-33', 'abstract': 'Hereditary angioedema is a relatively rare genetic disorder affecting between one in 10,000 and one in 50,000 individuals worldwide. The most common clinical symptoms observed are relapsing swelling of the skin and abdominal pain attacks. However, more serious and potentially fatal laryngeal attacks can also occur. Hereditary angioedema is most frequently caused by a deficiency of C1-inhibitor. Replacement therapy with Berinert, an intravenous pasteurized C1-inhibitor concentrate derived from human plasma, is a recommended treatment for rapid resolution of acute attacks of hereditary angioedema due to C1-inhibitor deficiency. Prophylactic therapy with C1-inhibitor is also available. Future advances may improve morbidity and mortality associated with hereditary angioedema.', 'journal': 'Expert review of clinical immunology', 'authors': 'Bork|Konrad|K|', 'pubdate': '2011', 'pmid': '22014012', 'mesh_terms': 'D015746:Abdominal Pain; D054179:Angioedemas, Hereditary; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D006801:Humans; D007262:Infusions, Intravenous; D061352:Pasteurization', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': 'D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; C469952:SERPING1 protein, human', 'keywords': '', 'doi': '10.1586/eci.11.72', 'references': '', 'delete': False, 'affiliations': 'Department of Dermatology, Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany. bork@hautklinik.klinik.uni-mainz.de', 'pmc': '', 'other_id': '', 'medline_ta': 'Expert Rev Clin Immunol', 'nlm_unique_id': '101271248', 'issn_linking': '1744-666X', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '22014012'}>,\n",
       "  <Document: {'content': \"Hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH) is a rare autosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin and/or the mucosa of the upper airways, as well as the intestinal mucosa. Here we report the case of a patient with HAE-C1INH without family history of angioedema. By sequencing the SERPING1 gene we detected a novel mutation (c.1249\\u2009+\\u20095G\\u2009>\\u2009A) affecting the 5' donor splice site in intron 7. We analyzed the SERPING1 cDNA expecting a defect in splicing process but only the wild type allele was detected. SNP analysis of the cDNA sequence demonstrated that only one of the two alleles was present, indicating that the mRNA from the mutated allele was completely degraded. This study reinforces the concept of incomplete penetrance of this disorder since the patients' mother never presented any sign of angioedema despite carrying the same mutation.\", 'content_type': 'text', 'score': 0.9960467219352722, 'meta': {'title': 'A novel splice site mutation in the SERPING1 gene leads to haploinsufficiency by complete degradation of the mutant allele mRNA in a case of familial hereditary angioedema.', 'issue': '34(5)', 'pages': '521-3', 'abstract': \"Hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH) is a rare autosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin and/or the mucosa of the upper airways, as well as the intestinal mucosa. Here we report the case of a patient with HAE-C1INH without family history of angioedema. By sequencing the SERPING1 gene we detected a novel mutation (c.1249\\u2009+\\u20095G\\u2009>\\u2009A) affecting the 5' donor splice site in intron 7. We analyzed the SERPING1 cDNA expecting a defect in splicing process but only the wild type allele was detected. SNP analysis of the cDNA sequence demonstrated that only one of the two alleles was present, indicating that the mRNA from the mutated allele was completely degraded. This study reinforces the concept of incomplete penetrance of this disorder since the patients' mother never presented any sign of angioedema despite carrying the same mutation.\", 'journal': 'Journal of clinical immunology', 'authors': 'Colobran|Roger|R|;Pujol-Borrell|Ricardo|R|;Hernández-González|Manuel|M|;Guilarte|Mar|M|', 'pubdate': '2014', 'pmid': '24760113', 'mesh_terms': 'D000328:Adult; D000483:Alleles; D054179:Angioedemas, Hereditary; D001483:Base Sequence; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D005260:Female; D057895:Haploinsufficiency; D006801:Humans; D007438:Introns; D008969:Molecular Sequence Data; D009154:Mutation; D019683:Penetrance; D022821:RNA Splice Sites; D020871:RNA Stability; D012333:RNA, Messenger', 'publication_types': 'D016428:Journal Article', 'chemical_list': 'D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D022821:RNA Splice Sites; D012333:RNA, Messenger; C469952:SERPING1 protein, human', 'keywords': '', 'doi': '10.1007/s10875-014-0042-3', 'references': '23348838;19178938;22452843;16199547;24412907;19162547;21905496;22305226', 'delete': False, 'affiliations': \"Immunology Division, Vall d'Hebron Research Institute (VHIR), Hospital Universitari Vall d'Hebron (HUVH), Barcelon, Spain.\", 'pmc': '', 'other_id': '', 'medline_ta': 'J Clin Immunol', 'nlm_unique_id': '8102137', 'issn_linking': '0271-9142', 'country': 'Netherlands'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '24760113'}>],\n",
       " 'root_node': 'Query',\n",
       " 'params': {'BM25Retriever': {'top_k': 100}},\n",
       " 'node_id': 'Reader'}"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "prediction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "2d86f1bb",
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_snipet_from_answer(pred):\n",
    "    is_extractive = pred.type == 'extractive'\n",
    "    answer = {}\n",
    "    answer['document'] =  globals.BIOASQ.doc_relative_url + pred.document_ids[0]\n",
    "    answer['text'] = pred.context\n",
    "    answer['offsetInBeginSection'] = pred.meta['abstract'].rfind(pred.context)\n",
    "    answer['offsetInEndSection'] = answer['offsetInBeginSection'] + len(pred.context)\n",
    "    answer[\"beginSection\"] = \"abstract\",\n",
    "    answer[\"endSection\"] = \"abstract\"\n",
    "    return answer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "1c1b9bd7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  0%|                                                                                                                    | 0/90 [00:00<?, ?it/s]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c6fff870d4814aedad162cc524276c1b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  1%|█▏                                                                                                          | 1/90 [00:06<09:46,  6.59s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "944821d42ef94c9db582f1d48ec72831",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  2%|██▍                                                                                                         | 2/90 [00:14<11:10,  7.62s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b6425cb31a444f3c89886482be9a62c4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  3%|███▌                                                                                                        | 3/90 [00:22<10:48,  7.46s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cbafa221e9c449f2bd0f0712f9154a20",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  4%|████▊                                                                                                       | 4/90 [00:25<08:28,  5.91s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "593fe20742da4da49f8ab2a7de04819d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  6%|██████                                                                                                      | 5/90 [00:33<09:06,  6.43s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "efdec8f9668a4c349cb263bafafb4fed",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  7%|███████▏                                                                                                    | 6/90 [00:41<09:58,  7.13s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f515fde6c4c9405c8facf38528e3dc28",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  8%|████████▍                                                                                                   | 7/90 [00:49<10:02,  7.26s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0ae552f390d44a039c4fd89f455c8a8b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  9%|█████████▌                                                                                                  | 8/90 [00:55<09:23,  6.87s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "782b84a46ba541a28977ee81fef7493c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 10%|██████████▊                                                                                                 | 9/90 [01:04<10:12,  7.56s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "2a5e2e9246414d40a8dc1aedb52a5b90",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 11%|███████████▉                                                                                               | 10/90 [01:11<09:52,  7.41s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b2161e6093a043e2a841e8f9e9c1c1f3",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 12%|█████████████                                                                                              | 11/90 [01:18<09:32,  7.25s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ca81e12a325842c8a2da68db0815eea2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 13%|██████████████▎                                                                                            | 12/90 [01:24<09:04,  6.98s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "92bc032757914e42b041440867a9fdeb",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 14%|███████████████▍                                                                                           | 13/90 [01:31<08:58,  7.00s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8666944963c143ec861c32f6167a892e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 16%|████████████████▋                                                                                          | 14/90 [01:36<07:56,  6.27s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8851c311ba41434fb1dd567e86c7d643",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 17%|█████████████████▊                                                                                         | 15/90 [01:43<08:08,  6.51s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6dbba4147f00409ba41862ff4f6dc67e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 18%|███████████████████                                                                                        | 16/90 [01:48<07:34,  6.14s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b456dd48b02d4791a14912045e6bf527",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 19%|████████████████████▏                                                                                      | 17/90 [01:54<07:32,  6.20s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0a8a6f12c06b4ebc859bb77b0761fa38",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 20%|█████████████████████▍                                                                                     | 18/90 [02:00<07:24,  6.18s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "bf5501b58228410bb3f1c63a5a8fe44a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 21%|██████████████████████▌                                                                                    | 19/90 [02:05<06:41,  5.65s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "000a5a82273c47a19fddadaef218a644",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 22%|███████████████████████▊                                                                                   | 20/90 [02:11<06:46,  5.81s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7fa83a75ee994f458429a08686d77357",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 23%|████████████████████████▉                                                                                  | 21/90 [02:17<06:47,  5.91s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1fc5fde34320460b8597367d46ff269b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 24%|██████████████████████████▏                                                                                | 22/90 [02:25<07:24,  6.53s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "fb87206abf3446a2a38aa3bff5fac54c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 26%|███████████████████████████▎                                                                               | 23/90 [02:34<07:54,  7.09s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0d6a98f990ff473c8215ae543eda3cec",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 27%|████████████████████████████▌                                                                              | 24/90 [02:42<08:08,  7.41s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1c3642409c4e43e8bec9e27e300e189c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 28%|█████████████████████████████▋                                                                             | 25/90 [02:48<07:40,  7.08s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b1656e2cf091424f954d8b766a02672a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 29%|██████████████████████████████▉                                                                            | 26/90 [02:55<07:30,  7.03s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6c67df08e1774858ae09ac04ee38c265",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 30%|████████████████████████████████                                                                           | 27/90 [03:03<07:34,  7.22s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "04fb8f77bf484e54a3f066098b468873",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 31%|█████████████████████████████████▎                                                                         | 28/90 [03:10<07:30,  7.27s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ff58c259a92449d5a220a42e763d8ac4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 32%|██████████████████████████████████▍                                                                        | 29/90 [03:16<06:58,  6.86s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e01cd4d3a8714065b68c29ece76916ad",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 33%|███████████████████████████████████▋                                                                       | 30/90 [03:22<06:41,  6.70s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "baf38430d5bb4c0ba7c8594e33a8be61",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 34%|████████████████████████████████████▊                                                                      | 31/90 [03:28<06:12,  6.31s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f3e9ac76f708423e9b7408f0068e63f7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 36%|██████████████████████████████████████                                                                     | 32/90 [03:32<05:39,  5.85s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7dbb18ddff8d4d5a8fab37d3fe5f812f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 37%|███████████████████████████████████████▏                                                                   | 33/90 [03:42<06:31,  6.87s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "236323508a524578aa74de04e2fd2123",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 38%|████████████████████████████████████████▍                                                                  | 34/90 [03:48<06:23,  6.84s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0ece423f5e7844f98e53b21b8729736f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 39%|█████████████████████████████████████████▌                                                                 | 35/90 [03:55<06:11,  6.76s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b26e25b8e6834429832a502cf41eeb9b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 40%|██████████████████████████████████████████▊                                                                | 36/90 [04:02<06:15,  6.96s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "886271a368dd41f580ba1945fe546173",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 41%|███████████████████████████████████████████▉                                                               | 37/90 [04:09<06:02,  6.84s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "05c8248faf3e4438a4a468c03de3ed98",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 42%|█████████████████████████████████████████████▏                                                             | 38/90 [04:15<05:44,  6.63s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d050b11c884f43dd99c73accc746ab34",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 43%|██████████████████████████████████████████████▎                                                            | 39/90 [04:23<05:57,  7.00s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d97a657094034583a3e503e94d06e75f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 44%|███████████████████████████████████████████████▌                                                           | 40/90 [04:31<06:04,  7.29s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "330cb431bfd8421e8f960ecf0012669c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 46%|████████████████████████████████████████████████▋                                                          | 41/90 [04:39<06:06,  7.49s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b7eb19dc6df64ba79fc46f0cdb1f1b0b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 47%|█████████████████████████████████████████████████▉                                                         | 42/90 [04:46<05:57,  7.44s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e1b0034949744693ae28d7377e4720ce",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 48%|███████████████████████████████████████████████████                                                        | 43/90 [04:55<06:06,  7.81s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "00336ab9fded472aad1f7adfd83dc6e5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 49%|████████████████████████████████████████████████████▎                                                      | 44/90 [05:01<05:38,  7.36s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cf4b434f380a4ce7b00111e3382fa1b5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 50%|█████████████████████████████████████████████████████▌                                                     | 45/90 [05:09<05:40,  7.58s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ee4984c6bec4423a921314b877f7d908",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 51%|██████████████████████████████████████████████████████▋                                                    | 46/90 [05:16<05:24,  7.37s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "614088aa68a145b39ffd2bf310363ba1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 52%|███████████████████████████████████████████████████████▉                                                   | 47/90 [05:24<05:26,  7.60s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5816e7428b694860b0a3d4efe4716455",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 53%|█████████████████████████████████████████████████████████                                                  | 48/90 [05:31<05:03,  7.23s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f8fc3037e43b4cc59127abeaae41ca11",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 54%|██████████████████████████████████████████████████████████▎                                                | 49/90 [05:39<05:08,  7.51s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8a3dfed734d4406a90536e9977a12e4c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 56%|███████████████████████████████████████████████████████████▍                                               | 50/90 [05:45<04:43,  7.09s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c29d1fad65d74e069c10c88399411a58",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 57%|████████████████████████████████████████████████████████████▋                                              | 51/90 [05:53<04:46,  7.35s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4ce7270d0b9346fea63113e205d43e8a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 58%|█████████████████████████████████████████████████████████████▊                                             | 52/90 [06:00<04:34,  7.23s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5050a47fe186459ebc6fdd01c3d857a9",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 59%|███████████████████████████████████████████████████████████████                                            | 53/90 [06:06<04:11,  6.80s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f7f6ab5f11d942f5902a6135f203f157",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 60%|████████████████████████████████████████████████████████████████▏                                          | 54/90 [06:12<04:02,  6.74s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "35a3e530876d4a08ad9b7a7454543ec5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 61%|█████████████████████████████████████████████████████████████████▍                                         | 55/90 [06:21<04:19,  7.42s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "bc8079db18f943159f52f957ea8d1812",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 62%|██████████████████████████████████████████████████████████████████▌                                        | 56/90 [06:27<03:54,  6.90s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5490391b60084b2eb8b1e404a3f906ed",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 63%|███████████████████████████████████████████████████████████████████▊                                       | 57/90 [06:35<03:59,  7.24s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "75d9b6bec7524b0492d860a7fd261466",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 64%|████████████████████████████████████████████████████████████████████▉                                      | 58/90 [06:44<04:06,  7.69s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "415862ecc8d34dd28c40b7539455ee5e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 66%|██████████████████████████████████████████████████████████████████████▏                                    | 59/90 [06:55<04:30,  8.73s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "70a3764c71c44a87a088e998e5cbddd5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 67%|███████████████████████████████████████████████████████████████████████▎                                   | 60/90 [07:01<04:02,  8.07s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ddfd50b8cdf2414b97117fb04ed02d1f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 68%|████████████████████████████████████████████████████████████████████████▌                                  | 61/90 [07:10<03:56,  8.14s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b6e58c3f8d1948f58b4624190760c7d1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 69%|█████████████████████████████████████████████████████████████████████████▋                                 | 62/90 [07:18<03:50,  8.24s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e580a0d4666348d889387730e80aff91",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 70%|██████████████████████████████████████████████████████████████████████████▉                                | 63/90 [07:25<03:30,  7.78s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "150137a5e4b54f669c63ad97f8377930",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 71%|████████████████████████████████████████████████████████████████████████████                               | 64/90 [07:35<03:39,  8.46s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "77831eb8dbd44a1996f9fb1ba1a2a2e4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 72%|█████████████████████████████████████████████████████████████████████████████▎                             | 65/90 [07:43<03:25,  8.21s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "915f371137f64513821b2a9f2c466867",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 73%|██████████████████████████████████████████████████████████████████████████████▍                            | 66/90 [07:52<03:24,  8.51s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b4ef774819f64a7fb53f7d16478588e2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 74%|███████████████████████████████████████████████████████████████████████████████▋                           | 67/90 [07:58<03:01,  7.88s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3afb5212788045d8a9d2af05e6bfcf82",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 76%|████████████████████████████████████████████████████████████████████████████████▊                          | 68/90 [08:05<02:49,  7.69s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7252a52763c8496194de15fcdca39c8d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 77%|██████████████████████████████████████████████████████████████████████████████████                         | 69/90 [08:13<02:42,  7.76s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "2a0d5d56bd9144a8a83b47d8e215b6ca",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/4 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 78%|███████████████████████████████████████████████████████████████████████████████████▏                       | 70/90 [08:24<02:51,  8.55s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "023157dc0d4b4310b8b5ce37c5d6d18e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 79%|████████████████████████████████████████████████████████████████████████████████████▍                      | 71/90 [08:31<02:32,  8.01s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "56d67c9df8614ddbacaa5056c3960296",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 80%|█████████████████████████████████████████████████████████████████████████████████████▌                     | 72/90 [08:33<01:57,  6.50s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b96fc25d752447cc9ea7678b327dd92f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 81%|██████████████████████████████████████████████████████████████████████████████████████▊                    | 73/90 [08:40<01:49,  6.43s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "39d74778d0c849f399b6ff0508db157f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 82%|███████████████████████████████████████████████████████████████████████████████████████▉                   | 74/90 [08:44<01:31,  5.71s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "2c2cdc7e76894b97b4740820901d3e10",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 83%|█████████████████████████████████████████████████████████████████████████████████████████▏                 | 75/90 [08:51<01:32,  6.18s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "325695208f8a406caeb0e355f2e5f421",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 84%|██████████████████████████████████████████████████████████████████████████████████████████▎                | 76/90 [08:58<01:28,  6.30s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ead86f1cdfba4fd5b983f8f191d846cc",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 86%|███████████████████████████████████████████████████████████████████████████████████████████▌               | 77/90 [09:04<01:21,  6.26s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9cee16e6a4f0470781e715d37a862032",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 87%|████████████████████████████████████████████████████████████████████████████████████████████▋              | 78/90 [09:10<01:13,  6.16s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e4812f0448dd4b0bb8795102d6a35500",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 88%|█████████████████████████████████████████████████████████████████████████████████████████████▉             | 79/90 [09:17<01:10,  6.44s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b9d852fee4874ac597e1828803322c06",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 89%|███████████████████████████████████████████████████████████████████████████████████████████████            | 80/90 [09:25<01:08,  6.81s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a5c68613a19f4ff1a12d102a6bee3ae4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 90%|████████████████████████████████████████████████████████████████████████████████████████████████▎          | 81/90 [09:33<01:04,  7.22s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "782bb2f78a6b4ab8bdbef173b51bbc82",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 91%|█████████████████████████████████████████████████████████████████████████████████████████████████▍         | 82/90 [09:40<00:58,  7.33s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6ac365825c39402cac2b36a17d321ea0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 92%|██████████████████████████████████████████████████████████████████████████████████████████████████▋        | 83/90 [09:47<00:50,  7.15s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "141fb849ac924c598d14214268ed909d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 93%|███████████████████████████████████████████████████████████████████████████████████████████████████▊       | 84/90 [09:53<00:41,  6.94s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5792055f19524930a9ba42f7462157ad",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 94%|█████████████████████████████████████████████████████████████████████████████████████████████████████      | 85/90 [10:00<00:33,  6.77s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "99b76580cb454b6694d97877dbefef0d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 96%|██████████████████████████████████████████████████████████████████████████████████████████████████████▏    | 86/90 [10:05<00:24,  6.22s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e5fe9cf98add404e8f8bed10884cb9d1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 97%|███████████████████████████████████████████████████████████████████████████████████████████████████████▍   | 87/90 [10:11<00:18,  6.33s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "603512ededb14959ba5dac51f517e650",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 98%|████████████████████████████████████████████████████████████████████████████████████████████████████████▌  | 88/90 [10:18<00:13,  6.55s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8b0e1ece79b64851bbcba4eda2d68d19",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 99%|█████████████████████████████████████████████████████████████████████████████████████████████████████████▊ | 89/90 [10:23<00:05,  5.89s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "fcd04461c804420c9d3470eb36a5dd98",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/3 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|███████████████████████████████████████████████████████████████████████████████████████████████████████████| 90/90 [10:30<00:00,  7.01s/it]\n"
     ]
    }
   ],
   "source": [
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    prediction = pipeline.run(query=sample['body'], params={\"BM25Retriever\": {\"top_k\": 100}, \"Ranker\": {\"top_k\": 50}, \"Reader\": {\"top_k\": 50} })\n",
    "    snippets = []\n",
    "    doc_list_by_snnipets = []\n",
    "    for ans in prediction['answers']:\n",
    "        if ans.score > 0.4:\n",
    "            snippet = get_snipet_from_answer(ans)\n",
    "            doc_list_by_snnipets.append(snippet['document'])\n",
    "            snippets.append(snippet)\n",
    "            \n",
    "    sample['snippets'] = snippets\n",
    "    doc_list = [ globals.BIOASQ.doc_relative_url + d.id for d in prediction['documents'] ]\n",
    "    #sample['documents'] = doc_list[0:10]\n",
    "    sample['documents'] = list(set(doc_list_by_snnipets))\n",
    "    \n",
    "# mindlab base ans.score > 0.3:\n",
    "# mindlab tns ans.score > 0.4 and only snnipets docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "03796e58",
   "metadata": {},
   "outputs": [],
   "source": [
    "for q in test_batch_json['questions']:\n",
    "    for s in q['snippets']:\n",
    "        s['beginSection'] = s['beginSection'][0] "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "2dfb7a11",
   "metadata": {},
   "outputs": [],
   "source": [
    "model_id = 'bm25_ranker_reader_bioqa_ans_score_0_4_sentence_sim'\n",
    "submission_file_name = f'{globals.PATH.home}/data/processed/{test_batch_doc.split(\"/\")[-1].replace(\".json\",\"\")}_model_{model_id}.json'\n",
    "\n",
    "with open(submission_file_name, \"w\") as outfile:\n",
    "    json.dump(test_batch_json, outfile, indent=2)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b06c307b",
   "metadata": {},
   "source": [
    "## Improve Passages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "fac25a09",
   "metadata": {},
   "outputs": [],
   "source": [
    "import editdistance\n",
    "import nltk.data\n",
    "import src.elastic_search_utils.elastic_utils as es_util\n",
    "\n",
    "tokenizer = nltk.data.load('tokenizers/punkt/english.pickle')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "f05f0949",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1.0"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from rapidfuzz.distance import Levenshtein\n",
    "Levenshtein.normalized_similarity(\"levenshtein\", \"levenshtein\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "fdea0aae",
   "metadata": {},
   "outputs": [],
   "source": [
    "test_batch_json = json.load(open(submission_file_name))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "f10b4fe2",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|███████████████████████████████████████████████████████████████████████████████████████████████████████████| 90/90 [00:01<00:00, 54.40it/s]\n"
     ]
    }
   ],
   "source": [
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    for s in sample['snippets']:\n",
    "        text_raw = s['text']\n",
    "        doc_id = s['document'].replace(globals.BIOASQ.doc_relative_url,'')\n",
    "        res = es_util.search_doc_by_id(doc_id)\n",
    "        doc_title = res[doc_id]['title']\n",
    "        doc_abstract =  res[doc_id]['abstract']\n",
    "        sentences = tokenizer.tokenize(doc_abstract)\n",
    "        # validate if the sentence is similar to the snippet\n",
    "        for sentence in sentences:\n",
    "            new_text = None\n",
    "            if text_raw in sentence: \n",
    "                new_text = sentence\n",
    "            else:\n",
    "                if Levenshtein.normalized_similarity(sentence,text_raw) > 0.5: \n",
    "                    new_text = sentence\n",
    "            if new_text:\n",
    "                    s['text'] = new_text\n",
    "                    s['offsetInBeginSection'] = doc_abstract.find(new_text)\n",
    "                    s['offsetInEndSection'] = s['offsetInBeginSection'] + len(new_text)\n",
    "                    s[\"beginSection\"] = \"abstract\"\n",
    "                    s[\"endSection\"] = \"abstract\"\n",
    "        # add title search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "6a88e9a8",
   "metadata": {},
   "outputs": [],
   "source": [
    "import copy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "c63d1f87",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|███████████████████████████████████████████████████████████████████████████████████████████████████████| 90/90 [00:00<00:00, 389162.23it/s]\n"
     ]
    }
   ],
   "source": [
    "copy_test_batch_json = copy.deepcopy(test_batch_json)\n",
    "\n",
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    sample['documents'] = sample['documents'][0:10]\n",
    "    sample['snippets'] = sample['snippets'][0:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "2d056fc5",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(submission_file_name, \"w\") as outfile:\n",
    "    json.dump(test_batch_json, outfile, indent=2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "4669bf91",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/opt/bioasq/col-un-bioasq11/data/processed/BioASQ-task11bPhaseA-testset3_model_bm25_ranker_reader_bioqa_ans_score_0_4_sentence_sim.json'"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "submission_file_name"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1076d150",
   "metadata": {},
   "source": [
    "# ChatGPT search"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "ca7d0789",
   "metadata": {},
   "outputs": [],
   "source": [
    "chat_gpt_fn = f'{globals.PATH.home}/data/11b_testset/ChatGPT.json'\n",
    "chat_gpt = json.load(open(chat_gpt_fn, \"r\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "9a892652",
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'chat_gpt' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[1], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m chatgpt_questions \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mdict\u001b[39m((elem[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mid\u001b[39m\u001b[38;5;124m'\u001b[39m],elem) \u001b[38;5;28;01mfor\u001b[39;00m elem \u001b[38;5;129;01min\u001b[39;00m \u001b[43mchat_gpt\u001b[49m[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mquestions\u001b[39m\u001b[38;5;124m'\u001b[39m])\n",
      "\u001b[0;31mNameError\u001b[0m: name 'chat_gpt' is not defined"
     ]
    }
   ],
   "source": [
    "chatgpt_questions = dict((elem['id'],elem) for elem in chat_gpt['questions'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "696a0594",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|█████████████████████████████████████████████████████████████████████████████████████████████████████████| 75/75 [00:00<00:00, 8160.76it/s]\n"
     ]
    }
   ],
   "source": [
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    doc_list = []\n",
    "    snippet_list = []\n",
    "    for s in sample['snippets']:\n",
    "        text_raw = s['text']\n",
    "        # validate if the sentence is similar to the snippet\n",
    "        query = chatgpt_questions[sample['id']]['chatgpt-out']['short-ans']\n",
    "        if Levenshtein.normalized_similarity(query,text_raw) > 0.1: \n",
    "            snippet_list.append(s)\n",
    "            doc_list.append(s['document'])\n",
    "    sample['snippets'] = snippet_list\n",
    "    doc_list = set(doc_list)\n",
    "    sample['documents'] = list(doc_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "ee74cbfd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'questions': [{'id': '63f03006f36125a426000018',\n",
       "   'type': 'summary',\n",
       "   'body': 'What were the results of the DESTINY-Breast04 Trial?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35665782',\n",
       "     'text': \"CONCLUSIONS\\nIn this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.\",\n",
       "     'offsetInBeginSection': 2191,\n",
       "     'offsetInEndSection': 2414,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36386213',\n",
       "     'text': 'DESTINY-Breast04 (NCT03734029) has demonstrated the antitumor activity of trastuzumab deruxtecan (T-DXd).',\n",
       "     'offsetInBeginSection': 172,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31022475',\n",
       "     'text': 'After evaluating the results of these 6 studies, none of the SNPs was significantly associated with ONJ.',\n",
       "     'offsetInBeginSection': 732,\n",
       "     'offsetInEndSection': 836,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35666611',\n",
       "     'text': 'Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 200,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33023880',\n",
       "     'text': 'using a validated scoring criterion.\\n\\n\\nRESULTS\\nOne hundred and seven studies met the inclusion criteria. The median quality score across studies was 1',\n",
       "     'offsetInBeginSection': 1053,\n",
       "     'offsetInEndSection': 1203,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31039047',\n",
       "     'text': 'In total, 45 samples were positive with breath testing and the number of positives with established forensic methods was 46.',\n",
       "     'offsetInBeginSection': 1411,\n",
       "     'offsetInEndSection': 1535,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33023880',\n",
       "     'text': 'and temperature selected in over 50% of the studies. Malaria incidence (47%) and prevalence (35%) were the most commonly mapped outcomes, with Bayesia',\n",
       "     'offsetInBeginSection': 1333,\n",
       "     'offsetInEndSection': 1483,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31039047',\n",
       "     'text': 'In 54 of these cases (81%) the results regarding a positive or negative drug test result agreed and in 13 they disagreed.',\n",
       "     'offsetInBeginSection': 884,\n",
       "     'offsetInEndSection': 1005,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2748781',\n",
       "     'text': 'Yet like him, physicians must realize that the small successes they can achieve while contending against destiny are what count.',\n",
       "     'offsetInBeginSection': 134,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17690310',\n",
       "     'text': 'We report here the 30-day mortality and 6- and 12-month functional outcomes from the DESTINY trial.',\n",
       "     'offsetInBeginSection': 177,\n",
       "     'offsetInEndSection': 276,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/2748781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35666611',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36386213',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17690310',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31022475',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31039047',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35665782',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33023880']},\n",
       "  {'id': '641ad941690f196b5100003d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are LOQ and LOD the same?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8013092',\n",
       "     'text': 'of the corresponding statistical LODs. The empirical LODs and LOQs are identical for these GC-MS assays. The observations made here about the LOD/LOQ ',\n",
       "     'offsetInBeginSection': 988,\n",
       "     'offsetInEndSection': 1138,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20166602',\n",
       "     'text': 'The results indicated that the estimated LODs and LOQs were not equivalent and could vary by a factor of 5 to 6 for the different methods.',\n",
       "     'offsetInBeginSection': 488,\n",
       "     'offsetInEndSection': 626,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21603916',\n",
       "     'text': 'Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 236,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29110333',\n",
       "     'text': 'precision, accuracy, and robustness. The LOD and LOQ obtained were 0.8 and 2.7\\xa0μg/mL, respectively. In addition, the method offers higher sensitivity ',\n",
       "     'offsetInBeginSection': 518,\n",
       "     'offsetInEndSection': 668,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15936163',\n",
       "     'text': 'nt (r) of 0.9999, calculated by least square method. The LOD and LOQ were 0.08 and 0.26 microg/mL, respectively. Based on the preliminary spectrophoto',\n",
       "     'offsetInBeginSection': 632,\n",
       "     'offsetInEndSection': 782,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29110333',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8013092',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20166602',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21603916',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15936163']},\n",
       "  {'id': '642a029d57b1c7a315000011',\n",
       "   'type': 'summary',\n",
       "   'body': 'Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32157780',\n",
       "     'text': 'ansfer acetyl groups onto histones and thereby regulate both gene expression and chromosomal structures. Previous work has shown that the activation o',\n",
       "     'offsetInBeginSection': 63,\n",
       "     'offsetInEndSection': 213,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32695779',\n",
       "     'text': 'The eukaryotic histone acetylation cycle is composed of three classes of proteins, histone acetyltransferases (HATs) that add acetyl groups to lysine amino acids, bromodomain (BRD) containing proteins that are one of the most characterized of several protein domains that recognize acetyl-lysine (Kac) and effect downstream function, and histone deacetylases (HDACs) that catalyze the reverse reaction.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 402,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11112280',\n",
       "     'text': 'residues in the N-terminal tails of nucleosomal histones to promote transcriptional activation. Recent structural and enzymatic work on the GCN5/PCAF ',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12391296',\n",
       "     'text': 'ther transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequenc',\n",
       "     'offsetInBeginSection': 106,\n",
       "     'offsetInEndSection': 256,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12368900',\n",
       "     'text': ' A (CoA) to acetylate specific Lys residues within histones to regulate gene expression. The structure of an ESA1-CoA complex reveals structural simil',\n",
       "     'offsetInBeginSection': 108,\n",
       "     'offsetInEndSection': 258,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29261229',\n",
       "     'text': 'e family that regulates these processes by catalyzing the transfer of an acetyl moiety onto target proteins. Perturbations of cellular acetylation pro',\n",
       "     'offsetInBeginSection': 161,\n",
       "     'offsetInEndSection': 311,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12624111',\n",
       "     'text': ') are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine resi',\n",
       "     'offsetInBeginSection': 32,\n",
       "     'offsetInEndSection': 182,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10790315',\n",
       "     'text': 'Histone acetyltransferases (HATs) catalyze the acetyl-group transfer from acetyl-CoA to the epsilon-amino group of specific lysine residues within core histone proteins.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21057107',\n",
       "     'text': 'tisubunit complexes in which accessory proteins regulate substrate specificity and catalytic efficiency. Rtt109 is a particularly interesting example ',\n",
       "     'offsetInBeginSection': 54,\n",
       "     'offsetInEndSection': 204,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31818759',\n",
       "     'text': 'enzyme A (Ac-CoA) to lysine residues of substrate peptide, thus generating CoA molecule. Later, CoA, which acts as an initiator, can embrace its aptam',\n",
       "     'offsetInBeginSection': 371,\n",
       "     'offsetInEndSection': 521,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32157780',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31818759',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21057107',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12368900',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12624111',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32695779',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29261229',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10790315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12391296',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11112280']},\n",
       "  {'id': '6432fc0457b1c7a31500001f',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which gene is most frequently mutated in hereditary angioedema ?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34065094',\n",
       "     'text': 'he hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible',\n",
       "     'offsetInBeginSection': 185,\n",
       "     'offsetInEndSection': 335,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36203343',\n",
       "     'text': '), 8/79 (9%), and 3/79 (4%) of the patients respectively, revealing that SPTB is the most frequently mutated HS gene in Eastern China. Most SPTB and A',\n",
       "     'offsetInBeginSection': 539,\n",
       "     'offsetInEndSection': 689,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27470642',\n",
       "     'text': 'Angioedema can be caused by C1-inhibitor deficiency (C1-INH-hereditary angioedema and C1-INH-acquired angioedema), mutations in coagulation factor XII (FXII-hereditary angioedema), and treatment with angiotensin-converting enzyme inhibitors (ACEI-acquired angioedema).',\n",
       "     'offsetInBeginSection': 695,\n",
       "     'offsetInEndSection': 963,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30044938',\n",
       "     'text': 'BACKGROUND\\nHereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein-bradykinin cascade.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33780405',\n",
       "     'text': 'used by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation,',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 230,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36417927',\n",
       "     'text': 'The fundamental cause of hereditary angioedema in almost all patients is a mutation in the SERPING1 gene leading to a deficiency in C1-inhibitor.',\n",
       "     'offsetInBeginSection': 424,\n",
       "     'offsetInEndSection': 569,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33593719',\n",
       "     'text': 'childhood or adolescence. Most of these patients have mutations in the SERPING1 gene, causing either low C1 inhibitor production (hereditary angioedem',\n",
       "     'offsetInBeginSection': 353,\n",
       "     'offsetInEndSection': 503,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30146609',\n",
       "     'text': 'Genetic testing revealed a heterozygous nonsense mutation of the SERPING1 gene, and a diagnosis of hereditary angioedema was made.',\n",
       "     'offsetInBeginSection': 520,\n",
       "     'offsetInEndSection': 650,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24760113',\n",
       "     'text': 'utosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin ',\n",
       "     'offsetInBeginSection': 76,\n",
       "     'offsetInEndSection': 226,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27116602',\n",
       "     'text': 'd function of bradykinin. Alterations detected in at least one more gene (F12) are nowadays considered responsible for 25\\xa0% of cases of hereditary ang',\n",
       "     'offsetInBeginSection': 539,\n",
       "     'offsetInEndSection': 689,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36417927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34065094',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33780405',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30146609',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24760113',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27116602',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33593719',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36203343',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27470642',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30044938']},\n",
       "  {'id': '64178edb690f196b51000025',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is casimersen's mechanism of action?\",\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.',\n",
       "     'offsetInBeginSection': 201,\n",
       "     'offsetInEndSection': 381,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "     'text': 'In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.',\n",
       "     'offsetInBeginSection': 126,\n",
       "     'offsetInEndSection': 278,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "     'text': 'ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 305,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23089283',\n",
       "     'text': 'The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 118,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "     'text': 'mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N',\n",
       "     'offsetInBeginSection': 227,\n",
       "     'offsetInEndSection': 377,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29178131',\n",
       "     'text': 'However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 319,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19719780',\n",
       "     'text': 'd the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Mu',\n",
       "     'offsetInBeginSection': 185,\n",
       "     'offsetInEndSection': 335,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'nal heterogeneity in the specific vasoconstrictor involved. Oxygen-induced vasoconstriction may serve as a protective mechanism to reduce the oxidativ',\n",
       "     'offsetInBeginSection': 1422,\n",
       "     'offsetInEndSection': 1572,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10029375',\n",
       "     'text': 'These drugs can induce cell cycle arrest and apoptosis in colon cancer cell lines through a mechanism that is fundamentally different from the apoptosis caused by cancer chemotherapeutic agents.',\n",
       "     'offsetInBeginSection': 1011,\n",
       "     'offsetInEndSection': 1205,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/19719780',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29178131',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10029375',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23089283']},\n",
       "  {'id': '6402bf2b201352f04a000007',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the mechanism of action of tiragolumab?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': ' (16·2% [6·7-25·7]) in the placebo plus atezolizumab group had an objective response (p=0·031). Median progression-free survival was 5·4 months (95% C',\n",
       "     'offsetInBeginSection': 2161,\n",
       "     'offsetInEndSection': 2311,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32576590',\n",
       "     'text': 'tion with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically signifi',\n",
       "     'offsetInBeginSection': 52,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': 'INTERPRETATION\\nTiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC.',\n",
       "     'offsetInBeginSection': 2991,\n",
       "     'offsetInEndSection': 3259,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': 'BACKGROUND\\nTargeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.',\n",
       "     'offsetInBeginSection': 201,\n",
       "     'offsetInEndSection': 381,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26292636',\n",
       "     'text': 'Tramadol is an analgesic that is used worldwide for pain, but its mechanisms of action have not been fully elucidated.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 118,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35292828',\n",
       "     'text': 'Together these data suggest that the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical trial in colorectal cancer patients with MSS status.',\n",
       "     'offsetInBeginSection': 1406,\n",
       "     'offsetInEndSection': 1627,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35292828',\n",
       "     'text': 'Together these data suggest that the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical trial in colorectal cancer patients with MSS status.',\n",
       "     'offsetInBeginSection': 1406,\n",
       "     'offsetInEndSection': 1627,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35292828',\n",
       "     'text': 'Our aim was to evaluate ex vivo the capacity of the combination of atezolizumab (anti-PD-L1) and tiragolumab (anti-TIGIT) to reactivate the immune response of tumor infiltrating lymphocytes (TILs) in MSS-CRC.',\n",
       "     'offsetInBeginSection': 190,\n",
       "     'offsetInEndSection': 398,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35652612',\n",
       "     'text': \"Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 213,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32576590',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35652612',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26292636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35292828']},\n",
       "  {'id': '641d8fd6690f196b51000041',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34421896',\n",
       "     'text': 'Conclusions\\nOur study highlighted the importance of mitophagy in MS and suggested the potential application of PINK1 and PARKIN as biomarkers to predict disease activity.',\n",
       "     'offsetInBeginSection': 1039,\n",
       "     'offsetInEndSection': 1209,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35887254',\n",
       "     'text': 'This review aims to provide an update on recent studies regarding issues related to NMOSD, including the pathophysiology of the disease, the potential use of serum and cerebrospinal fluid cytokines as disease biomarkers, the clinical utilization of ocular coherence tomography, and the comparison of different animal models of NMOSD.',\n",
       "     'offsetInBeginSection': 549,\n",
       "     'offsetInEndSection': 882,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31471502',\n",
       "     'text': 'th a sensitivity of 73.0% and a specificity of 75.8%.\\n\\n\\nCONCLUSIONS\\nsGFAP and sNfL are likely to be good biomarkers of disease activity and disability',\n",
       "     'offsetInBeginSection': 1327,\n",
       "     'offsetInEndSection': 1477,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33019871',\n",
       "     'text': 'This article summarized the research progress in serum and cerebrospinal fluid biomarkers of astrocytes, neurons, myelin sheath, and other damage after the onset of NMOSD.',\n",
       "     'offsetInBeginSection': 619,\n",
       "     'offsetInEndSection': 790,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27049569',\n",
       "     'text': 'toimmune diseases. To explore the roles of the IL-12 family members IL-27 and IL-35 in the pathogenesis of neuromyelitis optica spectrum disorders (NM',\n",
       "     'offsetInBeginSection': 61,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25027264',\n",
       "     'text': 'Since the discovery of aquaporin 4-IgG, a sensitive and highly specific biomarker of neuromyelitis optica (NMO), a wide range of syndromes have been recognized as being associated with this condition.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 200,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36378751',\n",
       "     'text': 'ing remission may be predictive of future disease activity. Serial serum GFAP measurements are emerging as a biomarker to monitor disease activity in ',\n",
       "     'offsetInBeginSection': 1234,\n",
       "     'offsetInEndSection': 1384,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31471502',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34421896',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36378751',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35887254',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27049569',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25027264',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33019871']},\n",
       "  {'id': '6429d5c557b1c7a315000006',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the major thrombotic complications in patients with COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36289613',\n",
       "     'text': 'n has been associated with thrombotic complications, especially venous thromboembolism. Although arterial thrombotic complications are rarely seen in ',\n",
       "     'offsetInBeginSection': 17,\n",
       "     'offsetInEndSection': 167,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33569525',\n",
       "     'text': 'ne-third of COVID-19 patients show major thrombotic events, mostly pulmonary emboli. The endothelial expression of angiotensin-converting enzyme-2 rec',\n",
       "     'offsetInBeginSection': 794,\n",
       "     'offsetInEndSection': 944,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36113402',\n",
       "     'text': 'BACKGROUND\\nThromboembolic events are common complications of COVID-19. Clinical study results on safety and efficacy of anticoagulation in COVID-19 ar',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35967591',\n",
       "     'text': 'These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.',\n",
       "     'offsetInBeginSection': 94,\n",
       "     'offsetInEndSection': 300,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32586214',\n",
       "     'text': 'causing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke. Accordingly, the activation of coagulation (eg,',\n",
       "     'offsetInBeginSection': 1057,\n",
       "     'offsetInEndSection': 1207,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34512059',\n",
       "     'text': 'Various pathophysiological mechanisms for thrombotic events in COVID-19 have been proposed, these include virus-induced endothelial cell damage, inflammation, and excess production of pro-inflammatory cytokines.',\n",
       "     'offsetInBeginSection': 605,\n",
       "     'offsetInEndSection': 816,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34884354',\n",
       "     'text': 'INTRODUCTION\\nThrombosis and bleeding are recognized complications of the novel coronavirus infection (COVID-19), with a higher incidence described particularly in the critically ill.\\n\\n\\nMETHODS\\nA retrospective review of COVID-19 patients admitted to our intensive care units (ICU) between 1 January 2020 and 31 December 2020 was performed.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 338,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32551814',\n",
       "     'text': 'V-2). Coagulation dysfunction is a hallmark in patients with COVID-19. Fulminant thrombotic complications emerge as critical issues in patients with s',\n",
       "     'offsetInBeginSection': 159,\n",
       "     'offsetInEndSection': 309,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34271813',\n",
       "     'text': 'Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare.',\n",
       "     'offsetInBeginSection': 89,\n",
       "     'offsetInEndSection': 216,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36113402',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33569525',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34271813',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34512059',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34884354',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35967591',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32586214',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32551814',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36289613']},\n",
       "  {'id': '6433012b57b1c7a315000022',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is Cinryze?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23776358',\n",
       "     'text': 'ted States: Berinert(®) for treating acute attacks and Cinryze(®) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being con',\n",
       "     'offsetInBeginSection': 745,\n",
       "     'offsetInEndSection': 895,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20627701',\n",
       "     'text': 'Treatments approved by the Food and Drug Administration for routine prophylaxis include danazol given orally and the nanofiltered human C1 esterase inhibitor, CINRYZE, which is approved for intravenous administration.',\n",
       "     'offsetInBeginSection': 110,\n",
       "     'offsetInEndSection': 327,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21942916',\n",
       "     'text': 'Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze®) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26756974',\n",
       "     'text': 'o long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with ecall',\n",
       "     'offsetInBeginSection': 782,\n",
       "     'offsetInEndSection': 932,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22282695',\n",
       "     'text': 'he United States was limited to androgen therapy. The human plasma-derived C1 esterase inhibitor (Cinryze™), distributed by Lev Pharmaceuticals, was a',\n",
       "     'offsetInBeginSection': 734,\n",
       "     'offsetInEndSection': 884,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "     'text': 'a blocking the production or function of bradykinin. Cinryze® is a nanofiltered C1-INH, approved in Europe for the acute treatment, preprocedure preve',\n",
       "     'offsetInBeginSection': 406,\n",
       "     'offsetInEndSection': 556,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24805006',\n",
       "     'text': 'STUDY DESIGN AND METHODS\\nThe analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates.',\n",
       "     'offsetInBeginSection': 460,\n",
       "     'offsetInEndSection': 605,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24805006',\n",
       "     'text': 'Additional bands in the plasma-derived products were α1-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert).',\n",
       "     'offsetInBeginSection': 1354,\n",
       "     'offsetInEndSection': 1518,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26756974',\n",
       "     'text': 'ched to long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with',\n",
       "     'offsetInBeginSection': 776,\n",
       "     'offsetInEndSection': 926,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "     'text': 'Cinryze has FDA approval only for prophylaxis for children as young as 6 years old.',\n",
       "     'offsetInBeginSection': 1021,\n",
       "     'offsetInEndSection': 1104,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/23776358',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26756974',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21942916',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22282695',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24805006',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20627701']},\n",
       "  {'id': '64179337690f196b51000034',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Do machine learning-based methods outperform statistical methods for survival analysis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34862545',\n",
       "     'text': ' and within neurosciences, including neurosurgery. ML methods regularly outperform classical methods and have been successfully applied to, inter alia',\n",
       "     'offsetInBeginSection': 568,\n",
       "     'offsetInEndSection': 718,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12717015',\n",
       "     'text': 'It has been found that machine-learning methods outperform statistical methods and achieve an MCC of 0.11 when secondary structure information is used.',\n",
       "     'offsetInBeginSection': 633,\n",
       "     'offsetInEndSection': 784,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11185421',\n",
       "     'text': 'Despite their potential advantages over standard statistical methods, like their ability to model non-linear relationships and construct symbolic and interpretable models, their applications to survival analysis are at best rare, primarily because of the difficulty to appropriately handle censored data.',\n",
       "     'offsetInBeginSection': 149,\n",
       "     'offsetInEndSection': 453,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36227551',\n",
       "     'text': 'Our results reveal that machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model.',\n",
       "     'offsetInBeginSection': 847,\n",
       "     'offsetInEndSection': 1091,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30409119',\n",
       "     'text': 'on constraints (such as proportional hazard assumptions) and better predictive performance compared with statistical models. Upon comparing the concor',\n",
       "     'offsetInBeginSection': 1858,\n",
       "     'offsetInEndSection': 2008,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34910160',\n",
       "     'text': 'BACKGROUND\\nMachine learning-based risk prediction models may outperform traditional statistical models in large datasets with many variables, by identifying both novel predictors and the complex interactions between them.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 221,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30825008',\n",
       "     'text': 'MLAs provided higher identification accuracy (30.8-100%) than distance- (15.1-97.4%) and tree-based methods (11.1-87.5%), with SMO performing the best among the machine learning classifiers.',\n",
       "     'offsetInBeginSection': 1111,\n",
       "     'offsetInEndSection': 1301,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36028137',\n",
       "     'text': 'CONCLUSION\\nMachine learning algorithms such as the random forest were superior to conventional Cox regression and previously reported survival scores for predicting 1-month, 3-month, and 12-month survival following liver transplantation.',\n",
       "     'offsetInBeginSection': 2443,\n",
       "     'offsetInEndSection': 2680,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36227551',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34862545',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11185421',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30825008',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34910160',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36028137',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12717015',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30409119']},\n",
       "  {'id': '63f03c47f36125a42600001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'ZF2001 is used for which disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35034583',\n",
       "     'text': 'e (ZF2001) significantly increased neutralization titers to both WT and Omicron variant. Moreover, at day 14 post the third dose, neutralizing antibod',\n",
       "     'offsetInBeginSection': 670,\n",
       "     'offsetInEndSection': 820,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35596222',\n",
       "     'text': 'To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34021265',\n",
       "     'text': ' CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell V',\n",
       "     'offsetInBeginSection': 292,\n",
       "     'offsetInEndSection': 442,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36158819',\n",
       "     'text': 'iving the first dose of the ZF2001 RBD-subunit vaccine against coronavirus disease 2019 (COVID-19). Autopsy showed severe interstitial myocarditis, in',\n",
       "     'offsetInBeginSection': 109,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34877393',\n",
       "     'text': 'es (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, ',\n",
       "     'offsetInBeginSection': 598,\n",
       "     'offsetInEndSection': 748,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36426361',\n",
       "     'text': 'Background\\nIn response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of recombinant protein subunit vaccine (ZF2001) boosts immune responses.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 216,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35617368',\n",
       "     'text': 'eometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased',\n",
       "     'offsetInBeginSection': 2528,\n",
       "     'offsetInEndSection': 2678,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36426361',\n",
       "     'text': 'or the three groups (P=0.0005, P<0.0001, and P<0.0001).\\n\\n\\nConclusion\\nHeterologous boosting with ZF2001 was safe and immunogenic, and prime-boost inter',\n",
       "     'offsetInBeginSection': 1350,\n",
       "     'offsetInEndSection': 1500,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35634276',\n",
       "     'text': 'Conclusion\\nSARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients.',\n",
       "     'offsetInBeginSection': 1440,\n",
       "     'offsetInEndSection': 1543,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35634276',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34021265',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36158819',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34877393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35617368',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35596222',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36426361',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35034583']},\n",
       "  {'id': '642c82c557b1c7a315000012',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What mammal has the lowest known chromosome number?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27186334',\n",
       "     'text': 'The species have 2n=36, a number considered as a pleisomorphic feature in Arecoideae since the modern species, according to floral morphology, have the lowest chromosome number (2n=28 and 2n=30).',\n",
       "     'offsetInBeginSection': 1087,\n",
       "     'offsetInEndSection': 1282,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24500949',\n",
       "     'text': 'kelihood-inferred changes in chromosome numbers among close relatives. Typhonium, the focal genus, includes species with 2n = 65 and 2n = 8, the lowes',\n",
       "     'offsetInBeginSection': 486,\n",
       "     'offsetInEndSection': 636,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31879909',\n",
       "     'text': 'This system is based on hTERT-immortalized fibroblasts from a female Indian muntjac, a placental mammal with the lowest known chromosome number (n\\xa0=\\xa03).',\n",
       "     'offsetInBeginSection': 1305,\n",
       "     'offsetInEndSection': 1457,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25372387',\n",
       "     'text': 'ccur in nearby mountains (Hylomyscus and Beamys) were not recorded. Myosorex zinki, the only mammal endemic to Mt. Kilimanjaro, which previously was k',\n",
       "     'offsetInBeginSection': 797,\n",
       "     'offsetInEndSection': 947,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29706521',\n",
       "     'text': 'Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\xa0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.',\n",
       "     'offsetInBeginSection': 615,\n",
       "     'offsetInEndSection': 848,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22105874',\n",
       "     'text': ' patchy distribution, poor records and low abundances. It is also the phyllotine with the lowest known diploid chromosome number (2n = 18), however it',\n",
       "     'offsetInBeginSection': 74,\n",
       "     'offsetInEndSection': 224,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25379715',\n",
       "     'text': 'The referred species presented the lowest chromosome number observed for the subfamily Myrmicinae and for the Hymenoptera found in the Neotropical region.',\n",
       "     'offsetInBeginSection': 449,\n",
       "     'offsetInEndSection': 603,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/5444269',\n",
       "     'text': 'The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 153,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32843950',\n",
       "     'text': 'o-2-phenylindole) staining. The karyotype analyses show that the male B. sinicus possesses the lowest chromosome number (2n = 15) ever observed in Mec',\n",
       "     'offsetInBeginSection': 145,\n",
       "     'offsetInEndSection': 295,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/4841572',\n",
       "     'text': 'The chocolate gourami, Sphaerichthys osphromonoides, has the lowest chromosome number reported for fishes, with 2n = 16 and n = 8.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 130,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31879909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29706521',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32843950',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22105874',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27186334',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/4841572',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25379715',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25372387',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24500949',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/5444269']},\n",
       "  {'id': '6429b41757b1c7a315000004',\n",
       "   'type': 'list',\n",
       "   'body': 'When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30582583',\n",
       "     'text': 'Chromatin is subject to an array of diverse posttranslational modifications (PTMs) that mostly occur in the amino termini of histone proteins (i.e., histone tail) and regulate the accessibility and functional state of the underlying DNA.',\n",
       "     'offsetInBeginSection': 122,\n",
       "     'offsetInEndSection': 359,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22122749',\n",
       "     'text': 'n structure and function by modifying the biochemical properties of key amino acids. Histone methylation events, especially on arginine- and lysine-re',\n",
       "     'offsetInBeginSection': 329,\n",
       "     'offsetInEndSection': 479,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10825229',\n",
       "     'text': \"The most well studied posttranslational modification of histones is the acetylation of epsilon-amino groups on conserved lysine residues in the histones' amino-terminal tail domains.\",\n",
       "     'offsetInBeginSection': 214,\n",
       "     'offsetInEndSection': 396,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27423860',\n",
       "     'text': 'Overall histone acetylation states are assessed from complete protease digestion to single amino acids, which is followed by MS analysis.',\n",
       "     'offsetInBeginSection': 607,\n",
       "     'offsetInEndSection': 744,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16987819',\n",
       "     'text': 'Biochemical assays on histone peptides show that essentially all epigenetic modifications on the 21 N-terminal amino acids of histone H3 cause a significant reduction in enzymatic activity.',\n",
       "     'offsetInBeginSection': 294,\n",
       "     'offsetInEndSection': 483,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11395403',\n",
       "     'text': 'Among the well-known covalent modifications of histones, the reversible acetylation of internal lysine residues in histone amino-terminal domains has long been positively linked to transcriptional activation.',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 363,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22122749',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30582583',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10825229',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16987819',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11395403',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27423860']},\n",
       "  {'id': '643305b257b1c7a315000025',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which company produces Ruconest?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "     'text': 'Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-INH (Ruconest), bradykinin B2 receptor inhibitor (Icatibant), and kallikrein inhibitors (Ecallantide and lanadelumab).',\n",
       "     'offsetInBeginSection': 383,\n",
       "     'offsetInEndSection': 619,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26250409',\n",
       "     'text': 'This article will focus on the results of ten clinical studies demonstrating the efficacy and safety of Ruconest(®) (Pharming Group NV, Leiden, the Netherlands), which is now approved for use in Europe, Israel and the USA.',\n",
       "     'offsetInBeginSection': 821,\n",
       "     'offsetInEndSection': 1043,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.',\n",
       "     'offsetInBeginSection': 651,\n",
       "     'offsetInEndSection': 875,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25673959',\n",
       "     'text': 'Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 140,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.',\n",
       "     'offsetInBeginSection': 651,\n",
       "     'offsetInEndSection': 875,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24278067',\n",
       "     'text': 'as follows: EUR 15,226 per QALY (Ruconest(®)) and EUR 27,786 per QALY (Berinert(®) P). The probability of cost-utility (ICUR < EUR 24,279 per QALY) as',\n",
       "     'offsetInBeginSection': 1167,\n",
       "     'offsetInEndSection': 1317,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34832963',\n",
       "     'text': 'a-derived Berinert®) or immune reaction (human recombinant C1INH from rabbit milk, Ruconest®). This study describes the physicochemical and biological',\n",
       "     'offsetInBeginSection': 327,\n",
       "     'offsetInEndSection': 477,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/24278067',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25673959',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34832963',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26250409',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31592791']},\n",
       "  {'id': '641635fa690f196b5100001c',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is usually the age of diagnosis in Duchenne muscular dystrophy?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28802771',\n",
       "     'text': 'Duchenne Muscular Dystrophy (DMD) is the most frequent muscular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 147,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16638505',\n",
       "     'text': 'ctioning of 25 Dutch males with Duchenne muscular dystrophy (mean age 10.1 years) were systematically assessed. This study relied on the use of a new ',\n",
       "     'offsetInBeginSection': 237,\n",
       "     'offsetInEndSection': 387,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "     'text': 'The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12.',\n",
       "     'offsetInBeginSection': 137,\n",
       "     'offsetInEndSection': 303,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11929208',\n",
       "     'text': ' walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su',\n",
       "     'offsetInBeginSection': 178,\n",
       "     'offsetInEndSection': 328,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "     'text': 'RESULTS\\nSurvey respondents included 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians.',\n",
       "     'offsetInBeginSection': 734,\n",
       "     'offsetInEndSection': 885,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "     'text': 'METHODS\\nOnline surveys were sent to three groups: (a) people with a confirmed diagnosis of Duchenne muscular dystrophy (≥14 years), (b) parents and guardians and (c) neuromuscular clinicians in the UK NorthStar Clinical Network.',\n",
       "     'offsetInBeginSection': 417,\n",
       "     'offsetInEndSection': 645,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24814059',\n",
       "     'text': 'METHODS\\nWe performed a cross-sectional analysis of electrical impedance myography and quantitative ultrasound in 24 healthy boys and 24 with Duchenne muscular dystrophy, aged 2 to 14 years with trained research assistants performing all measurements.',\n",
       "     'offsetInBeginSection': 391,\n",
       "     'offsetInEndSection': 641,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7334343',\n",
       "     'text': 'A well examined muscular biopsy is usually conclusive without using an electron microscope, from the age of one year, if serous activity of CPK reaches twenty times the normal rate.',\n",
       "     'offsetInBeginSection': 609,\n",
       "     'offsetInEndSection': 790,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28802771',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7334343',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24814059',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11929208',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16638505']},\n",
       "  {'id': '6402c868201352f04a00000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Was erythropoietin effective for optic neuritis in the TONE trial?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22926853',\n",
       "     'text': 'INTERPRETATION\\nThese results give the first indications that erythropoietin might be neuroprotective in optic neuritis.',\n",
       "     'offsetInBeginSection': 1767,\n",
       "     'offsetInEndSection': 1886,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9103884',\n",
       "     'text': 'ned pathology, therapy of this disease, and summarized our previous cases. Intravenous methylpredonisolone treatment is effective from our experience.',\n",
       "     'offsetInBeginSection': 167,\n",
       "     'offsetInEndSection': 317,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35501141',\n",
       "     'text': 'icosteroids accelerated visual recovery in optic neuritis (ON) without improving outcome. This finding related largely to multiple sclerosis (MS), and',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30151023',\n",
       "     'text': 'ears and provided valuable data about clinical course, efficacy of steroid treatment, and risk of conversion to MS. Compared to the many studies in We',\n",
       "     'offsetInBeginSection': 330,\n",
       "     'offsetInEndSection': 480,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26932144',\n",
       "     'text': 'ys or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started ',\n",
       "     'offsetInBeginSection': 1547,\n",
       "     'offsetInEndSection': 1697,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10340796',\n",
       "     'text': 'oup than in the control (P<.05).\\n\\n\\nCONCLUSIONS\\nPulse treatment does not appear effective for idiopathic optic neuritis even though visual function in ',\n",
       "     'offsetInBeginSection': 1064,\n",
       "     'offsetInEndSection': 1214,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22465890',\n",
       "     'text': 'OBJECTIVE\\nTo investigate the safety, tolerability, and short-term efficacy of treatment with erythropoietin in patients with optic neuritis as a first demyelination event.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22926853',\n",
       "     'text': 'OBJECTIVE\\nBased on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 206,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22926853',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35501141',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26932144',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10340796',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22465890',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9103884',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30151023']},\n",
       "  {'id': '6424154d690f196b5100004a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the R value with respect to hepatoxicity',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33620007',\n",
       "     'text': 'Overall, 79 cases (76%) had no acute liver injury or hepatotoxicity, and 25 (24%) developed hepatoxicity.',\n",
       "     'offsetInBeginSection': 1007,\n",
       "     'offsetInEndSection': 1112,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33620007']},\n",
       "  {'id': '64299b6a57b1c7a315000001',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36367927',\n",
       "     'text': ' caused by the Omicron variant in renal transplant recipients (RTRs) is unknown.\\n\\n\\nMETHODS\\nInterviews were conducted with 447 RTRs regarding the statu',\n",
       "     'offsetInBeginSection': 136,\n",
       "     'offsetInEndSection': 286,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36238984',\n",
       "     'text': 'ronavirus Disease 2019 (COVID-19)\\xa0pandemic in Shanghai, but over 90% of patients were mild. This study included 1139 COVID-19 patients mildly infected',\n",
       "     'offsetInBeginSection': 119,\n",
       "     'offsetInEndSection': 269,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35869843',\n",
       "     'text': 'BACKGROUND\\nIn the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 145,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "     'text': 'Unlike the previous two waves, COVID-19 due to the Omicron variant\\xa0was less severe with only 5% of hemodialysis patients\\xa0requiring admission to the intensive care unit compared to 25% during the previous waves.',\n",
       "     'offsetInBeginSection': 792,\n",
       "     'offsetInEndSection': 1002,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "     'text': 'Unlike the previous two waves, COVID-19 due to the Omicron variant\\xa0was less severe with only 5% of hemodialysis patients\\xa0requiring admission to the intensive care unit compared to 25% during the previous waves.',\n",
       "     'offsetInBeginSection': 792,\n",
       "     'offsetInEndSection': 1002,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36466505',\n",
       "     'text': 'Furthermore, liver damages caused by viral infection of the omicron variant were largely attenuated when compared to those by infection of the wild-type or the delta variant SARS-CoV-2.',\n",
       "     'offsetInBeginSection': 1292,\n",
       "     'offsetInEndSection': 1477,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "     'text': 'ly effective in protecting against severe Covid-19 infections.Omicrons may be less severe than other variants of concern. However, its immune evasiven',\n",
       "     'offsetInBeginSection': 1314,\n",
       "     'offsetInEndSection': 1464,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36090988',\n",
       "     'text': 'ively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization co',\n",
       "     'offsetInBeginSection': 1963,\n",
       "     'offsetInEndSection': 2113,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36285226',\n",
       "     'text': 'Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron.',\n",
       "     'offsetInBeginSection': 372,\n",
       "     'offsetInEndSection': 591,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "     'text': 'However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants.',\n",
       "     'offsetInBeginSection': 772,\n",
       "     'offsetInEndSection': 903,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36090988',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36238984',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35869843',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36466505',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36285226',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36367927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36072085']},\n",
       "  {'id': '6432ffdf57b1c7a315000021',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is hereditary angioedema?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3397981',\n",
       "     'text': 't with hereditary angioedema. Hereditary angioedema, one of the inherited complement deficiencies, has been reported in association with a number of a',\n",
       "     'offsetInBeginSection': 75,\n",
       "     'offsetInEndSection': 225,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22179171',\n",
       "     'text': 'In addition to edema of the glottis, hereditary angioedema often results in edema of the gastrointestinal tract, which can be incapacitating.',\n",
       "     'offsetInBeginSection': 577,\n",
       "     'offsetInEndSection': 718,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33233873',\n",
       "     'text': 'The disease can either present with hypocomplementemia owing to the presence of pathogenic variants in the gene encoding complement C1 inhibitor (hereditary angioedema with C1-inhibitor deficiency) or present with normocomplementemia and associate with elevated estrogen levels owing to gain-of-function variants in the genes encoding coagulation proteins involved in the kallikrein-kinin system (namely, coagulation FXII [FXII-associated hereditary angioedema], plasminogen [PLG-associated hereditary angioedema], and high-molecular-weight kininogen [KNG1-associated hereditary angioedema]).',\n",
       "     'offsetInBeginSection': 603,\n",
       "     'offsetInEndSection': 1195,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22195758',\n",
       "     'text': 'Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedures prior to a diagnosis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 175,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19849675',\n",
       "     'text': 'Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1-esterase inhibitor of the classic complement pathway.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 166,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22073494',\n",
       "     'text': 'Hereditary angioedema is a rare form of angioedema that can be diagnosed by screening with a C4 level.',\n",
       "     'offsetInBeginSection': 322,\n",
       "     'offsetInEndSection': 424,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31283393',\n",
       "     'text': 'Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34904566',\n",
       "     'text': 'INTRODUCTION\\nHereditary angioedema is an infrequent genetic disorder; which mainly manifests with cutaneous and mucosal swelling.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 129,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32178893',\n",
       "     'text': 'Hereditary angioedema is an autosomal dominant disorder, presenting as sudden and recurring episodes of variable severity of subcutaneous and mucosa edema that may occur spontaneously or in response to triggers.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22227095',\n",
       "     'text': 'Hereditary angioedema is a rare disease, often diagnosed with delay because of a heterogeneous clinical presentation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 117,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34904566',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33233873',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22179171',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19849675',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22195758',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32178893',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22073494',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31283393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22227095',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3397981']},\n",
       "  {'id': '64178ec2690f196b51000024',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is viltolarsen's mechanism of action?\",\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.',\n",
       "     'offsetInBeginSection': 201,\n",
       "     'offsetInEndSection': 381,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "     'text': 'In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating disorder prevention group program.',\n",
       "     'offsetInBeginSection': 126,\n",
       "     'offsetInEndSection': 278,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29178131',\n",
       "     'text': 'However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged.',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 319,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "     'text': 'ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 305,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23089283',\n",
       "     'text': 'The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 118,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "     'text': 'mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N',\n",
       "     'offsetInBeginSection': 227,\n",
       "     'offsetInEndSection': 377,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'nal heterogeneity in the specific vasoconstrictor involved. Oxygen-induced vasoconstriction may serve as a protective mechanism to reduce the oxidativ',\n",
       "     'offsetInBeginSection': 1422,\n",
       "     'offsetInEndSection': 1572,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10029375',\n",
       "     'text': 'These drugs can induce cell cycle arrest and apoptosis in colon cancer cell lines through a mechanism that is fundamentally different from the apoptosis caused by cancer chemotherapeutic agents.',\n",
       "     'offsetInBeginSection': 1011,\n",
       "     'offsetInEndSection': 1205,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11068911',\n",
       "     'text': 'ialdehyde antimicrobial agent, the mechanism of action of which has been little studied. The aims of this paper are to examine what is currently known',\n",
       "     'offsetInBeginSection': 46,\n",
       "     'offsetInEndSection': 196,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6572387',\n",
       "     'text': 'enylate cyclase activities that are stimulated by human chorionic gonadotropin (hCG) and thyrotropin, respectively. Both cell types also respond to ch',\n",
       "     'offsetInBeginSection': 96,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29178131',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6572387',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10029375',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11068911',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23089283']},\n",
       "  {'id': '64040bd8201352f04a00000e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should be used bexarotene for relapsing-remitting multiple sclerosis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19242067',\n",
       "     'text': 'ified as having Relapsing-Remitting Multiple Sclerosis accordingly with Lublin were collected for oxidative stress markers quantification.\\n\\n\\nRESULTS\\nN',\n",
       "     'offsetInBeginSection': 341,\n",
       "     'offsetInEndSection': 491,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26701666',\n",
       "     'text': 'We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.',\n",
       "     'offsetInBeginSection': 543,\n",
       "     'offsetInEndSection': 675,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21975773',\n",
       "     'text': 'y profile of NTZ is warranted. NTZ should be used only by skilled neurologists in MS centres under surveillance programs.All the data in this review c',\n",
       "     'offsetInBeginSection': 4062,\n",
       "     'offsetInEndSection': 4212,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23994714',\n",
       "     'text': 'remitting multiple sclerosis was treated with immunomodulatory agents, interferon β or glatiramer acetate. The secondary progressive multiple sclerosi',\n",
       "     'offsetInBeginSection': 703,\n",
       "     'offsetInEndSection': 853,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14978418',\n",
       "     'text': 'It can also be used in secondary progressive and progressive relapsing remitting multiple sclerosis.',\n",
       "     'offsetInBeginSection': 110,\n",
       "     'offsetInEndSection': 210,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28639482',\n",
       "     'text': 'Additionally, a match between being adequately challenged by work, while still having the capacity to meet those work demands, is needed, as is long-term financial stability.',\n",
       "     'offsetInBeginSection': 1243,\n",
       "     'offsetInEndSection': 1417,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31099778',\n",
       "     'text': 'The data presented in the current work may be used for the construction of a biomarker panel, to differentiate primary progressive and relapsing-remitting courses of multiple sclerosis on the initial stages of the disease.',\n",
       "     'offsetInBeginSection': 1032,\n",
       "     'offsetInEndSection': 1254,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35652121',\n",
       "     'text': 'Myelin-sensitive MRI such as magnetization transfer imaging has been widely used in multiple sclerosis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 103,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30042638',\n",
       "     'text': 'Thus, it is consequential to emphasize the value of tailored intervention for attending to these factors in the treatment and rehabilitation agendas for improvement of health-related quality of life in relapsing-remitting multiple sclerosis.',\n",
       "     'offsetInBeginSection': 1809,\n",
       "     'offsetInEndSection': 2050,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31099778',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30042638',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21975773',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23994714',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19242067',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26701666',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28639482',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14978418',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35652121']},\n",
       "  {'id': '6422e7f0690f196b51000045',\n",
       "   'type': 'list',\n",
       "   'body': 'Hepcidin is a key regulator of what processes?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23531037',\n",
       "     'text': 'BACKGROUND\\nHepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients with renal insufficiency, which may con',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23807042',\n",
       "     'text': 'BACKGROUND\\nHepcidin is a key regulator of iron metabolism. It binds to ferroportin and causes the trapping of iron in cells, rendering it unavailable ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21136948',\n",
       "     'text': 'Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 106,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19681654',\n",
       "     'text': 'Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 116,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19249912',\n",
       "     'text': 'Hepcidin is a key regulator of iron homeostasis, while hemojuvelin is an important component of the hepcidin regulation pathway.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 128,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24293278',\n",
       "     'text': 'Hepcidin, which is mainly produced by the liver, is the key regulator in iron homeostasis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 90,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15886319',\n",
       "     'text': 'Hepatic peptide hormone hepcidin is the key regulator of iron metabolism and the mediator of anemia of inflammation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 116,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25782630',\n",
       "     'text': 'Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 126,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16198622',\n",
       "     'text': 'Hepcidin is thought to be a key regulator in iron metabolism and has been implicated in ACD.',\n",
       "     'offsetInBeginSection': 126,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16497104',\n",
       "     'text': 'Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 119,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/23807042',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24293278',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16497104',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19681654',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16198622',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21136948',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15886319',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25782630',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23531037',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19249912']},\n",
       "  {'id': '6429ee7457b1c7a31500000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35738594',\n",
       "     'text': 'The COVID-19 vaccination can cause specific side-effects, such as axillary lymph node swelling; therefore, breast oncologists should pay attention to such occurrences.',\n",
       "     'offsetInBeginSection': 144,\n",
       "     'offsetInEndSection': 311,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36276167',\n",
       "     'text': 'when given to Saudi Arabian adults. All reported side-effects were mild to moderate. The findings will likely persuade vaccine-hesitant individuals an',\n",
       "     'offsetInBeginSection': 1264,\n",
       "     'offsetInEndSection': 1414,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35952506',\n",
       "     'text': 'tients with BECTS reported having side effects; all effects were mild that could be relieved themselves. For Sinopharm (Beijing): BBIBP-CorV (Vero cel',\n",
       "     'offsetInBeginSection': 860,\n",
       "     'offsetInEndSection': 1010,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34940894',\n",
       "     'text': 'The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%).',\n",
       "     'offsetInBeginSection': 1062,\n",
       "     'offsetInEndSection': 1182,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35775049',\n",
       "     'text': 'etween 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.\\n\\n\\nConclusions\\nAccording t',\n",
       "     'offsetInBeginSection': 1514,\n",
       "     'offsetInEndSection': 1664,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35334998',\n",
       "     'text': 'cination among Arab populations are usually non-life-threatening; flu-like symptoms and injection site pain. Certain predisposing factors have greater',\n",
       "     'offsetInBeginSection': 2211,\n",
       "     'offsetInEndSection': 2361,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34197678',\n",
       "     'text': 'The common side effects reported following Covid-19 vaccination were mostly self-restricted local reactions that resolved quickly.',\n",
       "     'offsetInBeginSection': 261,\n",
       "     'offsetInEndSection': 391,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767100',\n",
       "     'text': 'The efficacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophenolate/mycophenolic acid (MMF), and rituximab (RTX).',\n",
       "     'offsetInBeginSection': 712,\n",
       "     'offsetInEndSection': 921,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35383912',\n",
       "     'text': 'd individuals with DS (median age = 19.5\\xa0years), with 50% reporting no side effects from COVID-19 vaccination. Increased seizures following COVID-19 v',\n",
       "     'offsetInBeginSection': 943,\n",
       "     'offsetInEndSection': 1093,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35244157',\n",
       "     'text': 'period of 3-13 days after COVID-19 vaccination. None was under immunosuppressive therapy. The 3 patients recovered in a few weeks and the subsequent d',\n",
       "     'offsetInBeginSection': 709,\n",
       "     'offsetInEndSection': 859,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35334998',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34940894',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35738594',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35383912',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35775049',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36276167',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35952506',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34197678',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35244157',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34767100']},\n",
       "  {'id': '6433050157b1c7a315000024',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24556385',\n",
       "     'text': 'BACKGROUND\\nConestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22171564',\n",
       "     'text': 'BACKGROUND\\nRecombinant human C1-inhibitor (rhC1INH; Ruconest®) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) due to heterozygous deficiency of C1INH.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 209,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30021471',\n",
       "     'text': ' an established treatment for both on demand and prophylaxis of HAE. Conestat alfa is a recombinant form of human C1-INH (rhC1-INH) produced in transg',\n",
       "     'offsetInBeginSection': 219,\n",
       "     'offsetInEndSection': 369,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30280305',\n",
       "     'text': 'Fifty (63.3%) attacks were treated with recombinant human C1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH).',\n",
       "     'offsetInBeginSection': 694,\n",
       "     'offsetInEndSection': 941,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32923264',\n",
       "     'text': 'The targeted therapy for HAE consists of plasma-derived or recombinant C1-INH, ecallantide, and icatibant or bradykinin receptor antagonist.',\n",
       "     'offsetInBeginSection': 577,\n",
       "     'offsetInEndSection': 717,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21753889',\n",
       "     'text': 'n findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement product',\n",
       "     'offsetInBeginSection': 208,\n",
       "     'offsetInEndSection': 358,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "     'text': 'tor (C1-INH) or via blocking the production or function of bradykinin. Cinryze® is a nanofiltered C1-INH, approved in Europe for the acute treatment, ',\n",
       "     'offsetInBeginSection': 388,\n",
       "     'offsetInEndSection': 538,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17559913',\n",
       "     'text': ' likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is',\n",
       "     'offsetInBeginSection': 396,\n",
       "     'offsetInEndSection': 546,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21753889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30280305',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22171564',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24556385',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17559913',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32923264',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30021471']},\n",
       "  {'id': '6417900b690f196b5100002a',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can viltolarsen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022',\n",
       "     'text': 'Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\xa0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 305,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32519222',\n",
       "     'text': 'nter of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA p',\n",
       "     'offsetInBeginSection': 167,\n",
       "     'offsetInEndSection': 317,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "     'text': 'be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29579701',\n",
       "     'text': 'BACKGROUND\\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33285037',\n",
       "     'text': \"n gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen's ability to induce dystr\",\n",
       "     'offsetInBeginSection': 101,\n",
       "     'offsetInEndSection': 251,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12692454',\n",
       "     'text': 'This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 172,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36449321',\n",
       "     'text': 'disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr',\n",
       "     'offsetInBeginSection': 77,\n",
       "     'offsetInEndSection': 227,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "     'text': 'A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 271,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "     'text': 'en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta',\n",
       "     'offsetInBeginSection': 420,\n",
       "     'offsetInEndSection': 570,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32483212',\n",
       "     'text': 'Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year.',\n",
       "     'offsetInBeginSection': 483,\n",
       "     'offsetInEndSection': 569,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12692454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32519222',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33285037',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36401022',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36449321',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32483212',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29579701']},\n",
       "  {'id': '63f57ea133942b094c000005',\n",
       "   'type': 'list',\n",
       "   'body': 'What is the triad of the Cat eye syndrome?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33465332',\n",
       "     'text': 'The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients.',\n",
       "     'offsetInBeginSection': 127,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16145841',\n",
       "     'text': 'osome 22q11. The patients demonstrate specific abnormalities of heart, kidney, and eye. Here we attempted to produce a model for this defect by expres',\n",
       "     'offsetInBeginSection': 84,\n",
       "     'offsetInEndSection': 234,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3109242',\n",
       "     'text': 'The cat eye syndrome, blepharophimosis or Kohn-Romano syndrome, Rieger syndrome, and other disorders are discussed in relationship to this entity.',\n",
       "     'offsetInBeginSection': 236,\n",
       "     'offsetInEndSection': 382,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11332976',\n",
       "     'text': 'riable pattern of multiple congenital anomalies of which coloboma of the iris and anal atresia are the best known. CES is cytogenetically characterise',\n",
       "     'offsetInBeginSection': 46,\n",
       "     'offsetInEndSection': 196,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/410302',\n",
       "     'text': 'hniques, we studied a child with typical cat-eye syndrome and ocular retraction syndrome. Although the mother was was chromosomally normal, other mate',\n",
       "     'offsetInBeginSection': 38,\n",
       "     'offsetInEndSection': 188,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35911297',\n",
       "     'text': 'The classic clinical triad includes coloboma of the iris, ears, and anal malformations.',\n",
       "     'offsetInBeginSection': 101,\n",
       "     'offsetInEndSection': 188,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2072964',\n",
       "     'text': 'In a cyanotic newborn with characteristic features of Cat-Eye-Syndrome, cytogenetic examination disclosed a supernumerary small bisatellited chromosome.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 152,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23928108',\n",
       "     'text': 'e 22, with a variable phenotype comprising anal atresia, coloboma of the iris and preauricular tags or pits. We report a girl with cat eye syndrome, p',\n",
       "     'offsetInBeginSection': 129,\n",
       "     'offsetInEndSection': 279,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31034246',\n",
       "     'text': 'Most of the sample was assigned moderate or high risk for Triad CRA and RED-S CAT (Triad: 54.7% moderate and 7.9% high; RED-S: 63.2% moderate and 33.0% high).',\n",
       "     'offsetInBeginSection': 964,\n",
       "     'offsetInEndSection': 1122,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25648072',\n",
       "     'text': 'Individuals with cat-eye syndrome are characterized by the presence of preauricular pits and/or tags, anal atresia, and iris coloboma.',\n",
       "     'offsetInBeginSection': 67,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/23928108',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25648072',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2072964',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/410302',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11332976',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31034246',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33465332',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3109242',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16145841',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35911297']},\n",
       "  {'id': '64281a47690f196b5100004f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34258537',\n",
       "     'text': 'INTRODUCTION\\nThe therapy to reduce urinary oxalate excretion in primary hyperoxaluria type 1 is still required.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 111,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32165440',\n",
       "     'text': 'combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in pa',\n",
       "     'offsetInBeginSection': 268,\n",
       "     'offsetInEndSection': 418,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "     'text': 'order that causes overproduction and urinary excretion of oxalate. Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1',\n",
       "     'offsetInBeginSection': 69,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35015123',\n",
       "     'text': '1), with doses and intervals according to body weight. Little is known as to its use in infants; the aim of this study was to describe treatment outco',\n",
       "     'offsetInBeginSection': 127,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33985991',\n",
       "     'text': 'Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate production.',\n",
       "     'offsetInBeginSection': 194,\n",
       "     'offsetInEndSection': 304,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22215125',\n",
       "     'text': 'The primary disease is treated by combined liver-kidney transplantation, although pathological fracturing also occurs in the posttransplant period.',\n",
       "     'offsetInBeginSection': 363,\n",
       "     'offsetInEndSection': 510,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23830800',\n",
       "     'text': 'Aside from combined liver/kidney transplantation, no curative treatment exists.',\n",
       "     'offsetInBeginSection': 300,\n",
       "     'offsetInEndSection': 379,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "     'text': 'Combined liver and kidney transplant and preemptive liver transplant could be proper options for these patients.',\n",
       "     'offsetInBeginSection': 1561,\n",
       "     'offsetInEndSection': 1673,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35071135',\n",
       "     'text': 'ney failure and systemic oxalosis. Lumasiran, is a liver-directed RNA interference therapeutic agent. It has been shown to reduce hepatic oxalate prod',\n",
       "     'offsetInBeginSection': 163,\n",
       "     'offsetInEndSection': 313,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779234',\n",
       "     'text': 'NA interference medication is now available. Lumasiran® is already available on prescription and targets the messenger RNA of glycolate oxidase, thus ',\n",
       "     'offsetInBeginSection': 781,\n",
       "     'offsetInEndSection': 931,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22215125',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35779234',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35015123',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33985991',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34258537',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32165440',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23830800',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35071135']},\n",
       "  {'id': '6429cfb557b1c7a315000005',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34222281',\n",
       "     'text': 'ated with negative COVID-19 related health outcomes. Individuals with COPD should take precautions to limit the risk of COVID-19 exposure to negate th',\n",
       "     'offsetInBeginSection': 1675,\n",
       "     'offsetInEndSection': 1825,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34222281',\n",
       "     'text': 'ociated with negative COVID-19 related health outcomes. Individuals with COPD should take precautions to limit the risk of COVID-19 exposure to negate',\n",
       "     'offsetInBeginSection': 1672,\n",
       "     'offsetInEndSection': 1822,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34476396',\n",
       "     'text': 'Asthma should be managed as outlined in local and international guidelines.Ensure an adequate supply of medication, and inhaled corticosteroids should not be withdrawnChronic obstructive pulmonary disease (COPD) is associated with severe COVID-19 disease and poor outcomes.',\n",
       "     'offsetInBeginSection': 330,\n",
       "     'offsetInEndSection': 603,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12877818',\n",
       "     'text': 'Although inhaled glucocorticoids are highly effective in controlling airway inflammation in asthma, they are ineffective in the small group of patients with glucocorticoid-dependent and -resistant asthma.',\n",
       "     'offsetInBeginSection': 127,\n",
       "     'offsetInEndSection': 331,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35747745',\n",
       "     'text': 'ions such as inhaled corticosteroids (ICS) and biologics on COVID-19 is unclear. This systematic literature review analyzed the published evidence on ',\n",
       "     'offsetInBeginSection': 172,\n",
       "     'offsetInEndSection': 322,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33248363',\n",
       "     'text': 'Considering what is available in literature, there are no known infection-related hazards to an uninfected patient and also a patient with COVID-19 that preclude the use of a nebulizer at home, but it fundamental that all patients, regardless of whether or not suffering from COVID-19, always follow some practical advices.',\n",
       "     'offsetInBeginSection': 1066,\n",
       "     'offsetInEndSection': 1389,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34568369',\n",
       "     'text': '. 007 ± 0.38; P < 0.05) during the COVID-19 pandemic. In contrast, among COPD patients, there were no significant differences in AE frequency, clinic ',\n",
       "     'offsetInBeginSection': 1553,\n",
       "     'offsetInEndSection': 1703,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25750734',\n",
       "     'text': ' also enhance the efficacy of inhaled glucocorticoids in chronic obstructive pulmonary disease (COPD). In both conditions, these drugs are believed to',\n",
       "     'offsetInBeginSection': 846,\n",
       "     'offsetInEndSection': 996,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35887681',\n",
       "     'text': 'In addition, the comparison of asthma with COPD patients confirmed the greater frailty of the latter, according to their multiple comorbidities.',\n",
       "     'offsetInBeginSection': 1791,\n",
       "     'offsetInEndSection': 1935,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33276252',\n",
       "     'text': 'CONCLUSIONS\\nOur study supports the recommendation that patients with chronic pulmonary diseases, including asthma and COPD who require treatment with either inhaled or systemic corticosteroids, should continue their use during the COVID-19 pandemic.',\n",
       "     'offsetInBeginSection': 1477,\n",
       "     'offsetInEndSection': 1726,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34476396',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33248363',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35887681',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25750734',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34222281',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33276252',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34568369',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35747745',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12877818']},\n",
       "  {'id': '6432f75757b1c7a31500001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34276674',\n",
       "     'text': 'At present, three different covalent BTKis, ibrutinib, acalabrutinib and zanubrutinib, are FDA-approved and many new inhibitors are under development.',\n",
       "     'offsetInBeginSection': 406,\n",
       "     'offsetInEndSection': 556,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "     'text': 'As compared to first-generation ibrutinib, zanubrutinib has higher BTK selectivity which may result in fewer off-target effects and improved potential for combination with other targeted therapies.',\n",
       "     'offsetInBeginSection': 798,\n",
       "     'offsetInEndSection': 995,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32484067',\n",
       "     'text': '-fold for 26-weeks and 39-weeks of treatment, respectively. Zanubrutinib was not genotoxic. Fertility studies showed no abnormal findings in both male',\n",
       "     'offsetInBeginSection': 832,\n",
       "     'offsetInEndSection': 982,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35993294',\n",
       "     'text': 'TKi-related adverse events, but major rates of neutropenia, and its approval is awaited. With the aim of overcoming drug resistance, noncovalent BTKi ',\n",
       "     'offsetInBeginSection': 676,\n",
       "     'offsetInEndSection': 826,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32484067',\n",
       "     'text': \"Zanubrutinib an oral irreversible Bruton's tyrosine kinase (BTK) inhibitor, is under development for the treatment of a variety of B-cell malignancies and has received accelerated approval by the US Food and Drug Administration for treatment of adult patients with mantel cell lymphoma who have received at least one prior therapy.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 331,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32731259',\n",
       "     'text': ', a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease w',\n",
       "     'offsetInBeginSection': 198,\n",
       "     'offsetInEndSection': 348,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'ewer patients experience side effects and quit treatment. Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have',\n",
       "     'offsetInBeginSection': 3152,\n",
       "     'offsetInEndSection': 3302,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'ater selectivity was developed. In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle',\n",
       "     'offsetInBeginSection': 511,\n",
       "     'offsetInEndSection': 661,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35507054',\n",
       "     'text': 'labrutinib, and zanubrutinib (the latter not yet approved for this disease but included in the NCCN guidelines). In this review, we will elucidate our',\n",
       "     'offsetInBeginSection': 165,\n",
       "     'offsetInEndSection': 315,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31420873',\n",
       "     'text': 'Whether zanubrutinib, a second-generation selective BTK inhibitor, has similar effects as ibrutinib remains to be determined.',\n",
       "     'offsetInBeginSection': 203,\n",
       "     'offsetInEndSection': 328,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35507054',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31420873',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34276674',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32484067',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35993294',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32731259']},\n",
       "  {'id': '64178fea690f196b51000028',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What types of DMD can eteplirsen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23907995',\n",
       "     'text': 'OBJECTIVE\\nIn prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 212,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30526286',\n",
       "     'text': 'Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 248,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22086232',\n",
       "     'text': 'We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.)',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 371,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "     'text': 'ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari',\n",
       "     'offsetInBeginSection': 102,\n",
       "     'offsetInEndSection': 252,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29907124',\n",
       "     'text': 'BACKGROUND\\nExon skipping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 116,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34120909',\n",
       "     'text': 'BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, based on demonstrated dystrophin production.ObjectiveTo report results from PROMOVI, a phase 3, multicenter, open-label study evaluating efficacy and safety of eteplirsen in a larger cohort.MethodsAmbulatory patients aged 7-16 years, with confirmed mutations amenable to exon 51 skipping, received eteplirsen 30\\u200amg/kg/week intravenously for 96 weeks.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 501,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31261494',\n",
       "     'text': 'This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who participated in two clinical studies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 154,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27807823',\n",
       "     'text': 'Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.',\n",
       "     'offsetInBeginSection': 135,\n",
       "     'offsetInEndSection': 346,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "     'text': 'However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years.',\n",
       "     'offsetInBeginSection': 330,\n",
       "     'offsetInEndSection': 544,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29752304',\n",
       "     'text': 'OBJECTIVE\\nTo describe the quantification of novel dystrophin production in patients with Duchenne muscular dystrophy (DMD) after long-term treatment with eteplirsen.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 165,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34120909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27807823',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29907124',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30526286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23907995',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29752304',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22086232',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31261494']},\n",
       "  {'id': '63eef94ff36125a426000010',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Cinpanemab effective for Parkinson’s Disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "     'text': 'The trial was stopped after the week 72 interim analysis owing to lack of efficacy.',\n",
       "     'offsetInBeginSection': 1215,\n",
       "     'offsetInEndSection': 1298,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23223310',\n",
       "     'text': 'Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects, known in their complex as L-DOPA-induced dyskinesia (LID).',\n",
       "     'offsetInBeginSection': 105,\n",
       "     'offsetInEndSection': 323,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "     'text': \"Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.\",\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35500112',\n",
       "     'text': 'in patients with Parkinson’s disease (PD). However, its therapeutic mechanism of action is unknown. The healthy striatum exhibits rich dynamics result',\n",
       "     'offsetInBeginSection': 117,\n",
       "     'offsetInEndSection': 267,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29874003',\n",
       "     'text': 'The present therapeutic drugs for PD can only alleviate the patients’ symptoms, but cannot prevent or delay progression of the disease.',\n",
       "     'offsetInBeginSection': 114,\n",
       "     'offsetInEndSection': 249,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26236796',\n",
       "     'text': 'Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect.',\n",
       "     'offsetInBeginSection': 308,\n",
       "     'offsetInEndSection': 416,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31731332',\n",
       "     'text': 'Conclusion\\nAs detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.',\n",
       "     'offsetInBeginSection': 1067,\n",
       "     'offsetInEndSection': 1241,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35404466',\n",
       "     'text': ' associated with neurodegeneration  but  have  failed  to  identify  preventive  or  curative  therapies.  This  failure  mainly  originates  from  th',\n",
       "     'offsetInBeginSection': 233,\n",
       "     'offsetInEndSection': 383,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26464310',\n",
       "     'text': 'The current drug treatment for PD is palliative and does not meet the clinical challenges of the disease, such as levodopa-induced dyskinesia, non-motor symptoms, and neuroprotection.',\n",
       "     'offsetInBeginSection': 147,\n",
       "     'offsetInEndSection': 330,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29714967',\n",
       "     'text': 'Parkinson’s disease(PD)diagnosis based on speech data has been proved to be an effective way in recent years.There are still some problems on preprocessing samples,ensemble learning,and so on.The problems can further cause misleading of classifiers,unsatisfactory classification accuracy and stability.This paper proposed a new diagnosis algorithm of PD by combining multi-edit sample selection method and random forest.At the end of it,this paper presents a group of experiments carried out with the newest public datasets.Experimental results showed that this proposed algorithm realized the classification of the samples and the subjects of PD.Furthermore,it achieved average classification accuracy of 100% and obtained improvement of up to 29.44% compared to those provided by the subjects.This paper proposes a new speech diagnosis algorithm for PD based on instance selection;and the method algorithm has a higher and more stable classification accuracy,compared with the other algorithms.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 996,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26236796',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29874003',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23223310',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35404466',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35500112',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31731332',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26464310',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29714967']},\n",
       "  {'id': '6426d131690f196b5100004e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'In what organ would you find the Ashwell receptor?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "     'text': 'The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18488037',\n",
       "     'text': 'The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 179,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27207430',\n",
       "     'text': 'This review will focus on the mechanisms of platelet senescence with specific emphasis on the role of post-translational modifications in platelet life-span and thrombopoietin production downstream of the hepatic Ashwell-Morrell receptor.',\n",
       "     'offsetInBeginSection': 241,\n",
       "     'offsetInEndSection': 479,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "     'text': \"Among these components, clearance by the liver's AMR is enhanced by exposure of terminal galactose on the glycan chains.\",\n",
       "     'offsetInBeginSection': 968,\n",
       "     'offsetInEndSection': 1088,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/18488037',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27207430']},\n",
       "  {'id': '6429e17657b1c7a315000007',\n",
       "   'type': 'list',\n",
       "   'body': 'What histone marks are indicative of enhancers in the chromatin landscape of a given cell?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649883',\n",
       "     'text': 'or instance, active enhancers are commonly occupied by both marks H3K4me1 and H3K27ac. The traditional bottom-up MS strategy identifies and quantifies',\n",
       "     'offsetInBeginSection': 417,\n",
       "     'offsetInEndSection': 567,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32058623',\n",
       "     'text': 'In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.',\n",
       "     'offsetInBeginSection': 725,\n",
       "     'offsetInEndSection': 939,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28981749',\n",
       "     'text': 'The intersection of the proteomics data with ChIP-seq and RNA-seq analyses revealed the existence of novel subpopulations of enhancers, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me2 combinations mark distinct classes of intronic enhancers.',\n",
       "     'offsetInBeginSection': 996,\n",
       "     'offsetInEndSection': 1339,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26957309',\n",
       "     'text': 'We tested 40 chromatin signatures on this unbiased enhancer set and identified H2BK20ac, a little-studied histone modification, as the most predictive mark of active enhancers.',\n",
       "     'offsetInBeginSection': 347,\n",
       "     'offsetInEndSection': 523,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32058623',\n",
       "     'text': 'In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.',\n",
       "     'offsetInBeginSection': 725,\n",
       "     'offsetInEndSection': 939,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29089515',\n",
       "     'text': 'These elements are characterized by distinct epigenomic profiles, such as expanded deposition of histone marks H3K27ac for super enhancers and H3K4me3 for broad domains, however little is known about how they interact with each other and the rest of the genome in three-dimensional chromatin space.',\n",
       "     'offsetInBeginSection': 152,\n",
       "     'offsetInEndSection': 450,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32286315',\n",
       "     'text': 'Here, we present chromatin immunoprecipitation sequencing (ChIP-Seq) data for the oncogenic transcription factors, MYCN and MYC, as well as regulatory histone marks H3K4me1, H3K4me3, H3K27Ac, and H3K27me3 in ten commonly used human neuroblastoma-derived cell line models.',\n",
       "     'offsetInBeginSection': 208,\n",
       "     'offsetInEndSection': 479,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21106759',\n",
       "     'text': 'stem cells and several adult tissues in the mouse. We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements ',\n",
       "     'offsetInBeginSection': 667,\n",
       "     'offsetInEndSection': 817,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22955985',\n",
       "     'text': 'all types of chromatin marks examined, including promoter, enhancer, elongation, and repressive marks. The fine-resolution signal shapes discovered by',\n",
       "     'offsetInBeginSection': 1403,\n",
       "     'offsetInEndSection': 1553,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22955985',\n",
       "     'text': 'digestion and high-depth sequencing. Here we relate 14 chromatin signals (12 histone marks, DNase, and nucleosome positioning) to the binding sites of',\n",
       "     'offsetInBeginSection': 453,\n",
       "     'offsetInEndSection': 603,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28981749',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32058623',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21106759',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28649883',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32286315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26957309',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29089515',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22955985']},\n",
       "  {'id': '643306cc57b1c7a315000027',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35719360',\n",
       "     'text': '0 min), and CRISPR/Cas12a-mediated detection (37°C, 8 min), can be completed within 70 min. A fluorescence reader (for fluorescence CRISPR-CLA) or a l',\n",
       "     'offsetInBeginSection': 1652,\n",
       "     'offsetInEndSection': 1802,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32486913',\n",
       "     'text': 'These results indicate that Cas12a is able to detect both DNA and RNA targets, making it an appropriate and convenient tool to detect all types of pathogens.',\n",
       "     'offsetInBeginSection': 1008,\n",
       "     'offsetInEndSection': 1165,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33159392',\n",
       "     'text': 'However, whether single-stranded DNA in CRISPR system can cause false positives remains undetermined.',\n",
       "     'offsetInBeginSection': 202,\n",
       "     'offsetInEndSection': 303,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31413315',\n",
       "     'text': 'h attomolar sensitivity but, to our knowledge, it has not been used for the detection of small molecules. Bacterial allosteric transcription factors (',\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32093010',\n",
       "     'text': 'This proof of principle study demonstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therapeutic implications.',\n",
       "     'offsetInBeginSection': 1361,\n",
       "     'offsetInEndSection': 1562,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33329659',\n",
       "     'text': 'By using this simple and high-efficiency CRISPR/Cas12a system, multiple targets can be modified to obtain multigene simultaneous knockout mutants in tree species, which will provide powerful tools with which to facilitate genetic studies of forest trees.',\n",
       "     'offsetInBeginSection': 1212,\n",
       "     'offsetInEndSection': 1466,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33991961',\n",
       "     'text': 'ns-cleaves ssDNA and this feature has been widely harnessed for nucleic acid detection. Herein, we introduce a new type of Cas12a reporter, G-triplex ',\n",
       "     'offsetInBeginSection': 24,\n",
       "     'offsetInEndSection': 174,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34794559',\n",
       "     'text': 'By means of the unique combination of Cas12a with ECL technique based on BPE, it can convert the recognition of target ATP into a detectable ECL signal.',\n",
       "     'offsetInBeginSection': 720,\n",
       "     'offsetInEndSection': 872,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36214815',\n",
       "     'text': 'e degraded, leaving the single-stranded DNA (ssDNA). The CRISPR/Cas12a can accurately locate ssDNA without PAM, then initiating its trans-cleavage act',\n",
       "     'offsetInBeginSection': 868,\n",
       "     'offsetInEndSection': 1018,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34653714',\n",
       "     'text': 'Although CRISPR-Cas12a and CRISPR-Cas13a systems work individually effective on gene detection, their multiplex detection capability is limited due to the lack of specific probe cleavage mechanism.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 197,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36214815',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34794559',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32093010',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35719360',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32486913',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31413315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33991961',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33329659',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33159392',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34653714']},\n",
       "  {'id': '64178ffb690f196b51000029',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can casimersen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33861387',\n",
       "     'text': 'Casimersen (Amondys 45™) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that is amenable to exon\\xa045 skipping.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 286,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "     'text': 'ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari',\n",
       "     'offsetInBeginSection': 102,\n",
       "     'offsetInEndSection': 252,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "     'text': 'be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12692454',\n",
       "     'text': 'This study examined Three Wishes (a projective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 172,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29791760',\n",
       "     'text': 'of dystrophin-deficient muscle. We tested the hypothesis that Duchenne muscular dystrophy (DMD) patients would have elevated levels of the macrophage-',\n",
       "     'offsetInBeginSection': 882,\n",
       "     'offsetInEndSection': 1032,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29579701',\n",
       "     'text': 'BACKGROUND\\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36449321',\n",
       "     'text': 'disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr',\n",
       "     'offsetInBeginSection': 77,\n",
       "     'offsetInEndSection': 227,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "     'text': 'A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 271,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34105177',\n",
       "     'text': 'Casimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most TEAEs were mild, nonserious, and unrelated to casimersen. Pl',\n",
       "     'offsetInBeginSection': 1478,\n",
       "     'offsetInEndSection': 1628,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7599358',\n",
       "     'text': 'sed as potential treatments for inherited myopathies, such as Duchenne muscular dystrophy (DMD). The success of myoblast implantation in mouse models,',\n",
       "     'offsetInBeginSection': 63,\n",
       "     'offsetInEndSection': 213,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12692454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7599358',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33861387',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34105177',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36449321',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29791760',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29579701']},\n",
       "  {'id': '63eeefc5f36125a426000009',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is targeted by CIS43LS?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34511592',\n",
       "     'text': ' dose of the CIS43LS monoclonal antibody resulted in protection against malaria. These new findings have implications for the seasonal control of mala',\n",
       "     'offsetInBeginSection': 1100,\n",
       "     'offsetInEndSection': 1250,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34379916',\n",
       "     'text': 'ody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. Part A of the trial assessed the safety, initial side-e',\n",
       "     'offsetInBeginSection': 248,\n",
       "     'offsetInEndSection': 398,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34379916',\n",
       "     'text': 'administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Aller',\n",
       "     'offsetInBeginSection': 1993,\n",
       "     'offsetInEndSection': 2143,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36317783',\n",
       "     'text': 'BACKGROUND\\nCIS43LS is a monoclonal antibody that was shown to protect against controlled <i>Plasmodium falciparum</i> infection in a phase 1 clinical trial.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 156,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36317783',\n",
       "     'text': 'falciparum</i> infection over a 6-month malaria season in Mali without evident safety concerns.',\n",
       "     'offsetInBeginSection': 1837,\n",
       "     'offsetInEndSection': 1932,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33332286',\n",
       "     'text': 'CIS43 is a potent neutralizing human mAb that targets a highly conserved \"junctional\" epitope in the Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 161,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33332286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34511592',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36317783',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34379916']},\n",
       "  {'id': '6415b422690f196b5100000a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What does Cal-light do?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28650460',\n",
       "     'text': 'We present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.',\n",
       "     'offsetInBeginSection': 130,\n",
       "     'offsetInEndSection': 292,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28650460']},\n",
       "  {'id': '64172bb2690f196b5100001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'To which region of a gene does an RNA polymerase bind to initiate transcription?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31863129',\n",
       "     'text': 'RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.',\n",
       "     'offsetInBeginSection': 131,\n",
       "     'offsetInEndSection': 363,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8065261',\n",
       "     'text': 'Furthermore, two proteins (M(r) 12,000 and 35,000) which interact with and may activate transcription from the ndh promoter under these conditions were detected by gel retardation analysis.',\n",
       "     'offsetInBeginSection': 1234,\n",
       "     'offsetInEndSection': 1423,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6382259',\n",
       "     'text': 'The RNA polymerase from bacteriophage T4-infected Escherichia coli, which specifically initiates transcription at phage T4 late promoters, is extensively modified by ADP-ribosylation of core subunits and by binding several virus-encoded subunits.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9603525',\n",
       "     'text': 'Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24600005',\n",
       "     'text': 'from a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces t',\n",
       "     'offsetInBeginSection': 639,\n",
       "     'offsetInEndSection': 789,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7022450',\n",
       "     'text': 'nscription at certain promoters recognized by unmodified enzyme. In the T4tRNA gene region, only one of the two promoters is active with the modified ',\n",
       "     'offsetInBeginSection': 226,\n",
       "     'offsetInEndSection': 376,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6194892',\n",
       "     'text': 'A sensitive hybridization technique was used to demonstrate that the purified polymerase, even when supplemented with a transcription factor that binds specifically to the 5S RNA gene internal control region, is unable to initiate synthesis at the start site of the 5S RNA gene.',\n",
       "     'offsetInBeginSection': 246,\n",
       "     'offsetInEndSection': 524,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3380786',\n",
       "     'text': 'kurstaki HD-1-Dipel that directs transcription from the promoter region of an insecticidal crystal protein gene.',\n",
       "     'offsetInBeginSection': 101,\n",
       "     'offsetInEndSection': 213,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2648001',\n",
       "     'text': ' facilitates binding of the RNA polymerase to the proper region of the promoter. The Ada protein possesses two known methyl acceptor sites, Cys69 and ',\n",
       "     'offsetInBeginSection': 1617,\n",
       "     'offsetInEndSection': 1767,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8496187',\n",
       "     'text': 'actor responsible for the assembly of a transcription complex on the 5 S RNA gene. We have analyzed the effect of deleting various regions of yeast TF',\n",
       "     'offsetInBeginSection': 120,\n",
       "     'offsetInEndSection': 270,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/6194892',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24600005',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6382259',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31863129',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8065261',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9603525',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8496187',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7022450',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3380786',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2648001']},\n",
       "  {'id': '63f9ccdc33942b094c00000f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is PRP-40 involved in microexon splicing?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "     'text': 'ion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dep',\n",
       "     'offsetInBeginSection': 527,\n",
       "     'offsetInEndSection': 677,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "     'text': 'f neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependen',\n",
       "     'offsetInBeginSection': 532,\n",
       "     'offsetInEndSection': 682,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7935475',\n",
       "     'text': 'However, any such splicing factor containing the helicase motifs in vertebrates has not been identified.',\n",
       "     'offsetInBeginSection': 286,\n",
       "     'offsetInEndSection': 390,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23026070',\n",
       "     'text': 'ated by fPACAP-38 in a concentration-dependent manner, but was not regulated by fPRP-45. Results from real-time quantitative polymerase chain reaction',\n",
       "     'offsetInBeginSection': 1307,\n",
       "     'offsetInEndSection': 1457,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18945809',\n",
       "     'text': 'Our findings suggest that in addition to its important regulatory function in the C. elegans germ line, prp-8(rr40) may provide further insight into the etiology of this splicing-associated human disorder.',\n",
       "     'offsetInBeginSection': 1520,\n",
       "     'offsetInEndSection': 1725,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23026070',\n",
       "     'text': 'ulated by fPACAP-38 in a concentration-dependent manner, but was not regulated by fPRP-45. Results from real-time quantitative polymerase chain reacti',\n",
       "     'offsetInBeginSection': 1305,\n",
       "     'offsetInEndSection': 1455,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23026070',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18945809',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7935475']},\n",
       "  {'id': '641790d6690f196b5100002d',\n",
       "   'type': 'factoid',\n",
       "   'body': 'At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22115006',\n",
       "     'text': 'f corticosteroids slowed the loss of ambulation that develops in mid to late childhood. Corticosteroids, however, frequently produce unacceptable side',\n",
       "     'offsetInBeginSection': 226,\n",
       "     'offsetInEndSection': 376,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12363102',\n",
       "     'text': 'nsuing year that resulted in loss of independent ambulation at the age of 10. Both boys remained around the 50th centile for height and weight, and sh',\n",
       "     'offsetInBeginSection': 622,\n",
       "     'offsetInEndSection': 772,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31588416',\n",
       "     'text': 'The impact of the disease presents as early as infancy with significant developmental delays, and ultimately loss of ambulation and respiratory insufficiency.',\n",
       "     'offsetInBeginSection': 142,\n",
       "     'offsetInEndSection': 300,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35625891',\n",
       "     'text': 'wasting during early childhood, and loss of ambulation and death by early adulthood. Chronic inflammation due to myofiber instability leads to fibrosi',\n",
       "     'offsetInBeginSection': 123,\n",
       "     'offsetInEndSection': 273,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21784636',\n",
       "     'text': 'Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12. Long-term steroids have lengthened ambulation by 2-5 years. Ischial weight-',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12466073',\n",
       "     'text': 'Loss of independent gait occurred at similar ages in both groups (10.3 vs. 10.5 years).',\n",
       "     'offsetInBeginSection': 971,\n",
       "     'offsetInEndSection': 1058,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17388226',\n",
       "     'text': 'Subsequently, the disease immobilizes the patient (ages 9 to 14 years) and severe respiratory failure occurs due to chest and vertebral column deformity.',\n",
       "     'offsetInBeginSection': 261,\n",
       "     'offsetInEndSection': 414,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25643053',\n",
       "     'text': 'ents with Duchenne muscular dystrophy aged 17.1 ± 4.8 years (range: 9 - 28.1 years). The average Brooke functional score of these patients was 4.6 ± 1',\n",
       "     'offsetInBeginSection': 641,\n",
       "     'offsetInEndSection': 791,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23440719',\n",
       "     'text': 'Glucocorticoid-treated patients who were IAAM homozygotes lost ambulation at 12.5 ± 3.3 years compared to 10.7 ± 2.1 years for treated VTTT heterozygotes or homozygotes.',\n",
       "     'offsetInBeginSection': 787,\n",
       "     'offsetInEndSection': 956,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "     'text': 'Historically, DMD has resulted in loss of ambulation between ages 7 and 13 years and death in the teens or 20s.',\n",
       "     'offsetInBeginSection': 303,\n",
       "     'offsetInEndSection': 414,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22115006',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21784636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31588416',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35625891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12363102',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23440719',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17388226',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12466073',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25643053']},\n",
       "  {'id': '6404199d201352f04a000019',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is ocrelizumab effective for primary progressive multiple sclerosis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32920498',\n",
       "     'text': 'ary progressive multiple sclerosis (PPMS) with efficacy proven in a phase 3 randomised controlled trial. Eleven months prior to the European regulator',\n",
       "     'offsetInBeginSection': 182,\n",
       "     'offsetInEndSection': 332,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "     'text': 'Conclusions: Our real-world study supports the tolerability, safety, and effectiveness of ocrelizumab in clinical practice.',\n",
       "     'offsetInBeginSection': 1453,\n",
       "     'offsetInEndSection': 1576,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32777270',\n",
       "     'text': ' remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and even',\n",
       "     'offsetInBeginSection': 83,\n",
       "     'offsetInEndSection': 233,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "     'text': 'of RMS patients who were followed for at least 1 year. Ocrelizumab was generally well-tolerated; the most common adverse events were infusion-related ',\n",
       "     'offsetInBeginSection': 1249,\n",
       "     'offsetInEndSection': 1399,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35456175',\n",
       "     'text': 'In conclusion, our study highlighted that early ocrelizumab treatment is effective in modifying the disability accrual in MS patients.',\n",
       "     'offsetInBeginSection': 2061,\n",
       "     'offsetInEndSection': 2195,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36454397',\n",
       "     'text': 'OBJECTIVES\\nOcrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33868559',\n",
       "     'text': 'BACKGROUND\\nOcrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 159,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30160679',\n",
       "     'text': 'lizumab, are widely coming to multiple sclerosis (MS) therapy. Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) ',\n",
       "     'offsetInBeginSection': 71,\n",
       "     'offsetInEndSection': 221,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32920498',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36454397',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30160679',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33868559',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32777270',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35456175']},\n",
       "  {'id': '641b7bba690f196b5100003e',\n",
       "   'type': 'summary',\n",
       "   'body': 'How is Indocyanine green (ICG) used?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35874138',\n",
       "     'text': 's an operation burdened with severe postoperative complications. Fluorescence imaging, particularly using indocyanine green (ICG), offers the ability ',\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12140046',\n",
       "     'text': 'PURPOSE\\nTo report an altered uptake and possible complication associated with the use of indocyanine green (ICG) dye, internal limiting membrane (ILM) peeling, and infrared diode laser.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 185,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33965600',\n",
       "     'text': 'We describe a case using indocyanine green (ICG) fluorescence imaging for diagnosis of postoperative gastrointestinal fistula.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 126,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28316935',\n",
       "     'text': 'Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 117,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9018428',\n",
       "     'text': 'Indocyanine green (ICG) is a fluorescent dye that can be used to image both retinal and choroidal vessels.',\n",
       "     'offsetInBeginSection': 131,\n",
       "     'offsetInEndSection': 237,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7553712',\n",
       "     'text': 'Systemic indocyanine green (ICG) clearance has been used to estimate splanchnic blood flow, but the results may be compromised by altered hepatic dye extraction.',\n",
       "     'offsetInBeginSection': 145,\n",
       "     'offsetInEndSection': 306,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35668312',\n",
       "     'text': 'Indocyanine green (ICG) is one of the methods used to assess vascularization, but this assessment is usually subjective.',\n",
       "     'offsetInBeginSection': 152,\n",
       "     'offsetInEndSection': 272,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35601636',\n",
       "     'text': 'ntly available in Korea. Indocyanine green (ICG) can be applied as an alternative agent. However, studies on colonoscopic tattooing by the direct inje',\n",
       "     'offsetInBeginSection': 157,\n",
       "     'offsetInEndSection': 307,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35662771',\n",
       "     'text': 'Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher sensitivity than naked-eye observation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 189,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28316935',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33965600',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35601636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7553712',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9018428',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35874138',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35668312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12140046',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35662771']},\n",
       "  {'id': '6428da74690f196b51000052',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the process that generates multiple transcripts from the same gene?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29074233',\n",
       "     'text': 'Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome diversity and regulate mRNA levels.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22961303',\n",
       "     'text': 'Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional regulatory mechanism for expanding proteomic diversity and functional complexity in higher eukaryotes.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 253,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28402429',\n",
       "     'text': 'Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 143,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30852095',\n",
       "     'text': 'Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 151,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20396891',\n",
       "     'text': 'We have shown earlier that this sunflower gene is interrupted by nine introns and generates multiple mRNAs by alternative splicing of its primary transcript (Lazarescu et al.',\n",
       "     'offsetInBeginSection': 208,\n",
       "     'offsetInEndSection': 382,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29368663',\n",
       "     'text': 'ranscriptional regulation of gene expression. Selection of transcript cleavage and polyadenylation sites is a dynamic process that produces multiple t',\n",
       "     'offsetInBeginSection': 82,\n",
       "     'offsetInEndSection': 232,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1508684',\n",
       "     'text': 'The chicken beta tropomyosin gene generates three major transcripts by alternative splicing.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 92,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28968750',\n",
       "     'text': 'on can occur at multiple locations through a process known as alternative polyadenylation (APA). Therefore, APA is a form of co-transcriptional gene r',\n",
       "     'offsetInBeginSection': 255,\n",
       "     'offsetInEndSection': 405,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33793927',\n",
       "     'text': 'nt accordingly by regulating gene expression at multiple levels. Alternative splicing (AS), a widespread mechanism in eukaryotes that post-transcripti',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 230,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34383135',\n",
       "     'text': 'Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 103,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34383135',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30852095',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29074233',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28402429',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22961303',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33793927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20396891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28968750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29368663',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1508684']},\n",
       "  {'id': '63f9cdcc33942b094c000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Does silencing of SRRM4 inhibit tumor growth across cancers?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30100395',\n",
       "     'text': 'Whether SRRM4 can also regulate a stem-cell gene network for NEPC development remains unclear.',\n",
       "     'offsetInBeginSection': 437,\n",
       "     'offsetInEndSection': 531,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30100395',\n",
       "     'text': 'dependent manners in DU145 cells, RNA depletion of SOX2 compromises SRRM4-mediated stimulation of pluripotency genes. More importantly, this SRRM4-SOX',\n",
       "     'offsetInBeginSection': 1553,\n",
       "     'offsetInEndSection': 1703,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27346347',\n",
       "     'text': 'quently occurs in cancer, but the mechanism and functional role of this silencing in oncogenesis are not fully understood. Here, we show that oncogeni',\n",
       "     'offsetInBeginSection': 92,\n",
       "     'offsetInEndSection': 242,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27180064',\n",
       "     'text': 'ated adenocarcinoma cells to express NEPC biomarkers, and this effect was exacerbated by ARPI. ARPI combined with a gain of SRRM4-induced adenocarcino',\n",
       "     'offsetInBeginSection': 1388,\n",
       "     'offsetInEndSection': 1538,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27180064',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30100395',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27346347']},\n",
       "  {'id': '64179aac690f196b51000037',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the life expectancy for Duchenne muscular dystrophy patients?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6696607',\n",
       "     'text': 'eater Los Angeles area. Regardless of their ages, which ranged from 12 years to 21, the majority of the patients, as well as the majority of the paren',\n",
       "     'offsetInBeginSection': 258,\n",
       "     'offsetInEndSection': 408,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27234309',\n",
       "     'text': 'A total of 85 boys with Duchenne muscular dystrophy aged 8-18 years and 136 age, sex and living place matched healthy controls were included in this study.',\n",
       "     'offsetInBeginSection': 159,\n",
       "     'offsetInEndSection': 314,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10193393',\n",
       "     'text': 'tients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines the effect',\n",
       "     'offsetInBeginSection': 68,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19078632',\n",
       "     'text': 'ION\\nLong-term steroid treatment in Duchenne muscular dystrophy (average. 65 mo) proved beneficial m terms of muscle strength, function, and tolerable ',\n",
       "     'offsetInBeginSection': 1328,\n",
       "     'offsetInEndSection': 1478,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33075081',\n",
       "     'text': 'lar dystrophy (DMD) is a childhood onset muscular dystrophy leading to shortened life expectancy. There are gaps in published DMD care guidelines rega',\n",
       "     'offsetInBeginSection': 27,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34053847',\n",
       "     'text': 'As a result of progressive muscle weakness, pulmonary function decreases during the second decade of life and lung disease contributes significantly to morbidity and mortality in these patients.',\n",
       "     'offsetInBeginSection': 83,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28099279',\n",
       "     'text': 'and clinical history of Duchenne muscular dystrophy who is currently 53 years old. Because of improvements in cardiopulmonary care, there has been a g',\n",
       "     'offsetInBeginSection': 45,\n",
       "     'offsetInEndSection': 195,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17939910',\n",
       "     'text': 'RESULTS\\nThe mean (SD) age was 26 (6) years and the mean age at which mechanical ventilation had initiated in the patients was 21 (5) years.',\n",
       "     'offsetInBeginSection': 429,\n",
       "     'offsetInEndSection': 568,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "     'text': 'RESULTS\\nSurvey respondents included 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians.',\n",
       "     'offsetInBeginSection': 734,\n",
       "     'offsetInEndSection': 885,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/10193393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19078632',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28099279',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33075081',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17939910',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27234309',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6696607',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34053847']},\n",
       "  {'id': '64041e97201352f04a00001e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is daridorexant effective for insomnia?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306405',\n",
       "     'text': 'BACKGROUND\\nThe dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 274,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36473030',\n",
       "     'text': 'were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\\u2009=\\u20091.19; 95% ',\n",
       "     'offsetInBeginSection': 861,\n",
       "     'offsetInEndSection': 1011,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32341187',\n",
       "     'text': 'OBJECTIVE\\nTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 127,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36054921',\n",
       "     'text': 'in the two placebo-controlled phase III trials that evaluated the efficacy and safety of daridorexant. The DCE design was informed by a two-phase qual',\n",
       "     'offsetInBeginSection': 279,\n",
       "     'offsetInEndSection': 429,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36098753',\n",
       "     'text': 'e events were nasopharyngitis and headache.\\n\\n\\nCONCLUSION\\nDaridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare',\n",
       "     'offsetInBeginSection': 936,\n",
       "     'offsetInEndSection': 1086,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36309969',\n",
       "     'text': 'Morning administration is not relevant for daridorexant use by insomnia patients.',\n",
       "     'offsetInBeginSection': 1246,\n",
       "     'offsetInEndSection': 1327,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35065036',\n",
       "     'text': ' p=0·012 at month 3). Compared with the placebo group, no significant differences were observed among participants in the daridorexant 10 mg group for',\n",
       "     'offsetInBeginSection': 4108,\n",
       "     'offsetInEndSection': 4258,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35065036',\n",
       "     'text': 'th 1; -1·0 [-2·0 to 0·01], p=0·053 at month 3). In study 2, WASO was significantly reduced among participants in the daridorexant 25 mg group compared',\n",
       "     'offsetInBeginSection': 3306,\n",
       "     'offsetInEndSection': 3456,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36473030',\n",
       "     'text': ' (RR\\u2009=\\u20092.01; 95% CI, 1.21-3.36; P\\u2009=\\u20090.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly h',\n",
       "     'offsetInBeginSection': 1116,\n",
       "     'offsetInEndSection': 1266,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34331678',\n",
       "     'text': 'Daridorexant was safe and well tolerated and its pharmacokinetics were consistent with previous data.',\n",
       "     'offsetInBeginSection': 1528,\n",
       "     'offsetInEndSection': 1629,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35306405',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36054921',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32341187',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36309969',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36098753',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34331678',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35065036',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36473030']},\n",
       "  {'id': '6422ee03690f196b51000046',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What cells produce erythroferrone?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31723763',\n",
       "     'text': 'Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.',\n",
       "     'offsetInBeginSection': 825,\n",
       "     'offsetInEndSection': 1012,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30097509',\n",
       "     'text': 'Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown mechanism.',\n",
       "     'offsetInBeginSection': 117,\n",
       "     'offsetInEndSection': 274,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28739636',\n",
       "     'text': 'Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 125,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35464433',\n",
       "     'text': 'Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24880340',\n",
       "     'text': 'pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress',\n",
       "     'offsetInBeginSection': 305,\n",
       "     'offsetInEndSection': 455,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28629515',\n",
       "     'text': 'Among the number of factors proposed as mediators linking erythropoiesis with liver hepcidin suppression, erythroferrone, a hormone produced and secreted by erythroid precursors, appears the best candidate.',\n",
       "     'offsetInBeginSection': 1033,\n",
       "     'offsetInEndSection': 1239,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35628152',\n",
       "     'text': 'Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and characterized as a suppressor of hepcidin synthesis to allow iron mobilization and facilitate erythropoiesis.',\n",
       "     'offsetInBeginSection': 894,\n",
       "     'offsetInEndSection': 1129,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31846624',\n",
       "     'text': ' blood islands where initial erythropoiesis occurs and later in circulating blood cells. ERFE knockdown does not alter the expression of etv.2, aplnr ',\n",
       "     'offsetInBeginSection': 624,\n",
       "     'offsetInEndSection': 774,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27161430',\n",
       "     'text': 'ency, hypoxia and EPO treatment. Erythroferrone, produced by EPO-stimulated erythropoiesis, inhibits hepcidin only when the activity of BMP/SMAD pathw',\n",
       "     'offsetInBeginSection': 1315,\n",
       "     'offsetInEndSection': 1465,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31808893',\n",
       "     'text': 'Furthermore, hepcidin regulation by erythropoiesis is attributed in large part to a bone marrow-derived hormone erythroferrone.',\n",
       "     'offsetInBeginSection': 494,\n",
       "     'offsetInEndSection': 621,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35628152',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35464433',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31808893',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30097509',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28629515',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28739636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27161430',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31846624',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24880340',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31723763']},\n",
       "  {'id': '6429f86657b1c7a31500000d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the role of the Mediator in gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10611325',\n",
       "     'text': 'Therefore, the gene-specific function of Mediator as an integrator of transcriptional regulatory signals is evolutionarily conserved and is essential for C. elegans development.',\n",
       "     'offsetInBeginSection': 771,\n",
       "     'offsetInEndSection': 948,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21854862',\n",
       "     'text': 'The Mediator complex serves a crucial function in gene regulation, forming a link between gene-specific transcription factors and RNA polymerase II.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 148,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16885160',\n",
       "     'text': 'ChREBP and Mlx dimerize and function together as a glucose-responsive transcription factor to regulate target genes, such as liver-type pyruvate kinase, acetyl-CoA carboxylase 1, and fatty acid synthase.',\n",
       "     'offsetInBeginSection': 204,\n",
       "     'offsetInEndSection': 407,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21854862',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10611325',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16885160']},\n",
       "  {'id': '6415c0df690f196b51000010',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What does FBDD stand for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23410157',\n",
       "     'text': ' the chances of identifying active molecules. Among them, the Fragment Based Drug Design (FBDD) is surely worth noting. The FBDD entails the screening',\n",
       "     'offsetInBeginSection': 169,\n",
       "     'offsetInEndSection': 319,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20345344',\n",
       "     'text': 'In the last decade, fragment-based drug discovery (FBDD) has evolved from a novel approach in the search of new hits to a valuable alternative to the high-throughput screening (HTS) campaigns of many pharmaceutical companies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 225,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348623',\n",
       "     'text': 'Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceutical industry.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 165,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25420726',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has caused a revolution in the process of drug discovery and design, with many FBDD leads being developed into clinical trials or approved in the past few years.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 198,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36044560',\n",
       "     'text': 'The technique of Fragment-Based Drug Design (FBDD) considers the interactions of different moieties of molecules with biological targets for the rational construction of potential drugs.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32339336',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has become an established approach for the generation of early lead candidates.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 116,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22459076',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 200,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21482811',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chemical ligands as starting points for drug-discovery pursuits.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 163,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32133344',\n",
       "     'text': 'Fragment-based drug (or lead) discovery (FBDD or FBLD) has developed in the last two decades to become a successful key technology in the pharmaceutical industry for early stage drug discovery and development.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 209,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32850968',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 151,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/25420726',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23410157',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32339336',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36044560',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32850968',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21482811',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20345344',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22459076',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34348623',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32133344']},\n",
       "  {'id': '64041dae201352f04a00001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is deucravacitinib effective for psoriasis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34239295',\n",
       "     'text': 'The latest IL-17 and IL-23 inhibitors include bimekizumab, netakimab and mirikizumab as well as oral small molecules, such as deucravacitinib, a tyrosine kinase 2 selective inhibitor, and piclidenoson, an agonist of the Gi protein-associated A3 adenosine receptor.',\n",
       "     'offsetInBeginSection': 1260,\n",
       "     'offsetInEndSection': 1524,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36369798',\n",
       "     'text': ' (OR 1.6 [95% CI 0.8, 2.9]; nominal P\\xa0=\\xa00.08 versus placebo). Response rates were higher with deucravacitinib treatment for BICLA, CLASI-50, LLDAS, an',\n",
       "     'offsetInBeginSection': 1188,\n",
       "     'offsetInEndSection': 1338,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36369798',\n",
       "     'text': 'OBJECTIVE\\nTo assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36115523',\n",
       "     'text': 'vs 8.6% and 33.9%; P < 0.0001 for both). Efficacy was maintained until Week 52 with continuous deucravacitinib. The most frequent adverse event (AE) w',\n",
       "     'offsetInBeginSection': 832,\n",
       "     'offsetInEndSection': 982,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35820547',\n",
       "     'text': ' oral psoriasis treatments are needed.\\n\\n\\nOBJECTIVE\\nTo compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibit',\n",
       "     'offsetInBeginSection': 36,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35960487',\n",
       "     'text': 'so reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromb',\n",
       "     'offsetInBeginSection': 1115,\n",
       "     'offsetInEndSection': 1265,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36469536',\n",
       "     'text': 'Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast.',\n",
       "     'offsetInBeginSection': 621,\n",
       "     'offsetInEndSection': 710,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35241426',\n",
       "     'text': 'OBJECTIVE\\nTo evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 170,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767869',\n",
       "     'text': 'of deucravacitinib versus lower doses or placebo.\\n\\n\\nCONCLUSION\\nRobust clinical efficacy with deucravacitinib treatment was associated with decreases i',\n",
       "     'offsetInBeginSection': 1563,\n",
       "     'offsetInEndSection': 1713,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35820547',\n",
       "     'text': 'CONCLUSION\\nDeucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.',\n",
       "     'offsetInBeginSection': 1191,\n",
       "     'offsetInEndSection': 1347,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36469536',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34239295',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36369798',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35820547',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34767869',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35241426',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35960487',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36115523']},\n",
       "  {'id': '6415b6eb690f196b5100000b',\n",
       "   'type': 'list',\n",
       "   'body': 'What processes do orexin/hypocretin neurons regulate?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32314734',\n",
       "     'text': 'e in the hypothalamus and project throughout the brain to regulate sleep/wakefulness. Ablation of orexin neurons decreases wakefulness and results in ',\n",
       "     'offsetInBeginSection': 101,\n",
       "     'offsetInEndSection': 251,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34052808',\n",
       "     'text': 'However, cellular-resolution calcium imaging and optogenetic studies show that orexin neurons regulate self-generated and sensory-evoked movement on rapid, subsecond timescales.',\n",
       "     'offsetInBeginSection': 233,\n",
       "     'offsetInEndSection': 410,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12106679',\n",
       "     'text': 'ypothalamic orexin/hypocretin-containing neurons in the control of sleep-wakefulness. To help determine if adenosine might play a role in the control ',\n",
       "     'offsetInBeginSection': 122,\n",
       "     'offsetInEndSection': 272,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16731510',\n",
       "     'text': 'ote wakefulness (their loss causes narcolepsy) and also regulate metabolism and reward. Here we demonstrate that their inhibition by glucose is mediat',\n",
       "     'offsetInBeginSection': 214,\n",
       "     'offsetInEndSection': 364,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16054072',\n",
       "     'text': ' have emerged as instrumental in triggering arousal and regulating energy metabolism. The lack of hypocretin signaling is the cause of narcolepsy whil',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20307612',\n",
       "     'text': 'is a critical regulator of physiological processes including sleep/wakefulness and feeding. Using organotypic slice culture of rat hypothalamus, we fo',\n",
       "     'offsetInBeginSection': 48,\n",
       "     'offsetInEndSection': 198,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12495630',\n",
       "     'text': 'Neurons that release hypocretin/orexin modulate sleep, arousal, and energy homeostasis; the absence of hypocretin results in narcolepsy.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 136,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22813966',\n",
       "     'text': 'hrough interactions with neuronal systems that regulate emotion, reward, and energy homeostasis. Here, we briefly summarize the progress of orexin/hyp',\n",
       "     'offsetInBeginSection': 437,\n",
       "     'offsetInEndSection': 587,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/12495630',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34052808',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22813966',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16054072',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32314734',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12106679',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20307612',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16731510']},\n",
       "  {'id': '6428da47690f196b51000051',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can the epigenetic status of introns affect gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18319396',\n",
       "     'text': 'However, not all introns affect gene expression, and direct testing is currently the only way to identify stimulatory introns.',\n",
       "     'offsetInBeginSection': 86,\n",
       "     'offsetInEndSection': 212,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24213601',\n",
       "     'text': 'Epigenetic modifications affect gene expression and thereby govern a wide range of biological processes such as differentiation, development and tumorigenesis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 159,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32187179',\n",
       "     'text': 'n, and their contributions to genetic diversity and evolution, remain poorly understood. In this study, we investigated the genome-wide distribution o',\n",
       "     'offsetInBeginSection': 369,\n",
       "     'offsetInEndSection': 519,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15673716',\n",
       "     'text': 'and exons of human genes is shown here to negatively correlate with among-tissues breadth of gene expression. The nucleosome formation potential is al',\n",
       "     'offsetInBeginSection': 66,\n",
       "     'offsetInEndSection': 216,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34823400',\n",
       "     'text': 'Epigenetic modifications can affect gene expression and function and can also mediate crosstalk between genes and the environment.',\n",
       "     'offsetInBeginSection': 264,\n",
       "     'offsetInEndSection': 394,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24737381',\n",
       "     'text': 'We conclude that alterations in the methylation status of protein-coding genes and various miRNA genes are influenced by HPV infection, the viral genotype, the physical state of the viral DNA, and viral oncogenic risk.',\n",
       "     'offsetInBeginSection': 829,\n",
       "     'offsetInEndSection': 1047,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31235724',\n",
       "     'text': 'Introns can increase gene expression levels using a variety of mechanisms collectively referred to as Intron Mediated Enhancement (IME).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 136,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22645558',\n",
       "     'text': 'Introns exist in the transcribed DNA and the nascent RNA, and could affect expression from either location.',\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24455281',\n",
       "     'text': 'Epigenetic modifications can affect the long-term gene expression without any change in nucleotide sequence of the DNA.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 119,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18287520',\n",
       "     'text': 'However, in yeast only 283 of the 6000 genes contain introns and their impact on cell function is not clear.',\n",
       "     'offsetInBeginSection': 96,\n",
       "     'offsetInEndSection': 204,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/18319396',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32187179',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34823400',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22645558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31235724',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24737381',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24213601',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24455281',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15673716',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18287520']},\n",
       "  {'id': '6415c5d4690f196b51000014',\n",
       "   'type': 'list',\n",
       "   'body': 'What was Keytruda originally approved for by the FDA?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29209918',\n",
       "     'text': 'ons in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-ce',\n",
       "     'offsetInBeginSection': 318,\n",
       "     'offsetInEndSection': 468,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34647523',\n",
       "     'text': \" Drug Administration (FDA) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no publ\",\n",
       "     'offsetInBeginSection': 218,\n",
       "     'offsetInEndSection': 368,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513',\n",
       "     'text': 'rug Administration approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval expands the pembrolizumab indication in s',\n",
       "     'offsetInBeginSection': 1937,\n",
       "     'offsetInEndSection': 2087,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34156377',\n",
       "     'text': 'Pembrolizumab (Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 130,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17280539',\n",
       "     'text': 'Thus, while the circulatory support was initially tolerated for short periods to permit recovery of cardiac function, this technology eventually provided effective circulatory support for increasing periods that permitted the FDA to approve devices for bridging patients in end-stage cardiac failure awaiting transplant and eventually a device for destination therapy where patients in end-stage heart failure are not cardiac transplant candidates.',\n",
       "     'offsetInBeginSection': 685,\n",
       "     'offsetInEndSection': 1133,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3477937',\n",
       "     'text': 'Two of the EWCL brands were approved by the United States Food and Drug Administration (FDA) for wear by the public, while two of the brands were uninvestigated.',\n",
       "     'offsetInBeginSection': 145,\n",
       "     'offsetInEndSection': 306,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26429199',\n",
       "     'text': 'A total of 130 FDA-approved drugs, originally intended against other diseases, could be repurposed against 78 potential targets in M. tuberculosis.',\n",
       "     'offsetInBeginSection': 712,\n",
       "     'offsetInEndSection': 859,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32645193',\n",
       "     'text': 'The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 296,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12179363',\n",
       "     'text': 'The fact that this IUD is approved for 6 years makes it an even more attractive option for women choosing a contraceptive method.\"',\n",
       "     'offsetInBeginSection': 1104,\n",
       "     'offsetInEndSection': 1234,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28235882',\n",
       "     'text': 'On September 4, 2014, the FDA approved pembrolizumab (KEYTRUDA; Merck Sharp & Dohme Corp.) with a recommended dose of 2 mg/kg every 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 345,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28235882',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26429199',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32645193',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28835513',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12179363',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17280539',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29209918',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34647523',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3477937',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34156377']},\n",
       "  {'id': '63f5713733942b094c000003',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are clinical features of the Achard-Thiers syndrome?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1201353',\n",
       "     'text': 'The Achard syndrome is a well-defined clinical entity consisting of widespread dysostoses and increased ligament laxity.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 120,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/518037',\n",
       "     'text': 'The clinical and neuroradiological features in 4 patients with the syndrome of aberrant regeneration of the third nerve are presented.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 134,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8166424',\n",
       "     'text': 'ions in two of the boys, confirmed diagnosis. The clinical, hematological and radiological features are discussed in order to better define what appea',\n",
       "     'offsetInBeginSection': 330,\n",
       "     'offsetInEndSection': 480,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10560599',\n",
       "     'text': 'ile other manifestations, including clinical features, CSF pressures, and imaging abnormalities, are variables dependent on the CSF volume. The term C',\n",
       "     'offsetInBeginSection': 1260,\n",
       "     'offsetInEndSection': 1410,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10560599',\n",
       "     'text': 'What determines the various clinical and imaging features of this syndrome seems to be the loss of CSF volume as the independent variable, while other manifestations, including clinical features, CSF pressures, and imaging abnormalities, are variables dependent on the CSF volume.',\n",
       "     'offsetInBeginSection': 1119,\n",
       "     'offsetInEndSection': 1399,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28695356',\n",
       "     'text': 'METHODS\\nThe following clinical and MRI findings were assessed: age, gender, pain, pain attributable to lesion, tumour location, tumour length, presence, depth of endosteal scalloping, bone marrow oedema, soft tissue oedema, cortical destruction, periosteal reaction, bone expansion, macroscopic fat, calcification, soft tissue mass, haemorrhage, dynamic contrast-enhanced MRI.',\n",
       "     'offsetInBeginSection': 172,\n",
       "     'offsetInEndSection': 548,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24173296',\n",
       "     'text': 'Obesity, hypertension and angiopathy were present in most of these patients.',\n",
       "     'offsetInBeginSection': 163,\n",
       "     'offsetInEndSection': 239,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/1201353',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8166424',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10560599',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24173296',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/518037',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28695356']},\n",
       "  {'id': '642d4c9b57b1c7a315000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are Luminopsins a fusion proteins of luminol and Rhodopsin ?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429fe4e57b1c7a31500000f',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are coactivators?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9806345',\n",
       "     'text': 'ent and indicates a dual role for coactivators as bridging factors and chromatin remodeling proteins. The opposites of coactivators are corepressors, ',\n",
       "     'offsetInBeginSection': 879,\n",
       "     'offsetInEndSection': 1029,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "     'text': 'Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modulator drugs.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 160,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9096323',\n",
       "     'text': 'uld be rescued from E1A inhibition by overexpression of CBP or p300. CBP and p300 act as coactivators of p65-driven gene activation and may play an im',\n",
       "     'offsetInBeginSection': 909,\n",
       "     'offsetInEndSection': 1059,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10379889',\n",
       "     'text': 'In fact, squelching becomes even more severe when coactivators are abundant.',\n",
       "     'offsetInBeginSection': 1084,\n",
       "     'offsetInEndSection': 1160,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11893487',\n",
       "     'text': 'Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 127,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17476305',\n",
       "     'text': 'development and physiology. These coactivators are nuclear proteins and transcription co-regulators that function to facilitate the transcription init',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "     'text': 'ogen-sensitive and -insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine ',\n",
       "     'offsetInBeginSection': 1188,\n",
       "     'offsetInEndSection': 1338,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "     'text': '160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans',\n",
       "     'offsetInBeginSection': 413,\n",
       "     'offsetInEndSection': 563,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12376547',\n",
       "     'text': 'Coactivators such as TIF2 and SRC-1 modulate the positioning of the dose-response curve for agonist-bound glucocorticoid receptors (GRs) and the partial agonist activity of antiglucocorticoid complexes.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17244199',\n",
       "     'text': 'relevant brain regions coexpress nuclear receptor coactivators and steroid receptors. Confocal analysis revealed that in oestrogen-primed rats, most o',\n",
       "     'offsetInBeginSection': 1159,\n",
       "     'offsetInEndSection': 1309,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/17244199',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12376547',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10379889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9096323',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9806345',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17476305',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11893487']},\n",
       "  {'id': '6412331b201352f04a000038',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What are PROTACs?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31873151',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) are an emerging strategy for promoting targeted protein degradation by inducing the proximity between targeted proteins and E3 ubiquitin ligases.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34175722',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) have been developed to be an effective technology for targeted protein degradation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 124,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34494353',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs), an emerging paradigm-shifting technology, hijacks the ubiquitin-proteasome system for targeted protein degradation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 157,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35916511',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent degradation of proteins.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 174,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15876533',\n",
       "     'text': 'PROTACS are small molecule chimera which comprise a ligand and a peptide recognition motif for an E3 ligase.',\n",
       "     'offsetInBeginSection': 130,\n",
       "     'offsetInEndSection': 238,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32475992',\n",
       "     'text': ' as a potential therapeutic strategy for cancer. PROTACs are heterobifunctional molecules consisting of one ligand for binding to a protein of interes',\n",
       "     'offsetInBeginSection': 115,\n",
       "     'offsetInEndSection': 265,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35533582',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs), bifunctional molecules consisting of a ligand of protein of interest (POI), an E3 ligase ligand and a linker, have been developed to hijack the ubiquitin-proteasome system (UPS) to induce different POIs degradation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 257,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35001407',\n",
       "     'text': 'Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 129,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34034148',\n",
       "     'text': 'Chemical knockdown of therapeutic targets using proteolysis targeting chimeras (PROTACs) is a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that generally show poor bioavailability due to their relatively high molecular weight.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 264,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31538491',\n",
       "     'text': 'h the potential to revolutionize drug discovery. PROTACs are heterobifunctional molecules comprising of a ligand targeting a protein of interest, a li',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34175722',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35916511',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34494353',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15876533',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32475992',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35533582',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31538491',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35001407',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34034148',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31873151']},\n",
       "  {'id': '62008022c9dfcb9c0900001b',\n",
       "   'type': 'list',\n",
       "   'body': 'Which variables are included in the ALBI grade?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30026834',\n",
       "     'text': 'A newly developed scoring system called albumin-bilirubin grade (ALBI grade), consists of albumin and bilirubin to assess liver function reserve objectively.',\n",
       "     'offsetInBeginSection': 253,\n",
       "     'offsetInEndSection': 410,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33788758',\n",
       "     'text': 'RESULTS\\nALBI grade 2/3 was significantly associated with older age, male sex, advanced pT status, and histological type.',\n",
       "     'offsetInBeginSection': 556,\n",
       "     'offsetInEndSection': 676,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30077606',\n",
       "     'text': 'The albumin-bilirubin (ALBI) grade, a measure of liver function based on albumin and bilirubin, has the potential to detect Child-Pugh grade A HCC patients with poor prognosis.',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 331,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33392490',\n",
       "     'text': 'Here we have used a validated approach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in 2 phase III placebo-controlled studies.',\n",
       "     'offsetInBeginSection': 2136,\n",
       "     'offsetInEndSection': 2359,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31191834',\n",
       "     'text': \"Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded.\",\n",
       "     'offsetInBeginSection': 497,\n",
       "     'offsetInEndSection': 612,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28688815',\n",
       "     'text': 'Serum albumin, bilirubin, and platelet values were used to determine ALBI and PALBI grades.',\n",
       "     'offsetInBeginSection': 734,\n",
       "     'offsetInEndSection': 825,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33392490',\n",
       "     'text': 'BACKGROUND & AIMS\\nThe albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 195,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32411593',\n",
       "     'text': 'Multivariate analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS.',\n",
       "     'offsetInBeginSection': 1048,\n",
       "     'offsetInEndSection': 1202,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26462681',\n",
       "     'text': 'METHODS\\nWe evaluated the correlations between the ALBI grade and Child-Pugh score, adverse events, and survival in 89 patients with advanced HCC who were prospectively treated with sorafenib.',\n",
       "     'offsetInBeginSection': 241,\n",
       "     'offsetInEndSection': 432,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36411535',\n",
       "     'text': 'BACKGROUND\\nAlbumin-bilirubin (ALBI) grade is an index of liver function based on total bilirubin (T-BIL) and albumin levels, and its usefulness has been widely reported.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36411535',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28688815',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30026834',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32411593',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31191834',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33788758',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26462681',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30077606',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33392490']},\n",
       "  {'id': '64240f33690f196b51000049',\n",
       "   'type': 'list',\n",
       "   'body': 'What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19482534',\n",
       "     'text': 'fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a',\n",
       "     'offsetInBeginSection': 52,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33799985',\n",
       "     'text': 'ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 341,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/793459',\n",
       "     'text': 'Serum antibodies to the feline infectious peritonitis (FIP) virus were measured in cats, using an indirect fluorescent antibody procedure.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 138,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31375588',\n",
       "     'text': 'Our recombinant FCoVs are powerful tools for increasing our understanding of the viral life cycle and pathogenesis of FIP-inducing type I FCoV.IMPORTANCE Feline coronavirus (FCoV) is one of the most significant coronaviruses, because this virus induces feline infectious peritonitis (FIP), which is a lethal disease in cats.',\n",
       "     'offsetInBeginSection': 1498,\n",
       "     'offsetInEndSection': 1822,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36002137',\n",
       "     'text': 'Research has demonstrated efficacy of new antivirals in FIP treatment, but these products are not legally available in many countries at this time.',\n",
       "     'offsetInBeginSection': 1694,\n",
       "     'offsetInEndSection': 1841,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36387398',\n",
       "     'text': 'ive and no relapse was observed.\\n\\n\\nConclusions and relevance\\nGS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces',\n",
       "     'offsetInBeginSection': 1427,\n",
       "     'offsetInEndSection': 1577,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19058829',\n",
       "     'text': 'The lethal pathology associated with FIP (granulomatous inflammation and T-cell lymphopenia) is thought to be mediated by aberrant modulation of the immune system due to infection of cells such as monocytes and macrophages.',\n",
       "     'offsetInBeginSection': 188,\n",
       "     'offsetInEndSection': 411,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15123155',\n",
       "     'text': 'ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18196725',\n",
       "     'text': 'All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.',\n",
       "     'offsetInBeginSection': 620,\n",
       "     'offsetInEndSection': 736,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20180212',\n",
       "     'text': 'Current treatments are crude and involve supportive care and immunosuppression.',\n",
       "     'offsetInBeginSection': 439,\n",
       "     'offsetInEndSection': 518,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/19058829',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19482534',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/793459',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36002137',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18196725',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33799985',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31375588',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15123155',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20180212',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36387398']},\n",
       "  {'id': '6428da98690f196b51000053',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32511488',\n",
       "     'text': 'Few studies have compared these clinical features and outcomes of COVID-19 to other acute respiratory illnesses.',\n",
       "     'offsetInBeginSection': 151,\n",
       "     'offsetInEndSection': 263,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33947345',\n",
       "     'text': 'million cases have occurred worldwide as of June 16, 2020. However, it is important to distinguish COVID-19 from other respiratory infectious diseases',\n",
       "     'offsetInBeginSection': 88,\n",
       "     'offsetInEndSection': 238,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33821230',\n",
       "     'text': ' hospitalized patients with other viral pneumonias such as influenza is unknown.\\n\\n\\nObjectives\\nTo assess the incidence of venous and arterial thromboti',\n",
       "     'offsetInBeginSection': 327,\n",
       "     'offsetInEndSection': 477,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33907612',\n",
       "     'text': 'n most\\xa0other contagious respiratory illnesses. The\\xa0mechanisms underlying this difference remain unclear.\\n\\n\\nMETHODS\\nWe compared the immunological lands',\n",
       "     'offsetInBeginSection': 79,\n",
       "     'offsetInEndSection': 229,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32832306',\n",
       "     'text': 'COVID-19) are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 pandemic is caused by a novel virus - severe a',\n",
       "     'offsetInBeginSection': 40,\n",
       "     'offsetInEndSection': 190,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34111501',\n",
       "     'text': 'Although COVID-19 is often compared to other respiratory viral illnesses, few formal comparisons of these viruses on kidney health exist.',\n",
       "     'offsetInBeginSection': 169,\n",
       "     'offsetInEndSection': 306,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "     'text': 'Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking.',\n",
       "     'offsetInBeginSection': 214,\n",
       "     'offsetInEndSection': 404,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36410319',\n",
       "     'text': 'ose with dengue or influenza, adjusting for age, subregion, and days from illness onset to presentation for clinical care. Among 13,431 participants, ',\n",
       "     'offsetInBeginSection': 697,\n",
       "     'offsetInEndSection': 847,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34728719',\n",
       "     'text': 'other respiratory viral infections, such as Influenza, has not hitherto been extensively studied. We aimed to compare the prognostic value of NLR in C',\n",
       "     'offsetInBeginSection': 163,\n",
       "     'offsetInEndSection': 313,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34484383',\n",
       "     'text': 'CONCLUSION\\nDuring influenza season, differentiating other causes of respiratory illness from COVID-19 is difficult, because common clinical manifestations of COVID-19 mimic those of influenza.',\n",
       "     'offsetInBeginSection': 694,\n",
       "     'offsetInEndSection': 886,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36410319',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34111501',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34728719',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32511488',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33947345',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34484383',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33907612',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33821230',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32832306']},\n",
       "  {'id': '6415c8f1690f196b51000017',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26918039',\n",
       "     'text': 'used in the treatment of a variety of cancers, including those of squamous histology. In their formulation, both agents require solvents, which have b',\n",
       "     'offsetInBeginSection': 92,\n",
       "     'offsetInEndSection': 242,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18420499',\n",
       "     'text': 'xel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer.\\n\\n\\nMETHODS\\nWe enrolled 4950 women with axillary lymph node-posit',\n",
       "     'offsetInBeginSection': 83,\n",
       "     'offsetInEndSection': 233,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8629032',\n",
       "     'text': 'rubicin (Farmitalia Carlo Erba, Milan, Italy) in patients with metastatic breast cancer. In addition to standard eligibility criteria, patients with c',\n",
       "     'offsetInBeginSection': 169,\n",
       "     'offsetInEndSection': 319,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9865708',\n",
       "     'text': 'her doxorubicin or epirubicin has significant activity against metastatic breast cancer. However, the optimal schedule in terms of activity and toxici',\n",
       "     'offsetInBeginSection': 90,\n",
       "     'offsetInEndSection': 240,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11552225',\n",
       "     'text': 'While both paclitaxel and docetaxel may be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin (but not of docetaxel and doxorubicin) warrants that certain restrictions be followed for safe use.',\n",
       "     'offsetInBeginSection': 1324,\n",
       "     'offsetInEndSection': 1611,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12473512',\n",
       "     'text': 'apeutic agents for the first-line and second-line treatment of metastatic breast cancer, and their clinical use is widespread. However, for women whos',\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10426454',\n",
       "     'text': 're among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partiall',\n",
       "     'offsetInBeginSection': 106,\n",
       "     'offsetInEndSection': 256,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11129728',\n",
       "     'text': 'The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 152,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8629032',\n",
       "     'text': 'We conclude that the combination paclitaxel/epirubicin is safe for patients with metastatic breast cancer and, at this early evaluation, shows promising antitumor activity.',\n",
       "     'offsetInBeginSection': 1939,\n",
       "     'offsetInEndSection': 2111,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11432615',\n",
       "     'text': 'BACKGROUND\\nTreatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associated with significant cardiac toxicity.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 187,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26918039',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10426454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9865708',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11552225',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8629032',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11129728',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18420499',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12473512',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11432615']},\n",
       "  {'id': '63eeec79f36125a426000006',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Talquetamab was developed for treatment of which disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11449698',\n",
       "     'text': 'cepted as a standard chemotherapy (SC) for initial treatment of pulmonary tuberculosis in Japan. We studied the frequency of the treatment completion,',\n",
       "     'offsetInBeginSection': 81,\n",
       "     'offsetInEndSection': 231,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8100702',\n",
       "     'text': 'OBJECTIVES\\nThe objectives were to assess (a) the comparative merits of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration on the outcome of treatment.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 242,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "     'text': 'cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing s',\n",
       "     'offsetInBeginSection': 1620,\n",
       "     'offsetInEndSection': 1770,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "     'text': 'CASE REPORT\\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.',\n",
       "     'offsetInBeginSection': 451,\n",
       "     'offsetInEndSection': 715,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "     'text': 'CASE REPORT\\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.',\n",
       "     'offsetInBeginSection': 451,\n",
       "     'offsetInEndSection': 715,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25949982',\n",
       "     'text': \"ocrinology unit with excessive sweating. We started methimazole for Graves' disease. Without any additional immunosuppressive treatment, at week 12 of\",\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12772593',\n",
       "     'text': 'In this case report, it is suggested that tofisopam is effective for the treatment of PSVT.',\n",
       "     'offsetInBeginSection': 920,\n",
       "     'offsetInEndSection': 1011,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26193648',\n",
       "     'text': 'It was indicated that danaparoid sodium was an anticoagulant unlikely to cause adverse effects such as hemorrhage and might be an effective drug for treatment of portal venous thrombosis.',\n",
       "     'offsetInBeginSection': 887,\n",
       "     'offsetInEndSection': 1074,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "     'text': 'Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 263,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36006441',\n",
       "     'text': 'as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of pa',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8100702',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25949982',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12772593',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36006441',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11449698',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26193648']},\n",
       "  {'id': '642321a5690f196b51000047',\n",
       "   'type': 'summary',\n",
       "   'body': 'Please summarize Feline Spongiform Encephalopathy(FSE',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11206004',\n",
       "     'text': 'Feline Spongiform Encephalopathy (FSE) is a related disorder in domestic cats.',\n",
       "     'offsetInBeginSection': 199,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12783238',\n",
       "     'text': 'Here we report an immunohistological analysis of the first FSE-affected cheetah born in France.',\n",
       "     'offsetInBeginSection': 168,\n",
       "     'offsetInEndSection': 263,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10349202',\n",
       "     'text': 'This review summarizes current knowledge of prion diseases and investigates connections between the bovine spongiform encephalopathy epidemic, observed in Great Britain since 1986, and the new variant of human Creutzfeldt-Jakob disease, reported for the first time in 1996.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 273,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19335885',\n",
       "     'text': 'BACKGROUND\\nTwo domestic shorthair cats presenting with progressive hind-limb ataxia and increased aggressiveness were necropsied and a post mortem diagnosis of Feline Spongiform Encephalopathy (FSE) was made.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12442705',\n",
       "     'text': 'Feline spongiform encephalopathy was confirmed by histological brain examination and positive immunohistochemistry for PrPSc.',\n",
       "     'offsetInBeginSection': 514,\n",
       "     'offsetInEndSection': 639,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1279883',\n",
       "     'text': 'Thirteen cats were referred with clinical neurological signs potentially indicative of feline spongiform encephalopathy (FSE).',\n",
       "     'offsetInBeginSection': 161,\n",
       "     'offsetInEndSection': 287,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35632724',\n",
       "     'text': 'To the best of our knowledge, this is the first report on genetic polymorphisms of the feline SPRN gene.',\n",
       "     'offsetInBeginSection': 2047,\n",
       "     'offsetInEndSection': 2151,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18725465',\n",
       "     'text': 'Clinically, it presents as a progressive fatal neurologic syndrome that is not easily distinguished from other feline neurologic conditions.',\n",
       "     'offsetInBeginSection': 332,\n",
       "     'offsetInEndSection': 472,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33374431',\n",
       "     'text': 'However, to date, investigations of PRNP polymorphisms are rare in cats, which are the major host of feline spongiform encephalopathy (FSE).',\n",
       "     'offsetInBeginSection': 284,\n",
       "     'offsetInEndSection': 424,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35632724',\n",
       "     'text': 'However, genetic polymorphisms in the feline SPRN gene and structural characteristics of the Sho have not been investigated in cats, a major host of feline spongiform encephalopathy (FSE).',\n",
       "     'offsetInBeginSection': 506,\n",
       "     'offsetInEndSection': 694,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/12783238',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33374431',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1279883',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18725465',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19335885',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11206004',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12442705',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10349202',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35632724']},\n",
       "  {'id': '6428d7da690f196b51000050',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can untranslated regions (UTRs) regulate gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21093468',\n",
       "     'text': \" (mRNA) 3' untranslated regions (UTRs) where they prevent translation or cause degradation of the message. Steroid hormone receptors (SHRs) are ligand\",\n",
       "     'offsetInBeginSection': 196,\n",
       "     'offsetInEndSection': 346,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21187351',\n",
       "     'text': ' regions (UTRs) of messenger RNAs. However, how the target sites change during evolution is largely unknown. MiR-iab-4 and miR-iab-4as are known to re',\n",
       "     'offsetInBeginSection': 183,\n",
       "     'offsetInEndSection': 333,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23949786',\n",
       "     'text': 'However, the functions of the segment-specific regions of the UTRs are not well known.',\n",
       "     'offsetInBeginSection': 210,\n",
       "     'offsetInEndSection': 296,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18615019',\n",
       "     'text': 'Structured RNAs embedded in the untranslated regions (UTRs) of messenger RNAs can regulate gene expression.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 107,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20563548',\n",
       "     'text': \"5' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 101,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21912852',\n",
       "     'text': \"3' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 101,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32995550',\n",
       "     'text': 'n of gene expression; however, the exact sequence features contributing to gene regulation are not yet fully understood. In this study, we report the ',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29223924',\n",
       "     'text': 'To facilitate this activation, plant mRNA contains untranslated regions (UTRs) that significantly increase the coding capacity of the genome by producing multiple mRNA variants from the same gene.',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 387,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8813126',\n",
       "     'text': \"The 3' untranslated regions (3' UTRs) of R1 and R2 messages contain sequences that are important in regulating gene expression through changes in message stability.\",\n",
       "     'offsetInBeginSection': 183,\n",
       "     'offsetInEndSection': 347,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31234415',\n",
       "     'text': \"Single nucleotide polymorphisms located in 5' untranslated regions (5'UTRs) can regulate gene expression and have clinical impact.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 130,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29223924',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31234415',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21912852',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20563548',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18615019',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8813126',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21093468',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23949786',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32995550',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21187351']},\n",
       "  {'id': '63f9cbb433942b094c00000c',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is alternative splicing associated with heart disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27049307',\n",
       "     'text': 'and 5 of the cTnT gene. Alternative splicing of cTnT exon 5 is developmentally regulated. cTnT isoforms containing exon 5 are expressed in the fetal a',\n",
       "     'offsetInBeginSection': 109,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30468920',\n",
       "     'text': 'assembly of the contractile apparatus. Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing va',\n",
       "     'offsetInBeginSection': 753,\n",
       "     'offsetInEndSection': 903,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25685889',\n",
       "     'text': ',333 cis sQTLs involving 2,650 unique genes. Many sQTL-associated genes (40%) undergo alternative splicing. Using the National Human Genome Research I',\n",
       "     'offsetInBeginSection': 428,\n",
       "     'offsetInEndSection': 578,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15652472',\n",
       "     'text': '(2005) demonstrate that a heart-specific knockout of one SR protein, ASF/SF2, produces cardiomyopathy and misregulation of specific alternative splicing events during early postnatal development.',\n",
       "     'offsetInBeginSection': 170,\n",
       "     'offsetInEndSection': 365,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32276354',\n",
       "     'text': 'In this review, we summarize the updated knowledge relative to RBM20 and PTBP1 structure and molecular function; their role in alternative splicing mechanisms involved in the heart development and function; RBM20 mutations associated with idiopathic dilated cardiovascular disease (DCM); and the consequences of RBM20-altered expression or dysfunction.',\n",
       "     'offsetInBeginSection': 904,\n",
       "     'offsetInEndSection': 1256,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30051286',\n",
       "     'text': 'Here, we review our current knowledge of alternative splicing in the heart, with a particular focus on the factors controlling cardiac alternative splicing and their role in cardiomyopathies and subsequent heart failure.',\n",
       "     'offsetInBeginSection': 757,\n",
       "     'offsetInEndSection': 977,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22561820',\n",
       "     'text': ' from individual genes; however, aberrant mRNA splicing is associated with various conditions, including heart disease. A recent study provides new me',\n",
       "     'offsetInBeginSection': 76,\n",
       "     'offsetInEndSection': 226,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24358217',\n",
       "     'text': 'Alternative splicing could play a role in the control of gene expression during CKD but it does not seem to be a major mechanism.',\n",
       "     'offsetInBeginSection': 1578,\n",
       "     'offsetInEndSection': 1707,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "     'text': 'e been reported in human heart defects. Defects in alternative splicing are associated with many heart diseases, yet relatively little is known about ',\n",
       "     'offsetInBeginSection': 213,\n",
       "     'offsetInEndSection': 363,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/15652472',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27049307',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30051286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30468920',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25685889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24358217',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32276354',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22561820']},\n",
       "  {'id': '61fa941ec9dfcb9c09000005',\n",
       "   'type': 'yesno',\n",
       "   'body': \"Should Intepirdine be used for Alzheimer's disease?\",\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29848076',\n",
       "     'text': 'cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors. Paradoxically, 5-HT6 receptor agonists have also been shown ',\n",
       "     'offsetInBeginSection': 1014,\n",
       "     'offsetInEndSection': 1164,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9179132',\n",
       "     'text': \"rement after instillation of tropicamide cannot be used as a reliable diagnostic test for Alzheimer's disease. Moreover, test-retest reliability with \",\n",
       "     'offsetInBeginSection': 1482,\n",
       "     'offsetInEndSection': 1632,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29212555',\n",
       "     'text': \"BACKGROUND\\nIn an effort to intervene earlier in Alzheimer's disease (AD), clinical trials are testing promising candidate therapies in preclinical disease.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 155,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32321414',\n",
       "     'text': 'It is predicted that some FDA-approved drugs, such as Paracetamol, Risperidone, Escitalopram, Simvastatin, Cilostazoand, and Ritalin-SR, could also be used in off-label ways for AD.',\n",
       "     'offsetInBeginSection': 1829,\n",
       "     'offsetInEndSection': 2010,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34095437',\n",
       "     'text': 'le safety profile similar to placebo.\\n\\n\\nDISCUSSION\\nIntepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo',\n",
       "     'offsetInBeginSection': 969,\n",
       "     'offsetInEndSection': 1119,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34095437',\n",
       "     'text': \"INTRODUCTION\\nA previous phase 2b study supported the use of the 5-HT6 receptor antagonist intepirdine as adjunctive therapy to donepezil for Alzheimer's disease (AD) dementia.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 175,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28253832',\n",
       "     'text': 'gress in current clinical trials and warrant consideration as emerging treatments for AD. Areas covered: This review discusses 5-HT6 antagonists curre',\n",
       "     'offsetInBeginSection': 621,\n",
       "     'offsetInEndSection': 771,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21752148',\n",
       "     'text': \"BACKGROUND AND PURPOSE\\nTo provide guidance regarding the most appropriate voxel-based morphometry (VBM)-derived method for assessing hippocampal atrophy in early Alzheimer's disease (AD).\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 187,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19012869',\n",
       "     'text': 'Thus, rDNA specific methylation pattern could be involved in AD and be used as a marker of the disease or of its progression.',\n",
       "     'offsetInBeginSection': 336,\n",
       "     'offsetInEndSection': 461,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28253832',\n",
       "     'text': \"Expert opinion: If current Phase-3 trials are positive, 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.\",\n",
       "     'offsetInBeginSection': 1152,\n",
       "     'offsetInEndSection': 1385,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/9179132',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29848076',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32321414',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21752148',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19012869',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28253832',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34095437',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29212555']},\n",
       "  {'id': '6422e2f1690f196b51000043',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28158620',\n",
       "     'text': 'Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs ∼30-fold in the clinic (1).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30570431',\n",
       "     'text': 'rotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available',\n",
       "     'offsetInBeginSection': 453,\n",
       "     'offsetInEndSection': 603,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30345352',\n",
       "     'text': ' peptide-1 receptor (GLP1R) can productively deliver ASO cargo to pancreatic β-cells both in vitro and in vivo. Ligand-conjugated ASOs silenced target',\n",
       "     'offsetInBeginSection': 461,\n",
       "     'offsetInEndSection': 611,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31303442',\n",
       "     'text': 'One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).',\n",
       "     'offsetInBeginSection': 259,\n",
       "     'offsetInEndSection': 457,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31099004',\n",
       "     'text': 'Herein we describe a targeted carrier system that can deliver siRNA to cancer cells overexpressing the human epidermal growth factor 2 (HER2) receptor.',\n",
       "     'offsetInBeginSection': 189,\n",
       "     'offsetInEndSection': 340,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15894474',\n",
       "     'text': 'ive vector of antisense oligonucleotide (ASO) and plasmid DNA for the hepatocyte targeting delivery. Gal-LMWC has been successfully prepared and MTT c',\n",
       "     'offsetInBeginSection': 256,\n",
       "     'offsetInEndSection': 406,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26546271',\n",
       "     'text': 'PA:LFn-GAL4:ASO transfection of non- or terminally-differentiated THP-1 cells and Vero cells resulted in 35.2 ± 19.1%, 36.4 ± 1.8% and 22.9 ± 6.9% (respectively) Synt5 expression after treatment with 200 pmol of ASO and demonstrated versatility.',\n",
       "     'offsetInBeginSection': 2003,\n",
       "     'offsetInEndSection': 2248,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29808997',\n",
       "     'text': 'eptor (ASGPR) can serve as potent targeting moieties for hepatocellular carcinoma (HCC) cells. However, efficient targeting to HCC via galactose moiet',\n",
       "     'offsetInBeginSection': 209,\n",
       "     'offsetInEndSection': 359,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16686729',\n",
       "     'text': 'SO and chemotherapy or small-interference RNA (siRNA) targeting the clusterin gene was also investigated.\\n\\n\\nRESULTS\\nBispecific ASO reduced Bcl-2 and B',\n",
       "     'offsetInBeginSection': 756,\n",
       "     'offsetInEndSection': 906,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24992960',\n",
       "     'text': 'GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.',\n",
       "     'offsetInBeginSection': 940,\n",
       "     'offsetInEndSection': 1106,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/24992960',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28158620',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26546271',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16686729',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31099004',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15894474',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30345352',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30570431',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31303442',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29808997']},\n",
       "  {'id': '64299fa957b1c7a315000002',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is rebound COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36324801',\n",
       "     'text': 'COVID-19 rebound was defined as documentation of negative then newly-positive SARS-CoV-2 tests.',\n",
       "     'offsetInBeginSection': 666,\n",
       "     'offsetInEndSection': 761,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36324801',\n",
       "     'text': 'Previous studies suggest that monoclonal antibodies are an effective outpatient treatment option for patients at high-risk of severe COVID-19, including those with systemic autoimmune rheumatic diseases (SARDs).Nirmatrelvir/ritonavir and molnupiravir are recently-authorized effective oral outpatient SARS-CoV-2 treatment options, but clinical trials were performed among the general population, mostly among unvaccinated and prior to Omicron viral variants.Oral outpatient SARS-CoV-2 treatments may result in COVID-19 rebound, characterized by newly-positive COVID-19 testing and recurrent symptoms, but no studies have investigated rebound prevalence among SARD patients.',\n",
       "     'offsetInBeginSection': 1973,\n",
       "     'offsetInEndSection': 2646,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35734093',\n",
       "     'text': 'Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 86,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36181334',\n",
       "     'text': ' infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound ',\n",
       "     'offsetInBeginSection': 72,\n",
       "     'offsetInEndSection': 222,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33132535',\n",
       "     'text': 'o its end, will COVID-19 return again in what is known as a second rebound of the pandemic? In this work, we developed a predictive model that can est',\n",
       "     'offsetInBeginSection': 444,\n",
       "     'offsetInEndSection': 594,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35794889',\n",
       "     'text': 'Importance\\nRecent case reports document that some patients who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32388934',\n",
       "     'text': 'till under global pandemic. China is facing the risks of importation and local rebound of COVID-19. Under the circumstances, preparations for medical ',\n",
       "     'offsetInBeginSection': 33,\n",
       "     'offsetInEndSection': 183,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35345769',\n",
       "     'text': '00 daily cases, from May 6 to August 14, 2020) and a rebound phase (>100 daily cases, from August 15 to December 31, 2020).\\n\\n\\nResults\\nArea-level socio',\n",
       "     'offsetInBeginSection': 842,\n",
       "     'offsetInEndSection': 992,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35794889',\n",
       "     'text': 'Main Outcomes and Measures\\nThree types of COVID-19 rebound outcomes (COVID-19 infections, COVID-19 related symptoms, and hospitalizations) were examined.',\n",
       "     'offsetInBeginSection': 1194,\n",
       "     'offsetInEndSection': 1347,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35982673',\n",
       "     'text': '.1 was the predominant subvariant. The risks of both COVID-19 rebound infections and symptoms 2-8 days after Paxlovid treatment were higher in the BA.',\n",
       "     'offsetInBeginSection': 959,\n",
       "     'offsetInEndSection': 1109,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36181334',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33132535',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35794889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35982673',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32388934',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35734093',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35345769',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36324801']},\n",
       "  {'id': '6432fb1957b1c7a31500001e',\n",
       "   'type': 'list',\n",
       "   'body': 'What clinical applications is Zanubrutinib approved for in the United States?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35950210',\n",
       "     'text': 'ond-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM i',\n",
       "     'offsetInBeginSection': 363,\n",
       "     'offsetInEndSection': 513,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "     'text': 'ial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutinib to ibrutinib in patients ',\n",
       "     'offsetInBeginSection': 1223,\n",
       "     'offsetInEndSection': 1373,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33306268',\n",
       "     'text': 'ed accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop ',\n",
       "     'offsetInBeginSection': 172,\n",
       "     'offsetInEndSection': 322,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31875923',\n",
       "     'text': \"n's tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochr\",\n",
       "     'offsetInBeginSection': 49,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27737804',\n",
       "     'text': 'e the turn of the century. The majority of devices have been for cervical arthroplasty. By contrast, biologic devices were most likely to go to panel ',\n",
       "     'offsetInBeginSection': 1662,\n",
       "     'offsetInEndSection': 1812,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306909',\n",
       "     'text': \"BTK) approved for the treatment of Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linke\",\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "     'text': 'Zanubrutinib, a second-generation BTK inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for r/r MCL on the basis of combined overall response rate of 84% in a total of 118 patients from two multicenter clinical trials, BGB-3111-AU-003 and BGB-3111-206.',\n",
       "     'offsetInBeginSection': 263,\n",
       "     'offsetInEndSection': 549,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenström macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.',\n",
       "     'offsetInBeginSection': 543,\n",
       "     'offsetInEndSection': 890,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "     'text': 'Even though zanubrutinib has been the third and last BTK inhibitor to currently penetrate the market for B-cell lymphoproliferative malignancies, we highlight the emergence of zanubrutinib as a key player in the forefront of the therapeutic landscape in WM.',\n",
       "     'offsetInBeginSection': 1833,\n",
       "     'offsetInEndSection': 2090,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.',\n",
       "     'offsetInBeginSection': 3210,\n",
       "     'offsetInEndSection': 3439,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33306268',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27737804',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35950210',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35306909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31875923']},\n",
       "  {'id': '61f7cb37882a024a10000029',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is rilonacept effective for pericarditis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36250662',\n",
       "     'text': 'RHAPSODY (rilonacept inhibition of interleukin-1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL-1α and -β cytokine trap) in recurrent pericarditis.',\n",
       "     'offsetInBeginSection': 143,\n",
       "     'offsetInEndSection': 383,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33200890',\n",
       "     'text': '-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine t',\n",
       "     'offsetInBeginSection': 22,\n",
       "     'offsetInEndSection': 172,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35874710',\n",
       "     'text': 'Rilonacept was efficacious and safe for the treatment of CAPS, FMF, recurrent pericarditis, and sJIA.',\n",
       "     'offsetInBeginSection': 1842,\n",
       "     'offsetInEndSection': 1943,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24839206',\n",
       "     'text': 'OBJECTIVE\\nTo assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 143,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36398320',\n",
       "     'text': 'It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II and III trials.',\n",
       "     'offsetInBeginSection': 780,\n",
       "     'offsetInEndSection': 884,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18668535',\n",
       "     'text': 'OBJECTIVE\\nTo assess the efficacy and safety of rilonacept (Interleukin-1 [IL-1] Trap), a long-acting and potent inhibitor of IL-1, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 285,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23754188',\n",
       "     'text': 'Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.',\n",
       "     'offsetInBeginSection': 2062,\n",
       "     'offsetInEndSection': 2162,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36316102',\n",
       "     'text': 'rapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.\\n\\n\\nTRIAL REGISTRATION NUMBER\\nNCT03737110.',\n",
       "     'offsetInBeginSection': 1909,\n",
       "     'offsetInEndSection': 2059,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33882846',\n",
       "     'text': ' and as an exploratory endpoint in a Phase 2 trial evaluating the efficacy and safety of rilonacept (IL-1α/IL-1β cytokine trap) to treat RP.\\n\\n\\nMETHODS',\n",
       "     'offsetInBeginSection': 151,\n",
       "     'offsetInEndSection': 301,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35350578',\n",
       "     'text': 'In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.',\n",
       "     'offsetInBeginSection': 2149,\n",
       "     'offsetInEndSection': 2353,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33200890',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35874710',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36316102',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36250662',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18668535',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35350578',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23754188',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24839206',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33882846',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36398320']},\n",
       "  {'id': '6413712a201352f04a00003e',\n",
       "   'type': 'list',\n",
       "   'body': 'The 1p19q co-deletion is associated with what types of tumors?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30661193',\n",
       "     'text': 'g prognostic information as well as prediction of treatment response in gliomas. Accurate determination of the IDH mutation status and 1p19q co-deleti',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34125374',\n",
       "     'text': 'INTRODUCTION\\nAnaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 107,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33361717',\n",
       "     'text': 'Together with isocitrate dehydrogenase (IDH) mutation, co-deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce testing for 1p19q codel.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 232,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25971646',\n",
       "     'text': \"ty and review the process of 1p19q co-deletion assessment using FISH in gliomas from a clinician's perspective. We also consider common alternative me\",\n",
       "     'offsetInBeginSection': 956,\n",
       "     'offsetInEndSection': 1106,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33482430',\n",
       "     'text': 'In the WHO glioma classification guidelines grade (glioblastoma versus lower-grade glioma), IDH mutation and 1p/19q co-deletion status play a central role as they are important markers for prognosis and optimal therapy planning.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "     'text': 'Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.',\n",
       "     'offsetInBeginSection': 871,\n",
       "     'offsetInEndSection': 1110,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19624298',\n",
       "     'text': 'We confirmed the high incidence (82%) of combined 1p19q deletion in LGOs and the feasibility of successful FISH testing in paraffin embedded specimens up to 10-years-old.',\n",
       "     'offsetInBeginSection': 1214,\n",
       "     'offsetInEndSection': 1384,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35114775',\n",
       "     'text': 'Of the 26 tumours, 6 oligodendrogliomas had 1p19q co-deletion and the remaining 3 oligodendrogliomas showed no co-deletion.',\n",
       "     'offsetInBeginSection': 746,\n",
       "     'offsetInEndSection': 869,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18416660',\n",
       "     'text': 'ion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular. A further likely prognostic bi',\n",
       "     'offsetInBeginSection': 513,\n",
       "     'offsetInEndSection': 663,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28340142',\n",
       "     'text': 'Tumor purity was found to be significantly decreased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, non-co-deleted gliomas.',\n",
       "     'offsetInBeginSection': 1342,\n",
       "     'offsetInEndSection': 1558,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33482430',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35114775',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19624298',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18416660',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25971646',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34125374',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33361717',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30661193',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28340142']},\n",
       "  {'id': '6429ad3857b1c7a315000003',\n",
       "   'type': 'factoid',\n",
       "   'body': 'The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9601019',\n",
       "     'text': 'ch maps to the X chromosome inactivation centre (Xic) and encodes an untranslated RNA. Truncation of Xist RNA by gene targeting is lethal for female e',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20657585',\n",
       "     'text': 'Xist encodes a noncoding RNA that influences the probability that the cis-linked X chromosome will be silenced.',\n",
       "     'offsetInBeginSection': 81,\n",
       "     'offsetInEndSection': 192,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26477563',\n",
       "     'text': 'Thus, the Xist gene carries within its coding sequence an antisense RNA that drives Xist expression.',\n",
       "     'offsetInBeginSection': 813,\n",
       "     'offsetInEndSection': 913,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23166390',\n",
       "     'text': 'e master regulator of X-inactivation. The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X c',\n",
       "     'offsetInBeginSection': 432,\n",
       "     'offsetInEndSection': 582,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14973270',\n",
       "     'text': 'This non-coding RNA becomes upregulated on the X chromosome that is to be inactivated upon differentiation.',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 185,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16227973',\n",
       "     'text': 'mes is inactivated in females to enable dosage compensation for X-linked gene products. In rodents and marsupials, only the X chromosome of paternal o',\n",
       "     'offsetInBeginSection': 37,\n",
       "     'offsetInEndSection': 187,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9487391',\n",
       "     'text': 'ipt (Xist) gene, which is known now to represent the master switch locus regulating X inactivation. In adult cells Xist is transcribed exclusively fro',\n",
       "     'offsetInBeginSection': 231,\n",
       "     'offsetInEndSection': 381,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21471966',\n",
       "     'text': 'The developmental regulation of this process has been extensively investigated in mice, where the X chromosome of paternal origin (Xp) is silenced during early embryogenesis owing to imprinted expression of the regulatory RNA, Xist (X-inactive specific transcript).',\n",
       "     'offsetInBeginSection': 123,\n",
       "     'offsetInEndSection': 388,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25000994',\n",
       "     'text': 'evelopment and is initiated by a unique locus, which produces a long noncoding RNA, Xist. The Xist transcript triggers gene silencing in cis by coatin',\n",
       "     'offsetInBeginSection': 241,\n",
       "     'offsetInEndSection': 391,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20950563',\n",
       "     'text': ', relies on monoallelic activation of the Xist gene. Xist produces a non-coding RNA that can coat the chromosome from which it is transcribed in cis a',\n",
       "     'offsetInBeginSection': 166,\n",
       "     'offsetInEndSection': 316,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/20950563',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9601019',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26477563',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25000994',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16227973',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14973270',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9487391',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20657585',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23166390',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21471966']},\n",
       "  {'id': '63f92fd033942b094c00000b',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are microexons?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508',\n",
       "     'text': 'The splicing of microexons (very small exons) is frequently dysregulated in the brain of individuals with autism spectrum disorder.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 131,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155820',\n",
       "     'text': 'Microexons are small sized (≤51\\u2009bp) exons which undergo extensive alternative splicing in neurons, microglia, embryonic stem cells, and cancer cells, giving rise to cell type specific protein isoforms.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35895262',\n",
       "     'text': 'However, the analysis of RNAs-seq data for detection and quantification of microexons, extremely short exons of length up to 30\\xa0nt, require specialized computational workflows.',\n",
       "     'offsetInBeginSection': 196,\n",
       "     'offsetInEndSection': 372,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10805741',\n",
       "     'text': 'ns six copies of the simple sequence GGGGCUG. The enhancer activates heterologous microexons and will work when located either upstream or downstream ',\n",
       "     'offsetInBeginSection': 716,\n",
       "     'offsetInEndSection': 866,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31559909',\n",
       "     'text': 'Neuronal microexons represent the most highly conserved class of alternative splicing events and their timed expression shapes neuronal biology, including neuronal commitment and differentiation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 195,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34836511',\n",
       "     'text': 'BACKGROUND\\nMicroexons are a particular kind of exon of less than 30 nucleotides in length.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 90,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33859668',\n",
       "     'text': 'Exons with a length ≤ 30 nt are defined as microexons that are unique in identification.',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 243,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30526869',\n",
       "     'text': '(2018) uncover novel mechanisms by which the cell regulates splicing of cryptic splice sites and microexons.',\n",
       "     'offsetInBeginSection': 117,\n",
       "     'offsetInEndSection': 225,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33378678',\n",
       "     'text': 'Overall, our findings identify QKI as an alternative splicing regulator governing a network of Rho GTPase microexons with implications for CNS remyelination and MS patients.',\n",
       "     'offsetInBeginSection': 936,\n",
       "     'offsetInEndSection': 1109,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33621242',\n",
       "     'text': 'expression or activity of splicing factors (SFs). Microexons are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserve',\n",
       "     'offsetInBeginSection': 73,\n",
       "     'offsetInEndSection': 223,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34346508',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31559909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33859668',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34155820',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10805741',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30526869',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33621242',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34836511',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35895262',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33378678']},\n",
       "  {'id': '64041f38201352f04a00001f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is tebentafusp effective for uveal melanoma?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19032679',\n",
       "     'text': 'therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p',\n",
       "     'offsetInBeginSection': 182,\n",
       "     'offsetInEndSection': 332,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16489097',\n",
       "     'text': 'therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p',\n",
       "     'offsetInBeginSection': 184,\n",
       "     'offsetInEndSection': 334,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35716258',\n",
       "     'text': 'PURPOSE\\nAnti-angiogenesis drug therapy is ineffective in treating uveal melanoma since it only targets angiogenesis leaving vasculogenic mimicry aside.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 151,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35115315',\n",
       "     'text': 'Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33572586',\n",
       "     'text': 'Thus far, no effective methods of pharmacotherapy of this cancer have been found.',\n",
       "     'offsetInBeginSection': 134,\n",
       "     'offsetInEndSection': 215,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35804863',\n",
       "     'text': 'cell receptor against the cancer molecule tebentafusp showed impressive antitumor effects. Meanwhile, oncolytic viruses and small molecule inhibitors ',\n",
       "     'offsetInBeginSection': 1143,\n",
       "     'offsetInEndSection': 1293,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34754859',\n",
       "     'text': ' signs of recurrence at 1 year after surgery.\\n\\n\\nCONCLUSION\\nSurgery is an effective treatment for metastatic uveal melanoma. In patients with liver met',\n",
       "     'offsetInBeginSection': 1100,\n",
       "     'offsetInEndSection': 1250,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34551229',\n",
       "     'text': 'Data showing a proven overall survival benefit with a systemic treatment are lacking.',\n",
       "     'offsetInBeginSection': 211,\n",
       "     'offsetInEndSection': 296,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23116575',\n",
       "     'text': 'However, there are still no effective therapies against metastatic uveal melanoma, which is almost always fatal.',\n",
       "     'offsetInBeginSection': 428,\n",
       "     'offsetInEndSection': 540,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27183438',\n",
       "     'text': 'n primary malignant intraocular tumor in adults and still lacks effective systemic therapies. Annexin A2 receptor (AXIIR), a receptor for Annexin II, ',\n",
       "     'offsetInBeginSection': 32,\n",
       "     'offsetInEndSection': 182,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/23116575',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27183438',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16489097',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35716258',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33572586',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34754859',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19032679',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35804863',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35115315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34551229']},\n",
       "  {'id': '6426bb49690f196b5100004d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the Fenton reaction',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26948406',\n",
       "     'text': 'm 5.0 nM to 1.0 μM with a detection limit of 2.4 nM. Because of the rapid kinetics of Fenton reaction and high specificity for H2O2, the proposed meth',\n",
       "     'offsetInBeginSection': 1128,\n",
       "     'offsetInEndSection': 1278,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25496478',\n",
       "     'text': 'INTRODUCTION\\nFenton reaction is the main source of free radicals in biological systems.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 87,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16896806',\n",
       "     'text': 'chelates are formed which inhibit the Fenton reaction owing to a full Fe(II) coordination sphere. In addition to natural nucleotides, we investigated ',\n",
       "     'offsetInBeginSection': 1200,\n",
       "     'offsetInEndSection': 1350,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19806722',\n",
       "     'text': 'The photo-Fenton reaction, oxidation of photoproduced ferrous iron by hydrogen peroxide, produces reactive oxidants that may be important to degradation of biologically and chemically recalcitrant organic compounds in surface waters at circum-neutral pH.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 254,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23414832',\n",
       "     'text': 'ium dioxide) and the Fenton reaction exhibited synergistically enhanced hydroxyl (OH) radical generation. Dihydroxybenzoic acid (DHBA) concentration a',\n",
       "     'offsetInBeginSection': 110,\n",
       "     'offsetInEndSection': 260,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17166556',\n",
       "     'text': 'Fenton reaction is a powerful oxidation technology used for the oxidation of groundwater pollutants.',\n",
       "     'offsetInBeginSection': 134,\n",
       "     'offsetInEndSection': 234,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31476718',\n",
       "     'text': 'Fenton reaction is widely used for hazardous pollutant degradation. Reducing agents (RAs) have been proven to be efficient in promoting the generation',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10401608',\n",
       "     'text': 'As anticipated, the Fenton reaction initiates radical formation in all the above targets.',\n",
       "     'offsetInBeginSection': 761,\n",
       "     'offsetInEndSection': 850,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34190261',\n",
       "     'text': 's that FeII-counteranion complexes are the real catalyst for fast aqueous Fenton reactions. In addition, we found that the Fenton oxidation mediated b',\n",
       "     'offsetInBeginSection': 708,\n",
       "     'offsetInEndSection': 858,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34494817',\n",
       "     'text': 'Ferroptosis therapy (FT) based on the Fenton reaction of ferrous nanoparticles has been becoming a unique strategy for cancer treatment; however, current ferrous nanoparticles suffer from slower Fenton reaction kinetics, lower ferroptosis efficacy, and long-term toxicity, so it is urgent to construct biocompatible ferrous nanomaterials with highly efficient Fenton reaction activity for cancer FT.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 399,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/19806722',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16896806',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31476718',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10401608',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34494817',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25496478',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17166556',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23414832',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34190261',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26948406']}]}"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_batch_json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "c94e5ac2",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(submission_file_name, \"w\") as outfile:\n",
    "    json.dump(test_batch_json, outfile, indent=2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "04af3265",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3f706d67",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "05ce89f1",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fcdd039a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0f513daf",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f1bb0647",
   "metadata": {},
   "outputs": [],
   "source": [
    "copy_test_batch_json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "debc113e",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:sentence_transformers.SentenceTransformer:No sentence-transformers model found with name /home/andresr/.cache/torch/sentence_transformers/deepset_roberta-base-squad2. Creating a new one with MEAN pooling.\n",
      "Some weights of the model checkpoint at /home/andresr/.cache/torch/sentence_transformers/deepset_roberta-base-squad2 were not used when initializing RobertaModel: ['qa_outputs.bias', 'qa_outputs.weight']\n",
      "- This IS expected if you are initializing RobertaModel from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing RobertaModel from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
      "Some weights of RobertaModel were not initialized from the model checkpoint at /home/andresr/.cache/torch/sentence_transformers/deepset_roberta-base-squad2 and are newly initialized: ['roberta.pooler.dense.weight', 'roberta.pooler.dense.bias']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n",
      "100%|███████████████████████████████████████████████████████████████████████████████████████████████████████████| 75/75 [00:55<00:00,  1.35it/s]\n"
     ]
    }
   ],
   "source": [
    "from sentence_transformers import SentenceTransformer, util\n",
    "\n",
    "model = SentenceTransformer('deepset/roberta-base-squad2')\n",
    "\n",
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    doc_list = []\n",
    "    snippet_list = []\n",
    "    query = chatgpt_questions[sample['id']]['chatgpt-out']['short-ans']\n",
    "    en_query = model.encode(query)\n",
    "    for s in sample['snippets']:\n",
    "        text_raw = s['text']\n",
    "        en_snippet = model.encode(text_raw)\n",
    "        result = util.cos_sim(en_query, en_snippet)\n",
    "        if result > 0.98:\n",
    "            snippet_list.append(s)\n",
    "            doc_list.append(s['document'])\n",
    "    sample['documents'] = doc_list[0:10]\n",
    "    sample['snippets'] = snippet_list[0:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "03c78602",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sentence_transformers import SentenceTransformer, util\n",
    "\n",
    "model = SentenceTransformer('deepset/roberta-base-squad2')\n",
    "\n",
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    doc_list = []\n",
    "    snippet_list = []\n",
    "    query = chatgpt_questions[sample['id']]['chatgpt-out']['short-ans']\n",
    "    en_query = model.encode(query)\n",
    "    for s in sample['snippets']:\n",
    "        text_raw = s['text']\n",
    "        en_snippet = model.encode(text_raw)\n",
    "        result = util.cos_sim(en_query, en_snippet)\n",
    "        if result > 0.98:\n",
    "            snippet_list.append(s)\n",
    "            doc_list.append(s['document'])\n",
    "    sample['documents'] = doc_list[0:10]\n",
    "    sample['snippets'] = snippet_list[0:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "1fbce183",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e92792e1",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2219665d",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "11f4fb1e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "e8dd8a4d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'questions': [{'id': '63f03006f36125a426000018',\n",
       "   'type': 'summary',\n",
       "   'body': 'What were the results of the DESTINY-Breast04 Trial?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '641ad941690f196b5100003d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are LOQ and LOD the same?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21603916',\n",
       "     'text': 'Real-time PCR (qPCR) is the principal technique for the quantification of pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (LOD) in qPCR.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 236,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21603916']},\n",
       "  {'id': '642a029d57b1c7a315000011',\n",
       "   'type': 'summary',\n",
       "   'body': 'Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18707894',\n",
       "     'text': 'Saccharomyces cerevisiae Rtt109 is an important class of histone acetyltransferases (HATs), which promote genome stability by directly acetylating newly synthesized histone H3 lysine 56 (H3-K56) through an unknown mechanism.',\n",
       "     'offsetInBeginSection': 101,\n",
       "     'offsetInEndSection': 325,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32695779',\n",
       "     'text': 'The eukaryotic histone acetylation cycle is composed of three classes of proteins, histone acetyltransferases (HATs) that add acetyl groups to lysine amino acids, bromodomain (BRD) containing proteins that are one of the most characterized of several protein domains that recognize acetyl-lysine (Kac) and effect downstream function, and histone deacetylases (HDACs) that catalyze the reverse reaction.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 402,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10790315',\n",
       "     'text': 'Histone acetyltransferases (HATs) catalyze the acetyl-group transfer from acetyl-CoA to the epsilon-amino group of specific lysine residues within core histone proteins.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35061542',\n",
       "     'text': 'Overall, our data reveal direct transfer of acetate between histone lysine residues to facilitate rapid transcriptional induction, an exchange that may be critical during changes in nutrient availability.',\n",
       "     'offsetInBeginSection': 850,\n",
       "     'offsetInEndSection': 1054,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30725455',\n",
       "     'text': 'The Michaelis constant (Km) of most histone acetyltransferases (HATs), which specifically target histone proteins, falls within the range of cellular acetyl-CoA concentrations.',\n",
       "     'offsetInBeginSection': 522,\n",
       "     'offsetInEndSection': 698,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16857587',\n",
       "     'text': 'Yeast acetyl-CoA synthetases (Acs1p and 2p) are exceptional, as they are important not only for carbon metabolism but also are shown here to supply the acetyl-CoA for histone acetylation by histone acetyltransferases (HATs).',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 304,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19056256',\n",
       "     'text': 'The ability of HATs to form distinct multi-subunit complexes provides a means to regulate HAT activity by altering substrate specificity, targeting to specific loci, enhancing acetyltransferase activity, restricting access of non-target proteins, and coordinating the multiple enzyme activities of the complex.',\n",
       "     'offsetInBeginSection': 458,\n",
       "     'offsetInEndSection': 768,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35849593',\n",
       "     'text': 'Histone acetyltransferases (HATs, also known as lysine acetyltransferases, KATs) catalyze acetylation of their cognate protein substrates using acetyl-CoA (Ac-CoA) as a cofactor and are involved in various physiological and pathological processes.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 247,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19577000',\n",
       "     'text': 'Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues.',\n",
       "     'offsetInBeginSection': 149,\n",
       "     'offsetInEndSection': 271,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28240169',\n",
       "     'text': 'Histone acetyltransferases (HATs) are epigenetic drivers that catalyze the acetyl transfer from acetyl-CoA to lysines of both histone and non-histone substrates and thereby induce transcription either by chromatin remodeling or direct transcription factor activation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 267,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/18707894',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32695779',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10790315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35061542',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30725455',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16857587',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19056256',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35849593',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19577000',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28240169']},\n",
       "  {'id': '6432fc0457b1c7a31500001f',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which gene is most frequently mutated in hereditary angioedema ?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36203343',\n",
       "     'text': '), 8/79 (9%), and 3/79 (4%) of the patients respectively, revealing that SPTB is the most frequently mutated HS gene in Eastern China. Most SPTB and A',\n",
       "     'offsetInBeginSection': 539,\n",
       "     'offsetInEndSection': 689,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27470642',\n",
       "     'text': 'Angioedema can be caused by C1-inhibitor deficiency (C1-INH-hereditary angioedema and C1-INH-acquired angioedema), mutations in coagulation factor XII (FXII-hereditary angioedema), and treatment with angiotensin-converting enzyme inhibitors (ACEI-acquired angioedema).',\n",
       "     'offsetInBeginSection': 695,\n",
       "     'offsetInEndSection': 963,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30044938',\n",
       "     'text': 'BACKGROUND\\nHereditary angioedema is a life-threatening illness caused by mutations in the gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of the kallikrein-bradykinin cascade.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32089523',\n",
       "     'text': 'sed by the structural abnormalities and dysfunction of motile cilia. The DNAH5 is the most frequently mutated gene in PCD patients and hot spot exons ',\n",
       "     'offsetInBeginSection': 86,\n",
       "     'offsetInEndSection': 236,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27271546',\n",
       "     'text': 'therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. I',\n",
       "     'offsetInBeginSection': 569,\n",
       "     'offsetInEndSection': 719,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27142368',\n",
       "     'text': 'Hereditary angioedema due to a mutation of the coagulation factor XII can be diagnosed exclusively by mutation analysis of FXII gene.',\n",
       "     'offsetInBeginSection': 1206,\n",
       "     'offsetInEndSection': 1339,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30530986',\n",
       "     'text': 'Hereditary angioedema (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency, resulting in recurrent attacks of severe swelling.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 223,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31574187',\n",
       "     'text': 'Over the last years, information grew fast, and mutations in different genes, in addition to C1-inhibitor, were found to be causative.',\n",
       "     'offsetInBeginSection': 168,\n",
       "     'offsetInEndSection': 302,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8792821',\n",
       "     'text': 'The polymerase chain reaction and nucleotide sequence analysis have been used to characterize a point mutation in the seventh exon of one allele of the C1-inhibitor gene in a family with type I hereditary angioedema.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 216,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34838707',\n",
       "     'text': 'Both type I and II HAE-C1INH result from inherited or spontaneous mutations in the SERPING1 gene, which encodes for C1INH.',\n",
       "     'offsetInBeginSection': 399,\n",
       "     'offsetInEndSection': 521,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36203343',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27470642',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30044938',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32089523',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27271546',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27142368',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30530986',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31574187',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8792821',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34838707']},\n",
       "  {'id': '64178edb690f196b51000025',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is casimersen's mechanism of action?\",\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6402bf2b201352f04a000007',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the mechanism of action of tiragolumab?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': 'INTERPRETATION\\nTiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC.',\n",
       "     'offsetInBeginSection': 2991,\n",
       "     'offsetInEndSection': 3259,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': 'BACKGROUND\\nTargeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35576957']},\n",
       "  {'id': '641d8fd6690f196b51000041',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29137920',\n",
       "     'text': 'Magnetic resonance imaging revealed central nervous system lesions typical of NMOSD and anti-aquaporin-4 antibodies in the serum were identified; however, eosinophilia was evident in the cerebrospinal fluid (CSF) at the early stage of the disease.',\n",
       "     'offsetInBeginSection': 144,\n",
       "     'offsetInEndSection': 391,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25027264',\n",
       "     'text': 'Since the discovery of aquaporin 4-IgG, a sensitive and highly specific biomarker of neuromyelitis optica (NMO), a wide range of syndromes have been recognized as being associated with this condition.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 200,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32169145',\n",
       "     'text': 'Aquaporin-4 antibodies are hallmark of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) that are distinct disease entities.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 153,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21550068',\n",
       "     'text': 'Albumin CSF/serum ratios, total protein and CSF L-lactate levels correlated significantly with disease activity as well as with the length of the spinal cord lesions in patients with acute myelitis.',\n",
       "     'offsetInBeginSection': 1462,\n",
       "     'offsetInEndSection': 1660,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34253347',\n",
       "     'text': 'ch preferentially affect the optic nerves and the spinal cord. Anti-aquaporin 4 antibody is a specific serological marker. Systemic lupus erythematosu',\n",
       "     'offsetInBeginSection': 130,\n",
       "     'offsetInEndSection': 280,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24964112',\n",
       "     'text': 'Serum autoantibodies against aquaporin-4 (AQP4) are detected in most cases of NMOSD.',\n",
       "     'offsetInBeginSection': 193,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21550068',\n",
       "     'text': 'Recently, however, highly specific serum autoantibodies (termed NMO-IgG or AQP4-Ab) have been discovered in a subset (60-80%) of patients with NMO.',\n",
       "     'offsetInBeginSection': 185,\n",
       "     'offsetInEndSection': 332,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29137920',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25027264',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32169145',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21550068',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34253347',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24964112',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21550068']},\n",
       "  {'id': '6429d5c557b1c7a315000006',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the major thrombotic complications in patients with COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33319192',\n",
       "     'text': 'In individuals with COVID-19, complications including thrombosis and endothelial dysfunction portend worse outcomes.',\n",
       "     'offsetInBeginSection': 146,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33577800',\n",
       "     'text': 'BACKGROUND\\nCOVID-19 is associated with both venous and arterial thrombotic complications.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 89,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32924567',\n",
       "     'text': 'aise it to nearly 60%. The most common thrombotic complication is pulmonary embolism, which though may occur in the absence of a recognizable deep ven',\n",
       "     'offsetInBeginSection': 548,\n",
       "     'offsetInEndSection': 698,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35967591',\n",
       "     'text': 'These include microvascular and macrovascular thrombotic complications such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias.',\n",
       "     'offsetInBeginSection': 94,\n",
       "     'offsetInEndSection': 300,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35643053',\n",
       "     'text': 'Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19.',\n",
       "     'offsetInBeginSection': 170,\n",
       "     'offsetInEndSection': 294,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34849435',\n",
       "     'text': 'It is important for emergency physicians to know that patients who had COVID-19 infection but not confirmed or not tested can visit the emergency department due to complications of COVID-19 infection such as thromboembolic events primarily.',\n",
       "     'offsetInBeginSection': 460,\n",
       "     'offsetInEndSection': 700,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32551814',\n",
       "     'text': 'V-2). Coagulation dysfunction is a hallmark in patients with COVID-19. Fulminant thrombotic complications emerge as critical issues in patients with s',\n",
       "     'offsetInBeginSection': 159,\n",
       "     'offsetInEndSection': 309,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33529513',\n",
       "     'text': 'Furthermore, COVID-19 can commonly be complicated with acute thrombotic events, including venous thromboembolism, acute stroke, acute myocardial infarction, clotting of hemodialysis and extracorporeal membrane oxygenation (ECMO) catheters, and acute limb ischemia.',\n",
       "     'offsetInBeginSection': 541,\n",
       "     'offsetInEndSection': 805,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33009340',\n",
       "     'text': 'In COVID-19 patients developing thrombotic complications, we identified higher D-dimer levels (17.5 ± 4.3 μg/mL vs. 8.0 ± 6.3 μg/mL; mean difference, 9.5 μg/mL; 95% CI, 13.9-5.1; p < 0.0001) but lower fibrinogen assay MCF (39.7 ± 10.8 mm vs. 50.1 ± 12.0 mm; mean difference, -11.2 mm; 95% CI, -2.1 to -20.2; p = 0.02) compared with patients without thrombosis.',\n",
       "     'offsetInBeginSection': 1554,\n",
       "     'offsetInEndSection': 1914,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34750061',\n",
       "     'text': 'nt thrombotic complications which commonly lead to multiorgan failure and increase the risk of death. Severe SARS-CoV-2 infection induces the cytokine',\n",
       "     'offsetInBeginSection': 41,\n",
       "     'offsetInEndSection': 191,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33319192',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33577800',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32924567',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35967591',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35643053',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34849435',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32551814',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33529513',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33009340',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34750061']},\n",
       "  {'id': '6433012b57b1c7a315000022',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is Cinryze?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23776358',\n",
       "     'text': 'ted States: Berinert(®) for treating acute attacks and Cinryze(®) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being con',\n",
       "     'offsetInBeginSection': 745,\n",
       "     'offsetInEndSection': 895,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20627701',\n",
       "     'text': 'Treatments approved by the Food and Drug Administration for routine prophylaxis include danazol given orally and the nanofiltered human C1 esterase inhibitor, CINRYZE, which is approved for intravenous administration.',\n",
       "     'offsetInBeginSection': 110,\n",
       "     'offsetInEndSection': 327,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21942916',\n",
       "     'text': 'Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze®) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "     'text': 'a blocking the production or function of bradykinin. Cinryze® is a nanofiltered C1-INH, approved in Europe for the acute treatment, preprocedure preve',\n",
       "     'offsetInBeginSection': 406,\n",
       "     'offsetInEndSection': 556,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28662509',\n",
       "     'text': 'Cinryze® (Shire ViroPharma Inc., Lexington, MA, USA), a nanofiltered C1 inhibitor (C1-INH), is approved in Europe for the treatment, preprocedure prevention, and routine prophylaxis of HAE attacks, and for the routine prophylaxis of attacks in the USA.',\n",
       "     'offsetInBeginSection': 167,\n",
       "     'offsetInEndSection': 419,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21895469',\n",
       "     'text': 'Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor (pdC1-INH) licensed for the prophylactic treatment of hereditary angioedema.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 158,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23282867',\n",
       "     'text': 'One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, and the second, Berinert, was approved by the FDA for treatment of acute attacks in October 2009.',\n",
       "     'offsetInBeginSection': 796,\n",
       "     'offsetInEndSection': 1025,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.',\n",
       "     'offsetInBeginSection': 651,\n",
       "     'offsetInEndSection': 875,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29279063',\n",
       "     'text': 'ts, and the mean age was 50.1 years. Cinryze and Berinert (both C1-esterase inhibitors) had the highest median scores (5.0) for patient confidence, fo',\n",
       "     'offsetInBeginSection': 986,\n",
       "     'offsetInEndSection': 1136,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23282867',\n",
       "     'text': 'le-blind studies. One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, ',\n",
       "     'offsetInBeginSection': 778,\n",
       "     'offsetInEndSection': 928,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/23776358',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20627701',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21942916',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28662509',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21895469',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23282867',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29279063',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23282867']},\n",
       "  {'id': '64179337690f196b51000034',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Do machine learning-based methods outperform statistical methods for survival analysis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31780915',\n",
       "     'text': 'However, for patients with reported GTR, none of the evaluated approaches was able to outperform the age-only baseline in a cross-validation setting, explaining the poor performance of approaches based on radiomics in the BraTS challenge 2018.',\n",
       "     'offsetInBeginSection': 1273,\n",
       "     'offsetInEndSection': 1516,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32628616',\n",
       "     'text': 'Comparison analysis showed that nonlinear models (K-nearest neighbor AUC 0.908, random forest AUC 0.938) outperform linear models (logistic regression AUC 0.865) on the same datasets, and machine-learning methods significantly surpassed traditional risk scales or fixed models (eg, Framingham cardiovascular disease risk models).',\n",
       "     'offsetInBeginSection': 1600,\n",
       "     'offsetInEndSection': 1929,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31780915',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32628616']},\n",
       "  {'id': '63f03c47f36125a42600001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'ZF2001 is used for which disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35596222',\n",
       "     'text': 'To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35596222']},\n",
       "  {'id': '642c82c557b1c7a315000012',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What mammal has the lowest known chromosome number?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29706521',\n",
       "     'text': 'Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\xa0= 6), to characterize and track individual chromosomes with distinct kinetochore size throughout mitosis.',\n",
       "     'offsetInBeginSection': 615,\n",
       "     'offsetInEndSection': 848,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25379715',\n",
       "     'text': 'The referred species presented the lowest chromosome number observed for the subfamily Myrmicinae and for the Hymenoptera found in the Neotropical region.',\n",
       "     'offsetInBeginSection': 449,\n",
       "     'offsetInEndSection': 603,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/5444269',\n",
       "     'text': 'The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mammal.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 153,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17189914',\n",
       "     'text': 'Among marine mammals, a C-value has been estimated only for the bottlenose dolphin (Tursiops truncatus).',\n",
       "     'offsetInBeginSection': 408,\n",
       "     'offsetInEndSection': 512,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29706521',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25379715',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/5444269',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17189914']},\n",
       "  {'id': '6429b41757b1c7a315000004',\n",
       "   'type': 'list',\n",
       "   'body': 'When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30582583',\n",
       "     'text': 'Chromatin is subject to an array of diverse posttranslational modifications (PTMs) that mostly occur in the amino termini of histone proteins (i.e., histone tail) and regulate the accessibility and functional state of the underlying DNA.',\n",
       "     'offsetInBeginSection': 122,\n",
       "     'offsetInEndSection': 359,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34877957',\n",
       "     'text': 'Although they both recognise and posttranslationally modify lysine residues in histone proteins, their difference in histone peptide-based substrates and inhibitors remains to be firmly established.',\n",
       "     'offsetInBeginSection': 145,\n",
       "     'offsetInEndSection': 343,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15184976',\n",
       "     'text': \"Enzymes such as histone acetyltransferases (HATs) and methylases covalently label the amino-termini of histones, thereby creating a 'histone code' of modifications that is interpreted by the recruitment of other proteins through recognition domains.\",\n",
       "     'offsetInBeginSection': 299,\n",
       "     'offsetInEndSection': 548,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30582583',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34877957',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15184976']},\n",
       "  {'id': '643305b257b1c7a315000025',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which company produces Ruconest?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "     'text': 'Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-INH (Ruconest), bradykinin B2 receptor inhibitor (Icatibant), and kallikrein inhibitors (Ecallantide and lanadelumab).',\n",
       "     'offsetInBeginSection': 383,\n",
       "     'offsetInEndSection': 619,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26250409',\n",
       "     'text': 'This article will focus on the results of ten clinical studies demonstrating the efficacy and safety of Ruconest(®) (Pharming Group NV, Leiden, the Netherlands), which is now approved for use in Europe, Israel and the USA.',\n",
       "     'offsetInBeginSection': 821,\n",
       "     'offsetInEndSection': 1043,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.',\n",
       "     'offsetInBeginSection': 651,\n",
       "     'offsetInEndSection': 875,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25673959',\n",
       "     'text': 'Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 140,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marketing authorization.',\n",
       "     'offsetInBeginSection': 651,\n",
       "     'offsetInEndSection': 875,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26250409',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25673959',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26106828']},\n",
       "  {'id': '641635fa690f196b5100001c',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is usually the age of diagnosis in Duchenne muscular dystrophy?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3728255',\n",
       "     'text': 'Duchenne muscular dystrophy, the most common childhood-onset muscular dystrophy, is X-linked and is associated with cardiac and mental abnormalities.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 149,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "     'text': '13 years and death in the teens or 20s. The average age at diagnosis is 5 years, despite earlier onset of symptoms. Becker muscular dystrophy is simil',\n",
       "     'offsetInBeginSection': 375,\n",
       "     'offsetInEndSection': 525,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "     'text': 'The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12.',\n",
       "     'offsetInBeginSection': 137,\n",
       "     'offsetInEndSection': 303,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16023755',\n",
       "     'text': 'MATERIALS AND METHODS\\nTwenty-two boys with Duchenne muscular dystrophy, mean age 11.4+/-4.0 years, were examined between February and March 2003.',\n",
       "     'offsetInBeginSection': 186,\n",
       "     'offsetInEndSection': 331,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7334343',\n",
       "     'text': 'A well examined muscular biopsy is usually conclusive without using an electron microscope, from the age of one year, if serous activity of CPK reaches twenty times the normal rate.',\n",
       "     'offsetInBeginSection': 609,\n",
       "     'offsetInEndSection': 790,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26721827',\n",
       "     'text': 'He had been diagnosed with Duchenne muscular dystrophy at 5 years of age, and had no locomotive capability except for that of the finger flexors and toe extensors.',\n",
       "     'offsetInBeginSection': 552,\n",
       "     'offsetInEndSection': 715,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2347279',\n",
       "     'text': 'A needle muscle biopsy through a fetoscope for the antenatal diagnosis of Duchenne muscular dystrophy (DMD) was reported the mother was a carrier of 30 years old with a family history of Duchenne muscular dystrophy.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 215,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30796500',\n",
       "     'text': 'trophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy expe',\n",
       "     'offsetInBeginSection': 150,\n",
       "     'offsetInEndSection': 300,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2476078',\n",
       "     'text': \"A total of 33 young boys (mean age 3.4 years) with Duchenne muscular dystrophy and 21 normal controls (mean age 3.5 years) were assessed using the Griffiths's mental development scales and the Reynell language scales.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 217,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22204944',\n",
       "     'text': 'There were 77 Duchenne muscular dystrophy (median age at gastrostomy placement 26 years, range 13-47 years), 40 myotonic dystrophy (median age 54.5 years, range 13-70 years), 11 Fukuyama congenital muscular dystrophy (median age 22 years, range 13-29 years), 5 limb girdle muscular dystrophy (median age 62 years, range 43-78 years), and 5 facioscapulohumeral muscular dystrophy (median age 52 years, range 28-67 years) patients.',\n",
       "     'offsetInBeginSection': 482,\n",
       "     'offsetInEndSection': 911,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/3728255',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16023755',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7334343',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26721827',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2347279',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30796500',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2476078',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22204944']},\n",
       "  {'id': '6402c868201352f04a00000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Was erythropoietin effective for optic neuritis in the TONE trial?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29778487',\n",
       "     'text': 'The average peripapillary retinal nerve fiber layers were 58.03\\u2009±\\u20098.73\\u2009µm, 64.34\\u2009±\\u200912.88\\u2009µm, and 78.12\\u2009±\\u200913.34\\u2009µm for the patients with myelin oligodendrocyte glycoprotein-optic neuritis, aquaporin-4-optic neuritis, and seronegative-optic neuritis, respectively, which showed no statistical difference between patients with myelin oligodendrocyte glycoprotein-optic neuritis and aquaporin-4-optic neuritis (P\\xa0=\\xa00.089), but were both thinner than patients with seronegative-optic neuritis (P\\xa0=\\xa00.001).',\n",
       "     'offsetInBeginSection': 1173,\n",
       "     'offsetInEndSection': 1673,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33240725',\n",
       "     'text': 'As compared to oral prednisone, intravenous steroids have been shown to be more effective in the treatment of ON in the Optic Neuritis Treatment Trial.',\n",
       "     'offsetInBeginSection': 780,\n",
       "     'offsetInEndSection': 931,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1841573',\n",
       "     'text': 'Magnetic resonance imaging, serologic studies (such as the antinuclear antibody test and the fluorescent treponemal antibody absorption test), chest roentgenography, and lumbar puncture were of limited utility in defining a cause for visual loss other than optic neuritis associated with demyelinative disease.',\n",
       "     'offsetInBeginSection': 633,\n",
       "     'offsetInEndSection': 943,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15601662',\n",
       "     'text': 'Functional and histo pathological data of retinal ganglion cells and optic nerves revealed that neuron and axon protection was most effective when erythropoietin treatment that was started at immunization was combined with high-dose methylprednisolone therapy given from days 1 to 3 of MOG-induced experimental autoimmune encephalomyelitis.',\n",
       "     'offsetInBeginSection': 1147,\n",
       "     'offsetInEndSection': 1487,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33201757',\n",
       "     'text': 'MANAGEMENT\\nAll participants were treated with high dose intravenous steroids followed by 11 days of oral steroids, per the optic neuritis treatment trial, which led to complete recovery of vision.',\n",
       "     'offsetInBeginSection': 382,\n",
       "     'offsetInEndSection': 578,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7749521',\n",
       "     'text': ' acute attack of optic neuritis reduces the rate at which multiple sclerosis develops over a 2-year period of follow-up. The findings of the trial hav',\n",
       "     'offsetInBeginSection': 261,\n",
       "     'offsetInEndSection': 411,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29778487',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33240725',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1841573',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15601662',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33201757',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7749521']},\n",
       "  {'id': '6424154d690f196b5100004a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the R value with respect to hepatoxicity',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64299b6a57b1c7a315000001',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "     'text': 'Unlike the previous two waves, COVID-19 due to the Omicron variant\\xa0was less severe with only 5% of hemodialysis patients\\xa0requiring admission to the intensive care unit compared to 25% during the previous waves.',\n",
       "     'offsetInBeginSection': 792,\n",
       "     'offsetInEndSection': 1002,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36150972',\n",
       "     'text': 'No association between gender or age and COVID-19 infection was found and none of the participants had a severe infection or died.',\n",
       "     'offsetInBeginSection': 1527,\n",
       "     'offsetInEndSection': 1657,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "     'text': 'Unlike the previous two waves, COVID-19 due to the Omicron variant\\xa0was less severe with only 5% of hemodialysis patients\\xa0requiring admission to the intensive care unit compared to 25% during the previous waves.',\n",
       "     'offsetInBeginSection': 792,\n",
       "     'offsetInEndSection': 1002,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36466505',\n",
       "     'text': 'Furthermore, liver damages caused by viral infection of the omicron variant were largely attenuated when compared to those by infection of the wild-type or the delta variant SARS-CoV-2.',\n",
       "     'offsetInBeginSection': 1292,\n",
       "     'offsetInEndSection': 1477,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36285226',\n",
       "     'text': 'Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered variants with absence of data regarding cardiac involvement by Omicron.',\n",
       "     'offsetInBeginSection': 372,\n",
       "     'offsetInEndSection': 591,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "     'text': 'However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants.',\n",
       "     'offsetInBeginSection': 772,\n",
       "     'offsetInEndSection': 903,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35751531',\n",
       "     'text': 'DISCUSSION\\nIn this study, symptoms of COVID-19 tended to be milder than described for previous SARS-CoV2 variants.',\n",
       "     'offsetInBeginSection': 1193,\n",
       "     'offsetInEndSection': 1307,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35215980',\n",
       "     'text': 'With the increasing occurrence of SARS-CoV-2 variants, current vaccines show decreased neutralizing activities, especially towards the Omicron variant.',\n",
       "     'offsetInBeginSection': 207,\n",
       "     'offsetInEndSection': 358,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36150972',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36466505',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36285226',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35751531',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35215980']},\n",
       "  {'id': '6432ffdf57b1c7a315000021',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is hereditary angioedema?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22179171',\n",
       "     'text': 'In addition to edema of the glottis, hereditary angioedema often results in edema of the gastrointestinal tract, which can be incapacitating.',\n",
       "     'offsetInBeginSection': 577,\n",
       "     'offsetInEndSection': 718,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33880569',\n",
       "     'text': 'Angioedema and hereditary angioedema are characterized by swelling of the subcutaneous and/or submucosal tissue, resulting in localized oedema.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 143,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14572812',\n",
       "     'text': 'Classic forms of hereditary angioedema are characterized clinically by recurrent episodes of angioedema, biochemically by reduced C1 inhibitor level and/or function, and genetically by a heterogeneous group of mutations in the C1 inhibitor gene that have an autosomal dominant mode of transmission.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 298,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22195758',\n",
       "     'text': 'Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedures prior to a diagnosis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 175,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22073494',\n",
       "     'text': 'Hereditary angioedema is a rare form of angioedema that can be diagnosed by screening with a C4 level.',\n",
       "     'offsetInBeginSection': 322,\n",
       "     'offsetInEndSection': 424,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31283393',\n",
       "     'text': 'Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32178893',\n",
       "     'text': 'Hereditary angioedema is an autosomal dominant disorder, presenting as sudden and recurring episodes of variable severity of subcutaneous and mucosa edema that may occur spontaneously or in response to triggers.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22227095',\n",
       "     'text': 'Hereditary angioedema is a rare disease, often diagnosed with delay because of a heterogeneous clinical presentation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 117,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2371584',\n",
       "     'text': 'Hereditary angioedema is a rare autosomal dominant disorder due to the deficiency of functionally active C1-inhibitor.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 118,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34983705',\n",
       "     'text': 'Background: Hereditary angioedema is an autosomal dominant disease that presents with recurrent episodic swelling of the submucosal and/or subcutaneous tissues of the cutaneous, gastrointestinal, and respiratory systems.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22179171',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33880569',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14572812',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22195758',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22073494',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31283393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32178893',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22227095',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2371584',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34983705']},\n",
       "  {'id': '64178ec2690f196b51000024',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is viltolarsen's mechanism of action?\",\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64040bd8201352f04a00000e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should be used bexarotene for relapsing-remitting multiple sclerosis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12938639',\n",
       "     'text': 'The tendency to the decrease of the severity of relapses, less need for steroid use and the decrease of EDSS score in patients with relapsing/remitting multiple sclerosis have been shown.',\n",
       "     'offsetInBeginSection': 329,\n",
       "     'offsetInEndSection': 516,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/12938639']},\n",
       "  {'id': '6422e7f0690f196b51000045',\n",
       "   'type': 'list',\n",
       "   'body': 'Hepcidin is a key regulator of what processes?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30798817',\n",
       "     'text': 'Hepcidin, the main regulator of iron metabolism, is synthesized and released by hepatocytes in response to increased body iron concentration and inflammation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 158,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19924283',\n",
       "     'text': 'BACKGROUND\\nHepcidin is a major regulator of iron metabolism and plays a key role in anemia of chronic disease, reducing intestinal iron uptake and release from body iron stores.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19681654',\n",
       "     'text': 'Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 116,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19249912',\n",
       "     'text': 'Hepcidin is a key regulator of iron homeostasis, while hemojuvelin is an important component of the hepcidin regulation pathway.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 128,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24293278',\n",
       "     'text': 'Hepcidin, which is mainly produced by the liver, is the key regulator in iron homeostasis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 90,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24739829',\n",
       "     'text': 'BACKGROUND\\nHepcidin, a key regulator of iron homeostasis, is increased by iron overload and inflammation while suppressed by hypoxia.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 133,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25782630',\n",
       "     'text': 'Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 126,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30204470',\n",
       "     'text': 'Hepcidin is a key regulator of iron metabolism and plays an important role in many pathologies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 95,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16198622',\n",
       "     'text': 'Hepcidin is thought to be a key regulator in iron metabolism and has been implicated in ACD.',\n",
       "     'offsetInBeginSection': 126,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19839848',\n",
       "     'text': 'Hepcidin is the key regulator of iron metabolism. Iron supplementation is often introduced in dialyzed patients to replete or to maintain iron stores,',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30798817',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19924283',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19681654',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19249912',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24293278',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24739829',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25782630',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30204470',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16198622',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19839848']},\n",
       "  {'id': '6429ee7457b1c7a31500000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767100',\n",
       "     'text': 'The efficacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophenolate/mycophenolic acid (MMF), and rituximab (RTX).',\n",
       "     'offsetInBeginSection': 712,\n",
       "     'offsetInEndSection': 921,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35383912',\n",
       "     'text': 'd individuals with DS (median age = 19.5\\xa0years), with 50% reporting no side effects from COVID-19 vaccination. Increased seizures following COVID-19 v',\n",
       "     'offsetInBeginSection': 943,\n",
       "     'offsetInEndSection': 1093,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34767100',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35383912']},\n",
       "  {'id': '6433050157b1c7a315000024',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22171564',\n",
       "     'text': 'BACKGROUND\\nRecombinant human C1-inhibitor (rhC1INH; Ruconest®) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) due to heterozygous deficiency of C1INH.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 209,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30280305',\n",
       "     'text': 'Fifty (63.3%) attacks were treated with recombinant human C1-INH (rhC1-INH); 17 (21.5%) with plasma-derived, pasteurized, nanofiltered C1-INH (pnfC1-INH); 13 (16.5%) with icatibant; and 1 (1.3%) with plasma-derived, nanofiltered C1-INH (nfC1-INH).',\n",
       "     'offsetInBeginSection': 694,\n",
       "     'offsetInEndSection': 941,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24801469',\n",
       "     'text': 'Conestat alfa, a recombinant human C1 inhibitor (rhC1-INH) is a novel therapeutic option for the acute treatment of hereditary angioedema due to C1-INH (HAE-C1-INH) deficiency.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 176,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28662509',\n",
       "     'text': 'tially life-threatening subcutaneous and submucosal edematous attacks. Cinryze® (Shire ViroPharma Inc., Lexington, MA, USA), a nanofiltered C1 inhibit',\n",
       "     'offsetInBeginSection': 96,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19093699',\n",
       "     'text': 'Several novel therapies have completed phase III trials in the US, including: (i) plasma-derived C1-INH replacement therapies (Berinert P and Cinryze); (ii) a recombinant C1-INH replacement therapy (conestat alfa; Rhucin); (iii) a kallikrein inhibitor (ecallantide [DX-88]); and (iv) a bradykinin-2-receptor antagonist (icatibant).',\n",
       "     'offsetInBeginSection': 661,\n",
       "     'offsetInEndSection': 992,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22171564',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30280305',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24801469',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28662509',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19093699']},\n",
       "  {'id': '6417900b690f196b5100002a',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can viltolarsen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022',\n",
       "     'text': 'Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\\xa0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 305,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "     'text': 'A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 271,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "     'text': 'The complete 14-kb cDNA for the gene causing the X-linked recessive muscular dystrophy (MD) type Duchenne (DMD) and Becker (BMD) has recently been cloned and made available for deletion/duplication screening in patients.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34938127',\n",
       "     'text': 'Viltolarsen is a mutation-specific drug and will work for 8% of the persons with DMD who carry mutations amenable to exon 53 skipping.',\n",
       "     'offsetInBeginSection': 991,\n",
       "     'offsetInEndSection': 1125,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8401582',\n",
       "     'text': 'About two thirds of Duchenne muscular dystrophy (DMD) patients have either gene deletions or duplications.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 106,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23637366',\n",
       "     'text': 'A digital micromirror device (DMD) is an array of individually switchable mirrors that can be used in many advanced optical systems as a rapid spatial light modulator.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 167,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26290039',\n",
       "     'text': 'Duchenne muscular dystrophy (DMD) is a progressive and fatal muscle degenerating disease caused by a dystrophin deficiency.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 123,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36401022',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34938127',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8401582',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23637366',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26290039']},\n",
       "  {'id': '63f57ea133942b094c000005',\n",
       "   'type': 'list',\n",
       "   'body': 'What is the triad of the Cat eye syndrome?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33465332',\n",
       "     'text': 'The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients.',\n",
       "     'offsetInBeginSection': 127,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34652311',\n",
       "     'text': 'The authors present the first case of concurrent floppy eyelid syndrome and upper eyelid imbrication reported in a cat eye syndrome patient.',\n",
       "     'offsetInBeginSection': 647,\n",
       "     'offsetInEndSection': 787,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35911297',\n",
       "     'text': 'The classic clinical triad includes coloboma of the iris, ears, and anal malformations.',\n",
       "     'offsetInBeginSection': 101,\n",
       "     'offsetInEndSection': 188,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2072964',\n",
       "     'text': 'In a cyanotic newborn with characteristic features of Cat-Eye-Syndrome, cytogenetic examination disclosed a supernumerary small bisatellited chromosome.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 152,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23928108',\n",
       "     'text': 'e 22, with a variable phenotype comprising anal atresia, coloboma of the iris and preauricular tags or pits. We report a girl with cat eye syndrome, p',\n",
       "     'offsetInBeginSection': 129,\n",
       "     'offsetInEndSection': 279,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33465332',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34652311',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35911297',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2072964',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23928108']},\n",
       "  {'id': '64281a47690f196b5100004f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15610227',\n",
       "     'text': 'Reduction of urinary oxalate levels can efficiently decrease calcium oxalate depositions; yet, no treatment is available that targets oxalate biosynthesis.',\n",
       "     'offsetInBeginSection': 408,\n",
       "     'offsetInEndSection': 563,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "     'text': 'order that causes overproduction and urinary excretion of oxalate. Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1',\n",
       "     'offsetInBeginSection': 69,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22215125',\n",
       "     'text': 'The primary disease is treated by combined liver-kidney transplantation, although pathological fracturing also occurs in the posttransplant period.',\n",
       "     'offsetInBeginSection': 363,\n",
       "     'offsetInEndSection': 510,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/15610227',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22215125']},\n",
       "  {'id': '6429cfb557b1c7a315000005',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34476396',\n",
       "     'text': 'Asthma should be managed as outlined in local and international guidelines.Ensure an adequate supply of medication, and inhaled corticosteroids should not be withdrawnChronic obstructive pulmonary disease (COPD) is associated with severe COVID-19 disease and poor outcomes.',\n",
       "     'offsetInBeginSection': 330,\n",
       "     'offsetInEndSection': 603,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9032192',\n",
       "     'text': 'This confirms the clinical impression that inhaled steroids have little antiinflammatory effect, at least in the short term in this group of patients, and suggests that the inflammatory process in COPD is resistant to the antiinflammatory effect of glucocorticoids.',\n",
       "     'offsetInBeginSection': 1638,\n",
       "     'offsetInEndSection': 1903,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34476396',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9032192']},\n",
       "  {'id': '6432f75757b1c7a31500001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "     'text': 'As compared to first-generation ibrutinib, zanubrutinib has higher BTK selectivity which may result in fewer off-target effects and improved potential for combination with other targeted therapies.',\n",
       "     'offsetInBeginSection': 798,\n",
       "     'offsetInEndSection': 995,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33025948']},\n",
       "  {'id': '64178fea690f196b51000028',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What types of DMD can eteplirsen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30526286',\n",
       "     'text': 'Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 248,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22086232',\n",
       "     'text': 'We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.)',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 371,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34120909',\n",
       "     'text': 'BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, based on demonstrated dystrophin production.ObjectiveTo report results from PROMOVI, a phase 3, multicenter, open-label study evaluating efficacy and safety of eteplirsen in a larger cohort.MethodsAmbulatory patients aged 7-16 years, with confirmed mutations amenable to exon 51 skipping, received eteplirsen 30\\u200amg/kg/week intravenously for 96 weeks.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 501,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31261494',\n",
       "     'text': 'This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who participated in two clinical studies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 154,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27807823',\n",
       "     'text': 'Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene amenable to exon 51 skipping.',\n",
       "     'offsetInBeginSection': 135,\n",
       "     'offsetInEndSection': 346,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34420980',\n",
       "     'text': 'BACKGROUND\\nStudies 4658-201/202 (201/202) evaluated treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 191,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29035327',\n",
       "     'text': 'he first AO-based drug, eteplirsen (Exondys 51), developed for DMD exon 51 skipping. An accurate and reproducible method to quantify exon skipping eff',\n",
       "     'offsetInBeginSection': 486,\n",
       "     'offsetInEndSection': 636,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28208626',\n",
       "     'text': 'After accelerated US approval of eteplirsen (Exondys 51), which targets dystrophin exon 51 for skipping, efforts are now focused on targeting other exons.',\n",
       "     'offsetInBeginSection': 390,\n",
       "     'offsetInEndSection': 544,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29067661',\n",
       "     'text': 'In 2016, the US Food and Drug Administration (FDA)-approved Exondys 51 (eteplirsen) and Spinraza (nusinersen), the first exon skipping and exon inclusion drugs, to treat patients with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), respectively.',\n",
       "     'offsetInBeginSection': 183,\n",
       "     'offsetInEndSection': 449,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35715998',\n",
       "     'text': 'Eteplirsen is a United States-approved treatment for patients with DMD and exon 51 skip-amenable mutations.',\n",
       "     'offsetInBeginSection': 105,\n",
       "     'offsetInEndSection': 212,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30526286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22086232',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34120909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31261494',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27807823',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34420980',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29035327',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28208626',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29067661',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35715998']},\n",
       "  {'id': '63eef94ff36125a426000010',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Cinpanemab effective for Parkinson’s Disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "     'text': \"Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.\",\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25801023',\n",
       "     'text': \"enerative diseases such as Alzheimer's disease (AD), Parkinson’s disease (PD), and Huntington's disease (HD). Finally, we show that necroptosis mediat\",\n",
       "     'offsetInBeginSection': 672,\n",
       "     'offsetInEndSection': 822,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25801023']},\n",
       "  {'id': '6426d131690f196b5100004e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'In what organ would you find the Ashwell receptor?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "     'text': 'The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be identified and isolated and the first lectin to be detected in mammals.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18488037',\n",
       "     'text': 'The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galactose and N-acetylgalactosamine.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 179,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18488037']},\n",
       "  {'id': '6429e17657b1c7a315000007',\n",
       "   'type': 'list',\n",
       "   'body': 'What histone marks are indicative of enhancers in the chromatin landscape of a given cell?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649883',\n",
       "     'text': 'or instance, active enhancers are commonly occupied by both marks H3K4me1 and H3K27ac. The traditional bottom-up MS strategy identifies and quantifies',\n",
       "     'offsetInBeginSection': 417,\n",
       "     'offsetInEndSection': 567,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32058623',\n",
       "     'text': 'In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.',\n",
       "     'offsetInBeginSection': 725,\n",
       "     'offsetInEndSection': 939,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28981749',\n",
       "     'text': 'The intersection of the proteomics data with ChIP-seq and RNA-seq analyses revealed the existence of novel subpopulations of enhancers, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me2 combinations mark distinct classes of intronic enhancers.',\n",
       "     'offsetInBeginSection': 996,\n",
       "     'offsetInEndSection': 1339,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26957309',\n",
       "     'text': 'We tested 40 chromatin signatures on this unbiased enhancer set and identified H2BK20ac, a little-studied histone modification, as the most predictive mark of active enhancers.',\n",
       "     'offsetInBeginSection': 347,\n",
       "     'offsetInEndSection': 523,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32058623',\n",
       "     'text': 'In silico analysis and integration of DNA methylation data with chondrogenesis chromatin states revealed that enhancers marked by histone marks H3K4me1 and H3K27ac were de-methylated during in vitro chondrogenesis.',\n",
       "     'offsetInBeginSection': 725,\n",
       "     'offsetInEndSection': 939,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29089515',\n",
       "     'text': 'These elements are characterized by distinct epigenomic profiles, such as expanded deposition of histone marks H3K27ac for super enhancers and H3K4me3 for broad domains, however little is known about how they interact with each other and the rest of the genome in three-dimensional chromatin space.',\n",
       "     'offsetInBeginSection': 152,\n",
       "     'offsetInEndSection': 450,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34054788',\n",
       "     'text': 'Eukaryotic chromatin landscapes are structured through histone protein variants, epigenetic marks, the activities of chromatin-remodeling complexes, and post-translational modification of histone proteins.',\n",
       "     'offsetInBeginSection': 148,\n",
       "     'offsetInEndSection': 353,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32286315',\n",
       "     'text': 'Here, we present chromatin immunoprecipitation sequencing (ChIP-Seq) data for the oncogenic transcription factors, MYCN and MYC, as well as regulatory histone marks H3K4me1, H3K4me3, H3K27Ac, and H3K27me3 in ten commonly used human neuroblastoma-derived cell line models.',\n",
       "     'offsetInBeginSection': 208,\n",
       "     'offsetInEndSection': 479,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24413398',\n",
       "     'text': 'Nevertheless, secretory and absorptive progenitors showed comparable levels of H3K4me2 and H3K27ac histone marks and DNase I hypersensitivity--signifying accessible, permissive chromatin-at most of the same cis-elements.',\n",
       "     'offsetInBeginSection': 1026,\n",
       "     'offsetInEndSection': 1246,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22955985',\n",
       "     'text': 'all types of chromatin marks examined, including promoter, enhancer, elongation, and repressive marks. The fine-resolution signal shapes discovered by',\n",
       "     'offsetInBeginSection': 1403,\n",
       "     'offsetInEndSection': 1553,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28649883',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32058623',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28981749',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26957309',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32058623',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29089515',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34054788',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32286315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24413398',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22955985']},\n",
       "  {'id': '643306cc57b1c7a315000027',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32486913',\n",
       "     'text': 'These results indicate that Cas12a is able to detect both DNA and RNA targets, making it an appropriate and convenient tool to detect all types of pathogens.',\n",
       "     'offsetInBeginSection': 1008,\n",
       "     'offsetInEndSection': 1165,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33329659',\n",
       "     'text': 'By using this simple and high-efficiency CRISPR/Cas12a system, multiple targets can be modified to obtain multigene simultaneous knockout mutants in tree species, which will provide powerful tools with which to facilitate genetic studies of forest trees.',\n",
       "     'offsetInBeginSection': 1212,\n",
       "     'offsetInEndSection': 1466,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32282899',\n",
       "     'text': 'Both CRISPR systems can induce the typical small deletions around the site of DNA cleavage and subsequent repair, but Cas12a does not induce the pure DNA insertions that are routinely observed for Cas9.',\n",
       "     'offsetInBeginSection': 976,\n",
       "     'offsetInEndSection': 1178,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32486913',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33329659',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32282899']},\n",
       "  {'id': '64178ffb690f196b51000029',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can casimersen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29579701',\n",
       "     'text': 'BACKGROUND\\nAlthough prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "     'text': 'A readily available animal model is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the lack of dystrophin protein, which results from frame-disrupting mutations in the DMD gene.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 271,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "     'text': 'The complete 14-kb cDNA for the gene causing the X-linked recessive muscular dystrophy (MD) type Duchenne (DMD) and Becker (BMD) has recently been cloned and made available for deletion/duplication screening in patients.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35213020',\n",
       "     'text': 'Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 247,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34105177',\n",
       "     'text': 'INTRODUCTION/AIMS\\nDuchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene resulting in the absence of dystrophin.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 130,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29579701',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35213020',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34105177']},\n",
       "  {'id': '63eeefc5f36125a426000009',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is targeted by CIS43LS?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6415b422690f196b5100000a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What does Cal-light do?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28650460',\n",
       "     'text': 'We present a dual-protein switch system, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner.',\n",
       "     'offsetInBeginSection': 130,\n",
       "     'offsetInEndSection': 292,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28650460']},\n",
       "  {'id': '64172bb2690f196b5100001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'To which region of a gene does an RNA polymerase bind to initiate transcription?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31863129',\n",
       "     'text': 'RNA polymerases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition requires the presence of specific DNA binding domains in the polymerase.',\n",
       "     'offsetInBeginSection': 131,\n",
       "     'offsetInEndSection': 363,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9113125',\n",
       "     'text': 'The basal transcription machineries composed of RNA polymerase and GTFs bind to a promoter and govern efficient and correct transcription for constitutive gene expression.',\n",
       "     'offsetInBeginSection': 248,\n",
       "     'offsetInEndSection': 419,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7400155',\n",
       "     'text': 'However, we tentatively conclude that initiation does occur preferentially at a few specific sites along the DNA, and that these sites may be near promoters at which the T7 RNA polymerase initiates transcription.',\n",
       "     'offsetInBeginSection': 350,\n",
       "     'offsetInEndSection': 562,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/4092686',\n",
       "     'text': 'This has led to a three-dimensional model which explains how RNA polymerase III could interact simultaneously with transcription factors bound at the internal control region of the 5S RNA gene and the start point of transcription.',\n",
       "     'offsetInBeginSection': 936,\n",
       "     'offsetInEndSection': 1166,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9776743',\n",
       "     'text': 'Many vertebrate small nuclear RNA gene promoters contain an SPH motif in their distal control regions that can confer transcriptional stimulation by RNA polymerase II or RNA polymerase III.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 189,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9603525',\n",
       "     'text': 'Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a preinitiation complex.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8647083',\n",
       "     'text': \"5'-deletion and 3'-deletion analyses revealed that this gene is specifically transcribed by RNA polymerase II in a manner that is dependent on the upstream regulatory region of the gene (-102 to -61), and that the 3' boundary of the minimal promoter element does not extend beyond +5.\",\n",
       "     'offsetInBeginSection': 168,\n",
       "     'offsetInEndSection': 452,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28531287',\n",
       "     'text': \"Bacterial RNA polymerase is able to initiate transcription with adenosine-containing cofactor NAD+, which was proposed to result in a portion of cellular RNAs being 'capped' at the 5' end with NAD+, reminiscent of eukaryotic cap.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 229,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18155246',\n",
       "     'text': 'In bacteria, the formation of a transcription-competent complex between RNA polymerase and a promoter involves DNA strand separation over a stretch of about 14 base pairs.',\n",
       "     'offsetInBeginSection': 86,\n",
       "     'offsetInEndSection': 257,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6194892',\n",
       "     'text': 'A sensitive hybridization technique was used to demonstrate that the purified polymerase, even when supplemented with a transcription factor that binds specifically to the 5S RNA gene internal control region, is unable to initiate synthesis at the start site of the 5S RNA gene.',\n",
       "     'offsetInBeginSection': 246,\n",
       "     'offsetInEndSection': 524,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31863129',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9113125',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7400155',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/4092686',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9776743',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9603525',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8647083',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28531287',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18155246',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6194892']},\n",
       "  {'id': '63f9ccdc33942b094c00000f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is PRP-40 involved in microexon splicing?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '641790d6690f196b5100002d',\n",
       "   'type': 'factoid',\n",
       "   'body': 'At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27524897',\n",
       "     'text': 'It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications.',\n",
       "     'offsetInBeginSection': 94,\n",
       "     'offsetInEndSection': 283,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20437929',\n",
       "     'text': 'Deflazacort 0.9 mg/kg/d was used at all centres, which was continued after loss of independent ambulation (11), along with routine calcium and vitamin D supplementation (10).',\n",
       "     'offsetInBeginSection': 846,\n",
       "     'offsetInEndSection': 1020,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35625891',\n",
       "     'text': 'wasting during early childhood, and loss of ambulation and death by early adulthood. Chronic inflammation due to myofiber instability leads to fibrosi',\n",
       "     'offsetInBeginSection': 123,\n",
       "     'offsetInEndSection': 273,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21784636',\n",
       "     'text': 'Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12. Long-term steroids have lengthened ambulation by 2-5 years. Ischial weight-',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17388226',\n",
       "     'text': 'Subsequently, the disease immobilizes the patient (ages 9 to 14 years) and severe respiratory failure occurs due to chest and vertebral column deformity.',\n",
       "     'offsetInBeginSection': 261,\n",
       "     'offsetInEndSection': 414,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "     'text': 'Historically, DMD has resulted in loss of ambulation between ages 7 and 13 years and death in the teens or 20s.',\n",
       "     'offsetInBeginSection': 303,\n",
       "     'offsetInEndSection': 414,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16950195',\n",
       "     'text': 'Serial clinical and echocardiographic data from 50 patients with Duchenne muscular dystrophy (aged 10 to 20 years) were retrospectively reviewed.',\n",
       "     'offsetInBeginSection': 362,\n",
       "     'offsetInEndSection': 507,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8496368',\n",
       "     'text': 'A separate group of 25 children to whom operation was offered but declined, was followed: these children ceased ambulating at a mean age of 10 years and ceased standing at a mean age of 10 2/12 years.',\n",
       "     'offsetInBeginSection': 542,\n",
       "     'offsetInEndSection': 742,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27382620',\n",
       "     'text': 'Duchenne muscular dystrophy is a progressive disease with loss of ambulation at around 9-10 years of age, followed, if untreated, by development of scoliosis, respiratory insufficiency, and death in the second decade of life.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 225,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30275245',\n",
       "     'text': ' weakness, loss of ambulation, and cardiopulmonary compromise by the second decade of life. Life expectancy has improved from mid-teenage years to mid',\n",
       "     'offsetInBeginSection': 189,\n",
       "     'offsetInEndSection': 339,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27524897',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20437929',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35625891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21784636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17388226',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16950195',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8496368',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27382620',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30275245']},\n",
       "  {'id': '6404199d201352f04a000019',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is ocrelizumab effective for primary progressive multiple sclerosis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31598138',\n",
       "     'text': 'Successful examples are the B-cell targeting monoclonal antibody ocrelizumab, effective in primary progressive MS, and the sphingosine-1-receptor modulator siponimod, effective in active forms of secondary-progressive MS. Apart from that, other medications such as the B-cell targeted antibody ofatumumab, cladribine due to T- and B-cell depletion, and other sphingosine-1-receptor modulators such as ozanimod and ponesimod are under development.',\n",
       "     'offsetInBeginSection': 837,\n",
       "     'offsetInEndSection': 1283,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35589638',\n",
       "     'text': 'New disease-modifying drugs (DMDs), such as ocrelizumab and Siponimod, have been proven to be efficacious for treating progressive multiple sclerosis (MS) and have marked a new era in the treatment of this disease.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34308352',\n",
       "     'text': 'Median baseline Expanded Disability Status Scale (EDSS) (IQR) was 3.0 (2.0-4.0) for RMS, 6.5 (6.0-7.5) for secondary progressive MS, and 6.5 (6.0-7.0) for primary progressive MS. Respiratory infections occurred in 40.1% and urinary tract infections in 33.1% of patients.',\n",
       "     'offsetInBeginSection': 488,\n",
       "     'offsetInEndSection': 758,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "     'text': 'of RMS patients who were followed for at least 1 year. Ocrelizumab was generally well-tolerated; the most common adverse events were infusion-related ',\n",
       "     'offsetInBeginSection': 1249,\n",
       "     'offsetInEndSection': 1399,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26970489',\n",
       "     'text': 'rituximab, ocrelizumab, ofatumumab) was shown to exert profound anti-inflammatory effect in MS with favorable risk-benefit ratio, with ocrelizumab demonstrating efficacy in both relapsing-remitting (RR) and primary-progressive (PP) MS in phase III clinical trials.',\n",
       "     'offsetInBeginSection': 490,\n",
       "     'offsetInEndSection': 754,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35185862',\n",
       "     'text': 'phropathy and mixed results in systemic lupus erythematosus. Ocrelizumab has been approved for the use in patients with relapsing-remitting multiple s',\n",
       "     'offsetInBeginSection': 1287,\n",
       "     'offsetInEndSection': 1437,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28674469',\n",
       "     'text': 'Niraparib (Zejula) for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; ocrelizumab (Ocrevus) for relapsing or primary progressive multiple sclerosis; and dupilumab (Dupixent) for moderate-to-severe atopic dermatitis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 244,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35079395',\n",
       "     'text': 'Ocrelizumab is a recombinant humanized antibody targeted against CD-20\\xa0molecule, which was approved for the treatment of relapsing and primary progressive multiple sclerosis.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 174,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28002688',\n",
       "     'text': 'We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.',\n",
       "     'offsetInBeginSection': 148,\n",
       "     'offsetInEndSection': 302,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34449289',\n",
       "     'text': 'Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen on B cells, which is approved for the treatment of both relapsing-remitting multiple sclerosis (RRMS) and primary-progressive multiple sclerosis (PPMS).',\n",
       "     'offsetInBeginSection': 88,\n",
       "     'offsetInEndSection': 317,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31598138',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35589638',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34308352',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26970489',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35185862',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28674469',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35079395',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28002688',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34449289']},\n",
       "  {'id': '641b7bba690f196b5100003e',\n",
       "   'type': 'summary',\n",
       "   'body': 'How is Indocyanine green (ICG) used?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36327490',\n",
       "     'text': 'Baseline characteristics and outcomes, including anastomotic leak, in patients who underwent indocyanine green fluorescence evaluation (ICG) and those who did not (nICG) were compared.',\n",
       "     'offsetInBeginSection': 566,\n",
       "     'offsetInEndSection': 750,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28316935',\n",
       "     'text': 'Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 117,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9018428',\n",
       "     'text': 'Indocyanine green (ICG) is a fluorescent dye that can be used to image both retinal and choroidal vessels.',\n",
       "     'offsetInBeginSection': 131,\n",
       "     'offsetInEndSection': 237,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35668312',\n",
       "     'text': 'Indocyanine green (ICG) is one of the methods used to assess vascularization, but this assessment is usually subjective.',\n",
       "     'offsetInBeginSection': 152,\n",
       "     'offsetInEndSection': 272,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12963458',\n",
       "     'text': 'We examined Indocyanine green (ICG) which is widely used in medical testing and is highly unstable.',\n",
       "     'offsetInBeginSection': 90,\n",
       "     'offsetInEndSection': 189,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25619336',\n",
       "     'text': 'found to be effectively suppressed by indocyanine green (ICG), a near infrared (NIR) dye. Upon NIR laser irradiation at 808 nm, ICG in the liposomes c',\n",
       "     'offsetInBeginSection': 73,\n",
       "     'offsetInEndSection': 223,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35662771',\n",
       "     'text': 'Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher sensitivity than naked-eye observation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 189,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31129192',\n",
       "     'text': 'Indocyanine green (ICG) is a dye used for fluorescent-guided surgery. This review article addresses the recent surge in reported uses of ICG in variou',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10410927',\n",
       "     'text': ' negatively charged, water-soluble, tricarbocyanine dye used primarily for medical imaging. ICG is only weakly fluorescent in the near-infrared region',\n",
       "     'offsetInBeginSection': 28,\n",
       "     'offsetInEndSection': 178,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1763451',\n",
       "     'text': 'Indocyanine green (ICG) fluorescent iridoangiography was used to diagnose pigmented tumors of the iris.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 103,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36327490',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28316935',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9018428',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35668312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12963458',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25619336',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35662771',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31129192',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10410927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1763451']},\n",
       "  {'id': '6428da74690f196b51000052',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the process that generates multiple transcripts from the same gene?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32484809',\n",
       "     'text': 'This task is complicated due to the complexity of alternative splicing - a mechanism by which the same gene may generate multiple distinct RNA transcripts.',\n",
       "     'offsetInBeginSection': 379,\n",
       "     'offsetInEndSection': 534,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28968750',\n",
       "     'text': 'on can occur at multiple locations through a process known as alternative polyadenylation (APA). Therefore, APA is a form of co-transcriptional gene r',\n",
       "     'offsetInBeginSection': 255,\n",
       "     'offsetInEndSection': 405,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16611169',\n",
       "     'text': 'Alternative splicing is a widespread mechanism in mammals that generates several mRNAs from one gene, thereby creating genetic diversity of the genome.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 151,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32484809',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28968750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16611169']},\n",
       "  {'id': '63f9cdcc33942b094c000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Does silencing of SRRM4 inhibit tumor growth across cancers?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29363543',\n",
       "     'text': 'Treatment with the selective estrogen receptor downregulator (SERD), ICI 182,780 (ICI), did not slow tumor growth, but induced adaptive responses in CSC activity, increased markers of plasticity including target gene reporters of Wnt/Notch signaling and epithelial-mesenchymal transition, and increased double-positive (K8/K5) cells.',\n",
       "     'offsetInBeginSection': 840,\n",
       "     'offsetInEndSection': 1173,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29363543']},\n",
       "  {'id': '64179aac690f196b51000037',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the life expectancy for Duchenne muscular dystrophy patients?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1760206',\n",
       "     'text': 'scular dystrophy case. Duration of the longest survival case was 4 years and 5 months. General physical conditions, complications, ADL and muscular at',\n",
       "     'offsetInBeginSection': 233,\n",
       "     'offsetInEndSection': 383,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34053847',\n",
       "     'text': 'As a result of progressive muscle weakness, pulmonary function decreases during the second decade of life and lung disease contributes significantly to morbidity and mortality in these patients.',\n",
       "     'offsetInBeginSection': 83,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30796500',\n",
       "     'text': 'trophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy expe',\n",
       "     'offsetInBeginSection': 150,\n",
       "     'offsetInEndSection': 300,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30275245',\n",
       "     'text': 'Life expectancy has improved from mid-teenage years to mid-20s with the use of glucocorticoids and beyond the third decade with ventilator support and multidisciplinary care.',\n",
       "     'offsetInBeginSection': 281,\n",
       "     'offsetInEndSection': 455,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26140505',\n",
       "     'text': 'There is currently no cure, and despite exhaustive palliative care, patients are restricted to a wheelchair by the age of 12 years and usually succumb to cardiac or respiratory complications in their late 20s.',\n",
       "     'offsetInBeginSection': 979,\n",
       "     'offsetInEndSection': 1188,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26799743',\n",
       "     'text': 'Five ambulatory, genetically confirmed Duchenne muscular dystrophy patients aged between 7–10 years were treated with L-arginine (3 x 2.5 g/d) and metformin (2 x 250 mg/d) for 16 weeks.',\n",
       "     'offsetInBeginSection': 433,\n",
       "     'offsetInEndSection': 618,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21482750',\n",
       "     'text': 'Caregivers (21 mothers and 6 fathers; mean age, 40.04 years) of 27 Duchenne muscular dystrophy patients (mean age, 11.26 years) completed the validated Children Health Questionnaire-Parent Form 50 and the Family Strain Questionnaire.',\n",
       "     'offsetInBeginSection': 286,\n",
       "     'offsetInEndSection': 519,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26721827',\n",
       "     'text': 'He had been diagnosed with Duchenne muscular dystrophy at 5 years of age, and had no locomotive capability except for that of the finger flexors and toe extensors.',\n",
       "     'offsetInBeginSection': 552,\n",
       "     'offsetInEndSection': 715,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3694224',\n",
       "     'text': 'Analysis of 176 autopsy cases of Duchenne muscular dystrophy (DMD) demonstrated that (1) hospitalized patients showed longer life spans than their non-hospitalized affected maternal uncles, (2) patients hospitalized recently lived longer than those hospitalized in the past, and (3) pulmonary infection has become a less frequent cause of death in recent years, whereas dystrophic changes of the cardiac and respiratory muscles are more closely related with recent fatal cases.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 477,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7985396',\n",
       "     'text': 'Progressive scolioses in 20 wheelchair patients with an age between 10.5-18.3 years (mean 14.6 years) were treated by CDI.',\n",
       "     'offsetInBeginSection': 227,\n",
       "     'offsetInEndSection': 349,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/1760206',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34053847',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30796500',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30275245',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26140505',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26799743',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21482750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26721827',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3694224',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7985396']},\n",
       "  {'id': '64041e97201352f04a00001e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is daridorexant effective for insomnia?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34331678',\n",
       "     'text': 'Daridorexant was safe and well tolerated and its pharmacokinetics were consistent with previous data.',\n",
       "     'offsetInBeginSection': 1528,\n",
       "     'offsetInEndSection': 1629,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32937014',\n",
       "     'text': 'Herein we describe our efforts leading to the identification of a promising set of dual orexin receptor antagonists (DORAs) which subsequently went through physiology-based pharmacokinetic and pharmacodynamic modelling>[1] and finally led to the selection of daridorexant, currently in phase 3 clinical trials for the treatment of insomnia disorders.',\n",
       "     'offsetInBeginSection': 399,\n",
       "     'offsetInEndSection': 749,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35843245',\n",
       "     'text': 'Many licensed drugs (including benzodiazepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available.',\n",
       "     'offsetInBeginSection': 3896,\n",
       "     'offsetInEndSection': 4136,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32603512',\n",
       "     'text': 'Daridorexant is a dual orexin receptor antagonist in clinical development for the treatment of insomnia.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 104,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34121345',\n",
       "     'text': 'The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 215,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34331678',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32937014',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35843245',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32603512',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34121345']},\n",
       "  {'id': '6422ee03690f196b51000046',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What cells produce erythroferrone?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31723763',\n",
       "     'text': 'Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron absorption and mobilization from stores.',\n",
       "     'offsetInBeginSection': 825,\n",
       "     'offsetInEndSection': 1012,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31655016',\n",
       "     'text': 'Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to erythropoietin stimulation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 116,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28739636',\n",
       "     'text': 'Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 125,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35464433',\n",
       "     'text': 'Erythroferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be induced in conditions of anemia or blood loss.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24880340',\n",
       "     'text': 'pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress',\n",
       "     'offsetInBeginSection': 305,\n",
       "     'offsetInEndSection': 455,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28629515',\n",
       "     'text': 'Among the number of factors proposed as mediators linking erythropoiesis with liver hepcidin suppression, erythroferrone, a hormone produced and secreted by erythroid precursors, appears the best candidate.',\n",
       "     'offsetInBeginSection': 1033,\n",
       "     'offsetInEndSection': 1239,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30042411',\n",
       "     'text': 'Hepcidin, the master regulator of iron metabolism, is regulated by circulating iron levels, erythroblast secretion of erythroferrone, and inflammation.',\n",
       "     'offsetInBeginSection': 259,\n",
       "     'offsetInEndSection': 410,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27725588',\n",
       "     'text': 'd by erythroferrone, a hormone produced by erythropoietin-stimulated erythroblasts. Hereditary hemochromatosis is caused by hepcidin deficiency or res',\n",
       "     'offsetInBeginSection': 808,\n",
       "     'offsetInEndSection': 958,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31846624',\n",
       "     'text': ' blood islands where initial erythropoiesis occurs and later in circulating blood cells. ERFE knockdown does not alter the expression of etv.2, aplnr ',\n",
       "     'offsetInBeginSection': 624,\n",
       "     'offsetInEndSection': 774,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31808893',\n",
       "     'text': 'Furthermore, hepcidin regulation by erythropoiesis is attributed in large part to a bone marrow-derived hormone erythroferrone.',\n",
       "     'offsetInBeginSection': 494,\n",
       "     'offsetInEndSection': 621,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31723763',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31655016',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28739636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35464433',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24880340',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28629515',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30042411',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27725588',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31846624',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31808893']},\n",
       "  {'id': '6429f86657b1c7a31500000d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the role of the Mediator in gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10611325',\n",
       "     'text': 'Therefore, the gene-specific function of Mediator as an integrator of transcriptional regulatory signals is evolutionarily conserved and is essential for C. elegans development.',\n",
       "     'offsetInBeginSection': 771,\n",
       "     'offsetInEndSection': 948,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/10611325']},\n",
       "  {'id': '6415c0df690f196b51000010',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What does FBDD stand for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32638146',\n",
       "     'text': 'Fragment-based drug discovery or FBDD is one of the main methods used by industry and academia for identifying drug-like candidates in early stages of drug discovery.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 166,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33759126',\n",
       "     'text': 'Medicinal chemistry society has enough arguments to justify the usage of fragment-based drug design (FBDD) methodologies for the identification of lead compounds.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 162,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20345344',\n",
       "     'text': 'In the last decade, fragment-based drug discovery (FBDD) has evolved from a novel approach in the search of new hits to a valuable alternative to the high-throughput screening (HTS) campaigns of many pharmaceutical companies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 225,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20817886',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has become a widely accepted tool that is complementary to high-throughput screening (HTS) in developing small-molecule inhibitors of pharmaceutical targets.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 194,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21371600',\n",
       "     'text': 'Among the rational or semirational design approaches, fragment-based drug discovery (FBDD) has emerged as a useful tool for the generation of lead structures.',\n",
       "     'offsetInBeginSection': 173,\n",
       "     'offsetInEndSection': 331,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26501900',\n",
       "     'text': 'During the past decade fragment-based drug discovery (FBDD) has rapidly evolved and several drugs or drug candidates developed by FBDD approach are clinically in use or in clinical trials.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 188,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348623',\n",
       "     'text': 'Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceutical industry.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 165,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25420726',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has caused a revolution in the process of drug discovery and design, with many FBDD leads being developed into clinical trials or approved in the past few years.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 198,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36044560',\n",
       "     'text': 'The technique of Fragment-Based Drug Design (FBDD) considers the interactions of different moieties of molecules with biological targets for the rational construction of potential drugs.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32339336',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has become an established approach for the generation of early lead candidates.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 116,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32638146',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33759126',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20345344',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20817886',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21371600',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26501900',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34348623',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25420726',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36044560',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32339336']},\n",
       "  {'id': '64041dae201352f04a00001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is deucravacitinib effective for psoriasis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36115523',\n",
       "     'text': 'vs 8.6% and 33.9%; P < 0.0001 for both). Efficacy was maintained until Week 52 with continuous deucravacitinib. The most frequent adverse event (AE) w',\n",
       "     'offsetInBeginSection': 832,\n",
       "     'offsetInEndSection': 982,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36469536',\n",
       "     'text': 'Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast.',\n",
       "     'offsetInBeginSection': 621,\n",
       "     'offsetInEndSection': 710,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35001782',\n",
       "     'text': 'Deucravacitinib, an allosteric TYK2 inhibitor discovered by BMS, is the most advanced molecule in clinical development and in 2021, it received positive phase 3 data for the treatment of plaque psoriasis. .',\n",
       "     'offsetInBeginSection': 849,\n",
       "     'offsetInEndSection': 1055,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36115523',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36469536',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35001782']},\n",
       "  {'id': '6415b6eb690f196b5100000b',\n",
       "   'type': 'list',\n",
       "   'body': 'What processes do orexin/hypocretin neurons regulate?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34052808',\n",
       "     'text': 'However, cellular-resolution calcium imaging and optogenetic studies show that orexin neurons regulate self-generated and sensory-evoked movement on rapid, subsecond timescales.',\n",
       "     'offsetInBeginSection': 233,\n",
       "     'offsetInEndSection': 410,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16054072',\n",
       "     'text': ' have emerged as instrumental in triggering arousal and regulating energy metabolism. The lack of hypocretin signaling is the cause of narcolepsy whil',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12495630',\n",
       "     'text': 'Neurons that release hypocretin/orexin modulate sleep, arousal, and energy homeostasis; the absence of hypocretin results in narcolepsy.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 136,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15548664',\n",
       "     'text': 'Considering the critical functions of the hypothalamic orexin (hypocretin) neuropeptides in promoting wakefulness and locomotor activity, we examined the role of orexin neurons in the adaptation to restricted feeding.',\n",
       "     'offsetInBeginSection': 103,\n",
       "     'offsetInEndSection': 320,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31386303',\n",
       "     'text': 'Hypocretin 1 and hypocretin 2 (orexin A and B) regulate sleep, wakefulness and emotion.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 87,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35698789',\n",
       "     'text': 'Those two peptides bind two receptors (orexin/hypocretin receptor 1 and receptor 2) that are widely distributed in the brain and involved in the central physiological regulation of sleep and wakefulness, orexin receptor 2 having the major role in the maintenance of arousal.',\n",
       "     'offsetInBeginSection': 239,\n",
       "     'offsetInEndSection': 513,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20861370',\n",
       "     'text': 'Orexin neurons (hypocretin neurons) have a critical role in the regulation of sleep/wakefulness, especially in the maintenance of arousal.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 138,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10481909',\n",
       "     'text': 'es orexin-containing neurons. We propose that orexin regulates sleep/wakefulness states, and that orexin knockout mice are a model of human narcolepsy',\n",
       "     'offsetInBeginSection': 576,\n",
       "     'offsetInEndSection': 726,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19246384',\n",
       "     'text': 'Thus, GABA(B) receptors on orexin neurons are crucial in the appropriate control of the orexinergic tone through sleep/wake states, thereby stabilizing the state switching mechanisms.',\n",
       "     'offsetInBeginSection': 1041,\n",
       "     'offsetInEndSection': 1224,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34052808',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16054072',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12495630',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15548664',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31386303',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35698789',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20861370',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10481909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19246384']},\n",
       "  {'id': '6428da47690f196b51000051',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can the epigenetic status of introns affect gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18319396',\n",
       "     'text': 'However, not all introns affect gene expression, and direct testing is currently the only way to identify stimulatory introns.',\n",
       "     'offsetInBeginSection': 86,\n",
       "     'offsetInEndSection': 212,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24737381',\n",
       "     'text': 'We conclude that alterations in the methylation status of protein-coding genes and various miRNA genes are influenced by HPV infection, the viral genotype, the physical state of the viral DNA, and viral oncogenic risk.',\n",
       "     'offsetInBeginSection': 829,\n",
       "     'offsetInEndSection': 1047,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17464246',\n",
       "     'text': 'Much of the excitement in this field relates to the possibility of therapeutic reversal of epigenetic changes by chromatin-modifying drugs.',\n",
       "     'offsetInBeginSection': 1053,\n",
       "     'offsetInEndSection': 1192,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23593031',\n",
       "     'text': 'Epigenetic variation, such as heritable changes of DNA methylation, can affect gene expression and thus phenotypes, but examples of natural epimutations are few and little is known about their stability and frequency in nature.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 227,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/18319396',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24737381',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17464246',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23593031']},\n",
       "  {'id': '6415c5d4690f196b51000014',\n",
       "   'type': 'list',\n",
       "   'body': 'What was Keytruda originally approved for by the FDA?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34156377',\n",
       "     'text': 'Pembrolizumab (Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 130,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34156377']},\n",
       "  {'id': '63f5713733942b094c000003',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are clinical features of the Achard-Thiers syndrome?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1201353',\n",
       "     'text': 'The Achard syndrome is a well-defined clinical entity consisting of widespread dysostoses and increased ligament laxity.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 120,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/899476',\n",
       "     'text': 'f hysterical and anxious-phobic disturbances of a hypochondriacal content, as well as of affective disorders appearing in the process of the disease. ',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 341,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/1201353',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/899476']},\n",
       "  {'id': '642d4c9b57b1c7a315000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are Luminopsins a fusion proteins of luminol and Rhodopsin ?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429fe4e57b1c7a31500000f',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are coactivators?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "     'text': 'Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modulator drugs.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 160,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "     'text': '160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans',\n",
       "     'offsetInBeginSection': 413,\n",
       "     'offsetInEndSection': 563,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12376547',\n",
       "     'text': 'Coactivators such as TIF2 and SRC-1 modulate the positioning of the dose-response curve for agonist-bound glucocorticoid receptors (GRs) and the partial agonist activity of antiglucocorticoid complexes.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19463689',\n",
       "     'text': 'To regulate transcription, AR recruits a series of coactivators that modify chromatin and facilitate transcription.',\n",
       "     'offsetInBeginSection': 158,\n",
       "     'offsetInEndSection': 273,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11108858',\n",
       "     'text': 'Coactivators are a diverse group of molecules that bring multiple structural and enzymatic functions to the promoter.',\n",
       "     'offsetInBeginSection': 287,\n",
       "     'offsetInEndSection': 404,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18081007',\n",
       "     'text': 'Therefore, current models of the role of acetylation in transcriptional regulation focus on the acetylation status of histones and designate histone acetyltransferases, which add acetyl groups to histones, as transcriptional coactivators and histone deacetylases as corepressors.',\n",
       "     'offsetInBeginSection': 258,\n",
       "     'offsetInEndSection': 537,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21664237',\n",
       "     'text': 'Coactivators are a diverse group of non-DNA binding proteins that induce structural changes in agonist-bound nuclear receptors (NRs) that are essential for NR-mediated transcriptional activation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 195,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10381882',\n",
       "     'text': 'The p160 family of coactivators, SRC-1, GRIP1/TIF2, and p/CIP, mediate transcriptional activation by nuclear hormone receptors.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 127,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10944516',\n",
       "     'text': 'Members of the 160-kDa protein (SRC-1/TIF2/AIB-1) family of coactivators, CBP/p300 and TRAP220/DRIP205, are shown to interact directly with PPARgamma and potentiate nuclear receptor transactivation function in a ligand-dependent fashion.',\n",
       "     'offsetInBeginSection': 296,\n",
       "     'offsetInEndSection': 533,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10669760',\n",
       "     'text': 'In yeast two-hybrid assays and in vitro, mZac1b bound to GRIP1, to CREB-binding protein (CBP) and p300 (which are coactivators for nuclear receptors and other transcriptional activators), and to nuclear receptors themselves in a hormone-independent manner.',\n",
       "     'offsetInBeginSection': 594,\n",
       "     'offsetInEndSection': 850,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12376547',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19463689',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11108858',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18081007',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21664237',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10381882',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10944516',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10669760']},\n",
       "  {'id': '6412331b201352f04a000038',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What are PROTACs?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31873151',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) are an emerging strategy for promoting targeted protein degradation by inducing the proximity between targeted proteins and E3 ubiquitin ligases.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35680848',\n",
       "     'text': 'In 2019, our group published a review article \"PROTACs: great opportunities for academia and industry\" in the journal, summarizing the representative compounds of PROTACs reported before the end of 2019.',\n",
       "     'offsetInBeginSection': 544,\n",
       "     'offsetInEndSection': 747,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36170570',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) must be cell permeable to reach their target proteins.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 95,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32558301',\n",
       "     'text': 'Proteolysis targeting chimeras, PROTACs, are emerging as a powerful strategy for exerting exogenous control over protein levels, allowing small molecules to exploit the ubiquitin-proteasome pathway for targeted protein degradation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 231,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32369353',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) represent an exciting inhibitory modality with many advantages, including substoichiometric degradation of targets.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 156,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34951318',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) are a powerful tool to hijack the endogenous ubiquitin-proteasome system (UPS) and to degrade the intracellular proteins of therapeutic importance.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 188,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31571504',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) have received much attention for their promising therapeutic intervention in recent years.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 131,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36124821',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) have emerged as a powerful technology for the degradation of disease-related proteins by the hijacking of the endogenous ubiquitin-proteasome system.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 190,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36285735',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) and targeted covalent inhibitors (TCIs) are currently two exciting strategies in the fields of chemical biology and drug discovery.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 172,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34175722',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) have been developed to be an effective technology for targeted protein degradation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 124,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31873151',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35680848',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36170570',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32558301',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32369353',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34951318',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31571504',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36124821',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36285735',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34175722']},\n",
       "  {'id': '62008022c9dfcb9c0900001b',\n",
       "   'type': 'list',\n",
       "   'body': 'Which variables are included in the ALBI grade?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30026834',\n",
       "     'text': 'A newly developed scoring system called albumin-bilirubin grade (ALBI grade), consists of albumin and bilirubin to assess liver function reserve objectively.',\n",
       "     'offsetInBeginSection': 253,\n",
       "     'offsetInEndSection': 410,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30077606',\n",
       "     'text': 'The albumin-bilirubin (ALBI) grade, a measure of liver function based on albumin and bilirubin, has the potential to detect Child-Pugh grade A HCC patients with poor prognosis.',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 331,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35812041',\n",
       "     'text': 'Recently, the albumin-bilirubin (ALBI) score, a continuous index consisting of only albumin and bilirubin, has been developed for objectively assessing liver function in patients with hepatocellular carcinoma (HCC).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 215,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28628718',\n",
       "     'text': 'Although only two serological parameters, albumin and total bilirubin, are used, assessment with ALBI-grade may be more useful than with LD-grade for avoiding a non-beneficial RFA procedure.',\n",
       "     'offsetInBeginSection': 1790,\n",
       "     'offsetInEndSection': 1980,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32953155',\n",
       "     'text': \"This study evaluates the ALBI grade's ability to predict overall survival and biochemical toxicity in patients undergoing resin Y90 radioembolization and body surface area dosimetry (BSA) for non-hepatocellular primary and metastatic liver malignancies compared to the CP class and Model for End-Stage Liver Disease (MELD) score.\",\n",
       "     'offsetInBeginSection': 380,\n",
       "     'offsetInEndSection': 709,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36411535',\n",
       "     'text': 'BACKGROUND\\nAlbumin-bilirubin (ALBI) grade is an index of liver function based on total bilirubin (T-BIL) and albumin levels, and its usefulness has been widely reported.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33442542',\n",
       "     'text': 'Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation.',\n",
       "     'offsetInBeginSection': 151,\n",
       "     'offsetInEndSection': 299,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31048923',\n",
       "     'text': 'The PALBI grade had a larger area under the receiver operator characteristic curve (AUC) than did the CTP class, MELD score, and ALBI grade (overall AUC: 0.675 vs. 0.633, 0.645, and 0.642, respectively; P < 0.001).',\n",
       "     'offsetInBeginSection': 834,\n",
       "     'offsetInEndSection': 1048,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30026834',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30077606',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35812041',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28628718',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32953155',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36411535',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33442542',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31048923']},\n",
       "  {'id': '64240f33690f196b51000049',\n",
       "   'type': 'list',\n",
       "   'body': 'What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19482534',\n",
       "     'text': 'fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a',\n",
       "     'offsetInBeginSection': 52,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31375588',\n",
       "     'text': 'Our recombinant FCoVs are powerful tools for increasing our understanding of the viral life cycle and pathogenesis of FIP-inducing type I FCoV.IMPORTANCE Feline coronavirus (FCoV) is one of the most significant coronaviruses, because this virus induces feline infectious peritonitis (FIP), which is a lethal disease in cats.',\n",
       "     'offsetInBeginSection': 1498,\n",
       "     'offsetInEndSection': 1822,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19058829',\n",
       "     'text': 'The lethal pathology associated with FIP (granulomatous inflammation and T-cell lymphopenia) is thought to be mediated by aberrant modulation of the immune system due to infection of cells such as monocytes and macrophages.',\n",
       "     'offsetInBeginSection': 188,\n",
       "     'offsetInEndSection': 411,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18196725',\n",
       "     'text': 'All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.',\n",
       "     'offsetInBeginSection': 620,\n",
       "     'offsetInEndSection': 736,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8588340',\n",
       "     'text': 'Feline infectious peritonitis (FIP) virus antigen was demonstrated after methanol, ethanol or formalin fixation in paraffin-embedded tissues by means of monoclonal and polyclonal antibodies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 190,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33644160',\n",
       "     'text': 'For the treatment of FIP, several effective antivirals were recently reported, but many of these are not available for practical use.',\n",
       "     'offsetInBeginSection': 142,\n",
       "     'offsetInEndSection': 275,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11033870',\n",
       "     'text': 'Treatment of ocular FIP is symptomatic, and the mainstay of palliative therapy is topical or systemic corticosteroids or both.',\n",
       "     'offsetInBeginSection': 535,\n",
       "     'offsetInEndSection': 661,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36015002',\n",
       "     'text': 'An ineffective immune response is an important component of FIP pathophysiology; hence treatment with an immune stimulant such as Polyprenyl Immunostimulant™ (PI), which enhances cell-mediated immunity by upregulating the innate immune response via Toll-like receptors, is a rational approach.',\n",
       "     'offsetInBeginSection': 107,\n",
       "     'offsetInEndSection': 400,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32441826',\n",
       "     'text': 'cranial and caudal segment disease with ocular imaging. Treatment with GS-441524 shows clinical efficacy and may result in clearance and long-term res',\n",
       "     'offsetInBeginSection': 1459,\n",
       "     'offsetInEndSection': 1609,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36297266',\n",
       "     'text': 'Feline infectious peritonitis (FIP) is a complex and historically fatal disease, though recent advances in antiviral therapy have uncovered potential treatments.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 161,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/19482534',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31375588',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19058829',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18196725',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8588340',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33644160',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11033870',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36015002',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32441826',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36297266']},\n",
       "  {'id': '6428da98690f196b51000053',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35412847',\n",
       "     'text': 'Differential diagnosis of COVID-19 and/or influenza (flu) at point of care is critical for efficient patient management and treatment of both these diseases.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 157,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34111501',\n",
       "     'text': 'Although COVID-19 is often compared to other respiratory viral illnesses, few formal comparisons of these viruses on kidney health exist.',\n",
       "     'offsetInBeginSection': 169,\n",
       "     'offsetInEndSection': 306,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "     'text': 'Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking.',\n",
       "     'offsetInBeginSection': 214,\n",
       "     'offsetInEndSection': 404,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32856744',\n",
       "     'text': 'As coronavirus disease 2019 (COVID-19) crashed into the influenza season, clinical characteristics of both infectious diseases were compared to make a difference.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 162,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32561409',\n",
       "     'text': 'l descriptions about influenza-like illnesses (ILI) in COVID-19 seem non-specific. We aimed to compare the clinical features of COVID-19 and influenza',\n",
       "     'offsetInBeginSection': 7,\n",
       "     'offsetInEndSection': 157,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33615750',\n",
       "     'text': 'However, as the treatments and prognoses of COVID-19 and influenza are different, it is important to accurately differentiate these two different respiratory tract infections on the basis of their respective early-stage characteristics.',\n",
       "     'offsetInBeginSection': 247,\n",
       "     'offsetInEndSection': 483,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34900356',\n",
       "     'text': 'However, unlike other viral respiratory tract infections such as influenza, bacterial coinfection in COVID-19 patients has uncommonly been described in adult and pediatric patients.',\n",
       "     'offsetInBeginSection': 316,\n",
       "     'offsetInEndSection': 497,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34016619',\n",
       "     'text': 'BACKGROUND\\nInfluenza epidemics were initially considered to be a suitable model for the COVID-19 epidemic, but there is a lack of data concerning patients with chronic respiratory diseases (CRDs), who were supposed to be at risk of severe forms of COVID-19.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 257,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33038391',\n",
       "     'text': 'Future work is needed to validate this histopathologic finding and, if confirmed, elucidate the mechanistic underpinnings and characterize any associations with clinically important outcomes.',\n",
       "     'offsetInBeginSection': 1661,\n",
       "     'offsetInEndSection': 1852,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "     'text': 'These findings highlight the higher risk for most complications associated with COVID-19 compared with influenza and might aid clinicians and researchers in recognizing, monitoring, and managing the spectrum of COVID-19 manifestations.',\n",
       "     'offsetInBeginSection': 2499,\n",
       "     'offsetInEndSection': 2734,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35412847',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34111501',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32856744',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32561409',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33615750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34900356',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34016619',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33038391',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33090987']},\n",
       "  {'id': '6415c8f1690f196b51000017',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33502252',\n",
       "     'text': 'd 3-weekly docetaxel regimens as neoadjuvant systemic therapy (NST) for breast cancer. Materials & methods: Patients (n\\xa0=\\xa0201) received NST comprising',\n",
       "     'offsetInBeginSection': 97,\n",
       "     'offsetInEndSection': 247,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11552225',\n",
       "     'text': 'While both paclitaxel and docetaxel may be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin (but not of docetaxel and doxorubicin) warrants that certain restrictions be followed for safe use.',\n",
       "     'offsetInBeginSection': 1324,\n",
       "     'offsetInEndSection': 1611,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11129728',\n",
       "     'text': 'The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 152,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8629034',\n",
       "     'text': 'pirubicin 60 mg/m2 can be administered safely to patients with metastatic breast cancer. Although response was not the primary end point of this trial',\n",
       "     'offsetInBeginSection': 1907,\n",
       "     'offsetInEndSection': 2057,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10403474',\n",
       "     'text': 'Given the single-agent activity of docetaxel and doxorubicin in metastatic breast cancer and their potential non-cross-resistance, several phase I/II pilot studies of either docetaxel/doxorubicin (TA) or TA plus cyclophosphamide (TAC) were conducted.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 250,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11970750',\n",
       "     'text': 'The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 247,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17028669',\n",
       "     'text': 'Two taxanes, paclitaxel and docetaxel, are among the most widely used chemotherapeutic agents in solid tumor oncology, with efficacy against tumors of the breast, lung, head and neck, ovary, prostate, stomach and urothelium.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 224,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15039596',\n",
       "     'text': 'Less than half of breast cancer patients respond to second-line chemotherapy with paclitaxel after failing treatment with anthracyclines such as doxorubicin.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 157,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17296814',\n",
       "     'text': 'These initiatives, including prospective trials and retrospective examinations of large clinical experience, have involved agents previously approved by the FDA for use in ovarian cancer (e.g., cisplatin, paclitaxel, topotecan, and liposomal doxorubicin) and the development of new strategies for drugs approved for other malignant conditions (e.g., gemcitabine, docetaxel, etoposide, irinotecan, vinorelbine, and bevacizumab).',\n",
       "     'offsetInBeginSection': 314,\n",
       "     'offsetInEndSection': 741,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11552226',\n",
       "     'text': 'Investigation of the combination of the taxanes with doxorubicin in the treatment of breast cancer has logically progressed, with the ultimate goal of identifying a safe and effective regimen for use in the adjuvant setting.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 224,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33502252',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11552225',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11129728',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8629034',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10403474',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11970750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17028669',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15039596',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17296814',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11552226']},\n",
       "  {'id': '63eeec79f36125a426000006',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Talquetamab was developed for treatment of which disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11449698',\n",
       "     'text': 'cepted as a standard chemotherapy (SC) for initial treatment of pulmonary tuberculosis in Japan. We studied the frequency of the treatment completion,',\n",
       "     'offsetInBeginSection': 81,\n",
       "     'offsetInEndSection': 231,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "     'text': 'CASE REPORT\\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.',\n",
       "     'offsetInBeginSection': 451,\n",
       "     'offsetInEndSection': 715,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "     'text': 'CASE REPORT\\nWe present the case of a 77-year-old male who received T cell redirecting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a second dose of talquetamab.',\n",
       "     'offsetInBeginSection': 451,\n",
       "     'offsetInEndSection': 715,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26193648',\n",
       "     'text': 'It was indicated that danaparoid sodium was an anticoagulant unlikely to cause adverse effects such as hemorrhage and might be an effective drug for treatment of portal venous thrombosis.',\n",
       "     'offsetInBeginSection': 887,\n",
       "     'offsetInEndSection': 1074,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "     'text': 'Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 263,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12772593',\n",
       "     'text': 'In this case report, the frequency of PSVT was significantly decreased and subjective symptoms of arrhythmia were eliminated after the administration of tofisopam.',\n",
       "     'offsetInBeginSection': 460,\n",
       "     'offsetInEndSection': 623,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36462062',\n",
       "     'text': 'From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of immunomodulatory agents (IMiDs) in the 1990s, proteasome inhibitors in the 2000s, monoclonal antibodies in the 2010s, and CAR-T treatments in the 2020s.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 295,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36462062',\n",
       "     'text': 'In this focused review, we discuss the novel Food & Drug Administration (FDA)-approved medications for R/R MM, including the recently approved first-in-class BCMA-directed bispecific antibody teclistamab.',\n",
       "     'offsetInBeginSection': 533,\n",
       "     'offsetInEndSection': 737,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15866475',\n",
       "     'text': 'There have been many encouraging studies on medical treatment of pulmonary hydatid disease due to Echinococcus granulosus infection.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 132,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/11449698',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26193648',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12772593',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36462062',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36462062',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15866475']},\n",
       "  {'id': '642321a5690f196b51000047',\n",
       "   'type': 'summary',\n",
       "   'body': 'Please summarize Feline Spongiform Encephalopathy(FSE',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6428d7da690f196b51000050',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can untranslated regions (UTRs) regulate gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21093468',\n",
       "     'text': \" (mRNA) 3' untranslated regions (UTRs) where they prevent translation or cause degradation of the message. Steroid hormone receptors (SHRs) are ligand\",\n",
       "     'offsetInBeginSection': 196,\n",
       "     'offsetInEndSection': 346,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15489276',\n",
       "     'text': \"To determine if RbcS mRNA untranslated regions (UTRs) in themselves could confer any characteristic C4 expression patterns, 5'- and 3'-UTRs of AhRbcS1 mRNA from the C4 dicot amaranth were linked to a gusA reporter gene.\",\n",
       "     'offsetInBeginSection': 97,\n",
       "     'offsetInEndSection': 316,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30297778',\n",
       "     'text': \"MicroRNAs (miRNAs) are well known to target 3' untranslated regions (3' UTRs) in mRNAs, thereby silencing gene expression at the post-transcriptional level.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 156,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19827082',\n",
       "     'text': \"These include alterations in the expression of canonical initiation factors, mutations in regulatory mRNA sequence elements in 5' and 3' untranslated regions (UTRs), such as upstream open reading frames (uORFs), internal ribosome entry segments (IRESs) and micro-RNA (miR) target sites, and the altered expression of trans-acting protein factors that bind to and regulate these elements.\",\n",
       "     'offsetInBeginSection': 431,\n",
       "     'offsetInEndSection': 818,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25999316',\n",
       "     'text': 'nslated regions (UTRs) of specific messenger RNAs (mRNAs) are known to control expression. The importance of unstructured regions adopting multiple co',\n",
       "     'offsetInBeginSection': 168,\n",
       "     'offsetInEndSection': 318,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20563548',\n",
       "     'text': \"5' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 101,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21912852',\n",
       "     'text': \"3' untranslated regions (UTRs) are important sequence elements that modulate the expression of genes.\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 101,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10977083',\n",
       "     'text': 'Untranslated regions (UTR) play important roles in the posttranscriptional regulation of mRNA processing.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 105,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8813126',\n",
       "     'text': \"The 3' untranslated regions (3' UTRs) of R1 and R2 messages contain sequences that are important in regulating gene expression through changes in message stability.\",\n",
       "     'offsetInBeginSection': 183,\n",
       "     'offsetInEndSection': 347,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21445367',\n",
       "     'text': \"miRNAs regulate target genes by binding to 3' untranslated regions (3'UTRs) of target mRNAs, and multiple binding sites for the same miRNA in 3'UTRs can strongly enhance the degree of regulation.\",\n",
       "     'offsetInBeginSection': 273,\n",
       "     'offsetInEndSection': 468,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21093468',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15489276',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30297778',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19827082',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25999316',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20563548',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21912852',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10977083',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8813126',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21445367']},\n",
       "  {'id': '63f9cbb433942b094c00000c',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is alternative splicing associated with heart disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30468920',\n",
       "     'text': 'assembly of the contractile apparatus. Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing va',\n",
       "     'offsetInBeginSection': 753,\n",
       "     'offsetInEndSection': 903,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15652472',\n",
       "     'text': '(2005) demonstrate that a heart-specific knockout of one SR protein, ASF/SF2, produces cardiomyopathy and misregulation of specific alternative splicing events during early postnatal development.',\n",
       "     'offsetInBeginSection': 170,\n",
       "     'offsetInEndSection': 365,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32276354',\n",
       "     'text': 'In this review, we summarize the updated knowledge relative to RBM20 and PTBP1 structure and molecular function; their role in alternative splicing mechanisms involved in the heart development and function; RBM20 mutations associated with idiopathic dilated cardiovascular disease (DCM); and the consequences of RBM20-altered expression or dysfunction.',\n",
       "     'offsetInBeginSection': 904,\n",
       "     'offsetInEndSection': 1256,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "     'text': 'Several genes that have splicing regulated by GATA4 have functional consequences and many are associated with dilated cardiomyopathy, suggesting a novel role for GATA4 in achieving the necessary cardiac proteome in normal and stress-responsive conditions.',\n",
       "     'offsetInBeginSection': 2062,\n",
       "     'offsetInEndSection': 2317,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33497365',\n",
       "     'text': 'Transcriptome analysis revealed gene expression and alternative splicing changes in ion transport genes that are associated with inherited cardiac conduction diseases, including a subset of genes involved in calcium handling.',\n",
       "     'offsetInBeginSection': 905,\n",
       "     'offsetInEndSection': 1130,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34573439',\n",
       "     'text': 'The aim of this review is to provide a brief insight into some of the available findings on the role of alternative splicing in cardiovascular disease, with a focus on atherosclerosis, myocardial infarction, heart failure, dilated cardiomyopathy and circular RNAs in myocardial infarction.',\n",
       "     'offsetInBeginSection': 1066,\n",
       "     'offsetInEndSection': 1355,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33425250',\n",
       "     'text': 'In this mini-review, we aim to illustrate I) mechanisms and regulation of alternative splicing, II) alternative splicing associated human disease, III) computational tools for the quantification of isoforms and alternative splicing from RNA-seq.',\n",
       "     'offsetInBeginSection': 928,\n",
       "     'offsetInEndSection': 1173,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28044974',\n",
       "     'text': 'In those cases, alternative splicing events may serve as disease-associated markers, or even as targets for corrective approaches.',\n",
       "     'offsetInBeginSection': 786,\n",
       "     'offsetInEndSection': 916,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33497365',\n",
       "     'text': 'Transcriptome analysis revealed gene expression and alternative splicing changes in ion transport genes that are associated with inherited cardiac conduction diseases, including a subset of genes involved in calcium handling.',\n",
       "     'offsetInBeginSection': 905,\n",
       "     'offsetInEndSection': 1130,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29186814',\n",
       "     'text': 'Alteration of Cav1.2 channel function has been implicated in multiple cardiovascular diseases, such as hypertension and cardiac hypertrophy.',\n",
       "     'offsetInBeginSection': 128,\n",
       "     'offsetInEndSection': 268,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30468920',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15652472',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32276354',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33497365',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34573439',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33425250',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28044974',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33497365',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29186814']},\n",
       "  {'id': '61fa941ec9dfcb9c09000005',\n",
       "   'type': 'yesno',\n",
       "   'body': \"Should Intepirdine be used for Alzheimer's disease?\",\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6422e2f1690f196b51000043',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34146170',\n",
       "     'text': 'Most of these molecules contain N-acetylgalactosamine (GalNAc) moieties that have high specificity for hepatocytes and therefore reduce concentration in other tissues.',\n",
       "     'offsetInBeginSection': 662,\n",
       "     'offsetInEndSection': 829,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30345352',\n",
       "     'text': ' peptide-1 receptor (GLP1R) can productively deliver ASO cargo to pancreatic β-cells both in vitro and in vivo. Ligand-conjugated ASOs silenced target',\n",
       "     'offsetInBeginSection': 461,\n",
       "     'offsetInEndSection': 611,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26546271',\n",
       "     'text': 'PA:LFn-GAL4:ASO transfection of non- or terminally-differentiated THP-1 cells and Vero cells resulted in 35.2 ± 19.1%, 36.4 ± 1.8% and 22.9 ± 6.9% (respectively) Synt5 expression after treatment with 200 pmol of ASO and demonstrated versatility.',\n",
       "     'offsetInBeginSection': 2003,\n",
       "     'offsetInEndSection': 2248,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29273501',\n",
       "     'text': 'We previously developed conjugated small interfering RNA (siRNA) sequences that selectively target serotonin (5-HT) or norepinephrine (NE) neurons after intranasal administration.',\n",
       "     'offsetInBeginSection': 371,\n",
       "     'offsetInEndSection': 550,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24992960',\n",
       "     'text': 'GalNAc conjugation also enhanced potency and duration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.',\n",
       "     'offsetInBeginSection': 940,\n",
       "     'offsetInEndSection': 1106,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26855051',\n",
       "     'text': 'Although a linker bearing a disulfide bond accumulated mainly in NPCs, hexamethylene succinimide linker accumulated mainly in hepatocytes.',\n",
       "     'offsetInBeginSection': 806,\n",
       "     'offsetInEndSection': 944,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21461383',\n",
       "     'text': 'To test the hypothesis, antisense oligonucleotides (ASO) or small interfering RNA (siRNA) targeted to JNK1 mRNA were incorporated or complexed with neutral or cationic liposomes, respectively, and administered systemically to mice prior to hypoxia exposure.',\n",
       "     'offsetInBeginSection': 317,\n",
       "     'offsetInEndSection': 574,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35623403',\n",
       "     'text': 'The β-galactopyranoside-conjugated liposomes (GAL-liposome) targeting liver synthesized hepcidin were prepared by thin lipid film hydration method to encapsulate siRNA and the conjugation of β-galactopyranoside to the lipid nanocarrier was achieved by covalent chemistry.',\n",
       "     'offsetInBeginSection': 256,\n",
       "     'offsetInEndSection': 527,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34146170',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30345352',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26546271',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29273501',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24992960',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26855051',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21461383',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35623403']},\n",
       "  {'id': '64299fa957b1c7a315000002',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is rebound COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36324801',\n",
       "     'text': 'Previous studies suggest that monoclonal antibodies are an effective outpatient treatment option for patients at high-risk of severe COVID-19, including those with systemic autoimmune rheumatic diseases (SARDs).Nirmatrelvir/ritonavir and molnupiravir are recently-authorized effective oral outpatient SARS-CoV-2 treatment options, but clinical trials were performed among the general population, mostly among unvaccinated and prior to Omicron viral variants.Oral outpatient SARS-CoV-2 treatments may result in COVID-19 rebound, characterized by newly-positive COVID-19 testing and recurrent symptoms, but no studies have investigated rebound prevalence among SARD patients.',\n",
       "     'offsetInBeginSection': 1973,\n",
       "     'offsetInEndSection': 2646,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35581387',\n",
       "     'text': 'The coronavirus disease 2019 (COVID-19) has been a global pandemic for more than 2 years and it still impacts our daily lifestyle and quality in unprecedented ways.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 164,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36181334',\n",
       "     'text': ' infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound ',\n",
       "     'offsetInBeginSection': 72,\n",
       "     'offsetInEndSection': 222,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36423925',\n",
       "     'text': 'ith decreased face covering use, increased social mixing and a rebound in ARI and asthma exacerbations. Associations between incident ARI and risk of ',\n",
       "     'offsetInBeginSection': 1536,\n",
       "     'offsetInEndSection': 1686,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36324801',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35581387',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36181334',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36423925']},\n",
       "  {'id': '6432fb1957b1c7a31500001e',\n",
       "   'type': 'list',\n",
       "   'body': 'What clinical applications is Zanubrutinib approved for in the United States?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35303070',\n",
       "     'text': 'Zanubrutinib, a highly selective BTK inhibitor, is approved for patients with MCL who have received ≥1 prior therapy.',\n",
       "     'offsetInBeginSection': 125,\n",
       "     'offsetInEndSection': 242,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "     'text': 'ial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutinib to ibrutinib in patients ',\n",
       "     'offsetInBeginSection': 1223,\n",
       "     'offsetInEndSection': 1373,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306909',\n",
       "     'text': \"BTK) approved for the treatment of Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linke\",\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "     'text': 'Zanubrutinib, a second-generation BTK inhibitor, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for r/r MCL on the basis of combined overall response rate of 84% in a total of 118 patients from two multicenter clinical trials, BGB-3111-AU-003 and BGB-3111-206.',\n",
       "     'offsetInBeginSection': 263,\n",
       "     'offsetInEndSection': 549,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenström macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy.',\n",
       "     'offsetInBeginSection': 543,\n",
       "     'offsetInEndSection': 890,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "     'text': 'Even though zanubrutinib has been the third and last BTK inhibitor to currently penetrate the market for B-cell lymphoproliferative malignancies, we highlight the emergence of zanubrutinib as a key player in the forefront of the therapeutic landscape in WM.',\n",
       "     'offsetInBeginSection': 1833,\n",
       "     'offsetInEndSection': 2090,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35957865',\n",
       "     'text': 'rosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects aft',\n",
       "     'offsetInBeginSection': 56,\n",
       "     'offsetInEndSection': 206,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy.',\n",
       "     'offsetInBeginSection': 3210,\n",
       "     'offsetInEndSection': 3439,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'Results of clinical studies on zanubrutinib treatment appear promising in patients with several types of B-cell malignancies, including mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia, and small lymphocytic lymphoma.',\n",
       "     'offsetInBeginSection': 2590,\n",
       "     'offsetInEndSection': 2881,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32753893',\n",
       "     'text': 'In addition to ibrutinib and acalabrutinib, the FDA recently approved zanubrutinib for the treatment of patients with relapsed/refractory MCL based on the results of two Phase 2 clinical trials showing overall response rates of 85-87% with complete responses in 30-77% of patients.',\n",
       "     'offsetInBeginSection': 414,\n",
       "     'offsetInEndSection': 695,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35303070',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35306909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35957865',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32753893']},\n",
       "  {'id': '61f7cb37882a024a10000029',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is rilonacept effective for pericarditis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36250662',\n",
       "     'text': 'RHAPSODY (rilonacept inhibition of interleukin-1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL-1α and -β cytokine trap) in recurrent pericarditis.',\n",
       "     'offsetInBeginSection': 143,\n",
       "     'offsetInEndSection': 383,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35874710',\n",
       "     'text': 'Rilonacept was efficacious and safe for the treatment of CAPS, FMF, recurrent pericarditis, and sJIA.',\n",
       "     'offsetInBeginSection': 1842,\n",
       "     'offsetInEndSection': 1943,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31895031',\n",
       "     'text': 'cades or more to become constrictive pericarditis. Pericardiectomy is an effective treatment method. Here, we report 2 cases of radiation pericarditis',\n",
       "     'offsetInBeginSection': 210,\n",
       "     'offsetInEndSection': 360,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36398320',\n",
       "     'text': 'It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II and III trials.',\n",
       "     'offsetInBeginSection': 780,\n",
       "     'offsetInEndSection': 884,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23754188',\n",
       "     'text': 'Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.',\n",
       "     'offsetInBeginSection': 2062,\n",
       "     'offsetInEndSection': 2162,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35350578',\n",
       "     'text': 'In the era of tailored medicine, anti-IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflammatory phenotype.',\n",
       "     'offsetInBeginSection': 2149,\n",
       "     'offsetInEndSection': 2353,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32324502',\n",
       "     'text': 'Rilonacept, a soluble IL-1 receptor chimeric fusion protein neutralizing IL-1α and IL-1β, has also shown promising results in a phase II study in recurrent/refractory pericarditis.',\n",
       "     'offsetInBeginSection': 1590,\n",
       "     'offsetInEndSection': 1770,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33618510',\n",
       "     'text': 'Interleukin-1 inhibitors, such as anakinra and rilonacept, significantly reduce the risk of recurrences in patients with RP while on treatment.',\n",
       "     'offsetInBeginSection': 1132,\n",
       "     'offsetInEndSection': 1275,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459270',\n",
       "     'text': 'In the Phase III trial, rilonacept was associated with a lower risk of recurrence, more persistent clinical response, and higher amount of days with no or minimal pericarditis symptoms, compared with placebo.',\n",
       "     'offsetInBeginSection': 589,\n",
       "     'offsetInEndSection': 797,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18668591',\n",
       "     'text': 'All patients received an initial loading dose of 300 mg of rilonacept by subcutaneous injection, were evaluated 6 and 10 days later for clinical efficacy, and remained off treatment until a clinical flare occurred.',\n",
       "     'offsetInBeginSection': 478,\n",
       "     'offsetInEndSection': 692,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36250662',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35874710',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31895031',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36398320',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23754188',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35350578',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32324502',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33618510',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34459270',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18668591']},\n",
       "  {'id': '6413712a201352f04a00003e',\n",
       "   'type': 'list',\n",
       "   'body': 'The 1p19q co-deletion is associated with what types of tumors?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25277207',\n",
       "     'text': 'The majority of oligodendrogliomas (ODGs) exhibit combined losses of chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H or IDH2-R172K).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 161,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33482430',\n",
       "     'text': 'In the WHO glioma classification guidelines grade (glioblastoma versus lower-grade glioma), IDH mutation and 1p/19q co-deletion status play a central role as they are important markers for prognosis and optimal therapy planning.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "     'text': 'Combined immunohistochemical analysis assessed by INA expression and/or the lack of CIC expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q state.',\n",
       "     'offsetInBeginSection': 871,\n",
       "     'offsetInEndSection': 1110,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18416660',\n",
       "     'text': 'ion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular. A further likely prognostic bi',\n",
       "     'offsetInBeginSection': 513,\n",
       "     'offsetInEndSection': 663,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23344797',\n",
       "     'text': 'However, there are still unanswered questions regarding whether upfront chemotherapy, omitting/deferring radiotherapy, in the desire to avoid late neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with a better toxicity profile, can be substituted for procarbazine, lomustine, and vincristine (PCV).',\n",
       "     'offsetInBeginSection': 1292,\n",
       "     'offsetInEndSection': 1686,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29027701',\n",
       "     'text': 'Most tumors have a missense mutation for IDH1 combined with 1p19q codeletion in oligodendrogliomas or ATRX/TP53 mutations in astrocytomas.',\n",
       "     'offsetInBeginSection': 128,\n",
       "     'offsetInEndSection': 266,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25674227',\n",
       "     'text': 'espectively. The latter encompassed all but one of the cases of oligodendroglial tumors. Patients with IDLGGs had longer overall survival than those w',\n",
       "     'offsetInBeginSection': 1595,\n",
       "     'offsetInEndSection': 1745,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18565359',\n",
       "     'text': 'uation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a bette',\n",
       "     'offsetInBeginSection': 1462,\n",
       "     'offsetInEndSection': 1612,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20711790',\n",
       "     'text': 'In addition, inner table thinning was noted directly adjacent to seven tumors with intact 1p and 19q alleles and in no tumors with the 1p/19q co-deletion (p\\u2009=\\u20090.020).',\n",
       "     'offsetInBeginSection': 1298,\n",
       "     'offsetInEndSection': 1464,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27401154',\n",
       "     'text': 'The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 175,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/25277207',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33482430',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18416660',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23344797',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29027701',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25674227',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18565359',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20711790',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27401154']},\n",
       "  {'id': '6429ad3857b1c7a315000003',\n",
       "   'type': 'factoid',\n",
       "   'body': 'The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7536936',\n",
       "     'text': 'We report that a region of the mouse X chromosome lying 15 kb distal to Xist contains several sites that show hypermethylation specifically associated with the active X chromosome.',\n",
       "     'offsetInBeginSection': 524,\n",
       "     'offsetInEndSection': 704,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26477563',\n",
       "     'text': 'Thus, the Xist gene carries within its coding sequence an antisense RNA that drives Xist expression.',\n",
       "     'offsetInBeginSection': 813,\n",
       "     'offsetInEndSection': 913,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/7536936',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26477563']},\n",
       "  {'id': '63f92fd033942b094c00000b',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are microexons?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508',\n",
       "     'text': 'The splicing of microexons (very small exons) is frequently dysregulated in the brain of individuals with autism spectrum disorder.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 131,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155820',\n",
       "     'text': 'Microexons are small sized (≤51\\u2009bp) exons which undergo extensive alternative splicing in neurons, microglia, embryonic stem cells, and cancer cells, giving rise to cell type specific protein isoforms.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35895262',\n",
       "     'text': 'However, the analysis of RNAs-seq data for detection and quantification of microexons, extremely short exons of length up to 30\\xa0nt, require specialized computational workflows.',\n",
       "     'offsetInBeginSection': 196,\n",
       "     'offsetInEndSection': 372,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31559909',\n",
       "     'text': 'Neuronal microexons represent the most highly conserved class of alternative splicing events and their timed expression shapes neuronal biology, including neuronal commitment and differentiation.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 195,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34836511',\n",
       "     'text': 'BACKGROUND\\nMicroexons are a particular kind of exon of less than 30 nucleotides in length.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 90,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33378678',\n",
       "     'text': 'Overall, our findings identify QKI as an alternative splicing regulator governing a network of Rho GTPase microexons with implications for CNS remyelination and MS patients.',\n",
       "     'offsetInBeginSection': 936,\n",
       "     'offsetInEndSection': 1109,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "     'text': 'Microexons (≤27 nt) play critical roles in nervous system development and function but create unique challenges for the splicing machinery.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 139,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27502555',\n",
       "     'text': 'We discover a conserved AS program comprising hundreds of alternative exons, microexons and introns that is differentially regulated in planarian stem cells, and comprehensively identify its regulators.',\n",
       "     'offsetInBeginSection': 396,\n",
       "     'offsetInEndSection': 598,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30388412',\n",
       "     'text': 'Here, we describe a CRISPR-based strategy for the genome-wide elucidation of pathways that control splicing and apply it to microexons with important functions in nervous system development and that are commonly misregulated in autism.',\n",
       "     'offsetInBeginSection': 190,\n",
       "     'offsetInEndSection': 425,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31999954',\n",
       "     'text': 'Microexons represent the most highly conserved class of alternative splicing, yet their functions are poorly understood.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 120,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34346508',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34155820',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35895262',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31559909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34836511',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33378678',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27502555',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30388412',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31999954']},\n",
       "  {'id': '64041f38201352f04a00001f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is tebentafusp effective for uveal melanoma?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35115315',\n",
       "     'text': 'Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29180934',\n",
       "     'text': 'Systemic chemotherapy and chemoimmunotherapy regimens extrapolated from cutaneous melanoma are considered to be ineffective in therapy of metastases from uveal melanoma.',\n",
       "     'offsetInBeginSection': 122,\n",
       "     'offsetInEndSection': 291,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10661768',\n",
       "     'text': 'Systemic chemotherapy that is effective in cutaneous melanoma has failed to show activity in uveal melanoma.',\n",
       "     'offsetInBeginSection': 739,\n",
       "     'offsetInEndSection': 847,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27183438',\n",
       "     'text': 'n primary malignant intraocular tumor in adults and still lacks effective systemic therapies. Annexin A2 receptor (AXIIR), a receptor for Annexin II, ',\n",
       "     'offsetInBeginSection': 32,\n",
       "     'offsetInEndSection': 182,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22453016',\n",
       "     'text': 'Nearly half of primary uveal melanoma tumors metastasize, but there are currently no effective therapies for metastatic uveal melanoma.',\n",
       "     'offsetInBeginSection': 72,\n",
       "     'offsetInEndSection': 207,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21083380',\n",
       "     'text': 'Constitutive activation of the pathway involving these two genes appears to be a major contributor to the development of uveal melanoma.',\n",
       "     'offsetInBeginSection': 1375,\n",
       "     'offsetInEndSection': 1511,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32816891',\n",
       "     'text': 'RESULTS\\nTebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma.',\n",
       "     'offsetInBeginSection': 705,\n",
       "     'offsetInEndSection': 861,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34754859',\n",
       "     'text': 'Nearly half of all primary uveal melanoma tumors metastasize; yet, there are currently no effective treatments for metastatic uveal melanoma.',\n",
       "     'offsetInBeginSection': 111,\n",
       "     'offsetInEndSection': 252,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1589858',\n",
       "     'text': 'However, several new approaches involving interferons and interleukin and combination chemotherapy have shown some activity against metastatic cutaneous melanoma.',\n",
       "     'offsetInBeginSection': 306,\n",
       "     'offsetInEndSection': 468,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11725206',\n",
       "     'text': 'ytotoxic agents. The combination of treosulfan + gemcitabine was universally effective, with 72% of cutaneous melanomas and 80% of uveal melanomas exh',\n",
       "     'offsetInBeginSection': 1582,\n",
       "     'offsetInEndSection': 1732,\n",
       "     'beginSection': ['abstract'],\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35115315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29180934',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10661768',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27183438',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22453016',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21083380',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32816891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34754859',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1589858',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11725206']},\n",
       "  {'id': '6426bb49690f196b5100004d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the Fenton reaction',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26690045',\n",
       "     'text': 'The feasibility of titanium dioxide (TiO2) photocatalysis, electrochemically assisted Fenton reaction (EC-Fenton) and direct electrochemical oxidation (EC) for simulation of phase I metabolism of drugs was studied by comparing the reaction products of buspirone, promazine, testosterone and 7-ethoxycoumarin with phase I metabolites of the same compounds produced in vitro by human liver microsomes (HLM).',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 405,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34494817',\n",
       "     'text': 'Ferroptosis therapy (FT) based on the Fenton reaction of ferrous nanoparticles has been becoming a unique strategy for cancer treatment; however, current ferrous nanoparticles suffer from slower Fenton reaction kinetics, lower ferroptosis efficacy, and long-term toxicity, so it is urgent to construct biocompatible ferrous nanomaterials with highly efficient Fenton reaction activity for cancer FT.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 399,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34138182',\n",
       "     'text': 'In spite of the tumor microenvironments responsive cancer therapy based on Fenton reaction (i.e., chemodynamic therapy, CDT) has been attracted more attentions in recent years, the limited Fenton reaction efficiency is the important obstacle to further application in clinic.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 275,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32596808',\n",
       "     'text': 'Fenton reaction-mediated oncotherapy is an emerging strategy which uses iron ions to catalytically convert endogenous hydrogen peroxide into hydroxyl radicals, the most reactive oxygen species found in biology, for efficient cancer therapy.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 240,\n",
       "     'beginSection': 'abstract',\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26690045',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34494817',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34138182',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32596808']}]}"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_batch_json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "400073da",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "59a3dfd9",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a2c5374e",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "501a8419",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  0%|                                                                                                                    | 0/75 [00:00<?, ?it/s]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "58d37f88e76e4dcf9201cf8849c32311",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  1%|█▍                                                                                                          | 1/75 [00:06<07:39,  6.20s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "DESTINY-Breast04 trial results Trastuzumab deruxtecan efficacy in breast cancer Phase III study of trastuzumab deruxtecan in HER2-positive breast cancer Clinical trial of trastuzumab deruxtecan in breast cancer DESTINY-Breast04 trial design and outcomes HER2-targeted therapy in metastatic breast cancer Trastuzumab deruxtecan safety profile in breast cancer Antibody-drug conjugate therapy for breast cancer\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a99e3fa8dcc840ee9d98bdfca3bbfb8c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  3%|██▉                                                                                                         | 2/75 [00:10<06:10,  5.07s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "LOQ vs. LOD Limit of quantification vs. limit of detection Analytical chemistry LOQ and LOD Clinical laboratory LOQ and LOD Biomedical assay sensitivity and specificity LOQ and LOD in medical research\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0a6ecc6d860044499750c631cb9d055b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  4%|████▎                                                                                                       | 3/75 [00:15<05:48,  4.84s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Function of histone acetylation Role of HATs in gene expression Epigenetic regulation by histone acetylation Histone acetylation and chromatin remodeling Lysine acetylation and protein function Acetylation of non-histone proteins\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8eac95b9104c4b2b83ff4d409a4c65eb",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  5%|█████▊                                                                                                      | 4/75 [00:19<05:33,  4.70s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Gene mutations in hereditary angioedema C1 inhibitor gene mutations in HAE SERPING1 mutations and HAE F12 gene mutations and HAE Angioedema and genetic mutations Hereditary angioedema genetics\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "70d886543e6a4d158e8fa7a696495e2b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  7%|███████▏                                                                                                    | 5/75 [00:23<05:22,  4.60s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Casimersen MOA Antisense oligonucleotides and exon skipping Duchenne muscular dystrophy and casimersen Pharmacokinetics and pharmacodynamics of casimersen Clinical trials of casimersen RNA splicing modulation by casimersen\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "16f2a545e0614bfd9f439a7bad5982b9",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  8%|████████▋                                                                                                   | 6/75 [00:28<05:26,  4.73s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "tiragolumab AND mechanism of action tiragolumab AND PD-1 tiragolumab AND immunotherapy tiragolumab AND cancer tiragolumab AND clinical trials\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a010267426244e86a239ea86be135d46",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  9%|██████████                                                                                                  | 7/75 [00:33<05:27,  4.82s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NMOSD serum biomarkers disease activity aquaporin-4 antibody NMOSD biomarkers glial fibrillary acidic protein NMOSD biomarkers myelin oligodendrocyte glycoprotein NMOSD biomarkers C-reactive protein NMOSD biomarkers\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5b9b5d43f29c42b4b7a965b1efeaa7be",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 11%|███████████▌                                                                                                | 8/75 [00:37<04:56,  4.43s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "COVID-19 thrombosis complications COVID-19 venous thromboembolism COVID-19 arterial thrombosis COVID-19 coagulopathy COVID-19 hypercoagulability\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7d7de229697945318e82797d0903eeac",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 12%|████████████▉                                                                                               | 9/75 [00:41<04:51,  4.41s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cinryze indication Cinryze mechanism of action Cinryze clinical trials Cinryze safety Cinryze efficacy\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "face0928cd914230bc0aa6f57a8bb56a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 13%|██████████████▎                                                                                            | 10/75 [00:46<04:57,  4.58s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Machine learning survival analysis Statistical survival analysis Machine learning vs statistical methods for survival analysis Comparison of machine learning and statistical methods for survival analysis\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c812166adcef4fdd9953f9087fc0adc0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 15%|███████████████▋                                                                                           | 11/75 [00:51<04:44,  4.45s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ZF2001 is used for which disease?\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "41fe4742028241598183b84edd16e13b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 16%|█████████████████                                                                                          | 12/75 [00:54<04:25,  4.22s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Mammal with lowest chromosome number Karyotype of mammals Chromosome number in mammals Animal genome sequencing\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "bddad6273b7141f4aab02ff2ddd82cad",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 17%|██████████████████▌                                                                                        | 13/75 [00:58<04:08,  4.01s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Histone modifications amino acids Histone acetyltransferases targets Histone methyltransferases targets Epigenetic modifications Histone code\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "24428f639eb64e968a2bd02f16e6ad5d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 19%|███████████████████▉                                                                                       | 14/75 [01:02<04:05,  4.02s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Ruconest manufacturer Rhucin manufacturer C1 esterase inhibitor manufacturer Plasma-derived therapies Hereditary angioedema treatment\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5347db6004b3453980962593aaf08376",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 20%|█████████████████████▍                                                                                     | 15/75 [01:06<04:03,  4.06s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Duchenne muscular dystrophy diagnosis age Clinical presentation Duchenne muscular dystrophy Motor milestones Duchenne muscular dystrophy Creatine kinase levels Duchenne muscular dystrophy Genetic testing Duchenne muscular dystrophy\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "987ff915fb6f46a0b0d46e2070e51108",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 21%|██████████████████████▊                                                                                    | 16/75 [01:10<04:04,  4.14s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TONE trial erythropoietin optic neuritis Erythropoietin optic neuritis clinical trial Optic neuritis treatment TONE trial Visual function outcomes erythropoietin optic neuritis Randomized controlled trial erythropoietin optic neuritis\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b76087e905fd4ed8bdf4cb469001a9e3",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 23%|████████████████████████▎                                                                                  | 17/75 [01:15<04:15,  4.41s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hepatotoxicity R value R value liver toxicity correlation R value hepatotoxicity hepatotoxicity Pearson correlation coefficient R squared value liver toxicity\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b859064056ca4162a135e299cdff4bdd",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 24%|█████████████████████████▋                                                                                 | 18/75 [01:21<04:28,  4.72s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "COVID-19 Omicron severity Omicron variant clinical outcomes COVID-19 variant comparison severity Omicron vs other variants disease severity SARS-CoV-2 Omicron severity\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4a4cd51cf7334378984cae7360125083",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 25%|███████████████████████████                                                                                | 19/75 [01:24<04:06,  4.41s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hereditary angioedema overview genetic basis of angioedema clinical presentation of hereditary angioedema treatment of hereditary angioedema pathophysiology of angioedema\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e4d866c2d3d34917942bb7a6c4935dea",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 27%|████████████████████████████▌                                                                              | 20/75 [01:28<03:48,  4.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "viltolarsen mechanism of action how does viltolarsen work viltolarsen pharmacodynamics mode of action of viltolarsen viltolarsen molecular mechanism\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b427d14a2bba47cbbc6d286a928968cc",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 28%|█████████████████████████████▉                                                                             | 21/75 [01:32<03:48,  4.22s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "bexarotene multiple sclerosis bexarotene relapsing-remitting multiple sclerosis efficacy of bexarotene in multiple sclerosis safety of bexarotene in multiple sclerosis bexarotene clinical trials multiple sclerosis\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ff851015b32e494bbbfc29948b0b8b12",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 29%|███████████████████████████████▍                                                                           | 22/75 [01:37<03:42,  4.20s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hepcidin regulation hepcidin function role of hepcidin in iron metabolism hepcidin and erythropoiesis hepcidin and inflammation\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "561ed03ab70741a6a1ceca4ba3035b33",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 31%|████████████████████████████████▊                                                                          | 23/75 [01:41<03:49,  4.40s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "analgesics antipyretics COVID-19 vaccine side effects management of COVID-19 vaccine side effects acetaminophen COVID-19 vaccine ibuprofen COVID-19 vaccine NSAIDs COVID-19 vaccine\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "38d38b7a523d4f42896122647167dd4d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 32%|██████████████████████████████████▏                                                                        | 24/75 [01:47<03:55,  4.63s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "recombinant human C1 inhibitor protein HAE first drug for acute HAE attacks C1INH for HAE treatment rhC1INH for HAE\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "76d9271ce077425a9e8a9e9ffed37214",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 33%|███████████████████████████████████▋                                                                       | 25/75 [01:50<03:41,  4.42s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "viltolarsen AND DMD viltolarsen AND Duchenne muscular dystrophy viltolarsen AND gene therapy viltolarsen AND exon skipping\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "87c798ec4c304e82975db18030128a08",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 35%|█████████████████████████████████████                                                                      | 26/75 [01:53<03:15,  3.99s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cat eye syndrome AND triad Cat eye syndrome AND chromosomal abnormalities Cat eye syndrome AND ocular abnormalities Cat eye syndrome AND preauricular tags Cat eye syndrome AND genetics\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d050768d24b4449d8d5f2cf21e2d9ee5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 36%|██████████████████████████████████████▌                                                                    | 27/75 [01:58<03:24,  4.27s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "OXLUMO AND lumasiran AND primary hyperoxaluria lumasiran AND RNAi AND primary hyperoxaluria lumasiran AND ALNYLAM-117 AND primary hyperoxaluria lumasiran AND clinical trials AND primary hyperoxaluria lumasiran AND mechanism of action AND primary hyperoxaluria\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7755f74b13b345f7aabcb30a941fb5f7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 37%|███████████████████████████████████████▉                                                                   | 28/75 [02:04<03:34,  4.57s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "inhaled glucocorticoids AND COVID-19 asthma AND COVID-19 AND glucocorticoids COPD AND COVID-19 AND glucocorticoids COVID-19 AND steroids AND respiratory disease COVID-19 AND corticosteroids AND respiratory disease\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8cd929546c2c46f8958034e50cdf12f9",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 39%|█████████████████████████████████████████▎                                                                 | 29/75 [02:08<03:32,  4.63s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Zanubrutinib AND BTK inhibitor AND FDA first-generation BTK inhibitor AND Zanubrutinib Zanubrutinib AND FDA approval AND BTK inhibitor Zanubrutinib AND clinical trials AND BTK inhibitor Zanubrutinib AND mechanism of action AND BTK inhibitor\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f1375ca630bb4c378cbb808ae390620a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 40%|██████████████████████████████████████████▊                                                                | 30/75 [02:13<03:30,  4.67s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "eteplirsen AND Duchenne muscular dystrophy eteplirsen AND dystrophin eteplirsen AND exon skipping eteplirsen AND clinical trials eteplirsen AND mechanism of action\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7371ccdf04384c7fb645b17f763e0538",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 41%|████████████████████████████████████████████▏                                                              | 31/75 [02:19<03:37,  4.95s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cinpanemab AND Parkinson's Disease Cinpanemab AND clinical trials Cinpanemab AND efficacy Cinpanemab AND safety Cinpanemab AND mechanism of action\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "39f6a1edd7e24a67acbfb668aec6a263",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 43%|█████████████████████████████████████████████▋                                                             | 32/75 [02:23<03:27,  4.82s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Ashwell receptor AND organ Ashwell receptor AND liver Ashwell receptor AND glycoprotein clearance Ashwell receptor AND hepatocytes\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d1534df76eed4fd9bdbfb531e5db6ebe",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 44%|███████████████████████████████████████████████                                                            | 33/75 [02:28<03:16,  4.68s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "enhancers AND chromatin landscape AND histone marks histone marks AND enhancer activity histone modifications AND gene regulation chromatin structure AND enhancers\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b87350ddadc44079ab322047d5f13f21",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 45%|████████████████████████████████████████████████▌                                                          | 34/75 [02:32<03:11,  4.67s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CRISPR/Cas12a AND EGFR mutations AND circulating DNA CRISPR diagnostics AND EGFR mutations CRISPR/Cas12a AND liquid biopsy AND cancer CRISPR/Cas12a AND sensitivity AND specificity\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5471bfe049e34cefa63c7b6fe895281a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 47%|█████████████████████████████████████████████████▉                                                         | 35/75 [02:36<02:55,  4.38s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Casimersen AND DMD Casimersen AND Duchenne muscular dystrophy Casimersen AND exon skipping therapy\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7142dab2a806492cb322e5f1ddc80f6d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 48%|███████████████████████████████████████████████████▎                                                       | 36/75 [02:41<02:52,  4.41s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CIS43LS AND target CIS43LS complement-dependent cytotoxicity CIS43LS acute myeloid leukemia\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8d67857ac9d74b14954364d8b9f85473",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 49%|████████████████████████████████████████████████████▊                                                      | 37/75 [02:46<02:57,  4.68s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cal-light AND function Cal-light fluorescence microscopy Cal-light synaptic transmission Cal-light T-cell activation\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1bdc819780d3405f9b53dcc4715dadca",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 51%|██████████████████████████████████████████████████████▏                                                    | 38/75 [02:50<02:48,  4.56s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "RNA polymerase binding site gene transcription Promoter region RNA polymerase gene transcription Transcription initiation site RNA polymerase RNA polymerase initiation complex gene transcription Transcription factor RNA polymerase binding gene\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "624d2cc96e844936af22d0844e204bd4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 52%|███████████████████████████████████████████████████████▋                                                   | 39/75 [02:54<02:41,  4.49s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PRP-40 microexon splicing Role of PRP-40 in microexon splicing PRP-40 and alternative splicing Microexon splicing and splicing factors PRP-40 and pre-mRNA splicing\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "af11c4d0b34c43bdbd9bd3acdb8ad947",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 53%|█████████████████████████████████████████████████████████                                                  | 40/75 [02:59<02:36,  4.47s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Age of loss of independent ambulation in Duchenne muscular dystrophy Duchenne muscular dystrophy and ambulation loss Mobility loss in Duchenne muscular dystrophy Age at wheelchair dependence in Duchenne muscular dystrophy Duchenne muscular dystrophy and motor function decline\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "523c2ef5c42f41fab51954c77fcaaf5d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 55%|██████████████████████████████████████████████████████████▍                                                | 41/75 [03:03<02:33,  4.52s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Ocrelizumab and primary progressive multiple sclerosis Effectiveness of ocrelizumab in primary progressive multiple sclerosis Clinical trials of ocrelizumab in primary progressive multiple sclerosis Ocrelizumab and disease-modifying therapy for primary progressive multiple sclerosis Ocrelizumab and outcomes in primary progressive multiple sclerosis\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b9af2302f3e1438dab159d36a437e4d5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 56%|███████████████████████████████████████████████████████████▉                                               | 42/75 [03:08<02:26,  4.45s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Indocyanine green (ICG) imaging Clinical applications of indocyanine green (ICG) Indocyanine green (ICG) fluorescence angiography Indocyanine green (ICG) and liver function assessment Indocyanine green (ICG) and lymphatic imaging\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ce49ab4d92ab4bb498b79439cfe6c9e7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 57%|█████████████████████████████████████████████████████████████▎                                             | 43/75 [03:13<02:27,  4.62s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Alternative splicing and gene expression Mechanisms of alternative splicing Splice variants and gene regulation Transcript diversity and gene function Post-transcriptional regulation of gene expression\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c604036d294f4036a94d95ef33d29a96",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 59%|██████████████████████████████████████████████████████████████▊                                            | 44/75 [03:19<02:40,  5.17s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "SRRM4 and tumor growth Silencing SRRM4 and cancer progression SRRM4 knockdown and cancer cell proliferation Role of SRRM4 in cancer Therapeutic potential of SRRM4 inhibition in cancer\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6449d7c20b784d3c8e72205150b09900",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 60%|████████████████████████████████████████████████████████████████▏                                          | 45/75 [03:23<02:27,  4.90s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Life expectancy in Duchenne muscular dystrophy Prognosis in Duchenne muscular dystrophy Survival rates in Duchenne muscular dystrophy Clinical outcomes in Duchenne muscular dystrophy Mortality in Duchenne muscular dystrophy\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "31faf52cf8794eef885326541e723dce",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 61%|█████████████████████████████████████████████████████████████████▋                                         | 46/75 [03:29<02:30,  5.18s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Daridorexant and insomnia Efficacy of daridorexant in treating insomnia Daridorexant clinical trials for insomnia Comparative effectiveness of daridorexant for insomnia Safety and tolerability of daridorexant in insomnia patients\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "99a9271aadfc46ffab4425ecde9083e1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 63%|███████████████████████████████████████████████████████████████████                                        | 47/75 [03:35<02:25,  5.19s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Erythroferrone-producing cells Cellular sources of erythroferrone Erythroferrone expression in different cell types Regulation of erythroferrone production in erythroid cells Erythroferrone and erythropoiesis\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4c7d25df279b42c8b0a744ae2c5da6db",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 64%|████████████████████████████████████████████████████████████████████▍                                      | 48/75 [03:40<02:19,  5.16s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Mediator complex and gene expression Mediator role in transcription Mechanisms of Mediator-mediated gene regulation Mediator function in RNA polymerase II activity Mediator and enhancer-promoter interactions\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "967d7ffc59254309835b45503917871b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 65%|█████████████████████████████████████████████████████████████████████▉                                     | 49/75 [03:43<02:00,  4.63s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Definition of FBDD FBDD acronym meaning FBDD and drug discovery Applications of FBDD in drug development Comparison of FBDD with other drug discovery approaches\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "68be8ca86fcd40c7a45e4a87fc05f304",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 67%|███████████████████████████████████████████████████████████████████████▎                                   | 50/75 [03:48<01:59,  4.79s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Deucravacitinib and psoriasis treatment Efficacy of deucravacitinib in psoriasis patients Clinical trials of deucravacitinib for psoriasis Safety profile of deucravacitinib in psoriasis patients Mechanisms of action of deucravacitinib in psoriasis\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "84ca88f3a8e445638cd5b3aa7cde03f0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 68%|████████████████████████████████████████████████████████████████████████▊                                  | 51/75 [03:53<01:53,  4.71s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Functions of orexin/hypocretin neurons Regulation of sleep-wake cycle by orexin/hypocretin neurons Orexin/hypocretin and feeding behavior Orexin/hypocretin and reward processing Role of orexin/hypocretin in addiction and drug abuse\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0d4a85063c4f4c6894c4666823924b77",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 69%|██████████████████████████████████████████████████████████████████████████▏                                | 52/75 [03:58<01:53,  4.93s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epigenetic modification of introns and gene expression Role of intronic DNA methylation in gene regulation Chromatin structure and intron-mediated gene expression Histone modifications in introns and gene expression\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9b0fd158ef0c4f9d8d1414583fd4a911",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 71%|███████████████████████████████████████████████████████████████████████████▌                               | 53/75 [04:02<01:42,  4.66s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Keytruda FDA approval history Pembrolizumab (Keytruda) indications FDA approved uses of Keytruda\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a04d6cc6563042c2bab6394577a00b22",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 72%|█████████████████████████████████████████████████████████████████████████████                              | 54/75 [04:05<01:27,  4.18s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Achard-Thiers syndrome clinical features Diabetes mellitus with hirsutism and virilism (Achard-Thiers syndrome) Achard-Thiers syndrome symptoms\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0c881251cad64bb1b8da5e32c6bb3ac7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 73%|██████████████████████████████████████████████████████████████████████████████▍                            | 55/75 [04:10<01:26,  4.34s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Luminopsins structure Luminopsins composition Fusion proteins of luminol and Rhodopsin Luminopsins function\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9bbbe5f8d9a143869cc4c9150eb099ec",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 75%|███████████████████████████████████████████████████████████████████████████████▉                           | 56/75 [04:13<01:17,  4.09s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "What are coactivators?\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "210e7666377b480794aaae44a1813bbf",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 76%|█████████████████████████████████████████████████████████████████████████████████▎                         | 57/75 [04:17<01:08,  3.81s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PROTACs definition Mechanism of action of PROTACs Applications of PROTACs Examples of successful PROTACs\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "15f9902965ed4057841963beaf7d2271",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 77%|██████████████████████████████████████████████████████████████████████████████████▋                        | 58/75 [04:22<01:12,  4.29s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ALBI grade components Variables in ALBI score Calculation of ALBI grade Use of ALBI score in liver disease\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "66a1f8c23ebd49de95082132bcca0d8f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 79%|████████████████████████████████████████████████████████████████████████████████████▏                      | 59/75 [04:26<01:07,  4.24s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Feline Infectious Peritonitis treatment drugs FIP therapy options in cats Antiviral therapy for FIP\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "72b0828d5f39478f820e94f577970428",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 80%|█████████████████████████████████████████████████████████████████████████████████████▌                     | 60/75 [04:32<01:11,  4.78s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Differentiating COVID-19 from influenza clinically Clinical features distinguishing COVID-19 from other respiratory illnesses Diagnosis of COVID-19 versus influenza COVID-19 and influenza differential diagnosis Comparing clinical characteristics of COVID-19 and influenza\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a24915381210466baba7642a166347b0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 81%|███████████████████████████████████████████████████████████████████████████████████████                    | 61/75 [04:38<01:09,  4.98s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Paclitaxel and cancer treatment Docetaxel and cancer treatment Doxorubicin and cancer treatment Epirubicin and cancer treatment Chemotherapy drugs and approved cancer indications\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4d7cfa7df44a4c01b456bd3ccf592452",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 83%|████████████████████████████████████████████████████████████████████████████████████████▍                  | 62/75 [04:42<01:01,  4.75s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Talquetamab clinical trials Talquetamab mechanism of action Talquetamab pharmacokinetics Talquetamab safety and efficacy Talquetamab and disease indication\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "563f90e1531946deae1010ea1cd8d2d8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 84%|█████████████████████████████████████████████████████████████████████████████████████████▉                 | 63/75 [04:46<00:53,  4.43s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Feline Spongiform Encephalopathy clinical features Transmission of Feline Spongiform Encephalopathy Feline Spongiform Encephalopathy diagnosis Pathology of Feline Spongiform Encephalopathy Control of Feline Spongiform Encephalopathy\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "30ab5ecc70eb48688e58a09aafd2c1d6",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 85%|███████████████████████████████████████████████████████████████████████████████████████████▎               | 64/75 [04:50<00:49,  4.51s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Untranslated regions and gene expression Role of UTRs in post-transcriptional regulation UTRs and mRNA stability Translation initiation sites and UTRs UTRs and microRNA-mediated gene regulation\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "17c9ae9924cb4a73aadf27f1f2edb52e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 87%|████████████████████████████████████████████████████████████████████████████████████████████▋              | 65/75 [04:55<00:46,  4.68s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Alternative splicing and heart disease Cardiac-specific alternative splicing events Splice variants and cardiac function Alternative splicing in cardiovascular development Dysregulation of alternative splicing in heart disease\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "100a2c91672340bd96e9950e54970347",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 88%|██████████████████████████████████████████████████████████████████████████████████████████████▏            | 66/75 [05:01<00:43,  4.87s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Intepirdine and Alzheimer's disease Efficacy of Intepirdine in Alzheimer's disease Clinical trials of Intepirdine for Alzheimer's disease Mechanism of action of Intepirdine in Alzheimer's disease Safety profile of Intepirdine in Alzheimer's disease\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0ecd4949c15b4ce185ca96a201792b4d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 89%|███████████████████████████████████████████████████████████████████████████████████████████████▌           | 67/75 [05:06<00:40,  5.08s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Gal-Nac conjugated siRNA and human cells Targeting liver cells with Gal-Nac conjugated siRNA or ASO Gal-Nac conjugated siRNA delivery to hepatocytes Gal-Nac conjugated ASO therapy for liver diseases\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7f4e7205fc6947d6a9b545bdf6ce59b2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 91%|█████████████████████████████████████████████████████████████████████████████████████████████████          | 68/75 [05:11<00:33,  4.85s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rebound COVID-19 Reinfection COVID-19 COVID-19 recurrence SARS-CoV-2 reactivation COVID-19 relapse\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "329e55b02200484198839dafb59071a0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 92%|██████████████████████████████████████████████████████████████████████████████████████████████████▍        | 69/75 [05:16<00:30,  5.03s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Zanubrutinib clinical applications Zanubrutinib FDA approval Zanubrutinib indications in the United States Zanubrutinib uses in cancer therapy\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8922adbdd42d42e3a40169584cfb3974",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 93%|███████████████████████████████████████████████████████████████████████████████████████████████████▊       | 70/75 [05:21<00:24,  4.97s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Rilonacept pericarditis Rilonacept efficacy in pericarditis Rilonacept clinical trials pericarditis Rilonacept mechanism of action pericarditis\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9a7426495af346dd91a8c2f5e15b2601",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 95%|█████████████████████████████████████████████████████████████████████████████████████████████████████▎     | 71/75 [05:26<00:20,  5.02s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1p19q co-deletion tumors 1p19q co-deletion and glioma 1p19q co-deletion and oligodendroglioma 1p19q co-deletion and anaplastic oligodendroglioma 1p19q co-deletion and mixed oligoastrocytoma\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "20046b5c4ba44b8aab34357bc84b690c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 96%|██████████████████████████████████████████████████████████████████████████████████████████████████████▋    | 72/75 [05:30<00:13,  4.60s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Xist gene function X-chromosome inactivation mechanism Xist gene product Xist RNA structure and function\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "360c273853204c3bb01c1c8ee00e9cb1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 97%|████████████████████████████████████████████████████████████████████████████████████████████████████████▏  | 73/75 [05:34<00:08,  4.41s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Microexon definition Microexon function Microexon splicing Microexon and neurodevelopmental disorders\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1f9f9c60216c4e738b52a0efd47ee59e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 99%|█████████████████████████████████████████████████████████████████████████████████████████████████████████▌ | 74/75 [05:38<00:04,  4.32s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tebentafusp clinical trials uveal melanoma Tebentafusp efficacy uveal melanoma Immunotherapy uveal melanoma Antigen-specific T-cell therapy uveal melanoma\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a1e2dfc7661a47e18c14b2de29289bf0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|███████████████████████████████████████████████████████████████████████████████████████████████████████████| 75/75 [05:42<00:00,  4.57s/it]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fenton reaction mechanism Hydroxyl radical generation in Fenton reaction Fenton reaction and oxidative stress Iron-catalyzed reactions in biological systems\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    query = sample['body']\n",
    "    if len(chatgpt_questions[sample['id']]['chatgpt-out']['queries']) > 1:\n",
    "        query = ' '.join(chatgpt_questions[sample['id']]['chatgpt-out']['queries'])\n",
    "    prediction = pipeline.run(query=query, params={\"BM25Retriever\": {\"top_k\": 50}, \"Ranker\": {\"top_k\": 30}, \"Reader\": {\"top_k\": 30} })\n",
    "    print(query)\n",
    "    snippets = []\n",
    "    doc_list_by_snnipets = []\n",
    "    for ans in prediction['answers']:\n",
    "        if ans.score > 0.4:\n",
    "            snippet = get_snipet_from_answer(ans)\n",
    "            doc_list_by_snnipets.append(snippet['document'])\n",
    "            snippets.append(snippet)\n",
    "\n",
    "    sample['snippets'] = snippets\n",
    "    doc_list = [ globals.BIOASQ.doc_relative_url + d.id for d in prediction['documents'] ]\n",
    "    #sample['documents'] = doc_list[0:10]\n",
    "    sample['documents'] = list(set(doc_list_by_snnipets))\n",
    "    \n",
    "# mindlab base ans.score > 0.3:\n",
    "# mindlab tns ans.score > 0.4 and only snnipets docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "a7bf5651",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'questions': [{'id': '63f03006f36125a426000018',\n",
       "   'type': 'summary',\n",
       "   'body': 'What were the results of the DESTINY-Breast04 Trial?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '641ad941690f196b5100003d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are LOQ and LOD the same?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '642a029d57b1c7a315000011',\n",
       "   'type': 'summary',\n",
       "   'body': 'Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6432fc0457b1c7a31500001f',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which gene is most frequently mutated in hereditary angioedema ?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64178edb690f196b51000025',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is casimersen's mechanism of action?\",\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6402bf2b201352f04a000007',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the mechanism of action of tiragolumab?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '641d8fd6690f196b51000041',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429d5c557b1c7a315000006',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the major thrombotic complications in patients with COVID-19?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6433012b57b1c7a315000022',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is Cinryze?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64179337690f196b51000034',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Do machine learning-based methods outperform statistical methods for survival analysis?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63f03c47f36125a42600001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'ZF2001 is used for which disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35596222',\n",
       "     'text': 'conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used ',\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34021265',\n",
       "     'text': ' CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell V',\n",
       "     'offsetInBeginSection': 292,\n",
       "     'offsetInEndSection': 442,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36158819',\n",
       "     'text': 'iving the first dose of the ZF2001 RBD-subunit vaccine against coronavirus disease 2019 (COVID-19). Autopsy showed severe interstitial myocarditis, in',\n",
       "     'offsetInBeginSection': 109,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34877393',\n",
       "     'text': 'es (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, ',\n",
       "     'offsetInBeginSection': 598,\n",
       "     'offsetInEndSection': 748,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36426361',\n",
       "     'text': 'Background\\nIn response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of rec',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35311493',\n",
       "     'text': 'ement was observed in both animal models. ZF2001 has been approved for emergency use in China, Uzbekistan, Indonesia, and Columbia. The high safety, i',\n",
       "     'offsetInBeginSection': 917,\n",
       "     'offsetInEndSection': 1067,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35617368',\n",
       "     'text': 'eometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased',\n",
       "     'offsetInBeginSection': 2528,\n",
       "     'offsetInEndSection': 2678,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34021265',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36158819',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34877393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35596222',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36426361',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35617368',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35311493']},\n",
       "  {'id': '642c82c557b1c7a315000012',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What mammal has the lowest known chromosome number?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429b41757b1c7a315000004',\n",
       "   'type': 'list',\n",
       "   'body': 'When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '643305b257b1c7a315000025',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which company produces Ruconest?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '641635fa690f196b5100001c',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is usually the age of diagnosis in Duchenne muscular dystrophy?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334',\n",
       "     'text': 'but sporadic cases are also frequent. The average age at diagnosis is 4.83 years but an early diagnosis is possible.\\n\\n\\nCLINICAL CASE\\nAn 18-month male ',\n",
       "     'offsetInBeginSection': 248,\n",
       "     'offsetInEndSection': 398,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/25996334']},\n",
       "  {'id': '6402c868201352f04a00000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Was erythropoietin effective for optic neuritis in the TONE trial?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6424154d690f196b5100004a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the R value with respect to hepatoxicity',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64299b6a57b1c7a315000001',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6432ffdf57b1c7a315000021',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is hereditary angioedema?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26819784',\n",
       "     'text': 'ntially life-threatening genetic disorder that results from an autosomal dominant trait. It is characterized by acute, recurrent attacks of severe loc',\n",
       "     'offsetInBeginSection': 41,\n",
       "     'offsetInEndSection': 191,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26819784']},\n",
       "  {'id': '64178ec2690f196b51000024',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is viltolarsen's mechanism of action?\",\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64040bd8201352f04a00000e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should be used bexarotene for relapsing-remitting multiple sclerosis?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6422e7f0690f196b51000045',\n",
       "   'type': 'list',\n",
       "   'body': 'Hepcidin is a key regulator of what processes?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27725588',\n",
       "     'text': 'lasma iron and iron stores. Reflecting a likely role of hepcidin in innate immunity, hepcidin is also induced by inflammation. Increased erythropoieti',\n",
       "     'offsetInBeginSection': 463,\n",
       "     'offsetInEndSection': 613,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27725588']},\n",
       "  {'id': '6429ee7457b1c7a31500000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6433050157b1c7a315000024',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6417900b690f196b5100002a',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can viltolarsen be used for?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63f57ea133942b094c000005',\n",
       "   'type': 'list',\n",
       "   'body': 'What is the triad of the Cat eye syndrome?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64281a47690f196b5100004f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429cfb557b1c7a315000005',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6432f75757b1c7a31500001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64178fea690f196b51000028',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What types of DMD can eteplirsen be used for?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63eef94ff36125a426000010',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Cinpanemab effective for Parkinson’s Disease?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6426d131690f196b5100004e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'In what organ would you find the Ashwell receptor?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429e17657b1c7a315000007',\n",
       "   'type': 'list',\n",
       "   'body': 'What histone marks are indicative of enhancers in the chromatin landscape of a given cell?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '643306cc57b1c7a315000027',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64178ffb690f196b51000029',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can casimersen be used for?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63eeefc5f36125a426000009',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is targeted by CIS43LS?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6415b422690f196b5100000a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What does Cal-light do?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64172bb2690f196b5100001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'To which region of a gene does an RNA polymerase bind to initiate transcription?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63f9ccdc33942b094c00000f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is PRP-40 involved in microexon splicing?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '641790d6690f196b5100002d',\n",
       "   'type': 'factoid',\n",
       "   'body': 'At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6404199d201352f04a000019',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is ocrelizumab effective for primary progressive multiple sclerosis?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '641b7bba690f196b5100003e',\n",
       "   'type': 'summary',\n",
       "   'body': 'How is Indocyanine green (ICG) used?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6428da74690f196b51000052',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the process that generates multiple transcripts from the same gene?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63f9cdcc33942b094c000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Does silencing of SRRM4 inhibit tumor growth across cancers?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64179aac690f196b51000037',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the life expectancy for Duchenne muscular dystrophy patients?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64041e97201352f04a00001e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is daridorexant effective for insomnia?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6422ee03690f196b51000046',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What cells produce erythroferrone?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429f86657b1c7a31500000d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the role of the Mediator in gene expression?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6415c0df690f196b51000010',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What does FBDD stand for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32013845',\n",
       "     'text': 'Fragment-Based Drug Design (FBDD) has established itself as a promising approach in modern drug discovery, accelerating and improving lead optimizatio',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32013845']},\n",
       "  {'id': '64041dae201352f04a00001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is deucravacitinib effective for psoriasis?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6415b6eb690f196b5100000b',\n",
       "   'type': 'list',\n",
       "   'body': 'What processes do orexin/hypocretin neurons regulate?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6428da47690f196b51000051',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can the epigenetic status of introns affect gene expression?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6415c5d4690f196b51000014',\n",
       "   'type': 'list',\n",
       "   'body': 'What was Keytruda originally approved for by the FDA?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35860268',\n",
       "     'text': ' has been approved by the US Food and Drug Administration for non-small-cell lung cancer. Here, we report a rare case of an abdominal fibroinflammator',\n",
       "     'offsetInBeginSection': 373,\n",
       "     'offsetInEndSection': 523,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34647523',\n",
       "     'text': \" Drug Administration (FDA) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no publ\",\n",
       "     'offsetInBeginSection': 218,\n",
       "     'offsetInEndSection': 368,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25395816',\n",
       "     'text': 'propion (Contrave) for weight management; pembrolizumab (Keytruda) for melanoma; dolutegravir/abacavir/lamivudine (Triumeq) for HIV-1; and immune glob',\n",
       "     'offsetInBeginSection': 13,\n",
       "     'offsetInEndSection': 163,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26631501',\n",
       "     'text': 'ntly approved for the second-line treatment of PD-L1-positive non-small-cell lung cancer and for unresectable/metastatic melanoma. This article will d',\n",
       "     'offsetInBeginSection': 326,\n",
       "     'offsetInEndSection': 476,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26631501',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35860268',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34647523',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25395816']},\n",
       "  {'id': '63f5713733942b094c000003',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are clinical features of the Achard-Thiers syndrome?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '642d4c9b57b1c7a315000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are Luminopsins a fusion proteins of luminol and Rhodopsin ?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429fe4e57b1c7a31500000f',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are coactivators?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9806345',\n",
       "     'text': 'ent and indicates a dual role for coactivators as bridging factors and chromatin remodeling proteins. The opposites of coactivators are corepressors, ',\n",
       "     'offsetInBeginSection': 879,\n",
       "     'offsetInEndSection': 1029,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "     'text': 'Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modula',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9096323',\n",
       "     'text': 'uld be rescued from E1A inhibition by overexpression of CBP or p300. CBP and p300 act as coactivators of p65-driven gene activation and may play an im',\n",
       "     'offsetInBeginSection': 909,\n",
       "     'offsetInEndSection': 1059,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10379889',\n",
       "     'text': 'ER. In fact, squelching becomes even more severe when coactivators are abundant. Supplying combinations of coactivators from the p160 class and the CR',\n",
       "     'offsetInBeginSection': 1080,\n",
       "     'offsetInEndSection': 1230,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11893487',\n",
       "     'text': 'Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription. Recent studies elucida',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17476305',\n",
       "     'text': 'development and physiology. These coactivators are nuclear proteins and transcription co-regulators that function to facilitate the transcription init',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "     'text': 'ogen-sensitive and -insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine ',\n",
       "     'offsetInBeginSection': 1188,\n",
       "     'offsetInEndSection': 1338,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "     'text': '160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans',\n",
       "     'offsetInBeginSection': 413,\n",
       "     'offsetInEndSection': 563,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16604175',\n",
       "     'text': 'ucible transcription factors requiring coactivators such as members of the SRC/p160 family to modulate the transcription of their target genes. This p',\n",
       "     'offsetInBeginSection': 34,\n",
       "     'offsetInEndSection': 184,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "     'text': 'ARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances transcriptional activ',\n",
       "     'offsetInBeginSection': 429,\n",
       "     'offsetInEndSection': 579,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11108858',\n",
       "     'text': 'ivation. Coactivators are a diverse group of molecules that bring multiple structural and enzymatic functions to the promoter. The existence of coacti',\n",
       "     'offsetInBeginSection': 278,\n",
       "     'offsetInEndSection': 428,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23380592',\n",
       "     'text': 'e transcription and they require the help of coactivators. Several TEAD-interacting coactivators are known and they can be classified into three group',\n",
       "     'offsetInBeginSection': 382,\n",
       "     'offsetInEndSection': 532,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11823864',\n",
       "     'text': \"uncovers a unique mechanism, called 'synergistic folding', through which p160 coactivators recruit CBP/p300 to allow transmission of the hormonal sign\",\n",
       "     'offsetInBeginSection': 1184,\n",
       "     'offsetInEndSection': 1334,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "     'text': ' treatment. AR coactivators are proteins which interact with one or more regions of the AR thus enhancing its function. Although several functions of ',\n",
       "     'offsetInBeginSection': 447,\n",
       "     'offsetInEndSection': 597,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21664237',\n",
       "     'text': 'Coactivators are a diverse group of non-DNA binding proteins that induce structural changes in agonist-bound nuclear receptors (NRs) that are essentia',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25024406',\n",
       "     'text': 'Transcriptional coactivators have evolved as an important new class of functional proteins that participate with virtually all transcription factors a',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19019695',\n",
       "     'text': 'Nuclear receptor (NR) coactivators are recruited to DNA by NRs, potentiating NR-dependent gene transcription. To obtain the complexity of NR-mediated ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10454556',\n",
       "     'text': 'functional interactions between the androgen receptor (AR) and 160-kDa nuclear receptor coactivators. Upon overexpression in mammalian cells, these co',\n",
       "     'offsetInBeginSection': 231,\n",
       "     'offsetInEndSection': 381,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29786798',\n",
       "     'text': 'vators is frequently reported in prostate cancer. Coactivators such as p300/CBP are involved in modulation of androgen receptor activity by increasing',\n",
       "     'offsetInBeginSection': 51,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27654711',\n",
       "     'text': 'tors represent a large class of proteins that partner with nuclear receptors and other transcription factors to regulate gene expression. Given their ',\n",
       "     'offsetInBeginSection': 8,\n",
       "     'offsetInEndSection': 158,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14766010',\n",
       "     'text': 'The p160 coactivators, steroid receptor coactivator-1 (SRC-1), transcriptional intermediary factor-2 (TIF2) and receptor-associated coactivator-3 (RAC',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9096323',\n",
       "     'text': 'CBP (CREB-binding protein) and p300 are versatile coactivators that link transcriptional activators to the basal transcriptional apparatus. In the pre',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19052561',\n",
       "     'text': 'osition in vivo. These results demonstrate that VDR and coactivators SRC2 and SRC3, which are also involved in other nuclear receptors as well, are cr',\n",
       "     'offsetInBeginSection': 1049,\n",
       "     'offsetInEndSection': 1199,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8571454',\n",
       "     'text': 'Coactivators are a novel class of transcriptional activator required at many eukaryotic promoters. Several coactivators have now been isolated, their ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11267654',\n",
       "     'text': ' of these factors is approximately 160 kDa, they are collectively termed p160 coactivators. So far, p160 coactivators have been cloned from human, mou',\n",
       "     'offsetInBeginSection': 158,\n",
       "     'offsetInEndSection': 308,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14973393',\n",
       "     'text': 'on as adaptors in a signaling pathway that transmits transcriptional responses from the DNA bound receptor to the basal transcriptional machinery. Hor',\n",
       "     'offsetInBeginSection': 752,\n",
       "     'offsetInEndSection': 902,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "     'text': ' redundant, specific functions have been identified and analyzed. The p160 group of coactivators, SRC-1, -2, and -3 not only potentiate the activation',\n",
       "     'offsetInBeginSection': 619,\n",
       "     'offsetInEndSection': 769,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10454563',\n",
       "     'text': 'al end of p160 coactivators. C-terminal coactivator fragments lacking AD1 but containing AD2 and the AR AF-1 binding site served as efficient coactiva',\n",
       "     'offsetInBeginSection': 1188,\n",
       "     'offsetInEndSection': 1338,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12039076',\n",
       "     'text': 'and CREB-binding protein (CBP). Since coactivators function as transcription amplifiers, subtle changes in expression levels of coactivators in certai',\n",
       "     'offsetInBeginSection': 341,\n",
       "     'offsetInEndSection': 491,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14973393',\n",
       "     'text': 'diated transcriptional activation. Coactivators function as adaptors in a signaling pathway that transmits transcriptional responses from the DNA boun',\n",
       "     'offsetInBeginSection': 698,\n",
       "     'offsetInEndSection': 848,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/14973393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23380592',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14766010',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16604175',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10454563',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11823864',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27654711',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10454556',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9806345',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21664237',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29786798',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19019695',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11267654',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10379889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9096323',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17476305',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25024406',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8571454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12039076',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19052561',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11108858',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11893487']},\n",
       "  {'id': '6412331b201352f04a000038',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What are PROTACs?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34411892',\n",
       "     'text': ' of diseases. The mechanism is to inhibit protein function by hijacking the ubiquitin E3 ligase for protein degradation. Heterogeneous bifunctional PR',\n",
       "     'offsetInBeginSection': 107,\n",
       "     'offsetInEndSection': 257,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32431173',\n",
       "     'text': 'rs represents an emerging mode of action in drug discovery. Proteolysis targeting chimeras (PROTACs) are small molecules that can recruit an E3 ligase',\n",
       "     'offsetInBeginSection': 54,\n",
       "     'offsetInEndSection': 204,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35702041',\n",
       "     'text': ' The mechanism is based on the inhibition of protein function by hijacking a ubiquitin E3 ligase for protein degradation. The heterobifunctional PROTA',\n",
       "     'offsetInBeginSection': 237,\n",
       "     'offsetInEndSection': 387,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34350175',\n",
       "     'text': 'd promising approach to target intracellular proteins for ubiquitination-mediated degradation, including those so-called undruggable protein targets, ',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35702041',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34411892',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32431173',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34350175']},\n",
       "  {'id': '62008022c9dfcb9c0900001b',\n",
       "   'type': 'list',\n",
       "   'body': 'Which variables are included in the ALBI grade?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64240f33690f196b51000049',\n",
       "   'type': 'list',\n",
       "   'body': 'What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11033870',\n",
       "     'text': 'ied by chorioretinitis. Treatment of ocular FIP is symptomatic, and the mainstay of palliative therapy is topical or systemic corticosteroids or both.',\n",
       "     'offsetInBeginSection': 511,\n",
       "     'offsetInEndSection': 661,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/11033870']},\n",
       "  {'id': '6428da98690f196b51000053',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6415c8f1690f196b51000017',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63eeec79f36125a426000006',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Talquetamab was developed for treatment of which disease?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '642321a5690f196b51000047',\n",
       "   'type': 'summary',\n",
       "   'body': 'Please summarize Feline Spongiform Encephalopathy(FSE',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6428d7da690f196b51000050',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can untranslated regions (UTRs) regulate gene expression?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63f9cbb433942b094c00000c',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is alternative splicing associated with heart disease?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '61fa941ec9dfcb9c09000005',\n",
       "   'type': 'yesno',\n",
       "   'body': \"Should Intepirdine be used for Alzheimer's disease?\",\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6422e2f1690f196b51000043',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64299fa957b1c7a315000002',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is rebound COVID-19?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6432fb1957b1c7a31500001e',\n",
       "   'type': 'list',\n",
       "   'body': 'What clinical applications is Zanubrutinib approved for in the United States?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '61f7cb37882a024a10000029',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is rilonacept effective for pericarditis?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6413712a201352f04a00003e',\n",
       "   'type': 'list',\n",
       "   'body': 'The 1p19q co-deletion is associated with what types of tumors?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6429ad3857b1c7a315000003',\n",
       "   'type': 'factoid',\n",
       "   'body': 'The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '63f92fd033942b094c00000b',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are microexons?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64041f38201352f04a00001f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is tebentafusp effective for uveal melanoma?',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '6426bb49690f196b5100004d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the Fenton reaction',\n",
       "   'snippets': [],\n",
       "   'documents': []}]}"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_batch_json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "bea1d4f1",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "68adbc26",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5f212dee45fa402ab4f4b1aba299b104",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/1.43k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8d83553f760444f39b80dc76927a81e5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/190 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4c686dcbd7a8499881e66f5e5f4afdf7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/4.45k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4288df407acc4b86ac6b3ab7abbd3158",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/691 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "62ed77945b5a40b1b6fdc03740f57b68",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/124 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "db2921a51a3e49fb8bff87d44685d93c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/767 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "73ae949d063a47f9b481f1436b39d27c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/433M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cee35cea39c8466ca5123370642ff6fd",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/53.0 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d10e143c89994fb982f0c26efcdc4225",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/300 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "115483ee905c45e7883678eb7b99a995",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/112 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9dbb944458e44f1bbe3dabb6122cee33",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/669k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ab87b1ef85964dbdacc577a3227c8bd8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/412 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "920a2b0d8cc647c5b3ada0693d768a14",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/213k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5a682617cabb46edb7aeb86a8af6ca0d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Downloading:   0%|          | 0.00/229 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[-0.7673091  -0.02201538  0.21489295 ...  0.4305086   0.9445836\n",
      "   0.3237879 ]\n",
      " [ 0.04580967  0.2503939   1.1280602  ...  0.34196827  0.4122522\n",
      "   0.14661177]]\n"
     ]
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e002ac71",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "haystack-py310",
   "language": "python",
   "name": "haystack-py310"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
